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Abstract 
 
Nicastrin is an essential component of the gamma-secretase (GS) enzyme complex, 
required for its synthesis and recognition of substrates for proteolytic cleavage. The purpose 
of this study was to investigate whether nicastrin has a prognostic value or the potential as a 
therapeutic target in breast cancer.  
Tissue microarrays (TMAs) (n = 1050), and breast cancer cell line analyses confirmed 
that nicastrin expression was upregulated in breast cancer compared to normal breast cells. In 
TMA patient samples, high nicastrin expression was observed in 47.5% of cases and 
correlated with worse breast cancer specific survival in the ERα negative cohort.  
Transient and stable gene silencing of nicastrin in vitro, resulted in the disruption of 
the GS complex activity and a decrease in Notch1 cleavage. Nicastrin silencing in invasive 
MDA-MB-231 and HCC1806 cells resulted in the loss of vimentin expression and a 
reduction in cell invasion, which was concomitant with the formation of cell-cell junctions, as 
well as cellular repolarisation. In a population of breast cancer cells harbouring the cancer 
stem cell phenotype (CD44
+
/CD24
-
), nicastrin depletion abrogated expression of the 
epithelial to mesenchymal (EMT) markers, vimentin, SIP1 and Snail. Furthermore, nicastrin 
overexpression in the non-malignant MCF10A breast cells increased expression of other GS 
components, Notch activation, vimentin expression and invasive capacity. These data 
indicate that nicastrin can function to maintain the EMT transition during breast cancer 
progression. We have developed anti-nicastrin polyclonal and monoclonal antibodies and 
have shown that they are able to decrease the invasive and proliferative capacity of MDA-
MB-231 breast cancer cells in vitro. In order to dissect the role of nicastrin within the GS 
complex from its presumed GS-independent signaling role in breast cancer cells, we have 
performed gene array analyses and identified a subset of genes that are nicastrin-dependent 
and are not affected by silencing of the Notch receptors. The data presented in this thesis 
therefore support our hypothesis that an antagonising monoclonal antibody could be suitable 
to inhibit nicastrin as a potential therapeutic target in invasive breast cancer. 
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1. Breast Cancer 
 
Cancer is the leading cause of death worldwide accounting for over 7 million deaths in 
2010. Based on recent estimates, cancer incidence across the world will rise from 11 million 
cancer cases diagnosed in 2002, to predicted 17 million in 2020 and alarming 27 million by 
2050 (1). Global mortality rates from malignant disease are also projected to increase from 
7.1 million in 2002 to 11.5 million in 2030 (2).  
1.1. Breast cancer incidence and mortality 
 
Breast cancer is the most frequent neoplasm diagnosed in women, and accounts for 
30% of all cancers in the female population. The cumulative lifetime risk of developing 
breast cancer is one in nine women (3), with the incidence rising by 1-3% yearly in most 
parts of the world (4). In 2002, there were 1.15 million cases of breast cancer diagnosed 
worldwide, while that number increased to 1.38 in 2010 (Figure 1a) (1). Known risk factors 
for developing breast cancer are related to: 
i)   Menstrual cycle (early menarche < 12 yrs; late menopause > 55 yrs);  
ii)  Pregnancy (nuliparity, late first birth > 30 yrs, multiple gestation > 35 yrs);  
iii) Pre-menopausal hormonal therapy i.e. oral contraceptives for > 10 yrs and/or     
post-menopausal hormono-replacement therapy for > 5 yrs; 
iv) Family history of breast cancer;  
v) Genetic susceptibility: BRCA1 and BRCA2 mutation carriers;  
vi) Lifestyle choices (alcohol intake, smoking, high body mass index, lack of physical 
activity etc.).  
Joint effects of cancer-susceptibility genes and other endogenous and lifestyle risk 
factors are likely to account for the majority of diagnosed breast cancers (5). Use of screening 
programs in developed countries, enabling diagnosis of breast cancer at an early stage, as 
well as changes in exposure to risk factors and improvements in the post-operative adjuvant 
systemic and targeted therapies, have reduced overall mortality from breast cancer in the past 
three decades (Figure 1b) (2) (6, 7). 
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Figure 1.Incidence of breast cancer. a) Projected change in female breast cancer incidence. In 2002, 
the incidence of breast cancer was 1.15 million; 1.5 million new cases were diagnosed in 2010. 
Population growth and ageing alone would account for approximately two-thirds of the increase; b) 
Age adjusted breast cancer mortality rates in the United Kingdom for screened and non-screened age 
groups: (http://info.cancerresearchuk.org/cancerstats/types/breast/mortality). 
 
Despite this obvious progress, there will still be women presenting with advanced and 
even metastatic disease at diagnosis, or will develop disseminated disease and eventually die. 
          
a) 
b) 
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    1.1.2. Cellular pathways promoting breast cancer 
 
In normal cells, a network of cellular signaling exists to maintain the homeostasis of 
cellular functions and balance tumour-suppressor versus oncogenic signals in favour of the 
former, to prevent cancer development.  
Cancers arises from cells that have undergone a malignant transformation as a 
consequence of accumulating molecular alterations that lead to a disturbance of cell 
homeostasis (8). Characteristics commonly attributed to cancer cells are: a) uncontrolled 
cellular proliferation, b) insensitivity to negative growth regulation, c) evasion of apoptosis, 
d) lack of senescence, e) invasion, f) metastasis, g) neo-angiogenesis, h) genomic elasticity 
(Figure 2) (8).  
 
Figure 2.The seven hallmarks of a cancer cell (8) 
Genes with highly diverse functions that are susceptible to alterations in cancer cells 
are grouped into three main categories: oncogenes, tumour suppressor genes and stability 
genes (9). Proteins encoded by these genes have complex roles in cellular processes and 
engage in the function of multiple cellular signaling networks (10). In cancer, oncogenes 
acquire so called „gain of function‟ mutations that render these genes constitutively active in 
a cell (exp. Extracellular signal regulated kinase, ERK).  
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Conversely, tumour suppressor genes are targeted by the „loss of function‟ alterations 
(e.g. p53). Stability genes are responsible for repairing damage caused in DNA replication, or 
damage of mutated genes (e.g. BRCA1). Mutations of these genes can occur in the germline 
or as somatic mutations. The former infer hereditary predisposition to malignant disease, 
while the latter underpin sporadic cancers. Molecular and gene signatures are novel tools that 
are used in the era of tailored patient treatment to determine the exact characteristics of a 
cancer and derive not only prognostic conclusions, but also predict response to certain types 
of treatment. 
The complexity in the management of cancers lays in the heterogeneity of the disease, 
the ability of cancer cells to make the pathways that have been inhibited by therapy 
redundant, and the capacity to activate alternative routes for survival. In a fully transformed 
malignant cell, communications between oncogenic pathways ensure that once one pro-
survival pathway has been inhibited by therapy, an alternative one is switched on to 
compensate, a phenomenon often referred to as „oncogene addiction‟ (10). 
1.1.3. Heterogeneity of breast cancer 
 
Breast cancer is a heterogeneous disease that presents with a continuum of clinical, 
histological and molecular features. Several breast cancer characteristics provide insight into 
the biology of the disease and act as prognostic and predictive parameters, and guide 
treatment decision-making. These features are: histological type (Figure 3), histological 
grade, presence of lympho-vascular invasion, presence of sentinel and/or axillary lymph node 
invasion, and expression of markers like hormone receptors (ERα, PR), and the growth factor 
receptor, HER2 (11). The most recent classification by the World Health Organisation 
(WHO) recognises at least 18 distinct histological types of breast cancer (12), majority of 
which (50-80%) are invasive ductal carcinomas of non specific type (IDC-NST). Invasive 
lobular carcinomas (ILC) are the second most frequent subtype of breast cancer (5-15%). All 
other histological patterns constitute up to 25% of the breast cancer histological milieu (Table 
1).  
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                 Table 1.Prevalence of different breast cancer histological subtypes (12) 
Histological type Prevalence 
(%)   
Invasive ductal carcinoma-non special type 50-80 
Invasive lobular carcinoma 5-15 
Pure tubular carcinoma < 2 
Invasive cribriform carcinoma 0.8-3.5 
Medullary carcinoma 1-7 
Mucinous carcinoma 2 
Neuroendocrine tumours 2-5 
Invasive papillary carcinoma 1-2 
Invasive micropapillary carcinoma < 2 
Apocrine carcinomas < 4 
Metaplastic carcinomas < 1 
Lipid-rich carcinomas < 1-6 
Secretory carcinomas < 0.15 
Adenoic cystic carcinomas 0.1 
Glycogen-rich clear-cell carcinomas 1-3 
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Figure 3.Breast tissue composition and main histological representations of normal and 
malignant breast tissue. a) Schematic of the breast architecture, and histological representation of  
b) normal breast tissue, c) ductal carcinoma in situ; d) invasive ductal carcinoma; e) invasive lobular 
carcinoma; f) tubular and cribriform breast carcinoma (13).  
 
The seminal work of Wellings et al. suggests that all invasive breast carcinomas and 
their in situ precursor lesions stem from the terminal ducto-lobular unit. Hence, ductal and 
lobular denomination does not indicate the site of origin but rather implies distinct 
architectural patterns, cytological and immunohistochemical profiles (14). 
a) 
b) 
c)
) 
d)
) 
e)
) 
f)
) 
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1.1.4. Taxonomy of breast cancer 
 
The era of microarray technology has yielded molecular signatures of breast cancer, 
which when compared to the histopathological surrogates and clinical features of the tumours 
reveal clear genetic-phenotypic correlations (15). 
The majority of breast cancers are of the luminal type (60-70%). They are commonly 
estrogen receptor (ERα) positive, and highly dependent on the ERα driven signaling, while at 
the same time expressing low molecular weight cytokeratins, CK 8/18/19, as well as the cell-
cell adhesion molecule E-cadherin. Within the luminal breast cancers, the luminal A type 
encompasses tumours with very high levels of the ERα, lower histological grade, lower 
mitotic index, and thus a favourable clinical prognosis. Luminal B and C type cancers have a 
lower ERα expression score and a less favourable prognosis, as their histological grade is 
usually higher, as is their rate of proliferation (Figure 4) (15).  
Epidermal growth factor receptor 2 (ErbB2/HER2) positive tumours, which comprise 
20-25% of all breast cancers are a separate entity, bearing overexpression of the HER2 
protein (HER2 3+ by immunohistochemistry), and/or amplification of the HER2 amplicon on 
chromosome 17q12 (Figure 4). They are highly aggressive cancers, predominantly ERα 
negative, which rely on the HER2 signaling axis for their growth and spread. According to 
gene expression patterns, about 20% of the HER2 positive tumours jointly express the ERα 
protein and belong to the luminal type B (15). 
Basal-like breast cancers are another group of ERα negative tumours, which represent 
~15% of all breast cancers and resemble the luminal progenitor cells of the normal breast. 
They often express P-cadherin, caveolins, epidermal growth receptor 1 (EGFR), while they 
lack or have very low levels of ERα, PR and HER2 (Figure 4). For that reason basal tumours 
are commonly referred to as triple negative, although these are not overlapping entities. Both 
basal like and triple negative breast cancers are highly aggressive and are often underpinned 
by the existence of BRCA1 mutations. They display a distinct pattern of metastasis favouring 
brain and lung as secondary deposit sites, and the overall survival after detection of 
metastatic disease is often shorter in these types of cancer, than the luminal and HER2 
positive. They often occur in younger women, before the age of 50, and are frequent in the 
African-American population (15).  
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Even though there are still many uncharacterised breast cancer subtypes, the 
molecular profiles, known histological types, clinical behaviour and the existing taxonomy of 
breast cancer, hold both prognostic and predictive value and drive disease management.  
 
      
Figure 4.Subtypes of breast cancer. Schematic representation of the degree of cancer cell 
proliferation vs. cancer cell differentiation in the main breast cancer subtypes.  
1.2. Targeted therapies for the treatment of breast cancer 
Patient-tailored treatment entails taking into account the molecular makeup of an 
individual tumour in order to target the cancer driving pathways and ensure a maximal anti-
tumour response. In this regard, introduction of monoclonal antibodies (MAbs) as therapies 
targeted against a specific oncogenic molecule expressed in cancer tissue, are one of the most 
significant recent advances in the treatment of leukaemias and solid tumours (16).  
The vision of selective targeting was introduced a century ago by Paul Ehrlich who 
hypothesised that the „magic bullet‟ could be developed to combat malignant disease (17). 
The development of the hybridoma technology by Köhler and Milstein has since 
revolutionised the field and enabled production of murine derived monoclonal antibodies 
(MAbs) (18). Poor immunogenicity and suboptimal recruitment of the immune system 
machinery, which represented a major hurdle in their implementation as therapeutics, were 
overcome by genetic manipulations and fitting these murine antibodies into the human IgG 
backbone (19). Several variants of MAbs were produced: i) chimeric MAbs, which are 
constructed from murine variable regions and human constant regions; ii) humanised MAbs 
where the murine complementarity-determining regions (CDRs) are fitted into the remainder 
of the human-source MAb construct, and; iii) human MAbs derived entirely from a human 
source (transgenic mice or phage display) (20). 
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Antibodies are Y shaped immunoglogulin (Ig) molecules, with a molecular weight of 150 
kDa, which are composed of two paired polypeptide heavy- (50-70 kDa) and two light- 
chains (25 kDa) (Figure 5). Heavy chains are linked together and to the light chains by 
disulfide bonds. The heavy chains can belong to five distinct classes (A, E, M, D, G), based 
on their structural and functional properties, thereby determining the antibody isotype and 
functionality. Therapeutic antibodies are typically of the IgG class. Heavy and light chains 
contain compactly folded sequences, each of about 110 amino acids, which form repetitive 
regions (CH1, CH2 and CH3). The first amino terminal region of both the heavy and the light 
chains greatly differ in their sequence amongst different antibodies, and are therefore termed 
as „variable regions‟ (Fv, (VH, LH)). The variable region is the one that determines the 
specificity of an antibody towards an antigen and thus harbours the antigen binding domain, 
while the remaining stable sequences form the constant region. Amino acid variability differs 
inside variable domains. The highest level of variability is in the so called hyper-variable 
regions, known as complementarity determining regions (CDR), which determine 
complementarity of the antigen-antibody interaction. Variable domains of heavy and light 
chains contain three CDRs (VLCDR1-3, VHCDR1-3) (21). Usually, VHCDRs make a major 
contribution to contact formation with the antigen and the geometrical center of the antibody-
antigen contact is usually  located  near the VHCDR3 (21). The antibody molecule can be 
readily cleaved by proteolytic enzymes such as papain, into functionally distinct fragments. 
Digestion yields: i) the fragment antigen binding domains (Fab) that contain the variable 
parts of the heavy and the light chains, and ii) the fragment with no antigen binding activity 
but with a tendency to crystallise (Fc), which interacts with the effector molecules and 
induces a cellular response by activating the complement system molecules and macrophages 
(Figure 5). 
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Figure 5.Architecture of a monoclonal antibody molecule. Antibodies are Y shaped molecules 
consisting of two paired polypeptides (heavy- and light-Ig chains). Heavy chains are linked by 
disulphide bonds. Heavy and light chains contain compactly folded sequences, which form repetitive 
regions (CH1, CH2, CH3). The first amino-terminal region of both the heavy and the light chains 
are termed „variable regions‟ (VH, LH). The antibody molecule can be cleaved by proteolytic 
enzymes such as papain into fragment antigen binding domains (Fab) and fragment 
crystallisable (Fc) domain. Antibody diagram reproduced from www.invitrogen.com 
 
The structure of an antibody molecule is not rigid. The hinge regions that join the Fab 
domains and the Fc fragment are flexible, and allow the arms of the antibody to assume a 
range of angles and capture the cognate antigens. The type of antibody-antigen binding, 
which can be monovalent (one site of attachment) or bivalent (two interaction sites), 
influences parameters such as: i) antibody affinity (the strength with which an antibody 
molecule binds an epitope), and ii) avidity (functional affinity, combined strength of multiple 
bond interactions the effect of which is synergistic) (22).  
A candidate target for MAbs is: i) a macromolecule overexpressed in cancer tissue 
compared to other vital organs, ii) whose overexpression relates to worse outcome of cancer 
patients given the ability of the antigen to confer oncogenic effects, such as cancer growth 
and invasion, iii) whose expression can be readily and reproducibly measured in obtained 
clinical samples, and iv) where interference with the MAb interrupts and inhibits antigen 
signaling yielding clinical response and survival benefit (23).   
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1.2.1. Factors influencing efficacy of therapeutic monoclonal antibodies  
 
Clinical efficacy of MAbs depends on multiple parameters related to the antigen 
itself, the antibody, as well as the nature of the antibody-antigen interaction (24, 25). The 
interplay between pharmacokinetics, pharmacodynamics and the therapeutic efficacy is of 
paramount importance. 
Antigen density and turnover at the cell membrane, affinity of the MAb, and the rate 
of MAb internalisation are all important determinants of MAb therapeutic efficacy. Minimal 
affinity is required for specific retention of MAbs in the tumour tissue (26). The off-rate of 
the MAb should ideally be faster than the antigen internalisation. If the MAb dissociation rate 
is slower than the antigen internalisation rate, MAb distribution is compromised as 
degradation of the MAb will occur faster than the equilibrium is achieved (27). Upon 
internalisation, the MAb is degraded in the endosomal/lysosomal compartment, but the 
antigen can be recycled and replaced by the newly synthesised protein. The rate of MAb 
internalisation is therefore dependent on the antigen recycling, while the rate of antigen 
endocytosis is unaffected by MAb binding (28, 29).  
Affinity of a MAb affects tissue penetration in an inverse fashion, a phenomenon 
termed as the „binding-site‟ barrier. This means that the majority of the antibody is taken up 
by the outer rim of the tumour, thereby limiting the diffusion into the tumour (30). The 
binding-site barrier is affected by multiple parameters: i) the tumour shape; ii) antigen 
density; iii) dose of the antibody; iv) vascularisation and lymphatic outflow of the tumour 
(31). Cross reactivity of the MAb with the antigen expressed in normal tissue (non-target 
pool of antigens) is involved in reducing the target effects, while the extravasation of MAbs 
is often compromised by heterogonous vasculature of the tumour and high interstitial 
pressure gradients. 
Antibody half-life is a crucial parameter that depends on the antibody isotype as well 
as the rate of antibody clearance from the organism (pharmacokinetics) through the 
reticuloendothelial system (RES). Chimeric MAbs have a shorter half-life than the humanised 
MAbs (8-10 days vs. 2-3 weeks, respectively) (32). The IgG1 and IgG2 isotypes both have 
half-lives of three weeks and induce respectable antibody-dependent cellular cytotoxicity 
(ADCC) as well as complement dependent cytotoxicity (CDC) host responses, while the IgG3 
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isotype has the same functional effects with the human serum half-life of only one week (33). 
Antibody clearance depends on the nature of the antigen as well as on the dose of the 
administered MAb. In the case of membrane associated antigens, as opposed to soluble 
antigens, the MAb clearance is influenced by the antigen kinetics at the membrane (as 
previously outlined), while reduced clearance is noted with increasing doses and repetitive 
administration of MAbs (32). 
1.2.2. Mechanisms of monoclonal antibody action 
 
Clinically effective MAbs deliver therapeutic effects using a combination of cytotoxic 
mechanisms and their effects on cancer cells can be direct and indirect. Direct effects of 
MAbs can be achieved by blocking ligand binding to the antigen and conjugation of MAbs to 
radioisotopes, drugs or toxins as vehicles to deliver these cytotoxic agents to tumour cells. In 
the case of indirect action, when the Fc domain of an antigen-bound MAb binds to an Fc 
receptor displayed on the surface of immune effector cells (macrophages, natural killer cells), 
it results in the activation of the ADCC cascade, inducing target-cell death. CDC is another 
indirect cell-targeting method of MAbs, believed to dominate the anti-tumour effects elicited 
by MAbs. The CH2 region of the MAb heavy chains binds to C1q (component of complement 
C1) triggering a cascade leading to a proteolytic release of C3 and C5 and formation of a 
membrane-attack complex which induces target-cell death (19).   
MAbs used for the treatment of malignant diseases are targeted against antigens 
expressed on tumour cells (in solid tumours and on circulating tumour cells), in the tumour-
associated stroma as well as tumour vasculature. Most commonly targeted tumour-associated 
antigens are growth factor receptors which are overexpressed in many cancer types. In the 
1980s, there was a surge of clinical initiations of MAb products. The official approval for 
clinical application in the USA and the EU was granted to a total of eighteen MAbs in the 
past decade (Table 2) (16). The majority are humanised MAbs with an application in 
oncology, followed by immunological and anti-infective MAbs.  
Toxicities associated with MAb therapy can be mechanism-independent 
(hypersensitivity, allergic-type reactions) and mechanism-dependent. The latter arise from a 
MAb binding to its target antigen in non-malignant, normal tissue and interfering with the 
physiological antigen-driven cellular functions. The severity of the side-effects depend on the 
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level of antigen expression in organs other than the tumour bearing tissue, the relevance of 
the antigen-related signaling in these organs, as well the dose of the MAb (therapeutic 
window). For example, one of the side-effects of the anti-HER2 MAb is cardiac toxicity (34), 
while the anti-VEGF Ab can cause hypertension, bleeding and thrombosis (35). 
 
 Table 2.Monoclonal antibodies approved for clinical implementation in the USA and EU (16) 
 
Generic Trade Description Therapeutic category 
Muromonab-CD3 Orthoclone OKT3 Murine, IgG2a anti-CD3 Immunological 
Abciximab ReoPro Chimeric, IgG1 anti-GPIIb/IIIa; Fab Hemostasis 
Rituximab Rituxan Chimeric IgG1 anti-CD20 Oncology 
Daclizumab Zenapax Humanized IgG1 anti-CD25 Immunological 
Basiliximab Simulect Chimeric IgG1 anti-CD25 Immunological 
Palivizumab Synagis Humanized IgG1anti-respiratory 
syncytial virus 
Anti-infective 
Infliximab Remicade Chimeric IgG1 anti-TNFα Immunological 
Trastuzumab Herceptin Humanized IgG1 anti-HER2 Oncology 
Gemtuzumab Mylotarg Humanized IgG4 anti-CD33 Oncology 
Alemtuzumab Campath-1H Humanized IgG1 anti-CD52 Oncology 
Ibritumomab 
Tiuxetan 
Biogen Idec Murine IgG1 anti-CD20 radiolabeled Oncology 
Adalimumab Humira Human IgG1 anti-TNFα Immunological 
Omalizumab Xolair Humanized IgG1 anti-IgE Immunological 
Tositumomab Bexxar Murine IgG2aλ anti-CD20 radiolabeled Oncology 
Efalizumab Raptiva Humanized IgG1 anti-CD11a Immunologial 
Cetuximab Erbitux Chimeric IgG1 anti-EGFR Oncology 
Bevacizumab Avastin Humanized IgG1 anti-VEGF Oncology 
Natalizumab Tysabri Humanized IgG4 anti-α4 integrin Immunological 
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1.2. Epithelial to Mesenchymal Transition  
  
Epithelial-to-mesenchymal (EMT) transition is a biological process which enables 
epithelial cells to acquire mesenchymal-like properties and behaviour. EMT is required 
during embryonal implantation and normal organ development (EMT type 1). This process is 
conserved in adult tissues where EMT facilitates wound healing and tissue repair after injury 
or inflammation (EMT type 2). However, EMT is also active in human malignancies (EMT 
type 3) (36).   
Epithelial-to-mesenchymal transformation has first been described by Elisabeth Hay 
and colleagues who studied a model of chick primitive streak formation (37). The process has 
since been renamed transition instead of transformation, in order to reflect its reversibility, 
i.e. mesenchymal-to-epithelial transition (MET). Therefore, central to the dynamic concept of 
EMT-MET is the observation of cellular plasticity during development and adulthood, which 
exists in both normal and malignant tissue. This means that cells can evolve from epithelial to 
mesenchymal phenotypic and functional derivatives and back, in order to accomplish a given 
developmental or neoplastic program (36). Extensive studies investigating properties of 
primary cancer cells, circulating tumour cells and counterpart cancer cells from metastatic 
lesions, confirm that once cancer cells complete the invasion-metastasis cascade, they indeed 
shed their EMT traits through MET in order to colonise a distant organ and form secondary 
tumour deposits (38).   
Hallmarks of EMT in cancer are: 
1) Activation of EMT inducing transcription factors; 
2) Expression of EMT cellular markers; 
3) Stimulation of EMT promoting signaling pathways. 
Finally, temporal interplay of these events results in completion of the EMT process, 
characterised by the dissociation of cell-to-cell junctions, disturbance of cellular connections 
to the basement membrane, production of extracellular matrix disintegrating factors and 
increased motility and invasiveness of the cells.  
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In cancer, therefore, EMT enables dissociation of epithelial cancer cells from the 
primary tumour, invasion into the surrounding stroma, extravasation and survival in systemic 
circulation, as well as homing in distant organs to form metastatic lesions. Genotypic, 
phenotypic and cell behavioural alterations imposed by the EMT promote resistance to 
apoptosis as well as anchorage independent growth, facilitating cancer cell survival during 
metastatic systemic spread through the circulation and evasion of cell death in response to 
certain anti-cancer therapies (39-41). To date, many EMT inducers originating from cancer 
cells, as well as from the tumour-surrounding stroma, and a spectrum of EMT markers and 
pathways driving EMT have been discovered. 
EMT inducers are: i) transcription factors (TFs) such as Snail and Slug, which are 
zinc finger proteins; ii) the basic helix-loop-helix protein Twist; iii) homebox protein 
Goosecoid; iv) forkhead-box proteins FOXC1 and FOXC2; v) E-box proteins ZEB1 and 
SIP1. Their expression is upregulated in EMT. Individual overexpression of Snail, Twist and 
Goosecoid in a human mammary epithelial cell line was sufficient to induce a set of 
molecular alterations resulting in a complete EMT program (42, 43). Growth factors 
originating from the tumour-surrounding stroma, such as the hepatocyte growth factor 
(HGF), fibroblast growth factor (FGF), platelet derived growth factor (PDGF), epidermal 
growth factor (EGF), transforming growth factor β (TGF-β), appear to act through a paracrine 
loop to activate these EMT-promoting TFs in cancer cells (41, 44-48). Recently, an 
expanding field of micro RNAs is yielding data to implicate miRNAs in the regulation of the 
EMT (49). Presence of tumour hypoxia, a state induced by compromised blood supply to the 
tumour tissue also favours the migratory/invasive pattern of cancer cell behaviour (50). 
Matrix metalloproteinases (MMPs) are strong promoters of EMT. They can be either 
expressed on the surface of tumour cells or secreted as soluble factors by tumour cells for the 
purpose of degrading components of the extracellular matrix (collagen, gelatine, matrylisin 
etc.), as well as disintegrating cellular adhesions and facilitating migration of cancer cells 
(51). 
Microarray gene analysis of the cells that have undergone EMT in response to these 
TFs has revealed a so called „EMT core signature‟, comprising of 159 downregulated and 87 
upregulated genes (43). Downregulation of E-cadherin and upregulation of N-cadherin and 
vimentin (52), the known hallmarks of EMT, were consistently reproduced in this core 
signature. The EMT transcriptome translates into an EMT proteome signature, which is 
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dominated by the expression of proinvasive, mesenchymal proteins: vimentin, fibronectin, 
laminin, collagens, SPARC (secreted protein acidic and rich in cysteine) protein, SMA 
(smooth muscle actin), MMPs (matrix metalloproteinases), proteoglycanes and their 
receptors etc. (53, 54). Expression of these proteins was found to be enriched in the so called 
„basal B‟ subtype of breast cancer cell lines (e.g. MDA-MB-231, MDA-MB-435, BT-549), as 
opposed to the „luminal‟ (e.g. MCF-7, BT-474, ZR75-1, T47D) and „basal A‟ (e.g. MDA-
MB-468, HCC1187, HCC3153) type cell lines, a taxonomy derived by Neve et al., which 
closely resembles the in vivo classification of breast cancer (15) (55).  
Transcription factors and protein denominators of the EMT phenotype elicit their pro-
migratory/invasive effects through multiple cellular signaling pathways in cancer cells, TGF-
β (56), LEF/β-catenin (57), MAPK and PI3K/Akt (58), Rho-GTPases (59, 60), canonical and 
non-canonical Wnt pathway, as well as through the Notch receptors (61) . 
Occurrence of EMT in clinical breast cancer samples has been somewhat debated, 
although more and more evidence is emerging to support this concept. Analysis of 490 
human breast tumours for expression of the EMT markers has revealed stratification of these 
biological samples into two clusters (62); cluster A which is negative for EMT markers, 
encompassing both ERα positive and ERα negative tumours that express epithelial 
cytokeratins CK8/18/19; and cluster B, defined by cancers that are ERα negative, high grade 
tumours, expressing basal cytokeratins CK5/6/14 together with the EMT markers (N-
cadherin, cadherin-11, vimentin, SPARC). When characteristics of the cluster B tumours 
were matched against the proposed markers defining basal breast cancers (63, 64), results 
strikingly demonstrated a positive correlation between basal like tumours and the presence of 
EMT markers.  
1.3.1. Monitoring EMT in a 3D context 
 
The majority of data regarding breast cancer cell lines‟ transcriptome, proteome and 
behavior, as well as the response to therapeutic drugs, has so far been derived from cell 
culture systems utilising 2D monolayers on a plastic substratum.  
Even though these results are largely reproducible and informative, the 2D monolayer 
culture model precludes microenvironmental input of the extracellular matrix, an important 
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regulator of the cell phenotype and behaviour (65). Breast cell lines adopt one of the four 
distinct morphologies in 3D culture (round, mass, grape-like and stellate) (Figure 6), which 
reflect and correspond to their transcriptional profiles, proteome content and cellular 
behaviour. Comparative studies of these cellular aspects between monolayers in 2D plastic 
substrata and respective 3D matrigel cultures, have revealed marked differences in genes 
encoding signal transduction proteins in 25 different breast cancer cell lines (66), a collection 
which broadly covers the scope of distinct breast cancer subtypes found in vivo (15, 55). 
Non-malignant breast cells form round, growth arrested, polarised acini spheroids when 
cultured in 3D conditions, while the architecture of malignant breast cells is in the form of 
disorganised, proliferative, non-polarised colonies, as represented by grape-like and stellate 
structures (Figure 6) (67).  
 
 
 
Figure 6.Morphology of the three-dimensional acini structures derived from different breast 
cancer cell lines and non-transformed breast epithelial cells (66) 
 
 
The use of the 3D cell culture system allows for investigation of cellular pathways 
and oncogenes that are capable of inducing malignant transformation, and equally of the 
drugs potent enough to revert the invasive phenotype (68). For example, overexpression of 
cyclin D1 and the retinoblastoma (Rb) protein in MCF10A (non-malignant) breast cells 
grown in 3D, results in enhanced proliferation but retention of the original round, polarised 
organisation. In contrast, overexpression of the HER2 oncogene is capable not only to 
stimulate cell proliferation but also to disturb acini organisation and induce a marked loss of 
apico-basal polarity (68).  
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In support of the pathways previously shown to be important regulators of the EMT in 
2D cultures, overexpression of  E-cadherin as well as the inhibition of the PI3K/Akt and 
MAPK pathways is able to induce reversion of the EMT in a 3D model of invasive MDA-
MB-231 and HMT-3522 cells (69, 70). Even though the traditional cell culture will always be 
utilised, the 3D cell cultures are rapidly becoming a preferred cellular model for studying the 
malignant cell behaviour, the inducers and inhibitors of the invasive phenotype, as they more 
closely recapitulate the in vivo conditions.              
        1.3.2. Epithelial-to-mesenchymal transition and stem cells  
 
The EMT endowes cancer cells with invasiveness, ability to evade apoptotic stimuli, 
resistance to chemotherapeutic agents and sustainment of anchorage independent growth 
(Figure 7). These traits are commonly used as intrinsic attributes of cancer initiating cells, 
often referred to as cancer stem-cells (CSCs) (54, 71). 
 
         
Figure 7.Steps involved in epithelial-to-mesenchymal transition and cellular markers affected 
by this process. Epithelial-to-mesenchymal transition (EMT) is characterised by the pro-migratory 
and proinvasive molecular, phenotypic and cell behavioural changes. During EMT, epithelial markers 
are lost, and invasion markers are upregulated. The reverse process is termed mesenchymal-to-
epithelial transition (MET). Figure reproduced from (72). 
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 1.4. Stem Cells and Breast cancer  
             The concept that cancers may arise from “stem cells” is 150 years old. In addition, 
over 40 years ago it has been suggested that cancer cells represent a maturation arrest of stem 
cells (73). This idea has been dormant for the past several decades, in which period 
substantial knowledge has been acquired on the molecular characteristics of cancer. Recently 
it has been reactivated in many studies, which have provided evidence that cancer cells and 
stem cells do share some similar traits.  
             Stem cells are defined as cells that have the ability to perpetuate themselves through 
self-renewal and to generate mature cells of a particular tissue through differentiation (74). 
The hallmark property of a stem cell is its ability to self-renew as well as to regulate the 
balance between self-renewal and differentiation. Loss of this hallmark also underpins the 
process of carcinogenesis. It is presumed that stem cells, being slow cycling with occasional 
bursts of proliferative activity, may be escaping effects of currently used cancer treatment 
modalities whenever they are not actively proliferating. Thus, the treatment is eradicating 
only well differentiated cancer cells, leaving the „root‟ cells behind. This may be a 
compelling reason why chemotherapy induces remission, yet rarely cures, and why we are 
seeing relapses of cancer with no substantial benefit in overall survival in metastatic patients 
(Figure 8) (75, 76). 
            Given their purpose, stem cells are by nature long-lived. For that reason alone they are 
subject to accumulation of mutations that may potentially be carcinogenic. Other shared 
properties between stem cells and cancer cells, apart from self-renewal and differentiating 
capacity, are activation of anti-apoptotic pathways, increased transmembrane transport, 
ability to migrate and metastasise (77). Normal stem cells are dormant, predominantly in G0 
phase of the cell cycle, until they receive an appropriate signal from the cell surroundings 
(niche), when they go into asymmetric cell division producing one exact replica of itself and 
a daughter cell that further undergoes differentiation into cell lineages of the tissue in 
question (78). Another route of stem cell division is in a symmetric manner i.e. producing 
two stem cell progeny. Through such a disregulated self-renewal, the pool of stem cells 
expands. 
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 The development of the human mammary gland during puberty, as well as  
pregnancy related cyclic involution and re-establishment of lactating function suggest that a 
mammary stem cell population resides within the mammary gland (79). The adult mammary 
gland has a tree-like structure comprised of three separate cell lineages: luminal epithelial 
cells, myoepithelial cells that secrete the basal lamina, which separates the mammary 
parenchyma from the stroma, and alveolar epithelial cells in the secretory acinar structures at 
the end of each branch that produce milk proteins (79, 80). Mammary stem cells may serve to 
give rise to more designated progenies that, at the end, form differentiated cell lineages of the 
breast, to allow for breast remodeling in and out of pregnancies, and possibly repair tissue 
damage. 
        1.4.1. Isolation of breast cancer stem cells 
 Led by the assumption that mammary stem cells are indeed present in the normal 
breast tissue and in breast cancer, substantial efforts have been invested into deriving optimal 
methodologies for their isolation and characterisation. 
       1.4.1.1. Use of the Hoechst 33342 dye 
 One such approach is using a Hoechst 33342 dye, which is an intercalating agent 
that binds to DNA (81). The use of the Hoechst 33342 dye technique resulted in isolating a 
unique cell staining profile from the bone marrow (81). The so called „side population‟ (SP) 
was well separated from the other cells, as visualised by flow cytometry, due to an elevated 
rate of Hoechst efflux from the cells.  Following this example, the presence of the SP was 
demonstrated in the mouse mammary epithelial preparations, where it represented 2-3% of 
the total epithelial cell preparations (82). Under mouse mammary epithelial clonal conditions, 
these SP cells grew as typical cytokeratin-expressing mammary epithelial cell clones (83). 
The same experiments were performed on human breast tissue obtained from reduction 
mammoplasty, with success rate of SP extraction varying across the groups from 0.2-5%. In 
in vitro cell culture, SP cells produced 2-7 times more colonies of both luminal and 
myoepithelial cells than the non-SP cells, suggesting that SP was indeed enriched for multi-
potent stem cells (84). 
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            On the other hand, a cultivation system was developed to support the propagation of 
mammary progenitors in an undifferentiated state. A neurosphere model was „copied‟ into a 
„mammary setting‟. In 1992, Raynolds and Weis showed that rat neural cells proliferate in 
suspension culture, generating spherical colonies, termed neurospheres. The ability to 
generate neurospheres in vitro corresponded with the number of stem cells in the tissue of 
origin (85, 86). Mammary epithelial cells from reduction mammoplasty were cultured on a 
non-adhesive substratum in the presence of EGF and/or FGF. The rationale behind this 
approach was that stem cells do not undergo anoikis, i.e. are able to self-renew and form 
spherical structures in anchorage independent growth conditions. Single cells isolated from 
mammospheres, when cultured, went on to differentiate into ductal, alveolar and 
myoepithelial cells, and have also generated 3D functional structures in Matrigel. 
 1.4.1.2. Breast Cancer Stem cell signature CD44
+
/CD24
low/-
  
 
            A breakthrough in the field of breast cancer stem cells was delivered by the seminal 
work of  Al-Hajj et al. who have identified a putative breast tumour stem-cell-like population 
that is defined by the presence or absence of two cell-surface markers, respectively: CD44 
and CD24 (87). CD24 is a small mucine-type glycosylphosphatidylinositol-linked cell 
surface molecule expressed by hematological malignancies as well as a wide range of solid 
tumours. It is strongly expressed on the majority of human breast cancer cell lines and in 
fresh specimens of human breast carcinoma. The localisation (membranous/cytoplasmic) and 
intensity of its expression correlate with histological grade. Further research into the 
implications of CD24 positivity in breast cancer suggested that it may also enhance 
metastatic potential of the tumour, because CD24 has been identified as a ligand for p-
selectin (an adhesion receptor on activated endothelial cells and platelets) (88). Combined 
expression of CD44 and CD24 in a CD44
+
/CD24
low/-
 phenotype is associated with the lack of 
differentiated breast epithelial cell lineage markers and has 10-50 fold increased ability to 
form tumours in xenografts compared to the bulk breast tumour cells (87, 89). 
 Following the footsteps of Al-Hajj et al., the group of Weinberg et al. elegantly 
recapitulated and expanded the characterisation of the CD44
+
/CD24
low/-
 population of cells. 
They have demonstrated a positive correlation between the stem cell phenotype and the EMT 
signature in breast cell lines, as well as in clinical specimens, and successfully converged 
39 
 
these two lines of research. Namely, as expected, human mammary epithelial cells stratified 
for the CD44
+
/CD24
low/-
 signature, were able to self-renew and form mammospheres with 
great efficacy. Single cell analysis of the mammospheres confirmed the presence of a mixed 
population of luminal (CK18 positive), basal/myoepithelial (CK14 positive) and a small 
fraction of bi-potential cells (CK18/14 positive). Conversely, CD44
low/-
/CD24
high 
counterpart 
population produced single cell clones predominantly positive for the luminal cytokeratin, 
CK18 (90). Importantly, cells harbouring the CD44
+
/CD24
low/- 
phenotype appeared to have 
pronounced mesenchymal features, and upon analysis of gene expression were shown to be 
significantly enriched for the EMT associated markers relative to the CD44
low/-
/CD24
high 
cells. E-cadherin (CDH1) levels were reduced 150 fold, while expression of vimentin (VIM), 
N-cadherin (CDH2), Twist1, Snail (SNAI1), Fibronectin (FN1), FOXC2 and SIP1 were 
elevated between 20- and 200-fold. Overexpression of Twist and Snail in the CD44
low/-
/CD24
high 
cells was sufficient to induce a complete EMT program which resulted in the 
expansion of this pool of cells and production of the population with the stem cell 
CD44
+
/CD24
low/- 
features (90). Stem cells isolated from both reduction mammoplasties and 
primary breast cancer tissue confirmed enrichment in EMT markers.  
            Aldehyde dehydrogenase 1 (ALDH1) has been identified as another reliable breast 
cancer stem cell marker, as it was demonstrated that fewer ALDH1
+
 than CD44
+
/CD24
low/-
 
cells were needed to give rise to tumours in nude mice (91), while analysis of 577 clinical 
specimens yielded ALDH1 as a significant prognostic indicator of adverse survival and 
correlated with high cancer grade, stage and presence of metastasis. Furthermore, the 
population of ALDH1
+
 cells, was cross-matched against the intrinsic characteristics of known 
breast cancer subtypes (15), and a striking overlap was observed between gene signatures 
obtained from ALDH1
+ 
cells and the basal like breast cancer cohort (92, 93).   
 Prevalence of breast cancer stem cells, either those identified by the 
CD44
+
/CD24
low/-
 or the aldehyde dehydrogenase 1 positivity (ALDH1) as a marker, was to 
date analysed in 12 clinical studies encompassing a total of 898 breast cancer cases. Meta-
analysis confirmed that both the presence of CD44
+
/CD24
low/-
 cells and ALDH1
+
 cells 
correlated with poor overall survival of breast cancer patients (p < 0.001) (94). 
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 There are multiple lines of evidence supporting convergence of the two fields of 
research, the cancer stem cells and the EMT. Further reinforcement of this notion lies in the 
findings that the CD44
+
/CD24
low/-  
phenotype appears to be predominant in the basal B group 
of cell lines (55, 87, 95), which are enriched for EMT markers, as well as experimental 
approaches which showed that transplantation of EMT-like tumour cells from conditioned 
mutant BRCA1 mice, produced cells with the CD44
+
/CD24
low/- 
phenotype (96); while 
mammary cells undergoing EMT in response to treatment with TGF-β displayed enhanced 
mammosphere forming capacity (97). Conversely, mammosphere forming ability of normal 
breast stem cells and breast cancer stem cells was inhibited by shutting down the EMT 
program (98).  
 More evidence arises from the studies which demonstrate that standard anti-cancer 
treatment regimens (chemotherapy and hormonal therapy) result in an increase of 
CD44
+
/CD24
low/- 
stem cells in residual tumour tissue irrespective of the breast cancer 
subtype, as determined by analysing pre- and post- treatment biopsies (99). Furthermore, 
expression of the EMT hallmark, vimentin, was found enhanced at the leading edge of the 
tumours in the post-treatment biopsies, indicating simultaneous activation of the EMT 
process by the administered therapies (100), while this induction of EMT contributed to 
decreased efficacy of chemotherapy in solid tumours (101, 102). 
 Concomitant expression of EMT markers and cancer stem cell characteristics was 
also observed in the population of circulating tumour cells (CTCs) of cancer patients, 
implying that these cells have undergone an intrinsic modification of their phenotype to 
supports aggressive, metastatic behavior (103). CTCs are cancer cells detectable in the 
peripheral blood of both patients with primary cancer and metastatic disease. They provide 
evidence of the early dissemination of primary tumours through the systemic blood flow and 
represent an attractive therapeutic target. Considerable efforts are being made to identify 
markers for sensitive and specific detection, and thereby targeting of the CTCs, as these cells 
are perceived to be precursors of metastatic disease. A standardised method of CTC isolation 
from peripheral blood entails enrichment of CTCs by using cell surface markers, CD45 
(lymphocyte marker), EpCAM (epithelial cell marker) and pan-cytokeratin (CK). The 
standard definition of CTCs is the CD45
-
/EpCAM
+
/CK
+ 
phenotype, however the loss of 
epithelial markers due to intrinsic EMT modifications that CTCs undergo, could be the 
reason why we may be underscoring the presence of CTCs by this conventional isolation 
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method. The fact that the activity of the PI3K/Akt pathway, as well as the expression of 
Twist, fibronectin, vimentin and ALDH1 are elevated in CTCs, proposes that these cells 
possess both the EMT and the cancer stem cell features (104).  Furthermore, a proportion of 
EpCAM
+
/CK
-  
cells from the blood of breast cancer patients display equally high levels of the 
EMT markers, fibronectin and vimentin (105). Most of these cells originated from patients 
whose tumours were of the basal phenotype, where downregulation of luminal cytokeratins is 
not a rare feature. Furthermore, limitations in detecting accurate numbers of CTCs may stem 
from the loss of surface EpCAM due to its cleavage, and explain why we are sometimes not 
detecting CTCs in patients with aggressive disease (106).  
            Breast cancer stem cells and EMT derived metastasis-initiating cells share many 
commonalities in the cellular genotype, phenotype, aggressive behaviour (107), as well as in 
the signaling pathways which sustain them (Hedghog, Wnt, Notch) (108-111). Collectively, 
these data support the hypothesis of acquisition of stemness through the EMT. Therefore, an 
integration of the cancer stem cell hypothesis with the EMT model may best explain the 
origin of cancer progression and yield a working platform for investigation and elucidation of 
markers and pathways best suited as therapeutic targets for timely prevention of metastasis 
(112).        
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Figure 8.Cancer stem cells. Cancer stem cells undergo symmetrical cell division expanding the pool 
of cancer stem cells, as well as asymmetrical cell division giving rise to cancer progenitor cells. They 
are able to differentiate into distinct cell lineages of the breast tumour, i.e. luminal and myoepithelial 
cells. Anti-cancer therapies are successful in eradicating differentiated cancer cells, while the cancer 
progenitor/stem cells evade the therapeutic effects and act as a reservoir of disease recurrence.  
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 1.5. Notch signaling 
 
            The Notch signaling pathway is referred to as the „aristocracy‟ on the „social ladder‟ 
of pathways, due to its preservation amongst the species and importance in both embryonal 
development and adult tissue function (113). Moreover, Notch signaling is found in a rare 
population of cancer stem cells that are proving to be a challenging target in oncology (110).             
Much of what we now know about Notch receptors and signaling comes from studies in 
Drosophila and C.elegans (114). Extensive data from studies on Notch in these two species 
served as a background to engage in the research about Notch in vertebrates. 
            Humans have four Notch receptors (Notch1-4). They are single-pass, type-I 
membrane proteins, composed of an extracellular
 
(ECD), transmembrane (TMD) and 
intracellular
 
(ICD) domains (115). Notch-ECD subunit contains a variable number of EGF-
like repeats, and three Lin/Notch repeats (Lin being the Notch-related gene in C.elegans) 
(116). The three Lin/Notch repeats constitute the negative regulatory region (NRR) of the 
Notch-ECD, which preserves the Notch receptor in a cleavage resistant conformation before 
the ligand-induced Notch activation (117). It therefore acts as a Notch auto-inhibitor in order 
to maintain cellular homeostasis of Notch signaling. The EGF-like repeats mediate Ca
2+
-
dependent interaction between Notch-ECD and Notch-TMD. Notch-ICD also includes a 
“RAM23” sequence, which is composed of: i) a series of ankyrin repeats (ANK); ii) a nuclear 
localisation sequence; iii) a poly-glutamin stretch and; iv) a PEST sequence that modulates 
receptor half-life (114, 115). 
              Three ligands identified in invertebrates bind to Notch receptors: Delta, Serrate and 
LAG-2, forming a DSL family. A mammalian homologue of Delta ligands are Delta-like 
ligands (Dll-1, -2 and -4). Mammalian equivalent of Serrate ligands are Jagged 1 and Jagged2 
(116).  Hence, there are at least 5 separate Notch ligands in humans. Notch receptors and 
ligands are subject to N-linked glycosylation. In 1990, Irvine et al. identified a gene in flies 
called Fringe, and in 1997 a mammalian Fringe family was identified consisting of three 
genes: Lunatic-, Manic- and Radical-Fringe (116). Proteins encoded by these genes are 
homologues to bacterial glycolyltransferases, suggesting they might regulate glycosylation of 
Notch and its ligands. Fringe proteins add a β1 3-linked N-acetyl-Glucosamine to the O-
linked Fucose residue of Notch and its ligands. Notch receptors acquire affinity ligand 
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binding through the O-fucosyltransferase 1 mediated fucosylation. Subsequently, Fringe acts 
to affect specificity of Notch for either ligand. It has not been elucidated yet which ligand 
activates which receptor. Most likely there is an overlap. There is also evidence that ligands 
other than Delta and Jagged, such as F3/contactin can also activate Notch in a CSL-
independent manner (118).   
               1.5.1. Notch signaling begins in the plasma membrane and ends in the 
nucleus 
Before ligand binding, the ECD of the Notch receptor is cleaved at the S1 cleavage 
site by a furine-like protease (117) (119). Ligand binding dissociates Notch-ECD from the 
TM domain, and the ECD-ligand complex is endocytosed into the neighbouring ligand-
expressing cell (120). Dissociation also triggers a cleavage of the Notch-ECD by ADAM10 
or ADAM17 enzymes at the S2 cleavage site, followed by the intra-membranous cleavage by 
the gamma-secretase (GS), at the S3 cleavage site. This releases the Notch-ICD, which then 
translocates to the cell nucleus and interacts with the DNA-binding, CSL (CBF1/Su(H)/Lag2) 
transcription factor and the transcriptional co-activator Mastermind (MML1) to modulate 
transcription of target genes (115). Notch target genes are transcriptional repressors such as 
Hes and Hey (121), as well as cyclin D1 (122), c-myc (123, 124), p21/WAF (125), Bcl-2 (126) 
etc. Cleavage of the Notch receptor by GS can occur at several positions within the 1743-
1746 a.a. region of the protein, yielding distinct species of Notch-ICDs, with variable half-
lives. Notch-ICD Val 1744 is the most stable one, and is the critical signaling component. 
Notch-ICD-Leu and -Ser are both short-lived species that, if generated, result in transient 
gene expression. However, at present, there are no reagents available to investigate the 
relative expression of these cleaved Notch variants in the tissue and determine their potential 
clinical significance (127). 
 1.5.2. Regulation of Notch signaling by Numb 
             Both in normal breast cell lines transformed by overexpression of Notch, and in 
cancer cell lines with innate Notch hyperactivation, a reduction or loss of Numb activity is 
noted. Numb is a negative regulator of Notch activity. It limits signaling through Notch, 
without altering receptor-ligand binding. Numb normally acts as an onco-suppressor and 
Notch/Numb antagonism controls proliferative/differentiation balance. When Notch is 
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overexpressed, Numb is lost through ubiquitination and proteasomal degradation. In normal 
breast tissue, staining for Numb is intense and homogenous, and in breast cancer samples 
Numb is lost, predominantly in high grade tumours (128). In support of the Notch-Numb 
biological antagonism, Numb overexpression targets Notch for polyubiquitination and 
proteosomal degradation (129).  
 In connection to the study of Stylianou et al., Numb overexpression in invasive 
breast cancer cell lines suppressed Notch, restored E-cadherin levels, and resulted in a change 
of cell morphology to a less invasive phenotype. Numb expression also correlated with stem 
cell markers in basal breast cancer, which are known for their dependency on Notch signaling 
(130). Furthermore, induction of Numb in breast cancer stem-cells, which exhibit the 
CD44
+
/CD24
low/-
 phenotype, impeded Notch-induced cell propagation (131). 
 Apart from the Notch/Numb signaling dependency, Notch is extensively related to 
other signaling pathways in the cell, where this cross-talk is certain to account for some of the 
effects of Notch activation. There is evidence that interactions between Notch and other 
pathways not only stimulate tumour development, but also tumour angiogenesis via the cross-
talk between tumour and endothelial cells, as well as cellular motility and invasiveness by 
upregulation of the EMT-promoting factors (132, 133). For example, a so called „love-hate‟ 
relationship between Notch and Ras has been explored in Drosophila and C.elegans, and to 
some extent in humans, revealing that both Ras and Notch may act as oncogenes and as 
tumour-suppressors. Their individual activity and nature of this cross-talk is highly context 
dependent (134). Ras-mediated activation of the p38 pathway is responsible for inducing 
Notch activity in Ras-transformed cells, while inhibition of Notch by genetic and chemical 
approaches partially reversed the Ras-transformed phenotype. Furthermore, the kinetics of 
Notch1 signaling is accelerated in Ras-transformed cells (135). The interaction between the 
Notch receptors is relatively unknown and may play a distinct role in maintaining the 
equilibrium of Notch signaling. It has been suggested that Notch2 activity may suppress 
Notch1 and Notch3, while Notch1 possessed the ability to induce expression of Notch4 
(136).  
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1.5.3. Notch in human malignancies        
Preclinical and clinical evidence support the role of Notch signaling in both 
hematological malignancies and solid tumours. Almost 60% of T-cell actute lymphoblastic 
leukemias (T-ALL) bear activating translocations in the Notch1 receptor, while constitutively 
active Notch is also present in B-cell chronic lymphocytic leukemia (B-CLL) (137, 138). 
Some studies report anti-tumour effects achieved by inhibiting Notch in Hodgkin lymphoma 
and multiple myeloma (139, 140). Aberrant Notch signaling has been discovered in 30% of 
non-small-cell lung cancers, concomitant with the loss of Numb expression, while 10% of 
these tumours were found to bear Notch activating mutations (141). Gene amplification of 
Notch3 causes its overexpression in non-small cell lung cancer and ovarian cancer (142, 
143). In the latter, high Notch3 levels are observed in > 60% of squamous-cell carcinomas 
and correlate with advanced stage of disease, resistance to chemotherapy and worse overall 
survival (144). High Notch1 levels confer worse prognosis in head and neck cancer (145). 
Signaling via Notch1 contributes to the development of colon cancer, and chemotherapy-
based regimens activate Notch1 in colon cancer as a means of developing resistance to 
treatment (146). Expression and activity of Notch are enhanced in metastatic prostate cancer 
compared to non-malignant prostate tissue (147). Targeted knockdown of Notch1 in prostate 
cancer cells results in inhibition of proliferation and invasion, mediated by Akt/mTOR 
pathways and MMP9/urokinase plasminogen activator (uPAR) (148, 149). Pancreatic cancer, 
being one of the most aggressive malignancies and certainly the one with the narrowest 
therapeutic spectrum, displays dependence on activated Notch1 and Notch3 for proliferation 
in vitro and in animal models. In addition, concomitant treatment of pancreatic cancer with 
Notch inhibitors and gemcitabine enhances response to chemotherapy (150). Glioblastoma 
multiforme is an aggressive brain tumour where Notch2 expression has been recorded. 
Inhibition of Notch 2 in this setting reduced tumour mass and enhanced response to both 
radiation treatment and chemotherapy (151).  
Even though Notch behaves as a potent oncogene in the majority of human 
malignancies, there are certain cancer types (skin cancers, small cell lung cancer, 
hepatocellular carcinoma), where Notch has been attributed the role of a tumour-suppressor 
(152). In a breast cancer MDA-MB-231 xenograft model, overexpression of active Notch2 
acted as an onco-suppressor and reduced tumour formation in nude mice (153).  
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The latest report suggests that silencing Notch1 and Notch2 in blood cells induces 
expression of genes specific for myelomonocitic lineage, resulting in a condition resembling 
chronic myeloide leukemia in mice. This study does not despute the oncogenic role of Notch 
in other hematological disorders such as lymphoma and T-ALL, but rather emphasises that 
the therapeutic window of Notch silencing may be dictated by the effects of Notch pathway 
inhibition on other cell types, such as myeloid progenitors (154).  
1.5.4. Notch in breast tissue 
             In a study by Stylianou and coworkers, normal breast tissue from reduction 
mammoplasty and breast cancer tissue were analysed for the presence and localisation of 
Notch receptors and their ligands (155). Results have shown that Notch1 and 3, Dll4 and 
Jagged1 and 2 are expressed in normal luminal epithelial cells of the breast. Marked 
reduction of E-cadherin was noted in Notch expressing cells, but no change in CK 8/18 
expression, confirming that these cells did not transform from luminal to myoepithelial, but 
rather that the observed change in cell morphology towards a spindle-like shape, occurred 
due to loss of cell-cell adhesions. Furthermore, viable single cells were seen, suggesting these 
cell lines were resistant to anoikis. Overexpression of Notch in normal breast cell lines 
abolished p53-mediated apoptotic response to cellular damage (155). In addition, in primary 
breast cancer tissue samples, colocalisation of Notch1 and Muc1 (luminal epithelial marker) 
confirmed upregulated Notch activation in luminal epithelial breast cancer cells. Increased 
Notch signaling was also found in premalignant breast lesions (156), while high Notch 
signaling in ductal carcinoma in situ (DCIS) was able to predict which lesions are likely to 
recur within five years (157). This suggests that aberrant Notch signaling may be an early 
event in breast tumour development. Particularly high levels of Notch activity have been 
associated with triple-negative breast cancers (158). Notch signaling was found activated in 
ERα positive breast cancers that possess de novo or acquired resistant to anti-hormonal agents 
(159). ERα positive breast cancers benefit from the well established treatment with tamoxifen 
(160). However, during the course of treatment ~50% of patients develop resistance and 
ultimately relapse. Notch has the capacity to activate ERα-related genes in both an estrogen-
dependent and an estrogen-independent manner.  
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Notch achieves this through the IKKα transcription factor dependent chromatin recruitment 
of the CSL/MML1/Notch-ICD transcriptional complex to the close proximity of the estrogen 
response elements (EREs) of target genes (159). In ERα negative breast cancers, Notch 
achieves its tumour-promoting role by supporting cell survival and inhibiting apoptosis (161). 
In clinical samples, co-overexpression on Notch1-ICD and survivin was segregated to ERα 
negative, basal breast cancers, which displayed a marked Notch-survivin gene signature and 
unfavorable overall survival (158). Regulation of surviving signaling by Notch has also been 
described in non-small-cell lung cancer (162). 
HER2 overexpressing/amplified breast cancers are candidates for targeted therapy 
with trastuzumab (anti-HER2 monoclonal antibody), where existence of de novo or acquired 
resistance is a major hurdle for therapeutic success. Activation of Notch signaling serves as 
one of the mechanisms of resistance to anti-HER2 therapies. Treatment with a gamma-
secretase inhibitor in a murine model of breast cancer resensitised breast cancer cells to 
trastuzumab (163). In colon cancer, treatment with several chemotherapeutic agents 
(irinotecan, 5-Fluorouracile and oxaliplatin) induced Notch1-ICD overexpression by 
elevating the enzymatic activity of the gamma-secretase through enhanced expression of 
presenilin and nicastrin. A gamma-secretase inhibitor in this model served to resensitise cells 
to chemotherapy agents (146). Cross-talk of EGFR and Notch has been identified in basal-
like breast cancers, lung and skin cancers, and glioma (164). Notch activation can also act to 
sustain Ras and PI3K/Akt and mTOR signaling (150, 165) in the presence of either EGFR or 
HER2 inhibition, thereby allowing cell survival and proliferation. These studies suggest that 
activation of Notch may be a means of resistance to both unselective (chemotherapy) and 
targeted therapies in multiple cancer types. Combinational therapies that would incorporate 
gamma-secretase or Notch inhibitors into existing protocols could deliver survival benefit to 
patients.  
1.5.5. Notch in EMT 
Downregulation of E-cadherin, the integral component of cell-to-cell adhesions, is 
one of the hallmarks of EMT, which occurs predominantly due to the transcriptional 
suppression of the CDH1 gene via functional cooperation of the bone fide EMT promoting 
TFs (Snail, Twist, Slug, SIP1) (166). These TFs appear to be transcriptional targets of an 
active Notch pathway in the state of hypoxia.  
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Namely, the hypoxia induced factor HIF1α, acts to increase expression of Notch 
receptors, ligands and Notch target genes in breast cancer cells, concomitantly elevating the 
levels of Snail and Slug, which repress E-cadherin expression. This results in increased breast 
cell motility and invasion (167, 168). Interestingly, the same functional interplay between 
Notch and E-cadherin transcriptional regulators in the state of reduced oxygenation of  
tumour cells was noted in cervical, ovarian, colon and glioblastoma cancer cell lines (169). In 
these cell lines, hypoxia triggered Notch1 signaling and binding of Notch1-ICD to Snail and 
Slug promoters, confirming that these important EMT promoting TFs are direct 
transcriptional targets of Notch (169). Furthermore, genetic inhibition of Notch, as well as the 
treatment with a gamma-secretase inhibitor, abrogated Snail-mediated repression of CDH1. 
Furthermore, Notch signaling was able to induce HIF1α expression and activity through 
Hes1-mediated induction of Stat3 upon treatment of HeLa cells with doxycyclin (170).  
Cooperation of TGF-β and Notch has been extensively studied in the context of EMT, 
since mammary cells exposed to TGF-β treatment demonstrate upregulated Notch activity, as 
well as increased expression of the Notch ligand Jagged1 (171). Notch inhibition limits TGF-
β-induced stimulation of EMT (171), and FGF and PDGF execute their pro-EMT effects 
partly through Notch1 (172). Importantly, Notch was described as a participant in the Rho-
GTPases signaling pathway known as potent inducer of cancer cell invasion (173, 174). In 
cervical cancer tissue Notch1 and RhoC expression colocalised, while inhibition of Notch 
signaling reduced RhoC levels (175). All of these results yield Notch signaling pathway as an 
important inducer and participant in the EMT program in cancer cells. 
   1.5.6. Notch in mammary cancer stem cells 
Some of the most compelling evidence for the role of Notch signaling in the 
maintenance of cancer stem cells comes from the models of breast cancer. Utilising the 
CD44
+
/CD24
low/-
/ESA
+
 phenotype, breast cancer stem cell (BCSC)-enriched population was 
isolated from MCF-7 and MDA-MB-231 cell lines, as well as clinical samples (cancer cells 
from pleural effusions of breast cancer patients) (176). The importamnce of individual Notch 
receptors was assessed for the survival and propagation of these cells. Interestingly, while 
expression of both active Notch1 and Notch4 were detected in the BCSCs from all three 
sources, signaling through Notch4 was notably more important, demonstrating 20-fold higher 
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levels in BCSCs than the non-stem cell counterpart. Inhibition of Notch signaling using a 
chemical compound DAPT (N-[N-(3,5- difluorophenacetyl)-L-alanyl]-S-phenylglycine t-
butyl ester), was able to reduce the mammosphere forming capacity of the BCSCs by 30%; 
Notch1 gene silencing had negligible effects; while the most potent inhibition of sphere 
growth (60%) was achieved through targeted silencing of Notch4 (176). Similarly, in an 
independent study, mammosphere forming efficiency of breast DCIS was inhibited by a 
Notch4 neutralising antibody (157). 
To further support the role of Notch in cancer stem cells, Notch3 and Jagged1 are 
upregulated in breast cancer stem cells due to increased p66Shc levels, where they cooperate 
to maintain survival of mammary stem cells in the state of hypoxia (177). Furthermore, 
inhibition of Notch signaling by DAPT significantly disabled the mammosphere forming 
potential of mammary stem cells bearing low levels of the p53 tumour suppressor gene (178). 
Overexpression of a constitutively active p63 (ΔNp63α) in MCF-7 breast cancer cells 
increased the CD44
+
/CD24
low/-
 stem cell population from 2.2 to 25 %, accompanied by an 
increase in Notch1 activity, enhanced cell proliferation, resistance to anoikis and potent 
xenograft growth (179).  
Strong evidence exists, both from cell lines and patient tumours, supporting the 
importance of Notch signaling, not only in differentiated tumour cells but cancer initiating 
cells alike. The Notch pathway is therefore an attractive therapeutic target in hematological 
malignancies and many solid tumours, including breast cancer. 
1.5.7. Targeting Notch signaling 
Notch signaling is highly context dependent and the contribution of the four 
individual Notch receptors is not equal in all tissues. The dynamics of the Notch signaling is 
variable and complete abolishment Notch activity in cells may not be required for achieving 
therapeutic benefit. Given the stepwise activation pattern of the Notch axis, inhibition of this 
pathway can be achieved on multiple levels.  
Since Notch receptors are activated by receptor-ligand binding, this step can be 
blocked by ligand blocking antibodies such as an antagonistic MAb against Dll-4. A peptide 
consisting of Notch1 EGF repeats that mimics the ligand binding site was also used in 
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keratinocytes to abolish Notch1 activation (180, 181). Prevention of the cleaved Notch-ECD-
ligand trans-endocytosis can also attenuate Notch signal emission (182).  
Given the severity of side effects that result from the simultaneous inhibition of Notch 
receptors, particularly Notch1 and Notch2, development of therapeutic MAbs against each 
individual Notch is a major breakthrough. Therapeutic antibodies directed against the NNRs 
of the individual Notch receptors interfere with conformational changes that are a prerequisite 
for cleavage by ADAM sheddases at the S2 cleavage site (183). Selective versus collective 
Notch targeting that these MAbs may achieve, could allow for a more specific treatment 
approach, reduced side effects and elucidation of discrete functions of individual Notch 
receptors. Next, the ADAM protease inhibitors can be used to prevent the sequential alpha 
cleavage that occurs in the Notch extracellular domain and renders it „recognisable‟ for the 
gamma-secretase cleavage at the S3 site (184). GS modulators and inhibitors are therefore 
being widely explored as attractive therapeutic tools to achieve Notch inhibition (185, 186).   
GS modulators are a subset of therapeutics whose mode of action relies on modifying 
the relative proportions of the Aβ isoforms, without changing the rate at which the amyloid 
precursor protein (APP) is processed (187). They can act either via targeting the gamma-
secretase enzyme, interfering with its conformation and therefore ability to cleave the 
substrate (188), or with the substrate itself (189). GS modulators are predominantly being 
designed as anti-Alzheimer‟s drugs, targeting the Aβ while there are few GSMs which 
simultaneously hinder Notch processing. 
Gamma-secretase inhibitors (GSIs) are another class of drugs used to inhibit Notch 
signaling. Several characteristics of the gamma-secretase (GS) enzyme represent an obstacle 
for the targeted drug design. Firstly, GS is a multi-protein enzyme complex. Secondly, 
detailed 3D structure and exact conformation of an active membrane embedded composite 
are unknown. Finally, there are over 60 described GS substrates apart from the Notch 
receptors (190), challenging the design of a substrate-specific GS inhibitor, which would be a 
desired notion in order to achieve therapeutic benefit while minimising side effects and 
toxicity. 
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1.6. Gamma-secretase inhibitors 
Gamma-secretase inhibitors (GSI) can be classified into three categories based on the 
location where they bind the GS complex.  
1) Transition-state analogues interact with the two aspartates in the active site of the 
enzyme, positioned at the internal interface of the presenilin N-terminal and C-terminal 
fragments (191). Immobilised transition-state analogues (peptide aldehydes) served to purify 
presenilin-accompanying molecules of the GS. However, since the APP substrate was 
copurified along with the enzyme complex, this implied that the active site and the substrate-
binding site of the GS are in close proximity but nevertheless distinct (192).  
2) Docking-site peptides (helical peptide inhibitors) were designed and affinity- 
labeled to mark the interaction point with the enzyme. It proved to be located on the outer 
presenilin N- and C- terminal interface (193).  
3) A spectrum of other GSIs comprises of DAPT (dipeptide analogue) (194), 
compound E (a potent GSI derived by C-terminal modification of DAPT with 
benzodiazepine-like moieties) (195), and related benzodiazepine-like (LY-411,575) (196), 
and sulphonamide analogues (MRK-560) (197), all with enhanced and adjusted in vivo 
properties. Affinity labeling of all these compounds suggested that presenilin is the preferred 
binding component of the GSIs (195). Do date, there are no GSIs directed against other GS 
components: Aph-1, PEN2 or NCT. 
Several non-competitive, orally administered GSIs are being investigated in clinical 
trials for the treatment of Azheimer‟s disease: LY-450139 (198, 199), BMS-299897 (200) 
etc.). Likewise, compounds like MK-0752 (Merck), PF-308414 (Pfizer), RO4929097 
(Roche), are introduced into Phase I and II clinical trials in patients with malignant disease 
(Table 3). They are administered as single agents or in combination with existing therapies 
(chemotherapy, hormonal treatment, anti-angiogenic agents), proving a synergistic effect and 
an enhancement in cancer cell apoptosis (201). The trials have been designed to establish 
safety and tolerability, pharmacokinetics and pharmacodynamics of GSIs, tumour response 
and biomarkers of response.  
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Table3.Clinical trials with gamma-secretase inhibitors (www.clinicaltrials.gov) 
 
GSI Trial Setting Additional drug / 
 
Primary Endpoint 
Phase 
RO4929097 Relapsed or Refractory Solid Tumours, 
CNS Tumours, Lymphoma, or T-Cell 
Leukemia 
Dexamethasone/  
side effects and best dose 
I and II 
RO4929097  Advanced Solid Tumours Cediranib maleate/Side effects 
Pharmacokinetic,Pharmacodynamic 
I 
RO4929097 Post-Menopausal Women With Hormone 
Receptor-Positive Stage II or Stage III 
Breast Cancer 
Letrozole/ side effects and best dose Neoadjuvant Ib 
RO4929097  Advanced or Metastatic Sarcoma Hedgehog antagonist GDC-0449/  
side effects and best dose 
I and II 
RO4929097  Recurrent or Metastatic Melanoma cisplatin, vinblastine,  
temozolomide/side effects and best dose 
Ib and II 
RO4929097  Advanced Solid Tumours gemcitabine hydrochloride/  
side effects and best dose 
I 
RO4929097 Stage IIIB, Stage IV, or Recurrent Non-
Small Cell Lung Cancer 
Erlotinib/  
side effects and best dose 
I 
RO4929097 Pre- and Postmenopausal Patients With 
Advanced or Metastatic Breast Cancer 
Exemestane/  
dose escalation and efficacy 
I and II 
 
RO4929097  Previously Treated Prostate Cancer Bicalutamide/efficacy II 
RO4929097 Previously Treated Metastatic Pancreatic 
Cancer 
None/efficacy II 
RO4929097 Stage II or Stage III Triple-Negative 
Breast Cancer 
Paclitaxel And Carboplatin/  
side effects and the best dose 
Neoadjuvant  I 
RO4929097 Advanced Non-Small Cell Lung Cancer 
Who Are Progression-Free After 
Finishing Treatment With Front-Line 
Chemotherapy 
None/Pharmacodinamics II 
RO4929097 Recurrent Invasive Gliomas None/ side effects and best dose I 
RO4929097 Multiple Myeloma after Autologous Stem 
Cell Transplant  
Melphalan/efficacy II 
RO4929097 Advanced Solid Tumours (kidney and 
endometrial cancers) 
Temsirolimus/ side effects and best dose I 
RO4929097 Recurrent and/or Metastatic Epithelial 
Ovarian Cancer, Fallopian Tube Cancer, 
or Primary Peritoneal Cancer 
None/ efficacy II 
RO4929097 Advanced, Metastatic, or Recurrent 
Breast Cancer 
None/ efficacy II 
RO4929097 Advanced Breast Cancer Hedgehog antagonist GDC-0449/  
Dose-escalation and side effects  
 I  
 
PF-03084014 Advanced Cancer And Leukemia  None/Dose escalation and safety I 
MK-0752 Early Stage Breast Cancer Combination with Tamoxifen or Letrozole/ 
safety and tolerability 
Neoadjuvant 
Pilot Study 
MK-0752 Treating patients With Advanced Cancer Ridaforolimus/efficacy I 
MK-0752 Stage IV Pancreatic Cancer That Cannot 
Be Removed by Surgery 
Gemcitabine hydrochloride/ side effects 
and best dose 
I and II 
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In terms of the mechanism of action by which the GSIs induce the anti-tumour 
effects, the compound PF-03084014 for example, induces a sub-G1 cellular arrest, cleavage 
of caspase-3 and PARP, and a robust regulation of the total Rb protein and p27/Kip1, which 
mediate apoptosis (202). The latest report from a pilot study using a GSI in breast cancer 
patients confirmed that a short exposure to MK-0752 in conjunction with tamoxifen or an 
aromatase inhibitor (AI) in ERα positive breast cancer patients, contributes towards 
significant biomarker changes in the tumour tissue, compared to hormonal treatment alone. 
Namely, the proliferative marker Ki67, as well as Notch1 and Notch4 were significantly 
decreased, while a pro-apoptotic marker NOXA was elevated in the combination arm 
compared to single agent AI or tamoxifen (203).  
Clinical trials to date have demonstrated that GSIs maintain either stable disease or 
induce a partial response in patients with advanced solid tumours and leukemias. Intermittent 
dosing regimen is superior to continuous drug administration, as it sustains anti-proliferative 
potency while reducing side-effects (202). GSIs beare significant mechanism-based toxic 
properties, possibly derived from the insufficient GS-substrate specificity. Goblet cell 
metaplasia (increased number of Goblet cells in the crypts of the small intestine) is induced 
due to simultaneous inhibition on Notch1 and Notch2 receptors in the intestines, and results 
in nausea and diarrhea as notable GI side-effects (204). The mechanism behind the GSI-
induced intestinal toxicity is Hes1-mediated transcriptional regulation of the Krüppel-like 
zink finger transcription factor (Klf4), functioning downstream of Notch in the intestines. 
Klf4 is required for goblet cell differentiation and is a direct target gene of a transcriptional 
repressor Hes1. Inhibition of Notch signaling via a GSI, and thereby reversal of Hes1 induced 
repression on Klf4, results in increased Klf4 expression and disregulated cell differentiation in 
the intestinal crypts and villi. This is ameliorated by simultaneous administration of 
dexamethasone (205). Other adverse events recorded due to Notch inhibition have been 
fatigue and rash (hand-foot syndrome). If presented as grade 3/4, these adverse events are 
taken as dose-limiting toxicities. Further clinical investigations of GSIs and improvements in 
the dose and treatment scheduling regimens continue. 
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1.6.1. The GSI response signature 
Molecular and gene signatures are novel tools used in the era of tailored patient 
treatment to determine the exact characteristics of the cancer and derive not only prognostic 
conclusions, but also predict response to certain types of treatment. Some of these assays are 
already incorporated into clinical practice (Oncotype DX, MammaPrint) (206, 207).  
Watters et al. have conducted de novo analysis of gene expression patterns occurring 
in response to a GSI (MRK-003). They used a murine models of HER2-inducible breast 
cancer, where analysed tumours (n = 107) displayed a range of histological breast cancer 
subtypes (luminal, basal), variable stromal involvement and cytokine staining, as well as a 
heterogeneity of the Notch pathway activation, determined by mRNA levels of Hes1 and 
Jagged1. The study unraveled 768 genes, termed the „GSI sensitivity signature‟, differentially 
regulated between the group of responders and non-responders. Signaling pathways enriched 
at baseline in the tumours that did not benefit from the GSI treatment, were the canonical 
Notch pathway, interleukine (IL-10) and chemokine signaling. (208).  
Another similar study used 15 T-ALL cell lines to determine the baseline activity of 
Notch and correlate it to the sensitivity to a GSI. The composite expression score, named the 
10 Notch Target Score (HES-1, HES-4, HES-5, HEY-L, HEY-2, DTX1, C-MYC, NRARP, 
PTCRA, and SHQ1) was established, which predicted sensitivity to GSIs (209).  
Overexpression of IL-6 and IL-8 in lung cancer cell lines and in the A459 xenograft model 
rendered tumours resistant to RO4929097 and ablated GSI inhibition of Notch signaling. This 
proposed that the serum levels of IL-6 and IL-8 may serve in preselecting the patients eligible 
for RO4929097 treatment. Indeed, in a phase I clinical trial, low baseline serum levels of IL-6 
and IL-8 predicted favourable response to RO4929097 (210). It remains to be tested whether 
the discovered gene signature sets or the interleukin serum level are able predict sensitivity to 
GSIs in other tumour types.  
Another attempt to establish a robust, reproducible and reliable prognostic assay that 
would indicate tumour sensitivity to GSIs is the development of an ex vivo GS activity assay 
(EXO Assay) (211). The method entails processing an excised tumour tissue to obtain a 
concentrated cell membrane preparation which is then incubated with a labeled GS substrate 
that emits a fluorescent signal upon cleavage by the active enzyme. The level of fluorescence 
corresponds to the degree of cleavage, i.e. to the level of GS activity (211). 
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 Some of these methodologies, alone or in combination, once further optimised and 
validated, may constitute a clinically approved GSI/Notch inhibition sensitivity test. 
1.7. The gamma-secretase enzyme 
The Gamma-secretase (GS) complex is one of the few known proteases capable of 
hydrolysing peptide bonds inside the membrane, where the hydrophobic environment 
excludes water molecules fundamental for peptide-bond cleavage. This process is termed the 
regulated intra-membrane proteolysis (RIP) (212).  
Molecular identification of the GS complex occurred in the mid-1990s when the 
autosomal dominant forms of familial Alzheimer‟s disease were associated with underlying 
genetic abnormalities in the form of presenilin missense mutations (213). The hydrophobic 
Aβ42 peptide produced by the GS cleavage of the amyloid precursor protein (APP) is prone 
to aggregation and forms neurotoxic, extracellular, senile plaques, which are the causative 
factor of Alzheimer‟s disease (AD).  
Gamma-secretase is a multi-protein complex formed by nicastrin (NCT), anterior 
pharynx defective homolog 1 (Aph-1), presenilin (PS) and the presenilin enhancer protein 
(PEN2) (Figure 9). Although PS is thought to be the catalytically active component of GS, all 
four proteins are necessary for full proteolytic activity (214). 
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Figure 9.Components of the gamma-secretase (GS) enzyme. Presenilin (PS), PEN2 and Aph-1 
contain multiple transmembrane (TM) spanning regions, whereas nicastrin (NCT) is the only GS 
member that has a single-pass transmembrane domain. In total, there are 19 transmembrane domains 
that contribute to the hydrophobicity of the GS enzyme. GS enzyme cleaves the substrates which are 
also transmembrane proteins. The extracellular domain of the GS substrates is shed by a sheddase 
before being eligible for GS recognition and cleavage. GS cleavage releases the intracellular domain 
(ICD) of the substrate, which is translocated to the cell nucleus, where it regulates target gene 
transcription (215). 
Given the high degree of homology between the human and mouse subunits of the 
GS, the group of De Strooper et al. has performed an elaborate analysis of in vivo GS 
complex expression in mice. Cell membrane preparation, followed by coimmunoprecipitation 
and blue native electrophoresis was used in order to isolate and evaluate GS complex 
components in various mouse tissues.  The GS enzyme was detected as a high molecular 
weight assembly which ranges in size between 380-550 kDa (average MW 440 kDa). The 
variability in the gel shift may be due to post-translational modifications of its components, 
or by the presence of additional cofactors binding the GS complex (216). 
 
 
 
58 
 
Since there are two Aph-1 isoforms (Aph-1a and Aph-1b), and two presenilin 
isoforms (PS1 and PS2) in mammalian cells, combinations of these components can yield 
different GS quartets (Figure 10) (213). It is unknown which cellular parameters influence the 
assembly of different GS complexes, and whether specific combinations of subunits yield an 
enzyme with substrate-preferences. Specific functional requirements and tissue distribution 
and expression levels of GS components and their isoforms may represent the determining 
factors. Recent evidence points that Aph-1a is the isoform required for Notch cleavage in 
mammalian cells, since Aph-1b/c knockout (KO) failed to exert Notch signaling failure in 
mice (217). However, Aph-1b and Aph-1c KO significantly decreased APP processing. 
Furthermore, the GS complex containing PS1 rather than PS2 is more efficient in processing 
the APP (218). Similarly, the PS2 KO mice suffer far less severe phenotypic malformations 
derived from deregulated Notch processing than the PS1 KO mice, indicating that PS2 may 
be dispensable for Notch cleavage by GS (219).  
 
 
                                                
Figure 10.Composition of distinct gamma-secretase complexes. There are two Aph-1 (Aph-1a and 
Aph-1b), and two presenilin isoforms (PS1 and PS2). Combinations of these components with NCT 
and PEN2 can yield different GS quartets. 
 
 
Coordinately high mRNA levels of GS components were detected in the liver, kidney 
and heart in the mouse models, while all four components were moderately transcribed in the 
testicles and weakly in the skeletal muscle. PS1 dominated over PS2 in the testis, with 
inverse levels of these PS isoforms in the liver (216). Surprisingly, protein levels did not 
reflect the abundance of the mRNA, as low expression of the GS members measured by 
western blotting was registered in liver, kidney and heart alike.  
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This suggests that post-translational regulation of GS components may be an 
important determinant of their protein expression and ultimately function. Interestingly, 
further analysis of PS1 and NCT expression in membrane preparations of various mouse 
tissues revealed that they are not coordinately regulated. PS1 was observed in the brain, lung 
and thymus, with low levels in the heart and skeletal muscle, while NCT was detected in the 
skeletal muscle, heart and brain, with lower levels in the liver, lung, spleen and kidnies (220). 
Disconcordance in mRNA levels of the PS1, PS2 and NCT were also detected in dog tissues, 
where NCT transcript levels were high in the liver, spleen, lungs and heart, in contrast to low 
mRNA levels of the PS1 and PS2 in the same organs. Protein levels were not examined, so it 
is plausible that the mRNA abundance did not translate to high levels of the functional 
protein (221). Notably, coimmunoprecipitation experiments using antibodies against PS 
isoforms confirmed that different GS complexes, i.e. one harbouring PS1 and another 
containing PS2, can coexist in the same cell line (216). 
Gene expression profiling using a mouse cDNA microarray has also been carried out 
to identify genes that are transcriptionally susceptible to GS activity (222). The transcriptome 
of the Chinese hamster ovary (CHO) cells engineered to overexpress GS, was compared with 
CHO treated with a GS inhibitor DAPT, revealing that a broad spectrum of functional gene 
groups, pertaining to diverse downstream cellular pathways, were affected by the GS activity. 
These were GS substrates themselves (Notch3, Jagged1, CD44, E-cadherin etc.), as well as 
members of the Wnt signaling pathway, cellular cytoskeleton/adhesion molecules, 
neurotransmitters and transcriptional regulators (222). It remains to be established whether 
this differential gene signature translates to other cellular models, nevertheless the data of 
Magold et al. confirm an overall importance of GS activity in governing diverse cellular 
pathways and functions.  
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1.7.1. Assembly and cellular localisation of the gamma-secretase complex 
Gamma-secretase complex assembly is a step-wise, dynamic and controlled process, 
which is characterised by intensive recycling/retrieval of the GS subunits and subcomplexes 
between the Golgi and the endoplasmic reticulum (ER) (190). GS composition is initiated in 
the ER, where all of the components are inserted after synthesis. Aph-1 binds the N-terminal 
sequence polar residues of the NCT-TMD to form the first subcomplex, a dimmer scaffold to 
which the other components are added (Figure 11) (223).  
 
 
Figure 11.Step-wise assembly of the gamma-secretase complex. NCT and Aph-1 form a dimmer. 
Next, presenilin is added to produce a trimmeric intermediate complex. Finally, PEN2 joins the other 
components and executes PS endoproteolysis which renders the GS complex enzyimatically active. 
 
Interestingly, the same TMD-site polar residues (T670, G674, S681, T685, Y686) that are 
required for Aph-1 binding to NCT, are important for its interaction with the regulatory 
protein retrieval to the endoplasmic reticulum 1 protein (Rer1p). Rer1p is a 23 kDa 
mammalian homologue of a yeast cargo receptor which shuttles between the ER and the 
intermediate compartments/cis-Golgi, where it recognises polar TMD residues of escaped, 
target-ER proteins and unassembled subunits of multimeric complexes, executing a unique 
ER quality-control (224). Interaction with the Rer1p facilitates the transport of NCT between 
the early biosynthetic compartments (225). When the immature NCT leaves the ER, it is 
bound to Rer1p in the cis-Golgi and recycled back to the ER to bind Aph-1, which then 
sterically masks the binding site for Rer1p on NCT, allowing the NCT-Aph-1 dimmer to 
become independent from the Rer1p control mechanism.  
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Repetition of this recycling step also ensures that an adequate amount of the NCT-
Aph-1 dimmer is formed in the ER, which influences the ultimate amount of the fully 
assembled GS complex. Another GS component possessing a Rer1p binding site is PEN2 
(226), suggesting that unassembled PEN2 is also kept in the ER.  
The following steps in GS assembly are subject to two hypotheses. According to the 
first, the PS holoprotein joins the NCT-Aph-1 scaffold (227), by binding to NCT-TMD, and 
forms a trimmeric intermediate subcomplex, most likely in the ER or during the ER-Golgi 
cycling. Since PS contains an ER-retention signal in its C-terminus domain (228) (229), this 
motif is most likely covered by the interaction with NCT-Aph dimmer, securing a maturing 
complex. Lastly, PEN2-TMD1 interacts with the PS-TMD4 to form a complete tatrameric 
assembly, and subsequently PEN2 executes PS endoproteolysis, to yield the PS-C-terminal 
fragment (CTF) and the PS-N-terminal fragment (NTF) (230). PS endoproteolysis takes place 
in the loop domain linking the PS-TMD6 and PS-TMD7. This loop domain may very well be 
blocking the GS substrate interaction with the PS exosite (docking site), explaining why the 
GS remains inactive prior to PS endoproteolysis (231). The second hypothesis prioritises the 
PEN2-mediated PS endoproteolysis before merging with NCT-Aph-1, since NCT-Aph-1-PS 
CTF and NCT-Aph-1-PS NTF subcomplexes have also been identified, and PEN2 has been 
shown to bind the PS holoprotein independently of the NCT-Aph-1 dimmer (Figure 11) 
(232).  
Collectively, generation of the tetrameric GS is achieved during the ER/cis-Golgi 
recycling. Further maturation and initial GS activity are detected in the Golgi/trans-Golgi 
network, finally allowing for the transport and localisation of the competent GS enzyme at 
the plasma membrane. Analyses of the isolated active complex show that the GS contains one 
of each component, i.e. that the GS is a monomeric enzyme with the NCT: Aph-1: PS: PEN2 
stochiometry that has a 1:1:1:1 ratio, respectively (233).  
Apart from Rer1p being the limiting factor which negatively regulates assembly and 
function of the GS, there are other reported endogenous GS-interacting molecules, like the 
CD147 (234) and the transmembrane protein 21 (TMP21) (235), which execute GS 
regulatory roles. CD147 is a transmembrane glycoprotein and a potent extracellular matrix-
metalloprotease inducer, with two Ig-like domains. It coimmunoprecipitates with NCT and 
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the PS1-CTF in a cervical cancer cell line (HeLa) cells, as well as a neuronal cell line HCN-
1A, and human embryonic kidney cells (HEK293) (234).  
CD147 genetic ablation did not influence NCT or PS1 protein levels, although the 
cleavage rate of Aβ was mildly increased (from 25% to 38%). TMP21, a type I 
transmembrane protein involved in vesicular protein transport, was also reported to be an 
accessory to the core GS complex, engaging its TMD segment to bind mature NCT and the 
PS1-NTF, thereby decreasing Aβ42 production (235).  These cofactors, however capable of 
modulating GS activity, are not stably associated with the active GS complex (236). 
1.7.2. Segregation of GS on the plasma membrane 
Plasma membrane is composed of the phospholipid bilayer and contains specialised 
floating compartments rich in cholesterol and sphingolipids, termed lipid rafts (237). Lipid 
rafts serve as organising centres for signaling molecules and compartmentalisation of cellular 
processes. Lipid rafts can be planar (in continuum with the plasma membrane) or 
invaginated, caveolin-rich structures (caveolae) (238). Lipid rafts are detergent insoluble, 
hence can be isolated from the rest of the membrane (239). Detergent solubilisation method 
using Triton X-100 and 3-[(3-Cholamidopropyl) dimethylammonio]-1-propanesulfonate 
(CHAPSO) has been utilised to separate lipid from non-lipid membrane domains. 
Active GS complex, containing all four protein members, associates with lipid rafts in 
a human neuroblastoma cell line (SH-SY5Y) (240). A non-ionic CHAPSO detergent was 
used in order to dissociate these detergent resistant membrane domains, since the treatment 
with the ionic Triton X-100 abolishes GS activity (241). In a PS1 and PS2 KO cells line, 
NCT and PEN2, but not Aph-1 shifted to non-lipid rafts, indicating that localisation of NCT 
and PEN2 in detergent resistant membrane domains is dependent on the presence of PS1/PS2, 
and that Aph-1 may therefore be important for the recruitment of other components to the 
lipid rafts. Since both the immature and the mature NCT equally localise in the lipid rafts, 
NCT glycosylation does not seems to be a requirement for its lipid raft topology. Cholesterol-
sequestration which renders lipid rafts detergent soluble, induced a shift of GS components 
(mature NCT, PS1-CTF, Aph-1 and PEN2) to the ER compartment, while cholesterol 
depletion by statins, although preserving protein levels of GS components, caused relocation 
to the non-lipid rafts. 
63 
 
Experimental photo-labeling of the PS-CTF by the covalently bound photo-reactive 
derivative of a potent transition-state analogue GSI (LY-685,458) in adult mouse brain tissue, 
identified that preferential, but not exclusive localisation of the active GS, are indeed the lipid 
raft-membrane microdomains (242). However, this group also proposed that certain GS 
substrates, like the Notch receptors, N-cadherin and deleted in colon cancer (DCC), are 
located and cleaved in the non-lipid rafts, and further suggested that this shift in membrane 
segregation of the GS substrates and the GS activity may be interchangeable between the 
embryonic and adult state. 
Since the support system of the lipid structure plays an important role in modulating 
GS function, reconstitution of the GS in complex lipid mixtures has revealed the contribution 
of individual lipid species in the regulation of GS activity (243). The most abundant 
phospholipid in cellular membranes is phosphatidylcholine (PC), with a lesser and variable 
contribution of phosphatidylethanolamine (PE), phosphoserine (PS), phosphatidylinositol 
(PI) and phosphatidic acid (PA). Removal of the detergent from the GS preparations 
increased the baseline GS activity by 2-fold, while still preserving the purity of the enzyme 
and the formation of the proteoliposomes closely resembling the native membrane 
environment. In such experimental conditions, GS activity was increased by addition of PE, 
PS and PA to the PC, while the addition of PI caused a decrease in GS activity. GS activity 
was greatly stimulated in an environment containing a combination of PC and sphingomyelin 
(SM), and even more with the addition of cholesterol to the PC/SM mix, which is the innate 
composition of the lipid rafts. Undoubtedly, the phospholipid content of the membrane, and 
more precisely the lipid raft sub-compartments where the GS resides, contribute greatly to the 
level of GS activity, presumably by influencing lipid packing and fluidity of the membrane 
and influencing GS conformation. 
1.7.3. Functional gamma-secretase and the spatial paradox 
The fact that all four GS members are synthesised in the ER, which is theoretically the 
earliest cellular compartment where assembly can take place (244), and yet GS activity is 
restricted to later secretory compartments and plasma membrane, a spatial paradox 
surrounding the composition and function of GS has been postulated (245). 
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A functional GS complex has been identified in multiple cellular compartments, like 
the Golgi/trans-Golgi network, lysosomes, phagosomes, and even mitohondria (246-248). 
Subcellular fractionation and analysis of the membrane vesicles in CHO cells, which express 
endogenous, mature NCT, and were stably transfected with human PEN2, Aph-1, PS and 
APP, revealed enrichment and functional interaction amongst the four components, as well as 
proteolytic generation of the Aβ in the Golgi/trans-Golgi compartment, compared to the ER.   
 Interestingly, proteomix analyses have also identified active GS in the purified 
phagosomes (a vacuole formed by the cell membrane around the particle absorbed by 
phagocytosis) of murine macrophage cells (249). GS members were detected in the maturing 
and mature phagosomes, excluding the option that GS is targeted for phagosomal 
degradation. Glycosylated NCT, processed PS fragments (PS1-CTF and PS1-NTF), Aph-1 
and PEN2 were all enriched in the CHAPSO resistant phagosomal lipid rafts, compared to 
the total membrane preparations. Two GS substrates, CD44 and the low density lipoprotein 
(LDL) are also integral members of the phagosomes, which further corroborates the 
likelihood of GS presence in these specialised membrane organelles. Furthermore, treatment 
with interferon γ (IFN-γ) increased GS activity in the phagosomes, indicating that GS activity 
may be important in the phagocyte-mediated immune response of macrophages (249, 250). 
  The endosomes and lysosomes are predominantly catabolic cellular organelles, 
although they are also involved in repairing plasma membrane tears, and are capable of 
exocytosing the proteins which have reached them. Endocytic vesicles can recycle membrane 
resident proteins multiple times before they are finally targeted for lysosomal degradation. 
PS1 possesses a lysosomal sorting sequence unlike NCT, but both were found to be major 
components of the outer lysosomal membranes. NCT is a resident lysosomal protein in its 
mature state. It colocalises with PS1-CTF, and forms a functional GS complex, executing 
cleavage of the APP to yield the Aβ peptide at the permissive pH of 4.5 in the lysosomes. 
Indeed, lysosomes were found to harbour 30% of the total cellular GS activity (251, 252). 
Another line of work has suggested that the precision of the GS cleavage inferred on its 
substrates may vary between the lysosomes and the plasma membrane due to diverse pH 
conditions (253).  
 
65 
 
It was first determined that PS1 possesses a mitochondrial targeting sequence and is 
present in this cell compartment in the rat brain and liver cells. Likewise, NCT has a 
mitochondrial targeting sequence in the N-terminus. Tissue preparations from the rat brain 
confirm NCT localisation in the mitochondria, and its colocalisation with PS1, Aph-1 and 
PEN2. Therefore, mitochondria contain a fully assembled GS complex that migrates at the 
molecular weight of approximately 500 kDa, in line with previous studies (254). 
Mitochondria are cellular organelles central in the regulation of the cell energy pool but also 
cell death. The GS complex is capable of cleaving the APP in the mitochondria. This is 
relevant in Alzheimer‟s disease where an Aβ42-induced increase in reactive oxygen species 
contributes to neuronal cell death (254). 
Taken together, GS activity is not only restricted to the plasma membrane, but seems 
to be widely distributed in other cellular compartments as well. Further research would be 
required to investigate the potential substrate specificity of the GS in distinct organelles, as 
well as to determine whether this is a uniform finding across all tissues.  
1.7.4. Three-dimensional structure of the gamma-secretase 
The GS enzyme is a unique multimeric complex as it contains 19 TM domains across 
its four subunits (NCT, Aph-1, PS and PEN2), which are embedded in the hydrophobic lipid 
milieu of the plasma membrane. Confoundedly, GS executes the proteolytic cleavage of 
substrates for which hydrophilic environment is preferred, probing the need for elucidation of 
its structure. Two independent predictions of the GS 3D structure came from performing 
negative stain electron microscopy (EM) and 3D reconstruction by Lazarov et al. and Ogura 
et al. They have revealed, albeit in low resolution, a glimpse of the GS three-dimensional 
structure (255, 256). 
Ogura et al. have identified that the assembled GS enzyme assumes a flattened heart 
shape with a boat-like bottom and two outward protruding arms, essentially hanging over the 
putative GS transmembrane domain. The 41,000 x EM magnification identified small cavities 
on the surface and a low-density area in the centre of the visualised structure, corroborating 
the speculation of the existence of the inner enzyme cavity (Figure 12a). Antibody labeling 
revealed that NCT predominantly binds to the arms of the structure and that PS1-CTF is 
closer to the inner pore (256).  
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In more detail, Lazarov et al. performed GS purification, single particle image 
analysis and 3D EM of the GS, identifying the following: i) a large 120 Å long, 70-80 Å 
wide, multi-globular structure, with a 60 Å high circumferential belt corresponding to the 
membrane embedded portion of the GS; ii) an interior cylinder chamber 20-40 Å in length, 
occluded from the hydrophobic surroundings; iii) four individual pores. The pores were 
localised to the top (the exit for the substrate‟s N-terminus into the extracellular space), 
bottom (the cytosolic release door for the cleaved substrate ICD), and at the two side pores of 
the complex postulated to enable entry for the substrates into the inner GS chamber. Labeling 
with lectin, which binds to mannose and glucose residues, localised NCT ectodomain, and 
therefore provided a top-to-bottom orientation of the complex. Likewise, it gave an indication 
that the NCT-ECD, which protrudes into the luminal space, may be shielding the upper pore 
and acting as a control lid that allows entry of the water molecules and exit of the substrate 
N-terminus upon GS cleavage (Figure 12b) (255). 
These data served as a stepping stone for a more detailed analysis utilising the cryo-
EM technique at the resolution of 12 Å. It was confirmed that the GS assumes a globular 
structure with a belt-like motif surrounding the complex, corresponding to the membrane 
imbedded portion of the GS oligomer, and multiple areas of low density depicting the 
predicted communication pores of the inner chamber. The cytoplasmic surface was visualised 
as smooth, while the dominating extracellular part exhibited irregular contours. The diameter 
of the complex was measured at 8-9 nm. A striking novel observation was the membrane 
facing side groove thought to harbour the substrate docking site (Figure 12c) (257). Finally,  
in order to propose a 3D reconstruction of the mature, catalytically active GS complex using 
single particle cryo-EM and a resolution of ~18 Å, the purified GS complex has been labeled 
with an established transition-state analogue GSI (L-685,458), which bound to, and annotated 
the location of the enzyme active site (258). The purified GS enzyme corresponded to a mass 
of ~200 kDa, and had dimensions of: 100 Å in width (x-axis); 70 Å in depth (y-axis), and; 
105 Å in height (z-axis). The 40-50 Å high, belt-like structure, considered to be the GS-
TMD, corresponded to the thickness of the eukaryotic cellular membrane. Nicastrin ECD was 
observed covering most of the membrane surface of the enzyme and measuring 50 Å in 
maximal height.  
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A single central chamber was apparent spanning from the concave surface of the 
NCT- ECD into the membrane, lead to a lateral opening and harboured the region mapped by 
the L-685,458, i.e. the GS active site (Figure 12d). Renzi et al. took a step further and 
compared the relative 3D structures of the NCT-Aph-1-PS trimmeric intermediate and of the 
fully assembled and active GS containing PEN2. PEN2 is required to execute PS 
endoproteolysis, a step which facilitates NCT glycosylation/maturation and conformational 
adjustment, establishing a functional GS enzyme (227). The above comparison indeed noted 
subtle rearrangements in the 3D region of NCT-ECD, corresponding to its conformational 
change, as well as the widening of the central chamber and formation of the lateral opening. 
These are important new information which may also be considered markers of GS functional 
capacity. 
There are some subtle differences between reports of the 3D GS structure, mostly 
derived from different map resolutions and varying detergent solubilising conditions. 
Nevertheless, the postulated 3D structure is intriguing. Much laborious work involving cryo-
EM with resolution < 10 Å and X-ray crystallography is still pending. The current model, 
although somewhat vague in delineating the exact particle position and boundaries, precise 
contours of the outer envelope and the inner pore, as well as the organisation of the active 
site, provides us with a solid GS 3D working model (259). 
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Figure 12.Three-dimensional representation of the GS complex. a) 3D reprojections: boat-like 
bottom and two outward protruding arms of the GS complex, in bright shades. b) Potential 
transmembrane, belt-like structure is outlined. Two openings are labeled: H1-top and H2-bottom 
connecting the inner GS chamber, * NCT ECD. c) 3D cryo-EM structure of the GS. Images from left 
to right correspond to the left-, front- and right-side views. Red line designates a potential substrate 
docking site. d) A double-headed arrow indicates the proposed location of the GS transmembrane 
region; the star depicts location of NCT-ECD; white arrow marks the cavity in the extracellular region 
that extends to the transmembrane region ending in a lateral opening (black arrow). 
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  1.7.5. Gamma-secretase degradome and substrate requirements 
The gamma-secretase degradome represents a subset of the membrane proteome, 
encompassing substrates eligible for GS cleavage. Thus far, over 60 different candidates 
prone to GS cleavage have been identified, and the list is ever growing (190). The range of 
substrates is cell context dependent, which explains why the searches for GS substrates in 
different cell lines yield similar, but not overlapping results. Even though there isn‟t a 
consensus motif in the interaction domain of the substrates with the GS, the enzyme is not 
indiscriminate, as some requirements characterising the putative GS substrates are known. 
Firstly, GS substrates are type-I, intra-membrane proteins whose ECD is truncated by 
ADAM10 or ADAM17 preceding the GS cleavage, while a restricted group of substrates 
undergo BACE1 sheddase cleavage of their ECD. This may be influenced by the presence or 
absence of a cognate ligand in a particular cell context which stimulates the substrate-ECD 
shedding. Generated peptides, annotated as Xβ, analogous to the Aβ denomination, are 
released into the cytosol to execute their specific roles. For example, the Nβ (Notch derived 
peptide) undergoes trans-endocytosis into the neighbouring cells, upon binding to Notch 
ligands, Jagged and Delta. The sequence is known only for a limited number of the cleaved 
peptides, like the Aβ, Nβ, CD44β (212). Secondly, the remaining stub, i.e. the C-terminal 
fragment (CTF) of the substrates needs to be smaller than 40 amino acids. Thirdly, certain 
determinants in the TMD and the cytoplasmic region of the substrates may be needed to 
allow complete endoproteolysis by GS, like a particular conformation of these regions that 
masks possible presence of GS cleavage inhibitory domains. Other determinants could be the 
proximity between the GS and the substrates, i.e. spatial segregation on the membrane, as 
well as accelerated trafficking of the substrates to the cell membrane and turn-over rate at the 
membrane. Some substrates‟ post-translational modifications (palmitoylation of p75) are 
prerequisites for GS processing (260).  
After the substrate is recognised by NCT, the role of the GS active site, which 
contains the highly conserved GxGD sequence motif with the PS C-terminal active site 
aspartate (PS-TMD6 and PS-TMD7), is crucial for the final substrate selection prior to 
cleavage (261). Small side chains of glycin within the GxGD sequence are a structural 
requirement of GS, whichs serve to minimise steric hindrance and allow the formation of the 
permissive conformation for docking of the substrates, and for the active site-substrate 
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interaction (262). There are indications as well, that the PS-TMD regions may play a role in 
GS substrate selectivity, as the I437 mutation in the PS-TMD9 blocked the cleavage of the 
APP while sparing Notch (263). 
1.7.6. Other gamma-secretase substrates 
      1.7.6.1. E-cadherin and its role in regulating cellular junctions 
           E-cadherin is the most important molecule in cell-cell adhesion in epithelial tissues. 
Classical cadherins, including E-cadherin and N-cadherin are single-pass, transmembrane, 
cell-surface proteins that enable formation of cell-cell adhesions and control of other cellular 
behaviours such as differentiation and tissue development. This is mediated by the Ca
2+
 
dependent homophilic interaction of cadherin extracellular domains on adjacent cells. 
Conserved regions on the E-cadherin cytoplasmic tail interact with beta- and gamma-
catenins, that in turn bind to alpha-catenin, docking the whole structure into the actin 
cytoskeleton (264).  
          Besides having a role in normal cells, E-cadherin plays a major role in the malignant 
cell transformation, since the control of cellular adhesion and motility represents the crucial 
mechanism in tumour initiation and progression. Loss of E-cadherin is the hallmark and a 
requisite of EMT. It allows for the tumour cells to detach from the primary site and engage in 
migration and invasion, finally homing themselves as secondary deposits (metastasis) in 
distant sites. In culture models, E-cadherin cDNA transfection converts invasive tumour 
behaviour to a markedly less invasive phenotype (265). Loss of E-cadherin in breast cancer is 
particularly notable in the in situ and the invasive lobular breast carcinomas, as well as basal 
and triple negative breast cancers that exhibit invasive behaviour. E-cadherin is lost in the 
high invasive ductal carcinomas, while it is still retained in almost 70% of the low grade 
ductal cancers (266).  
 Expression levels of E-cadherin are regulated by multiple mechanisms. E-cadherin 
gene (CDH-1) is often inactivated in human malignancies due to germline gene mutations or 
epigenetic changes (hypermethylation). Transcription of the CDH-1 is further regulated by 
several transcriptional factors, namely Twist1, Snail1 and Slug (267), all of which act as its 
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transcriptional repressors. Messenger RNA levels of the CDH-1 regulators are upregulated in 
cancer cells that have lost E-cadherin expression (268).  
 Post-translational regulation of E-cadherin also plays an important role in its 
expression and function on the cell surface. E-cadherin turn-over at the cell membrane is a 
dynamic process that determines the level and the availability of the functional E-cadherin. In 
this context, the GS enzyme which cleaves E-cadherin at the cell membrane emerges as an 
important regulator of the E-cadherin function. Cleavage of E-cadherin is stimulated by 
apoptosis or Ca
2+
 influx and occurs between the Leu731 and Arg732 residues at the 
membrane-cytoplasm interface. GS recognises both the full-length E-cadherin and the stub 
left after E-cadherin is cleaved extracellularly by a metalloprotease. The product of GS 
cleavage of E-cadherin is the 33kDa E-cad-CTF2 (269). 
1.7.6.2. E-cadherin, p120ctn and gamma-secretase: the super-complex 
            The p120 catenin (p120ctn) is the prototypic member of the family of armadillo-like 
proteins that include delta p0071, delta-catenin, NPRAP and ANCF. P120ctn exists 
predominantly in the cadherin-bound form where its core function is regulation of E-cadherin 
turnover at the cell membrane. P120ctn increases the half-life of E-cadherin, directly 
influencing its adhesive strength and the amount of E-cadherin available at the cell surface. 
The p120ctn binding site on E-cadherin (604-615 a.a.) is distinct from the β-catenin binding 
site, localised at the far end of the cytoplasmic tail (270). 
 The p120ctn catenin is also required for the binding of E-cadherin CTF2 to DNA 
in the nucleus, where it translocates after it has been cleaved by the GS. The E-cadherin 
CTF2/p120ctn dimmer regulates the transcription of not well characterised target genes. Thus 
far, it is known that E-Cad/CFT2-p120ctn dissociate transcriptional repressor Kaiso from the 
DNA, relieving the repression it enforces on its target genes, hence reactivating their 
transcription. One such gene that is driven by E-cad-CTF2/p120ctn is MMP-7 or matrylisin 
metalloprotease (269). Furthermore, p120ctn has emerged recently as a key linker protein and 
the pre-requisite for the formation of the E-cadherin/GS super-complex. The binding site on 
the E-cadherin-ICD involved in the binding of both p120ctn and PS, overlap. Interestingly, 
p120ctn can also colocalise with NCT at the site of cell-cell contact in HEK293 cells (270).  
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            The other form of p120ctn in the cells is its E-cadherin unbound fraction. It is 
generated in one of two ways: by dissociation from E-cadherin and by preventing p120ctn 
degradation. Cytosolic p120ctn assumes signaling function via regulation of Rho GTPases, 
RhoA and Rac1. Soluble p120ctn, in contrast to the p120ctn within adherence junction (AJ) 
complexes, promotes cellular motility and invasion by inducing lamellipodia and filopodia 
formation, and induction of MMP-7 (matrylisin) through its effect of displacing Kaiso 
transcriptional repressor from the DNA (271).  
1.7.6.3. CD44 as the gamma-secretase substrate 
            CD44 is belongs to a family of transmembrane glycoproteins. It is a receptor for 
hyaluronan that exists as a standard isoform (CD44s) and in multiple splice variants 
(CD44v2-10). Cell surface expression of CD44 is closely related to clinic-pathological 
parameters of breast tumours, such as grade, stage, presence of metastasis and survival. 
CD44s, CD44v3 and CD44v6 are upregulated in both in situ and invasive breast carcinomas, 
indicating a role of CD44 in early stages of breast cancer pathogenesis (272). CD44 is a 
substrate for GS cleavage upon the initial shedding of its extracellular domain by a 
metalloproteinase (273). The cleavage releases the CD44-ICD which binds unique 
downstream signaling effectors like the RhoA-ROCK, c-Src, p185 HER2, etc., and sets off 
tumour cell growth, invasion and migration, leading to breast cancer progression (274). A 
two-step processing of CD44 is initiated by Ca
2+ 
influx and 12-O-tetradecanoylphorbol-13-
acetate (TPA) treatment of the cells, similar to the triggering conditions for the GS cleavage 
of E-cadherin. Therefore it seems likely that the GS activity on the cell membrane is one of 
the key mechanisms that regulates the function of the cell-cell and cell-matrix adhesion 
proteins.  
1.7.6.4. Vascular endothelial growth factor receptor 1 and gamma-secretase 
In opposition to its anti-angiogenic role in vascular endothelial cells, the vascular 
endothelial growth factor receptor 1 (VEGFR1) stimulates tumour cell growth and invasion 
when expressed in non-endothelial, cancer cells (275). In response to VEGF stimulation and 
tyrosine phosphorylation, VEGFR1 undergoes shedding of its ECD which generates the 
soluble peptide (sVEGFR), a marker of disease progression in several malignancies, while 
the remaining membrane bound CTF fraction becomes a substrate for GS cleavage (276). The 
73 
 
exact role of the intracellular VEGFR1 remains to be elucidated. However, an indication 
arises from a recent report highlighting that the form of VEGFR1 predominantly expressed in 
invasive MDA-MB-231 breast cancer cells is its intracellular isoform, which promotes 
tumour cell invasion through a Src-mediated pathway (277). 
1.7.6.5. HER4 receptor and gamma-secretase 
HER4 (ErbB4) is a receptor tyrosine kinase member of the epidermal growth factor 
family of receptors, which also includes EGFR1, HER2 (ErbB2) and HER3 (ErbB3). These 
are growth factor dependent tyrosine kinases, which regulate a myriad of cellular functions 
including apoptosis, proliferation, invasion etc. (278). Stimulation of HER4 by the growth 
factor heregulin, as well as a protein kinase C (PKC) stimulator TPA, known to induce 
signals associated with cancer cell differentiation and apoptosis, causes shedding of the 
HER4-ECD by a metalloprotease and generation of the soluble, 80 kDa, HER4 peptide. 
Consequently, HER4 binds presenilin (279), facilitating GS cleavage, which liberates the 
HER4-ICD and is required for HER4-ICD nuclear translocation (280). HER4 indeed 
possesses a nuclear localisation and export signal in its cytoplasmic domain (281), indicating 
its ability to localise to the nucleus.  
HER4-ICD can mediate a range of cellular responses which is greatly dependent on 
its subcellular context and shuttling (282). Cytosolic HER4-ICD can negatively influence cell 
growth, i.e. exert pro-apoptotic effects, mediated by its mitochondrial, ER 
compartmentalisation and BH3 apoptotic initiating domain (279, 283). Conversely, HER4-
ICD growth stimulating effects seem to be associated with its successful nuclear translocation 
and cross-talk with ERα in breast cancer cells. Indeed, the proteolytic processing of HER4 
can be stimulated by the estrogen treatment in ERα positive breast cancer cell lines, and is 
involved in potentiating estrogen stimulated growth (284). HER4-ICD is therefore a potent 
physiological coregulator that forms a complex with the ERα on promoters of ERα inducible 
genes, such as PR, where HER4-ICD is sufficient and necessary for estrogen induced 
expression of PR (285). Furthermore, HER4-ICD nuclear localisation may be important for 
predicting response to hormonal therapy in ERα positive breast cancer patients (286). In vivo 
studies have indicated that nuclear HER4-ICD associates with worse patient outcome (282).  
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1.7.6.6. The epithelial cell adhesion molecule (EpCAM) and gamma-secretase 
The epithelial cell adhesion molecule (EpCAM) is a transmembrane glycoprotein 
overexpressed in human malignancies (breast, prostate, colon, pancreatic cancer etc.), as well 
as in cancer initiating cells, and serves an important role in cancer cell adhesion, 
differentiation, migration and proliferation (106). Recently, EpCAM has been identified as a 
substrate for GS cleavage in colon and hypopharinx cancer cells, as well as in HEK293 cells. 
Interestingly, EpCAM was found to interact with PS2- and not PS1- containing GS complex. 
Even though EpCAM and Notch share a high TMD sequence homology, GS cleavage sites 
do not overlap between these two substrates. The EpCAM-ECD shedding, which precedes 
the GS-mediated release of the EpCAM-ICD, liberates the soluble EpCAM-β peptide, which 
is capable of further promoting receptor proteolysis in an autocrine, positive feed-back loop 
manner. Upon generation, the EpCAM-ICD associates with the members of the Wnt 
signaling pathway to regulate target gene transcription (c-myc, cyclins etc.), and to promote 
cancer growth and invasion, both in vitro and in vivo (287). High expression of the nuclear 
EpCAM-ICD was detected in the aggressive thyroid carcinoma in vivo, where it conferred 
worse overall survival (288).  
1.7.6.7. N-cadherin as a gamma-secretase substrate 
N-cadherin, like E-cadherin, is an important cell surface glycomolecule, which 
regulates cell contact, motility and invasion via Ca
2+
-dependent homophilic interactions. 
Cadhrin switching, a phenomenon characterised by a downregulation of E-cadherin with 
concomitant overexpression of N-cadherin, is one of the hallmarks of EMT and tumour 
progression (289). N-cadherin has been identified as a GS substrate in neuronal cell lines, 
where its role in the formation and function of the hypocampal synaptic contact is paramount 
(290). N-cadherin-ICD accelerates proteosomal degradation of a transcriptional co-activator 
CBP (cAMP response element binding (CREB) binding protein), thereby affecting 
expression of many CBP-dependent transcriptional systems (291). The role of N-cadherin-
ICD in cancer remains to be explored.  
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   1.8. Nicastrin 
The human nicastrin (NCT) gene is located on the chromosome 1 (1q22-q23) and 
encodes a type-I, single-pass, transmembrane, glycoprotein of 709 amino acids, which shares 
a high degree of homology with other vertebrate orthologs. There are two isoforms of the 
human nicastrin (Figure 13). The sequence of the isoform 2 lacks the first 20 a.a., and the 
sequence 21-29 a.a. is changed from LSFCVLLAG to MDFNLILES. Functional 
consequences or tissue distribution differences of these distinct NCT isoforms remain to be 
explored. Nicastrin has a putative signal peptide (1-33 a.a.), an epitope presumed to be 
subjected to proteolytic cleavage (292), a long N-terminal hydrophilic domain harbouring the 
GS substrate recognistion/binding site (ECD), a 20-residue, hydrophobic, putative 
transmembrane domain (TMD), and a short hydrophilic carboxyl terminus of 20 residues 
(Figure 14). The estimated half-life of NCT is 30 hours in mammalian reticulocytes (in vitro), 
> 20 hours in yeast (in vivo), > 10 hours in E. coli (in vivo), and > 24h in mouse embryonic 
fibroblast (in vitro) (248). The predicted isoelectric point based on the amino-acid content is 
pI 5.8 (http://expasy.org/cgi-bin/protparam).  
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Q92542   MATAGGGSGADPGSRGLLRLLSFCVLLAGLCRGNSVERKIYIPLNKTAPCVRLLNATHQI 61 
Q92542-2 --------------------MDFNLILESLCRGNSVERKIYIPLNKTAPCVRLLNATHQI 41 
                             :.* ::* .******************************* 
 
Q92542   GCQSSISGDTGVIHVVEKEEDLQWVLTDGPNPPYMVLLESKHFTRDLMEKLKGRTSRIAG 121 
Q92542-2 GCQSSISGDTGVIHVVEKEEDLQWVLTDGPNPPYMVLLESKHFTRDLMEKLKGRTSRIAG 101 
         ************************************************************ 
 
Q92542   LAVSLTKPSPASGFSPSVQCPNDGFGVYSNSYGPEFAHCREIQWNSLGNGLAYEDFSFPI 181 
Q92542-2 LAVSLTKPSPASGFSPSVQCPNDGFGVYSNSYGPEFAHCREIQWNSLGNGLAYEDFSFPI 161 
         ************************************************************ 
 
Q92542   FLLEDENETKVIKQCYQDHNLSQNGSAPTFPLCAMQLFSHMHAVISTATCMRRSSIQSTF 241 
Q92542-2 FLLEDENETKVIKQCYQDHNLSQNGSAPTFPLCAMQLFSHMHAVISTATCMRRSSIQSTF 221 
         ************************************************************ 
 
Q92542   SINPEIVCDPLSDYNVWSMLKPINTTGTLKPDDRVVVAATRLDSRSFFWNVAPGAESAVA 301 
Q92542-2 SINPEIVCDPLSDYNVWSMLKPINTTGTLKPDDRVVVAATRLDSRSFFWNVAPGAESAVA 281 
         ************************************************************ 
 
Q92542   SFVTQLAAAEALQKAPDVTTLPRNVMFVFFQGETFDYIGSSRMVYDMEKGKFPVQLENVD 361 
Q92542-2 SFVTQLAAAEALQKAPDVTTLPRNVMFVFFQGETFDYIGSSRMVYDMEKGKFPVQLENVD 341 
         ************************************************************ 
 
Q92542   SFVELGQVALRTSLELWMHTDPVSQKNESVRNQVEDLLATLEKSGAGVPAVILRRPNQSQ 421 
Q92542-2 SFVELGQVALRTSLELWMHTDPVSQKNESVRNQVEDLLATLEKSGAGVPAVILRRPNQSQ 401 
         ************************************************************ 
 
Q92542   PLPPSSLQRFLRARNISGVVLADHSGAFHNKYYQSIYDTAENINVSYPEWLSPEEDLNFV 481 
Q92542-2 PLPPSSLQRFLRARNISGVVLADHSGAFHNKYYQSIYDTAENINVSYPEWLSPEEDLNFV 461 
         ************************************************************ 
 
Q92542   TDTAKALADVATVLGRALYELAGGTNFSDTVQADPQTVTRLLYGFLIKANNSWFQSILRQ 541 
Q92542-2 TDTAKALADVATVLGRALYELAGGTNFSDTVQADPQTVTRLLYGFLIKANNSWFQSILRQ 521 
         ************************************************************ 
 
Q92542   DLRSYLGDGPLQHYIAVSSPTNTTYVVQYALANLTGTVVNLTREQCQDPSKVPSENKDLY 601 
Q92542-2 DLRSYLGDGPLQHYIAVSSPTNTTYVVQYALANLTGTVVNLTREQCQDPSKVPSENKDLY 581 
         ************************************************************ 
 
Q92542   EYSWVQGPLHSNETDRLPRCVRSTARLARALSPAFELSQWSSTEYSTWTESRWKDIRARI 661 
Q92542-2 EYSWVQGPLHSNETDRLPRCVRSTARLARALSPAFELSQWSSTEYSTWTESRWKDIRARI 641 
         ************************************************************ 
 
Q92542   FLIASKELELITLTVGFGILIFSLIVTYCINAKADVLFIAPREPGAVSY 710 
Q92542-2 FLIASKELELITLTVGFGILIFSLIVTYCINAKADVLFIAPREPGAVSY 690 
         ************************************************* 
 
Figure 13.Human nicastrin isoforms. Human nicastrin isoform 1 (Q92542) and human nicastrin 
isoform 2 (Q92542-2), which lacks the first 20 a.a. and has the sequence LSFCVLLAG replaced 
by MDFNLILES (http://www.uniprot.org/uniprot/Q92542). 
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 Nicastrin was named after an Italian village, Nicastro, home to the members of an 
extended family diagnosed with familial Alzheimer‟s disease (FAD) (293). It was first 
identified as a PS-binding partner within the GS complex, participating in the cleavage of 
APP and generation of the toxic Aβ42 peptide, which inherently has a tendency to form 
aggregates in senile neuronal plaques as the underlying neuropathologic feature of 
Alzheimer‟s disease.  
 Nicastrin does not exhibit a high degree of homology with other functionally 
characterised proteins. However, the tendency of assigning function to protein sequence, and 
the fact that a region of NCT resembles aminopeptidase receptor family of proteins, has led to 
the assumption that NCT possess catalytic activity. In the true aminopeptidases, the 
„fingerprint‟ amino-acid sequence denoting their peptidase activity is composed of six 
residues (His85, 247; Asp87, 97, 160; and Glu132). Even though the central region of NCT 
(Asn263-Ala483) bears significant sequence homology and structural equivalence to human 
non-protease transferin receptor and Streptomyces griseus aminopeptidase, only one of the 
six residues is preserved (Asp87), while other critical zinc-binding residues have been lost 
through evolutionary changes. This implies that NCT does not possess catalytic activity, but 
retains the capacity to bind proteins (294, 295). Human NCT has 89% homology with the 
mouse NCT protein (708 a.a), 30% with the Drosophila (695 a.a.) and 22% with the C. 
elegans orthologues. The highest sequence conservation lies within the following regions: 
306-360 a.a., 419-458 a.a. and 625-662 a.a. (296). The DYIGS domain (336-340 a.a.) 
encompasses the putative „catalytic‟ residue (Glu333; E333) of the aminopeptidase 
superfamily. Of note is also the conservation of the cystine residues in the ECD of NCT 
(Cys195, Cys213, Cys230, Cys248). A NCT missense mutation (N417Y) identified in AD 
patients is not, however, conserved amongst the species (297). The least conserved domain of 
NCT, which also lacks any known functional sequence, is its C-terminus, the amino acid 
sequence of which is divergent among the species (mammals, C.elegans, Drosophila) (298).  
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1.8.1. Functional domains of nicastrin 
The DYIGS (336-340 a.a.) domain is a highly conserved region of NCT, located in 
the so called domain (261-502 a.a.) with aminopeptidase-like activity (DAP). It possesses a 
GS substrate binding function (Figure 14) (299). Missense mutations in this conserved 
domain (DYIGS to AAIGS) result in a marked increase in the Aβ42 production in HEK293 
cells, while deletions constructs encompassing the same region, in particular the NCTΔ312-
369,  inhibit predominantly Aβ generation and to a lesser extent Notch cleavage (296) (300). 
The DAP domain also harbours the anionic E333 residue, which does not participate in the 
formation of the GS enzyme active site, but has a role in  maintaining the intrinsic GS 
activity, both in terms of: i) participating in NCT maturation, and; ii) enabling the interaction 
between the α-amino group of the GS substrates and NCT. Nicastrin protein baring a Ser to 
Ala mutation (E333A) has been studied in several models: the Sf9 cell model (derived from 
Spodoptera frugiperda (Fall Armyworm)) (301), as well as in a mouse embryonic fibroblast 
cell line model (MEFs) (302). In both systems, NCT-E333A failed to undergo full maturation 
through glycosylation. The divergence was noted when NCT-E333A failed to incorporate 
into the GS complex in MEFs. In Sf9 cells, this mutation diminished GS activity by 50% 
(302). This reduction was not inferred through impaired PS catalytic function, since PS 
endoproteolysis, as well as the GS complex stochiometry, were mostly preserved in the NCT-
E333A mutants, but rather because of lower affinity of NCT-E333A to bind GS substrates 
(302). An elaborate set of NCT mutation constructs E333A, E333R, E333S and E333T in 
HEK292 cells resulted in GS substrate (APP) cleavage inhibition, unlike the conserved 
E333Q mutation (299). Altered substrate binding affinity was not noted in NCT-E333A 
MEFs. Therefore, it appears that the specific role of the E333 residue of the NCT DAP 
domain may be cell context dependent. Collectively, loss of this negatively charged residue 
impairs nicastrin maturation, thereby affecting GS activity, and in some cell systems 
additionally prevents GS substrate binding.  
Despite the prevailing scenario where the mature NCT binds GS substrates at the 
plasma membrane, immature NCT has been found coupled to GS substrates as well (300). In 
experiments where the chimeric constructs were generated by replacement of the NCT-TMD 
with the TMD of E-selectin, the APP-CTF was still pulled down together with NCT, 
indicating that that the NCT-TMD, although important for its binding to Aph-1, PS and PEN2 
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during GS assembly, is not required for substrate binding (302). The N-terminal, third portion 
of NCT-TMD, encompassing Thr3, Gly7, Ser14 and Thr18, is of particular importance for its 
interation with other GS components (223). Furthermore, specific mutations of the 
evolutionary conserved residues in this part of the NCT-TMD domain, S623A and W648A, 
prevented appropriate NCT glycosylation, interfered with the stability of NCT-Aph-1 
interaction and ultimately resulted in impaired GS function, as measured by reduced 
production of cleaved APP (303). Nicastrin C-terminus though appears dispensable for these 
interactions but may facilitate NCT membrane anchoring (223). Nicastrin signaling peptide 
was also attributed the function of facilitating membrane anchoring (292). 
    
Figure 14.Schematic of the nicastrin protein architecture. Nicastrin signaling peptide (SP), 
extracellular, transmembrane and cytoplasmic domains are annotated. The DAP domain containing 
the DYIGS is labeled blue. Blue balloons represent reported and predicted glycosylation sites while 
the pink balloon marks the reported palmytoilation site. 
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1.8.2. Contribution of nicastrin genetic mutations in Alzheimer’s disease 
pathogenesis 
Contribution of PS mutations in the pathogenesis of Alzheimer‟s disease has been 
well documented. There are 43 identified missense mutations in the coding regions of PS1 
that relate to presenile Alzheimer‟s disease, and only one splice site mutation resulting in the 
in-frame skipping of the exon 9, additionally brings on the symptoms of spastic paraplegia 
(304). Extensive efforts have been invested in analysing potential NCT mutations and 
polymorphisms in different populations, in the hope of deciphering whether NCT genetic 
perturbations may bear a causative role in Alzheimer‟s disease as well.  
Analysis of NCT genetic variations in a Dutch population-based study of patients with 
EOAD and late onset Alzheimer‟s disease (LOAD), revealed 14 NCT single nucleotide 
polymorphisms (SNPs), of which 10 intronic and 4 in the coding regions, 3 silent mutations 
and one missense mutation (N417Y), which however is not evolutionary conserved and was 
found at the same frequency in healthy controls. A similar NCT SNP haplotype distribution 
was noted between patients and controls (297). However, in the apolipoprotein epsilon 4 
negative group (APOE ε4, a known Alzheimer‟s susceptibility gene (305)) suffering from 
EOAD but not LOAD, the NCT haplotype B (IVS6+18C→G; GCGC) conferred an increased 
risk of developing the disease. A subsequent Finnish study reiterated this finding, however 
the association here was noted in the presence of the NCT haplotype D (IVS16-119G→C, 
ACCC), rather than haplotype B (306). The French study failed to replicate these results, 
suggesting a potential population specific contribution of NCT genetic mutations in the 
development of AD (307). 
A Chinese population study investigated a distinct SNP, rs10752637 (-922T/G), 
located in the promoter region of NCT. They found that the -922T allele (TT or TG genotype 
vs. GG genotype) significantly increased NCT promoter activity relative to the -922G, while 
its frequency was also increased in sporadic AD patients vs. controls, suggesting that the 
rs10752673 SNP may influence increased NCT expression, which in turn may play a role in 
the pathogenesis of AD (308). Ma et al. analysed the promoter region of NCT and identified a 
set of three SNPs (rs2147471, -1216C/A; rs10752637, -796T/G; rs1324738, -436C/T), where 
the frequency of the first two were associated with the risk for developing sporadic AD, 
regardless of the APOE ε4 allele status (309).  
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Namely, genotypes -1216CC and -796TT and -796TG were carriers of increased risk, 
while the -1216AA and -796GG seemed to be protective against developing AD. Most 
recently, a novel DNA pooling approach was used to perform deep sequencing of the NCT 
gene in order to identify genetic abnormalities in the coding regions, and it identified a 
previously reported non-synonymus SNP (N417Y) which was associated with Alzheimer‟s 
disease occurrence in the Greek population (310). Finally, an elaborate meta-analyses of 
genetic association studies in AD reported a SNP 119 in the intron 16 of the NCT gene as 
being significantly associated with occurrence of AD (305). 
In aggregate, genetic variations of NCT are evident in population based studies. Lack 
of data reproducibility in certain cohorts may be addressed by recruiting more patients into 
the studies. It would be equally important to investigate functional implications of the NCT 
genetic variations in terms of their impact on NCT expression and activity. 
1.8.3. Expression of nicastrin in various tissues 
Expression of NCT has predominantly been studied in rat and mouse tissues. Limited 
data is available on distribution of NCT in normal and diseased human tissues. Studies of the 
rat NCT gene have revealed the existence of a splice variant lacking exon 3, which encodes 
for a protein truncated by 62 amino acids. While the full length NCT was ubiquitously 
expressed, the spliced variant was preferentially found in embryonic and adult rat neurons, 
but not astrocytes and microglial cells. It was also detected in a human neuroblastoma cell 
line (LAN-5), suggesting it may be evolutionary conserved, hence possessing a distinct 
cellular function (311). Eukaryotic cells have a tight regulatory mechanism to distinguish 
between the normal and the premature termination codons, thereby assessing whether an 
mRNA transcripts is suitable for translation (312). This surveillance mechanism sends 
potentially harmful transcripts for accelerated degradation. The depleted exon 3 NCT variant 
may therefore have physiological, tissue-specific relevance since its expression is preserved 
in embryonic and adult rat neuronal cells. 
Analysis of NCT expression in membrane preparations of various mouse tissues using 
antibodies against the N- and the C- terminus of NCT highlighted, for the first time, that the 
glycosylation pattern of NCT may differ across organs, hinting that the N-terminal NCT 
glycoforms may even infer tissue-specific function of this protein (312).  
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Namely, the C-terminal NCT antibody detected mature and immature nicastrin forms 
(140 kDa and 125 kDa), with strong expression in the muscle, brain and heart. Low 
expression was noted in the lung and kidneys. Antibody recognising the N-terminal domain 
of NCT equally picked up the deglycosylated NCT (~80 kDa) form, which was absent in the 
heart preparations, while prominent in the brain and muscle (220). In aggregate with high 
mRNA levels of NCT found in the skeletal muscle, and the fact that NCT was detected 
within complexes of ~290 kDa as opposed to PS-containing complexes migrating at ~400 
kDa, it was proposed that NCT may have a PS/GS-independent role in the skeletal muscle 
tissue. Measuring mRNA and protein expression of GS components in mouse whole tissue 
extracts, De Strooper et al. observed that transcriptional levels of the NCT are not necessarily 
translated to equally high protein levels. For example, a disconcordance was noted between 
high NCT mRNA but low protein levels in the heart, and low NCT mRNA but high protein 
levels in the spleen. In contrast to Ilaya et al., higher protein levels of NCT were found in the 
liver, spleen, kidneys and lung than in the heart and muscle, while widely reported high levels 
of NCT mRNA and protein in the mouse skeletal muscle were low, but still exceeding those 
of PS1 and PS2, as previously reported (216, 220). Furthermore, mass spectrometry analysis 
of isolated murine lympocytes and murine primary splenocyte membrane preparations, 
revealed NCT as one of the integral plasma membrane constituents in these cells (313). 
Analysis of the canine brain and peripheral tissues for expression of NCT by means of RT-
PCR confirmed the abundance of the NCT transcript in the brain and skeletal muscle, while 
NCT mRNA was also detected in the liver, spleen and lungs (221). Collectively, analysis of 
NCT mRNA and protein levels in various animals tissues, although mainly in agreement, still 
propose that it is highly plausible that the post-translational modulation is indeed the critical 
step determining the actual levels of the functional protein, which may not necessarily be 
directly correlated with the abundance of the transcriptional template. 
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1.8.4. Nicastrin cellular localisation   
             Coimmunofluorescence (co-IF) analysis of NCT and the protein markers of 
subcellular compartments, calnexin (ER) and GM130 (Golgi), revealed that the cellular 
localisation of NCT in neuronal cells is predominant peri-nuclear and adopts a punctuated 
pattern. Additional cytolpasmic distribution of NCT implies its presence in the late secretory 
pathways. Colocalisation IF studies confirm that the full length NCT undergoes glycosylation 
dependent cellular localisation, with immature species colocalising with the ER, and the 
higher molecular weight, mature NCT, being visualised in the Golgi. In invertebrates 
(C.elegans), NCT IF also demonstrated localisation at the cell membrane (314). 
1.8.5. Effects of nicastrin depletion on other GS components 
In the absence of NCT, stability of other GS components (Aph-1, PS and PEN2) is 
diminished, their protein levels reduced, and the remaining amounts are predominantly 
sequestered in the ER (315-317). Hence, NCT appears to be required to support GS-
members‟ stability, as well as to regulate their exit from the ER and further cellular 
trafficking and maturation through the cis-Golgi/trans-Golgi network to the cell membrane 
(315). Interestingly, some amounts of the PS1 holoprotein-PEN2 complex are still delivered 
to the plasma membrane independently of NCT deficiency. Additionally, even though NCT 
depletion induces downregulation of GS components, PEN2 levels are partially NCT-
independent as they can be restored just by overexpression of exogenous PS1 and/or Aph-1 
(315). Even though the scaffold backbone in the GS complex assembly is the NCT-Aph-1 
dimmer (214), Aph-1 can also associate with the full length PS and PEN2 in NCT knockout 
cells (315). Since the products of PS endoproteolysis are not observed in cells lacking NCT, 
it is unlikely that the Aph-1/PS1/PEN2 trimmeric intermediate complex is able to execute 
intrinsic GS-like activity, so it is plausible that NCT contributes to the catalytic cleavage of 
PS, rendering the complex proteolytically competent. However, an absolute requirement of 
NCT for GS activity has recently been challenged by two independent reports. Presenilin 
mutations in MEFs, namely the S438P located in the PS-TMD8 and the F411Y mutation in 
the PS-TMD9, reduced NCT levels while not impairing the production of PS-NTF and PS-
CTF, nor affecting the levels of PEN2 and Aph-1, thereby sustaining wild-type GS protease 
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activity (cleaving APP and Notch). Also, a PS/PEN2/Aph-1 trimmer, not harbouring the 
above PS mutations was found to possess GS activity, albeit at lower levels compared to a 
fully assembled GS (318). However, the stability of the S438P/F411Y mutant PS-CTF, as 
well as the PS/PEN2/Aph-1 trimmer was severely shortened, re-emphasising the relevance of 
NCT for GS complex stability and maintenance of required cellular levels of GS activity  
(318) (319).   
1.8.6. Nicastrin post-translational modifications 
Post-translational modifications (PTMs) are chemical alterations in the form of 
covalent additions at particular amino acid residues, which affect the majority of the total 
cellular proteome, and regulate how a particular protein sequence will behave and what final 
folded structure it will assume in eukaryotic organisms. Understanding the protein‟s PTM 
pattern facilitates deciphering its involvement in the underlying cellular molecular processes. 
PTMs of one protein may vary across cellular types and organisms, enabling protein‟s 
participation in the context-designated cellular processes. PTMs enable protein shuttling 
between cellular compartments, as well as incorporation of the integral residential proteins 
into appropriate cellular organelles (lysosomes, mitochondria, plasma membrane). Similarly, 
protein PTMs may vary between normal and diseased conditions, inducing a differential 
expression pattern, as well as altered cellular localisation profile of the protein. There are 
multiple forms of PTMs: glycosylation, phosphorylation, palmitoylation, acetylation, 
methylation etc (320). 
1.8.6.1. Glycosylation 
Glycosylation is the most common PTM affecting ~ 50-70% of the protein pool in 
eukaryotic cells. It involves covalent linking of oligosaccharide chains to certain amino acid 
residues of the primary protein, mainly asparagines, serines and threonines (320). A wide 
range of protein‟s properties can be affected by glycosylation: folding, localisation, 
trafficking, solubility, activity, antigenicity, half-life, as well as protein-protein interactions.  
There are two main types types of glycosylation: N-linked (addition of a sugar to the 
amino group (NH2) of an asparagine at the Asn/X a.a./Ser consensus sequence, where X can 
be any amino acid except Proline), and O-linked (linkage of N-acetylgalactosamine, N-
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acetylglucosamine, mannose, fucose, phosphodiester linked N-acetylglucosamine, glucose, 
galactose or xylose to the hydroxyl -OH
-
 group of a Serine or Threonine, not requiring a 
consensus motif). N-linked glycoforms fall into three main categories: high mannose, hybrid 
and complex. N-linked glycosylation predominantly occurs in the ER, influencing protein 
folding, and is followed by the O-linked glycosylation, which takes place on the folded 
protein in the cis-Golgi network, and influences properties of the secreted and membrane 
glycoproteins (321).  
Newly synthesised proteins gain „core-oligosaccharides‟, including mannose residues 
in the ER, and only when properly folded they traffic to the Golgi, where some of the 
mannose residues are trimmed and replaced with terminal sugars. In order to understand the 
rationale behind using specific deglycosylating agents to monitor the PTM efficiency and 
stage, it is of note that glycoproteins within the ER and the cis-Golgi still contain mannose 
residues that can be removed by EndoH, while in the medial and distal Golgi, they become 
EndoH resistant (Figure 15) (322). 
The enzyme endoglycosidase H (Endo-β-N-acetylglucosaminidase H; EndoH), is a 
highly specific endoglycosidase which cleaves asparagine-linked high mannose moieties. 
EndoH is an enzyme widely used to follow the conversion of oligosaccharides from EndoH 
sensitive to EndoH resistant, as a means of following the transit of a glycoprotein from the 
ER to the Golgi. Endo H resistance is acquired through modification of the oligosaccharide 
portion of the glycoproteins in the medial Golgi apparatus (323). It is an important parameter 
in measuring whether the transport of glycoproteins from the ER to the Golgi is 
accomplished. Proteins that are processed aberrantly fail to escape from the ER, making them 
unable to gain EndoH resistance in the Golgi. Thus, the acquisition of EndoH resistance is an 
indication that the glycoproteins are folded and processed correctly. A peptide-N4-(N-acetyl-
beta-glucosaminyl) asparagine amidase (PNGase) is an enzyme that catalyses cleavage of all 
carbohydrate chains attached to asparagine residues. 
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Figure 15.Sequential glycosylation steps occurring in the endoplasmic reticulum and the Golgi 
apparatus. N-linked glycosylation (complex and hybrid) predominantly occurs in the ER, influencing 
protein folding. O-linked glycosylation takes place on the folded protein in the cis-Golgi network and 
influences properties of the secreted and membrane glycoproteins. Glycoproteins within the ER and 
the cis-Golgi contain mannose residues that can be removed by EndoH, while in the medial and distal 
Golgi, they become EndoH resistant. 
 
The primary amino-acid sequence of NCT translates to a ~80 kDa protein, which 
contains 16 putative N-glycosylation consensus sequences in the hydrophilic N-terminal 
domain (Figure 16). Nicastrin is a heavily glycosylated protein, and this PTM significantly 
affects its cellular localisation, function, as well as molecular weight, as determined by the 
western blotting experiments using the common deglycosylating agents: EndoH, PNGase, 
neuramidase and O-glucosidase. 
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1    MATAGGGSGADPGSRGLLRLLSFCVLLAGLCRGNSVERKIYIPLNKTAPCVRLLNATHQIGCQSSISGDT   70 
71   GVIHVVEKEEDLQWVLTDGPNPPYMVLLESKHFTRDLMEKLKGRTSRIAGLAVSLTKPSPASGFSPSVQC   140 
141  PNDGFGVYSNSYGPEFAHCREIQWNSLGNGLAYEDFSFPIFLLEDENETKVIKQCYQDHNLSQNGSAPTF   210 
211  PLCAMQLFSHMHAVISTATCMRRSSIQSTFSINPEIVCDPLSDYNVWSMLKPINTTGTLKPDDRVVVAAT   280 
281  RLDSRSFFWNVAPGAESAVASFVTQLAAAEALQKAPDVTTLPRNVMFVFFQGETFDYIGSSRMVYDMEKG   350 
351  KFPVQLENVDSFVELGQVALRTSLELWMHTDPVSQKNESVRNQVEDLLATLEKSGAGVPAVILRRPNQSQ   420 
421  PLPPSSLQRFLRARNISGVVLADHSGAFHNKYYQSIYDTAENINVSYPEWLSPEEDLNFVTDTAKALADV   490 
491  ATVLGRALYELAGGTNFSDTVQADPQTVTRLLYGFLIKANNSWFQSILRQDLRSYLGDGPLQHYIAVSSP   560 
561  TNTTYVVQYALANLTGTVVNLTREQCQDPSKVPSENKDLYEYSWVQGPLHSNETDRLPRCVRSTARLARA   630 
631  LSPAFELSQWSSTEYSTWTESRWKDIRARIFLIASKELELITLTVGFGILIFSLIVTYCINAKADVLFIA   700 
701  PREPGAVSY  709 
Figure 16.Nicastrin protein sequence with annotated regions and residues which are post-
translationally modified 
 
Nicastrin signaling peptide 
Nicastrin transmembrane domain 
Nicastrin cytoplasmic domain 
Nicastrin DYIGS domain  
Nicastrin glycosylation residues: reported (45 and 187 (324), 387 (324, 325), 612   
(325)), and predicted (55, 200, 204, 264, 417, 435, 464, 506, 530, 562, 573, 580, 612) 
Nicastrin palmitoylation residue 
 
In a wide spectrum of cell lines (247, 292, 326, 327), and in ex vivo cell preparations 
from the mouse brain tissue extracts (216, 247), endogenous NCT can be visualised as a close 
doublet band at molecular weights of ~140 kDa and ~125 kDa, corresponding to mature and 
immature NCT. The immature NCT contains high-mannose oligosaccharides and is gradually 
turned into mature NCT that contains a mix of EndoH sensitive and EndoH resistant 
oligosaccharide chains. Both forms contain one or more high-mannose moieties, as EndoH 
treatment induces a mobility shift of the mature and the immature NCT by ~15 kDa and ~40 
kDa, respectively, indicating that the mature NCT contains both high-mannose, EndoH 
resistant moieties, which persist at ~125 kDa, as well as Golgi-derived complex 
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oligosaccharides which are removed by EndoH (248, 292). Complete disappearance of the 
~140 kDa band after the EndoH treatment, without affecting the ~125 kDa band, is achieved 
by the addition of neuramidase which removes the sialic acid residues. This indicates that the 
fully mature NCT may be terminally sialyted as well as glycosylated (247). PNGase 
treatment, however, which removes all asparagine-linked glycoforms, including the high 
mannose linkages, reveales minor NCT bands at ~110 kDa and ~80 kDa, corresponding to 
incomplete and complete deglycosylation, respectively (326). O-glucosidase treatment 
doesn‟t affect the mature, nor the immature NCT species, confirming that NCT is post-
translationally modified by N-liked and not O-linked glycolylation (247 499, 326). 
Glycosylation pattern of NCT was analysed in MEFs by means of specific binding of lectins 
to carbohydrates. Reactivity of the immature NCT with Galanthus nivalis agglutinin 
recognising high mannose residues was higher than that of the mature NCT, indicating that 
the immature NCT is richer in these oligosaccharide moieties. Mature NCT reacted with 
Datura stramonium and Maackie amurensis agglutinins, which bind to complex and hybrid 
N-glycans, and sialic residues, respectively, while the immature NCT showed no reactivity. 
Absence of O-glycan modifications of immature and mature NCT was confirmed by the 
absence of reactivity with the peanut agglutinin (248). This data is in agreement with the 
EndoH sensitivity reports. Occasional discrepancies in molecular weight of NCT glycoforms 
reported in the literature are minor and most likely caused by cell-type specific PTM patterns 
of NCT, or the interpretation of gel mobility patterns due to the use of alternate protein 
ladders.  
Of note is that in the cells transfected with exogenous NCT, accumulation of the 
immature species is predominant, pointing out the inefficiency of the exogenous wild-type 
NCT protein glycosylation. In terms of interaction with PS, coimmunoprecipitation and GS 
activity experiments confirm the existence of tight cellular regulatory features, where it is the 
fully mature NCT that preferentially binds to PS. This indicates the necessity of NCT 
maturation for its full functionality within the GS. Furthermore, NCT fails to undergo full 
glycosylation in PS knockout cells, more so in PS1/PS2 double knockout cells than PS 
individual knockout cells (248), indicating that the presence of PS, but not its ability to form 
proteolytically functional heterodimers (PS-CTF/PS-NTF) (326), is a requirement for proper 
maturation and stabilisation of NCT (247, 298, 322).  
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Nicastrin mutants which affect the function of the protein and by inference of the GS 
enzyme, as measured by the generation of the Aβ42 peptide, also show a differential 
glycosylation pattern. NCT mutation (DYIGS→AAIGS) which induces increased Aβ42 
production, indicating enhanced GS activity, indeed confirmed that this double missense 
mutation lead to NCT trafficking-dependent glycosylation in the Golgi and full maturation of 
the protein, mimicking that of the wild type NCT. The Δ312-369 a.a. loss of function 
mutation of NCT caused a proportionate trafficking/glycosylation arrest of NCT and its 
accumulation in then ER (292) (327). The immature NCT possesses the ability to bind Aph-1 
forming a structural scaffold in the GS assembly process. This is also largely unaffected by 
PS or PEN2, since the immature NCT-Aph-1 dimmer persists even in the absence of PS and 
PEN2 (317).  
Conformational change of the NCT-ECD is another feature coupled to glycosylation, 
which is also a pre-requisite for complete structural activation of NCT (316). Nicastrin ECD 
plays a pivotal role in the GS function, and appears to do so by undergoing a conformational 
switch during the process of maturation and GS complex assembly (316). Mature, fully 
glycosylated NCT is mainly trypsin resistant like PEN2, but unlike its immature counterpart 
and the other GS components (PS-CTF, PS-NTF and Aph-1). The presence of PS seems to be 
necessary for the acquisition of NCT trypsin resistance, suggesting that this is a feature 
characteristic of a GS-associated NCT. Furthermore, NCT retains trypsin resistance, 
membrane localisation and association to PS, PEN2 and Aph-1 even upon kifunensine 
treatment (inhibition of mannosidase I, i.e. N-linked complex glycosylation) (248), which 
yields immature NCT, migrating to ~125 kDa. This, and the fact that functionally inactive 
NCT mutants are digested by trypsin, rules out the possibility that the branched 
oligosaccharide chains added through glycosylation are fully responsible for trypsin 
resistance, and emphasises that NCT assumes degradation resistant conformation upon full 
maturation and assembly into an active GS complex (316). 
Expression of NCT N-terminal domain mutants (Cys248, Pro262, Asp283, Glu333, 
Gly339) in a NCT knockdown background of HEK293 cells, which induces downregulation 
of all other GS components (PS1, PS2, PEN2 and Aph-1), demonstrated that the P262L, 
D283N, and the missense DY/AA mutations, largely restored GS component levels and 
activity, as well as NCT glycosylation and conformational maturation, unlike the C248S, 
E333Q and G339A mutants.  
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Maturation of the latter group of NCT mutants was severely impaired, and GS activity 
was not restored, despite a partial rescue of Aph-1 and formation of the NCT-Aph-1 dimmer, 
indicating that these residues of the NCT-ECD may be important for the NCT-Aph-1 dimmer 
binding to PS and PEN2 and/or are necessary for NCT to assume active conformation (316). 
Additionally, deletion of the NCT C-terminus has the capacity to impair glycosylation and 
maturation of the protein, despite the lack of known functional domains located in this part of 
NCT (298). In light of the differential cellular localisation, binding partners and functional 
importance of NCT glycosylation species and mutants forms (292), it can be concluded that 
this PTM of NCT is not only a marker of its cellular trafficking but also an important marker 
of its activity.  
1.8.6.2. Nicastrin palmitoylation 
Protein S-palmitoylation is a PTM which involves covalent addition of the 16-carbon 
fatty acid palmitate to the cysteine residue(s) of proteins. It is a reversible PTM that facilitates 
dynamic protein shuttling between cellular compartments, increases protein‟s hydrophobicity 
and contributes to the protein‟s membrane localisation (328). There are four groups of 
proteins subject to this type of PTM: a) G-protein coupled receptors (GPCRs) and likes 
thereof, that are palmitoylated on cysteine residues close to their transmembrane domains; b) 
Gα subunits, which are palmitoylated near their N-terminus; c) H-Ras and N-Ras that are 
modified near the C-terminus, and; d) peripheral membrane proteins, which are modified 
with a palmitate only (Figure 17) (329).  
 
 
Figure 17.Palmitate acid chain added in the process of S-palmitoylation to a cysteine residue of 
a protein. 
 
Nicastrin undergoes S-palmitoylation at the Cys689 residue in the ER. Another S-
palmitoylated member of the GS enzyme is Aph-1, at residues Cys182 and Cys245 (330). 
This PTM of NCT is not required for proper interaction with other GS components, nor does 
it greatly affect the enzymic potency of the GS in vitro, while in transgenic mouse models, 
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absence of NCT and Aph-1 palmitoylation reduces Aβ42 neuronal deposits. Furthermore, S-
palmitoylation affects protein stability of the immature NCT, as the C689S NCT mutants 
degrade much more rapidly than the palmitpylated protein, presumably as this PTM is 
thought to shield proteins from proteasomal degradation. S-palmitoylation also facilitates 
membrane anchoring of NCT, and by inference the GS complex into the membrane lipid-rafts 
(330).  
1.8.6.3. Nicastrin phosphorylation 
Phosphorylation is a key PTM which occurs in the cell nucleus or in the cytosol, and 
entails a transfer of a phosphate moiety from an adenosine-triphosphate (ATP) molecule to a 
threonine, serine or a tyrosine residue of a receptor molecule (320). Protein kinases catalyse 
cellular phosphorylation events which are of fundamental importance in the regulation of cell 
proliferation, differentiation, apoptosis, invasion etc. A protein kinase recognises acidic, basic 
or hydrophobic residues in the vicinity of the phosphorylation site as a determinant of its 
specificity (320). 
The first indication that NCT may be undergoing phosphorylation came from Kim et 
al., who reported that the extracellular signal regulated kinase 1/2 (ERK1/2) acts as a negative 
regulator of endogenous GS activity in HEK293 cells engineered to stably overexpress GS 
components, and in primary murine cortical neurons (331, 332). Inhibition of ERK1/2, a 
downstream effect of tyrosine kinase inhibitors (333), which are extensively used in the 
treatment of cancers, induced a marked increase in GS activity. Both the immature and the 
mature NCT were found to interact with ERK1/2, regardless of its phosphorylation status, 
and this interaction was able to increase the phosphorylation of NCT (331) and full length 
PS1 (332) in the in vitro kinase assays. Tumour-necrosis factor α (TNF-α) elicits regulation 
of GS activity through c-Jun N-terminal kinase 2 (JNK2)-mediated serine-threonine 
phosphorylation of NCT and PS1 (334). Specific NCT phosphorylation sites have not yet 
been identified. However, it is known that JNK2-mediated phosphorylation of PS1 occurs at 
Ser319/Thr320 residues and stabilises PS1-CTF cellular levels (334). In contrast to ERK1/2-
induced NCT phosphorylation, which attenuates GS activity, TNFα/JNK2-mediated 
phosphorylation of NCT and PS1 augments GS activity (334).  
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This indicates that NCT and PS1 harbour phosphorylation sites, which when 
activated, can act as both positive and negative regulators of GS activity in response to 
respective stimuli. Elucidation of these sites would be of paramount importance in the clinical 
settings where tyrosine kinase inhibitors are used, as the proposed increase in GS activity in 
this context may serve as a mechanism of resistance to the treatment modalities which induce 
ERK1/2 inhibition. This was corroborated by the finding by Osipo et al., where HER2 
inhibition in breast cancer cells resulted in a marked increase in the Notch pathway activity, 
possibly in part due to the above described mechanism (163). Predicted phosphorylation sites 
of NCT and their respective kinases are included in Table 4. 
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Biological significance of NCT phosphorylation may be discussed for the putative 
phosphorylation sites located in the NCT domain facing the cytosol. As the extracellular 
domain of NCT is facing the lumen of the secretory vesicles during ER-Golgi-plasma 
membrane transport, when it is reported not to be in contact with the cytosolic milieu that 
contains the intracellular kinases (214), it remains to be determined where the NCT 
phosphorylation sites are actually located, and how they are being post-translationally 
modified. 
 
 
 
 
 
Table 4. Predicted nicastrin phosphorylation sites 
using high stringency analysis 
(http://scansite.mit.edu/motifscan) 
 
Tyrosine kinase                    EGFR 
Site   Sequence  
Y94   TDGPNPPYMVLLESK   
Basophilic Ser/Thr kinase   PKA 
Site   Sequence  
S235   ATCMRRSSIQSTFSI   
Basophilic  Ser/Thr Kinase  PKC 
Site   Sequence  
S632   ARLARALSPAFELSQ   
Kinase binding site               ERK1 
Site   Sequence  
P179   AYEDFSFPIFLLEDE   
Kinase binding site              PDK1  
Site   Sequence  
S177   GLAYEDFSFPIFLLE   
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1.8.7. Nicastrin interactome 
Extensive analyses of the protein-protein interactions within the GS complex have 
demonstrated that Aph-1, PS and PEN2 interact with the N-terminal part of NCT-TMD and 
are able to coimmunoprecipitate upon isolation of the active GS complex (223). As the GS-
substrate recognition „device‟, NCT also interacts with the C-terminal fragments of the GS 
substrates (300). Furthermore, NCT is able to interact with BACE1 in vitro (335), promoting 
its catalytic function, required for the enzymic cleavage of the GS substrates‟ extracellular 
domains. Another binding partner of NCT is Neprilysin (MME), an enzyme which degrades 
the Aβ peptide (336). Nicastrin deficiency lowers MME expression and membrane-bound 
activity, while NCT overexpression restores this loss in a GS-dependent manner. The main 
cluster of NCT interacting partners is shown below (Figure 18). 
                    
Figure 18.Nicastrin interacting partners. A schematic depicting nicastrin interacting 
partners. Adopted from: http://string.embl.de/newstring_cgi/show_network_section.pl.     
Data obtained via     textmining;    database derived information;    experimental data. 
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1.8.8. Consequences of the loss of nicastrin in various system models 
Nicastrin expression is not eliminated upon inhibition of other GS components, rather 
NCT fails to fully mature under these circumstances. NCT silencing, however, results in a 
coordinated reduction of expression of all other GS components: PS, PEN2 and Aph-1 (317). 
This fact reinforces the notion that NCT is indeed a pivotal component of the GS complex 
(317). Genetic inhibition of NCT using the RNA silencing (siRNA) approach in C. elegans 
proved embryonically lethal and induced a phenotype comparable to that of the simultaneous 
loss of both PS orthologues (sel-1 and hop-1), and Notch inhibition (296, 337). In Drosophila 
(fruit fly), embryos lacking both maternal and zygotic NCT display a severe neurogenic 
phenotype, consistent with impaired Notch signaling (hyperplastic embryonic nervous 
system, wing notching, thickening of wing veins etc.) (338). Mice lacking NCT suffer severe 
growth retardation, vascular deformities and embryonic mortality with an onset at 10.5 days, 
all consistent with a pronounced „Notch phenotype‟, underlined by formation of extensive 
apoptotic areas in the brain and heart (339, 340). However, in mice with a double PS1 
knockout genotype, two distinct phenotypic outcomes were observed: i) the Notch-severe 
and; ii) the Notch-mild phenotype, the latter baring milder skeletal deformities. The modifier 
between the two was mapped to the distal chromosome 1, or more precisely to the NCT gene 
(341). The coding region of NCT in the Notch-severe vs. Notch-mild phenotype harboured 
two missense substitutions at residue 21 (Phe21 vs. Ser21) in the NCD-ECD, and at residue 
678 (Iso678 vs. Thr678), within the membrane-spanning region. 
 1.8.9. Gamma-secretase independent function of nicastrin 
             Even though NCT is largely viewed as the structural and functional requisite and an 
integral component of GS, it has recently been proposed that it may possess certain GS-
independent cellular activity. This has been observed in the context of p53-regulated cell 
death (342). Namely, overexpression of NCT in HEK293 and neuronal cell lines supported 
cell survival, inhibited activation of the proapoptotic caspase cascade, promoted Akt pathway 
activation and induced evasion of the staurosporin induced p53-mediated cell death via 
decreasing p53 transcriptional and phopho-protein levels.  
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Nicastrin mutants, AAIGS and Δ312-340 a.a., known to increase and inhibit GS 
catalytic activity, respectively, as well as NCT expression in the PS1-depleted fibroblast 
cells, and in cells treated with a GS inhibitor, were still able to exert the same protective 
effect on cell viability in a p53 dependent manner (342). P53 has previously been implicated 
in the bidirectional transcriptional and functional crosstalk with the members of the GS 
complex: Aph-1, PS and PEN2. Namely, overexpression of Aph-1, PS and PEN2 was also 
able to rescue cells from staurosporin induced apoptosis, but this feature was dependent on 
GS integrity (343). PS2 exerted predominantly a proapoptotic cellular response (344). 
Therefore, it is evident that p53 mediates GS dependent cellular functions. Importantly, NCT-
mediated effects do not require full molecular integrity of the GS enzyme. Thereby, Pardossi-
Piquard et al. demonstrated a GS-independent NCT cellular function in exerting both 
transcriptional and post-translational control of the p53 tumour suppressor (342). In support 
of NCT engagement in the control of cell-death, but in contrast to the above data, NCT 
DYIGS-AAIGS mutation known to increase GS activity and promote cell survival, was able 
to induce apoptosis in a neuroblastoma cell line, an effect accompanied by BAX expression 
as well as mitochondrial cytochrom C release (345). Therefore, one must bear in mind that 
NCT involvement in regulating cellular apoptotic machinery may be cell context dependent. 
1.8.10. Nicastrin degradation 
Protein degradation is executed through two major cellular pathways, the proteasome 
and the lysosome. It is critical for the regulation of the proteins‟ turn-over and half-lives, 
thereby maintaining homeostasis of cellular processes like proliferation, differentiation, 
apoptosis etc. Proteasomal degradation is a characteristic of the cytosolic and nuclear 
proteins, while lysosomes degrade long-lived, membrane proteins and endocytosed material 
(346). In cell lacking NCT, other GS components are destabilised and targeted for cellular 
degradation, as determined by their reduced half-lives. PS1 and PEN2 are subjects of 
proteasomal mediated digestion, while Aph-1 and NCT seem to be degraded by both the 
ubiquitin-proteasome pathway and the lysosome (315, 347). Apart from being localised in the 
ER, Golgi, mitohondria and the plasma membrane, NCT was recently named the residential 
protein of lysosomal membranes with properly orientated, cytoplasm-facing ectodomain, 
verifying its presence in this cellular organelle (252).  
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Nicastrin protein targeted for degradation is ubiquitinated, and cellular levels of 
ubiquitin and mature NCT are inversely correlated (348). Proteasomal inhibition using 
MG132 and lactacystin, and a lysosomal inhibitor chlorochin, increased cellular levels of 
NCT (moreso of the mature form), and also induced NCT accumulation in the ER and the 
lysosomes, respectively. Levels of the immature NCT were found elevated in cells lacking E3 
ubiquitin ligase (Synoviolin), implicated recently in the quality control of proteins through 
the ER, as well as in ER and proteasomal-mediated protein degradation. Immature NCT and 
Synoviolin were found to interact, indicating that immature NCT is a Synoviolin substrate 
(349). Furthermore, plasma membrane levels of both immature and mature NCT were 
increased in E3 ligase-null, cells implicating the importance of this ligase for the cellular 
trafficking of NCT (349).  
1.8.11. Nicastrin in other diseases 
Nicastrin polymorphisms have been analysed in the context of age related cognitive 
decline (350). Nicastrin haplotype B, previously linked to increased susceptibility to EOAD 
in the absence of the APOE ε4 allele, proved to impact on the general cognitive levels, rather 
than to induce cognitive changes with age. In a post-natal forebrain conditioned NCT 
knockout mouse model, animals displayed severe, age-related learning and memory 
impairment due to neuronal cell apoptosis (351). 
Acne inversa is a chronic inflammatory condition of the hair follicles characterised by 
the formation of skin abscesses and draining sinuses. Like Alzheimer‟s disease, it can be 
hereditary and sporadic. The fact that genetic inhibition of Notch via inhibiting the GS 
enzyme in mice resulted in skin changes resembling those occurring in acne inversa, 
prompted investigations into the possible genetic modifications of the GS components in this 
condition. Indeed, the haploinsuficiency of GS component genes was found as the underlying 
genetic basis for a subset of this disease. More precisely, distinct NCT mutations, one 
resulting in the formation of a premature termination codon (p.E584DfsX44), and another 
nonsense mutation at codon 117 (p.R117X), both yielded reduced NCT mRNA transcript 
levels and loss of function. The abnormal splice variant (skipping of exon 13) led to 32a.a. 
residue loss in the NCT protein (352). 
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It has previously been established that neurons are the predominant cell type of NCT 
localisation in the brain (311). Furthermore, it appears that the levels of NCT in murine 
neuronal cells in vivo are saturated to the extent that a 50% reduction of NCT mRNA levels, 
which induces a marked inhibition of APP processing in fibroblast cells, had no effect on 
APP cleavage in neurons (353). Traumatic brain injury (blunt head trauma, penetrating brain 
injury, intracranial hemorrhage, infarction or inflammation) induces a set of responsive, 
repair-intended reactions in the brain tissue, such as edema, accumulation of inflammation 
infiltrates and activation of astrocytes and microglial cells. In mice, it resulted in a marked 
increase of NCT levels, both in neurons and non-neuronal cells in the proximity of the 
wound, across the cerebral cortex, hippocampus, thalamus, hypothalamus, striatum and 
amygdala (354). The increased expression of NCT was maximal after 4-7 days after injury, 
and gradually declined thereafter. Since PS levels followed the same trend of increase and 
distribution, and colocalisied with NCT, this suggests that GS activity may regulate important 
healing processes after brain trauma (354). This possibly provides a mechanism for the 
finding that traumatic brain injury is also followed by increased Notch activity in cortical 
neurons (355). 
Analysis of NCT expression and function in human malignancies is still sparse. 
Treatment of a colon cancer cell line with a standard chemotherapy agent, oxaliplatin, 
induced activation of the Notch pathway, through increasing both NCT and PS1 protein 
levels, and thereby elevating cellular GS activity, potentially as a means of developing 
resistance to treatment (146). In the context of breast cancer, stable NCT depletion in a triple 
negative, but EGFR positive breast cancer cell line, HCC1806, resensitised these breast 
cancer cells to EGFR inhibition, by means of impeding Notch pathway and Akt activity 
(164).  
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1.8.12. Targeted inhibition of Nicastrin 
An experimental means of interfering with the GS activity via inhibition of NCT has 
been proposed via the introduction of a single chain variable fragment (scFv) against NCT 
into the cells, i.e. the NCT intrabody (356). The intrabody 5201F was constructed based on a 
template monoclonal anti-NCT ECD Ab. It consisted of the light and heavy chain variable 
regions which bound specifically to the NCT-ECD during the process of GS biosynthesis and 
assembly, thereby interfering with the enzymes catalytic maturation and function. The 
intrabody also arrested NCT maturation by inhibiting its glycosylation and ECD 
conformational change, rendering NCT readily degradable by trypsin digestion. All of this 
resulted in an overall loss of endogenous levels of the the mature NCT and of other GS 
components (356). This approach in inhibiting GS activity opens room for consideration of 
NCT inhibition as a valid modality to interfere with the GS enzyme. 
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2. Materials  
 
2.1. Suppliers: 
 
Abcam (Cambridge, UK)  
Amersham (Buckinghamshire, UK) 
Applied Biosystems (Warrington, UK)  
BD Bioscience/VWR International (Hitterworth, UK) 
BDH Chemicals (Poole, UK) 
Bio-Rad Laboratories (Hampsted, UK)  
DAKO (Ely, UK)  
Dharmacon (Lafayette, CO, USA) 
eBioscience (San Diego, CA, USA)  
Eurofins Genetic Services (London, UK)  
Fermentas (St. Leon-Rot, Germany) 
FirstLink (Birmingham, UK) 
GE Healthcare (Chalfont St. Giles, UK)  
Gibco/Invitrogen (Paisley, UK) 
GURR (High Wycombe Bucks, UK) 
Invitrogen (Paisley, UK) 
Leinco Technologies (Missouri, USA) 
Lonza Sales AG (Basel, CH)   
Millipore (Southampton, UK)  
New England Biolabs/Cell Signaling (Hertfordshire, UK) 
Origene (Rockville, USA) 
PAA Laboratories (Somerset, UK) 
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Qiagen (West Sussex, UK) 
R&D Systems (Minneapolis, USA) 
Roche Diagnostics (Burgess Hill, UK)  
Santa Cruz (Heidelberg, GE)  
Sigma-Aldrich (Gillingham, UK) 
US Biomax/Insight Biotechnologies (Wembley, UK) 
Vector Laboratories (Peterborough, UK) 
2.2. Reagents  
Small interfering RNA (siRNA) against nicastrin was obtained from Dharmacon. 
HiPerfect transfection reagent, AllStars Cell Death siRNA positive control, the RNAeasy 
RNA extraction kit, PAHS-013 gene array, RT² First Strand Kit, RT² qPCR SYBR 
Green/ROX Master Mix, cDNA Maxi and Mini Preparation Kits were all purchased from 
Qiagen. Dulbecco‟s Modified Eagel Medium (DMEM), RPMI-1640 medium (developed at 
Roswell Park Memorial Institute), trypsin, EDTA, L-glutamine, isopropanol, ethidium 
bromide, ampicilin, bovine serum albumin (BSA), TEMED, heparin, XP725 Protein array 
were all from Sigma. Penicillin-streptomycin solution, Lipofectamine 2000, puromycin, EGF, 
FGF, TA cloning kit were from Invitrogen. Foetal calf serum (FCS) was obtained from 
FirstLink. Matrigel, CycleTEST Plus DNA Reagent Kit and Dispase were obtained from BD 
Bioscience. Ethanol, methanol, agarose were from Fisher Scientific. Paraformaldehyde was 
purchased from BDH Chemicals. Mammary epithelial basal cell media was from Lonza. 
Protein kaleidoscope ladder and Bradford protein determination reagent were from Bio-Rad 
and 1kb DNA loading marker from Fermentas. The ECL western blotting detection reagent, 
the high performance chemiluminescent films and the Cy3 and Cy 5 dyes were obtained from 
GE Healthcare. Enhanced Immobilon Western chemiluminescent HRP substrate was from 
Millipore. BM Blue POD substrate, the First Strand CDA Synthesis Kit, PCR Grade Water 
and the Protease Inhibitor Cocktail were from Roche Diagnostics. SYBR Green PCR Master 
Mix and the green fluorescent protein (GFP) negative control siRNA were from Applied 
Biosystems. Nicastrin Blocking peptide (N164) was from Leinco Technologies. The α-MEM 
103 
 
media was from PAA Laboratories. Secondary antibodies were from DAKO, Sigma and 
eBioscience. Primary antibodies are listed below. 
2.3. Antibodies  
Abcam: nicastrin (ab2474), Aph-1a (ab19390), PEN2 (ab24743), Presenilin C-terminus 
(ab12272), β-actin (ab8226), GM130 (ab52649), Numb (ab4147), α6-integrin (ab20142), 
CD147 (MEM-M6/1; ab666), Akt (ab8805).  
New England Biolabs/Cell Signaling: Notch1 cleaved-D3B8/Val 1744 (4147), pAkt Ser473 
(193H12), eIEF4 (9742), rabbit IgG isotype control (3900). 
Santa Cruz: Notch4 C-19 (sc-644), Vimentin clone V-9 (sc-6260), Bcl-2(sc-23960). 
BD Biosciences: p21Cip/WAF1 (610234), p120-catenin (610133), β-catenin (C19229), E-
cadherin (610182), CD44-FITC (555478), CD24-PE (555428). 
Millipore: Ki67 (MAB4190) 
Sigma: nicastrin (N-1660), Anti-MAP kinase ERK1&2 (M5670), Anti-MAP Kinase, 
Activated-Diphosphorylated ERK-1&2 (M8159), monoclonal Anti-Rat IgG2b clone R2B-8, 
Monoclonal Anti-Rat κ & λ light chain clones RT-39 and RL-6, Goat Anti-Rabbit IgG-
Peroxidase, Rabbit Anti-Rat-Peroxidase 
eBioscience: Rat IgG2b isotype control, Anti-Rat IgG-FITC, Anti-Rabbit IgG-FITC 
DAKO:  Polyclonal Goat Anti-Mouse HRP, Polyclonal Goat Anti-Rabbit HRP. 
Molecular Probes/Invitrogen: anti-rabbit and anti-mouse IgG Alexa Flour
® 
-488 and -555
, 
phalloidin Alexa Fluor
®
-633. 
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2.4. Cell culture 
 
Breast cancer cell lines (MCF-7, MDA-MB-231, SKBR3, BT474) were from the 
American Type Culture Collection (ATCC). NCT 
+/+
 and NCT 
−/−
 mouse embryonic 
fibroblasts (MEFs) were obtained from Dr Philip Wong (Department of Neuropathology, 
Johns Hopkins University, ML, USA). HCC1806-Luc1 and HCC1806-NCTsh cells 
(generated as described below *)were a kind gift of Prof Michel Loren, (Department of Cell 
Biology and Physiology, Washington University School of Medicine). All tumourigenic cells 
were cultured in DMEM, except HCC1806-Luc1 and HCC1806-NCTsh cells that were 
cultured in the RPMI-1640 media, both supplemented with 10% FCS and 2 mM L-glutamine, 
100 U/ml penicillin, 0.1 mg/ml streptomycin in 5% CO2 at 37 °C. The non-tumourigenic 
immortal breast cell lines 184A1 (CRL-8798, ATCC) and MCF10A were cultured in basal 
mammary epithelial cell growth medium supplemented with bovine pituitary extract (13 
μg/ml), EGF (10 μg/ml), hydrocortisone (500 μg/ml), insulin (5 μg/ml), transferrin (0.005 
μg/ml), cholera toxin (1ng/ml), penicillin (100 U/ml), and streptomycin (0.1 mg/ml).  
 
*Short hairpins targeting human nicastrin with the sequences: 
5′-CCCATCTTTCTTCTTGAAGAT-3′; 
5′-GCTCTACTGAATACTCTACAT-3‟, were cloned into the lentiviral vector pLKO-puro. 
Lentiviral infections were carried out using FuGENE 6 transfection reagent (Roche) 
according to the manufacturer's instructions. Infected cells, HCC1806-NCTsh were selected 
in medium containing 2 μg/ml puromycin (164). 
2.5. RNA interference 
Double-stranded synthetic 21-mer RNA oligonucleotides (siRNA) were from 
Dharmacon. si GENOME set of 4 upgrade duplexes was used in deconvoluted and pooled 
analysis (Figure 19). 
siRNA1: D-008043-01: 5‟-UAUCUUUCCAGCGGCUCUCUU-3‟ 
siRNA2: D-008043-02: 5‟-UACUGUACAACAUAAGUGGUU-3‟ 
siRNA3: D-008043-03: 5‟-AUAGUGGGAAGGUUGGUGCUU-3‟ 
siRNA4: D-008043-04: 5‟-UACUCAUACAGAUCCUUGUUU-3‟ 
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Figure 19.Display of nicastrin gene regions targeted by the siRNA oligos. Image adopted from: 
http://www.tigerteamconsulting.com/SpliceCenter/siRNACheck 
The siRNA was used at a final concentration of 40 nM. HiPerfect transfection reagent 
(Qiagen) was used to transfect the cells. The combination of the D-008043-02 and D-008043-
04 siRNA oligos was the most efficient and was used in all experiments. Following each 
siRNA transfection experiment, the efficiency of downregulation of the targeted mRNA was 
assessed by RT-qPCR. GFP siRNA (AM4626, Ambion) was used as a negative control. 
2.6. RNA isolation and quantitative RT-qPCR 
Isolation of total RNA was performed using the RNeasy kit (Qiagen). Total RNA 
concentration was measured using a NanoDrop ND1000 spectrophotometer (Labtech 
international, East Sussex, UK). RNA (1 μg) was reverse transcribed using oligo dT and 
Transcriptor First Strand cDNA Synthesis Kit (Roche). RT-qPCR reactions were carried out 
in a 20 µl reaction volume containing 3.5 nM of each primer and SYBR Green PCR Master 
Mix (Applied Biosystems). The RT-qPCR amplification conditions were set up as follows: 
10 min at 95 ºC, followed by 40 cycles of 60 sec at 95 ºC, 30 sec at Ta  (60 ºC), 30 sec at 72 
ºC, on a 7900HT Thermocycler (Applied Biosystems, Warrington, UK). The PCR cycle 
number that generated the first fluorescence signal above a threshold (threshold cycle, CT; 10 
standard deviations above the mean fluorescence generated during the baseline cycles) was 
determined, and a comparative CT method was then used to measure relative gene 
expression.  
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Table 5.Primer sequences 
Gene Forward primer Reverse primer 
GAPHD 5‟- TGAAGGTCGGAGTCAACGGATTT-3‟ 5‟- GCCATGGAATTTGCCATGGGTGG-3‟ 
NCT 5‟- GGAGAACCAGCCGAATTG-3‟ 5‟- GGAGTAAACACCAAACCCA-3‟ 
PS1 5‟-TCACAGAAGATACCGAGACT-3‟ 5‟-GGATGACCTTATAGCACCTG-3‟ 
NOTCH1 
 
5‟-ACTGTGAGGACCTGGTGGAC-3‟ 5‟-TTGTAGGTGTTGGGGAGGTC-3‟ 
NOTCH4 
 
5‟-CTAGGGGCTCTTCTCGTCCT-3‟ 5‟-CAACTTCTGCCTTTGGCTTC-3‟ 
CDH1 5‟- GATTCTGCTGCTCTTGCT-3‟ 5‟-GTCAAAGTCCTGGTCCTC-3‟ 
VIM 
 
5‟-ACATTGAGATTGCCACCT-3‟ 5‟- TCCAGATTAGTTTCCCTCAAG -3‟ 
SIP1 5‟-TCATATCGGCTTGTGGAAT-3‟ 5‟-TCTGTGGCTCAATACGTTT-3‟ 
PEN2 5‟-TTCCTTGTCCCAGCCTACAC-3‟ 5‟-CAGGGGTATGGTGAAGGAGA-3‟ 
SNAI1 5‟-CCTAGCGAGTGGTTCTTC-3‟ 5‟-CTGGAAGGTAAACTCTGGATT-3‟ 
TWIST 5‟- CGGAGACCTAGATGTCATTG-3‟ 5‟- ACGCCCTGTTTGTTTGAAT-3‟ 
SPRY1 5‟-ATGGATCCCCAAAATCAACA-3‟ 5‟-CGAGGAGCAGGTCTTTTCAC-3‟ 
CDH2 5‟-GACAATGCCCCTCAAGTGTT-3‟ 5‟-CCATTAAGCCGAGTGATGGT-3‟ 
SPANXB2 5‟-AATGAGGCCAACAAGACGAT-3‟ 5‟-TCGGGGTTGATTCTGTTCTC-3‟ 
HES1 5‟- CACAGAAAGTCATCAAAGCC-3‟ 5‟- CAGAATGTCCGCCTTCTC-3‟ 
CST4 5‟-ACTTGGACACCTGTGCCTTC-3‟ 5‟-CCACATGCACACCTAAATGC-3‟ 
CTGF 5‟-GGAAAAGATTCCCACCCAAT-3‟ 5‟-TGCTCCTAAAGCCACACCTT-3‟ 
COL14A1  5‟- CACGACCACCAACTTTTCCT -3‟ 5‟- GCAACTTGGGTTCCATCTGT -3‟ 
ITGA4  5‟- GAGTGCAATGCAGACCTTGA -3‟ 5‟-TGGATTTGGCTCTGGAAAAC-3‟ 
ITGB2 5‟- CAAGCTGGCTGAAAACAACA -3‟ 5‟- ATTGCTGCAGAAGGAGTCGT -3‟ 
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2.7. Cell lysis for protein extraction 
Cells were lysed in NP40 lysis buffer. Lysates were incubated on ice for 20 min and 
vortexed every 2-3 min to facilitate lysis. Lysates were cleared of insoluble material by 
centrifugation at 15,000 g for 15 min at 4 °C, and protein concentrations were determined. 
NP40 lysis buffer: 50 mM Tris-HCl, pH 8.0, 150 mM NaCl, 10% glycerol, 0.5% NP40,  
5 mM DTT, 1 mM EDTA, 1 mM EGTA, 50 µM leupeptin, 30 µg/ml aprotinin. 
2.7.1. Total protein measurement 
Total protein concentration in each sample was determined by the Bradford (Bio-Rad 
Protein Assay, Bio-Rad Laboratories) assay procedure. Briefly, 160 μl of appropriately 
diluted bovine serum albumin standards and samples were placed in wells of a microtiter 
plate and 40 μl of dye reagent concentrate added to each well. After mixing and incubation 
for at least 5 min at room temperature (RT), the absorbance was measured at 595 nm.  
2.7.2. Sodium dodecyl sulphate polyacrylamide gel electrophoresis (SDS-
PAGE)  
Samples were denatured in sample buffer containing sodium dodecyl sulfate (SDS). 
After heating the samples at 95 ºC for 5 min, samples (20 µg protein) were loaded onto SDS-
polyacrylamide gels (8-12%). Electrophoresis was performed at 80 V for 90 min using the 
appropriate running buffer.  
SDS running buffer: 25 mM Tris-HCl, 200 mM glycin, 0.1% SDS 
SDS stacking gel: 0.1% SDS, 4% acrylamide, 130 mM Tris HCl pH 6.8, 0.09% APS, 0.12% 
TEMED 
SDS running gel: 0.1% SDS, 12.5% acrylamide, 130 mM Tris HCl pH 8.8, 0.09% APS, 
0.12% TEMED 
SDS sample buffer: 130 mM Tris-HCl pH 6.8, 10% β-mercaptoethanol, 20% glycerin, 4.6% 
SDS, 0.2% bromphenol blue was used to prepare loading samples. 
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2.7.3. Western blotting 
After separation on SDS-polyacrylamide gels, proteins were transferred onto a PVDF 
membrane (Hybond C super, Amersham Biosciences) using a wet-blot chamber (Mini Trans 
blot chamber, Biorad). Unspecific bindings were blocked by incubating the membrane in 
blocking solution for 1 h at RT. The membranes were then probed with the primary 
antibodies (diluted in blocking solution) and incubated for 12 h at 4 °C. Next, the membranes 
were washed 3 times for 10 min and incubated with the secondary antibodies (conjugated 
with horseradish peroxidase) for 1 h at RT, followed by 3 washing steps as previously 
described. Immunocomplexes were detected by chemiluminescence detection (GE, 
Healthcare), by mixing equal volumes of ECL solution A and B and incubating the 
membrane for 5 min. The intensity of bands was quantified using Image J software (NIH, 
Bethesda, MD). 
 
Blocking solution: 5% milk powder in 0.05% Tween-20 in PBS 
Washing buffer: 0.05% Tween-20 in PBS 
ECL solution A: 2.5 mM luminol, 0.4 mM paracumaric acid, 100 mM Tris-HCl pH 8.5 
ECL solution B: 5.4 mM H2O2, 100 mM Tris-HCl pH 8.5  
2.8. Cell Proliferation assay (Sulphorhodamine B, SRB) 
The sulphorhodamine B (SRB) assay was used to monitor the effects of various 
treatment conditions on cell proliferation. The assay relies on the ability of SRB to bind to 
protein components of cells that have been fixed to tissue culture plates by trichloroacetic 
acid (TCA). SRB is a bright pink aminoxanthene dye with two sulphonic groups that bind to 
basic amino-acid residues under mild acidic conditions, and dissociate under basic 
conditions. As the binding of SRB is stoichiometric, the amount of dye extracted from stained 
cells is directly proportional to the cell mass. To determine the effect of different treatment 
modalities on cell number over time, SRB assays were performed as described. Cells were 
seeded in flat-bottomed 96-well plates (3x10
3 cells/well). The cells were allowed to adhere 
overnight, and then media containing treatment was added. One plate was assayed at this time 
point (Day 0) and further plates were assayed at 1 or 2-day intervals. The cells were fixed by 
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adding 100  μl per well of ice-cold 40% TCA to each well for 60  min. The plates were 
washed five times in running tap water and stained with 100 μl per well of the SRB reagent 
(0.4% w/v SRB in 1% acetic acid) for 30 min. The plates were washed five times in 1% 
acetic acid and allowed to dry overnight. SRB was solubilised with 100 μl per well 10 mM 
Tris-base, shaken for 30 min and the optical density was measured at 492 nm.  
2.9. Gamma-secretase activity assay 
GS activity was measured using the Gamma-secretase Activity Kit (R&D Systems, 
FP-003) following the manufacturer‟s instructions. Briefly, cells were transfected with 
control or nicastrin siRNA, or the GSI1, and harvested after 72 h in cell extraction buffer 
followed by incubation on ice for 10 min. Lysates were centrifuged at 10,000 x g for 1 min 
and supernatants were collected with a total protein yield of 0.5–1.0 mg/ml. Pierce BCA 
Protein Assay was used to determine protein concentration. Protein (200 μg) was incubated 
with the GS fluorogenic substrate for 1 h at 37 °C and fluorescence was measured at 
355/460 nm.  
2.10. Cell migration and invasion 
Cells (1 × 10
4
) were plated on glass bottomed 24-well plates and imaged by digital 
recording at a time-lapse interval of 10 min for 16 h in an environmentally controlled 
ImageXpress Micro microscope (Molecular Devices, UK). The average speed of cell 
migration (mean ± s.e.m.; n > 100 cells) was determined (357). Cell invasion assays were 
performed using Matrigel-coated polycarbonate transwell filters (8 μm pore size) (Beckton 
Dickinson). 70 μl Matrigel (diluted 1:1 in α-MEM) was added to the upper chamber and 
allowed to polymerise for 1 h at 37°C. Keratinocyte growth medium consisted of α-MEM 
supplemented with 10% FCS, 100 IU/ml penicillin, 100 μg/ml streptomycin, 250 ng/ml 
amphotericin B (Gibco), 1.8 × 10
−4
 M adenine, 5μg/ml insulin, 0.5μg/ml hydrocortisone, 10 
ng/ml EGF, and 1 × 10
−10
 M cholera toxin. 500 μl of this medium was placed in the lower 
chamber to act as a chemoattractant.  
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Cells were plated in the upper chamber of triplicate or quadruplicate wells per 
treatment condition, at a density of 5 × 10
4
 in 200 μl of α-MEM and incubated at 37 °C for 
72 h. Cells in the lower chamber (including those attached to the under surface of the 
membrane) were trypsinised and counted using a Casy 1 counter (Sharfe System GmbH, 
Germany). Mean and standard error of the mean (SEM) of independent experiments were 
calculated. Statistical analysis was performed using a two-tailed Student‟s t-test to determine 
the statistical significance of the differences observed. A p-value below 0.05 was considered 
significant. 
2.11. Immunofluorescent staining and confocal microscopy 
Immunostaining and confocal imaging were carried out as previously described (358). 
1×10
4
 cells were seeded on 13 mm diameter glass cover slips, fixed in 4% w/v 
paraformaldehyde at 37 °C and incubated in immunofluorescent blocking buffer (2% v/v 
FCS and 1% BSA) followed by incubation with 1/100 nicastrin pAb, 1/100 E-cadherin, or 
1/100 p120 catenin antibodies. Incubation with 1/1,000 anti-rabbit or anti-mouse-IgG Alexa 
Fluor
®
-488 or -555 or phalloidin Alexa Fluor
®
-633 (Molecular Probes, UK). Nuclear 
counterstaining was carried out using TO-PRO-3 and coverslips were mounted using 
Vectashield H-1200 (Vector Laboratories). Images were captured using a Zeiss LSM 410 
confocal microscope (63× lens; 1.40 NA oil; Leica) using Immersol 518F oil (Zeiss). Image 
composites of ~20 × 0.5 μm z-stacks were obtained using Axiovision LE software (Zeiss). 
Photoshop 8.0 (Adobe Software) was used for post-acquisition editing of images.  
2.12. Fluorescence Activated Cell Sorter (FACS) analysis 
2.12.1. Cell cycle analysis 
For flow cytometry analysis approximately 1 x 10
6
 adherent cells (treated with control 
siRNA, nicastrin siRNA, Rabbit IgG Isotype control, anti-NCT PcAb) were washed with ice-
cold PBS and lysed as per CycleTEST Plus DNA Reagent Kit protocol. Analysis was 
performed on a FACS LSR II flow cytometer using the CELLQuestPro software 3.0 (Becton-
Dickinson, Belgium), counting 10,000 events per experiment. Detection of DNA 
fragmentation with done with PI as fluorescent indicator.  
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2.12.2. FACS analysis using fluorescein isothiocyanate (FITC)-conjugated 
antibodies 
MDA-MB-231 cells and MCF-7 cells were used to investigate the capacity of the 
developed anti-nicastrin polyclonal and monoclonal antibodies to bind endogenous, cell 
surface expressed nicastrin. Cells were cultured to 70-80% confluence and detached from the 
cell culture flasks using EDTA. Cell pellets were obtained and washed with cold PBS 
containing 0.1% BSA and 0.02 % sodium-azide (NaN3). All further steps were performed on 
ice and all centrifugation steps at 4 ºC. Anti-nicastrin antibodies were added and incubated on 
an orbital shaker at 4 ºC for 1 h. Cells were washed three times in cold PBS + BSA+ NaN3, 
and the secondary, species specific anti-rabbit (rat) IgG-FITC-conjugated
 
Abs were added at 
1:100 dilution for 45 min, and incubated on the orbital shaker in the dark. Cells were then 
washed twice in PBS+BSA+NaN3 and finally resuspended in 400 µl of PBS. 
Immunofluorescent staining acquisition and analysis of 10,000 gated, live cells was done 
using FACSCanto II (Becton-Dickinson, Belgium) and FlowJo software, Version 7.1 (Tree 
Star, Inc., Ashland, OR, USA).   
2.13. Affymetrix gene array performance and analysis 
MDA-MB-231 cells were transfected with nicastrin siRNA (40 nm final 
concentration) for the period of 72 h. GFP siRNA was used as a negative control. Cells were 
harvested and processed for mRNA extraction. Nicastrin knockdown was confirmed by RT-
qPCT (> 90%) and mRNA was sent for gene expression analysis. The gene arrays were done 
on an Affymetrix 2.0 platform by the Northwestern University Genomics Core Facility in 
Chicago, IL, USA. Each sample was run in biological duplicates. Data analysis was 
performed by the bioinformatics group at Northwestern University and revised by Dr. Chindo 
Hicks, Director of Cancer Bioinformatics, University of Mississippi Cancer Institute. 
2.14. RT² Profiler™ PCR Array: Extracellular Matrix and Adhesion 
The PCR Array PAHS-013 (Qiagen) consisted of a set of optimised real-time PCR 
primers on a 96-well plate. The array included built-in positive control elements for: i) proper 
data normalisation, ii) detection of genomic DNA contaminations; iii) quality of the mRNA 
samples. HCC1806-Luc1 and HCC1806-NCTsh cells were cultured and 1 x 10
6 
cells were 
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lysed using the RNAlater (Qiagen), and mRNA was prepared as previously described. cDNA 
was made using the RT² First Strand Kit (Qiagen). RT² qPCR SYBR Green/ROX Master Mix 
was used in the reactions according to the manufacturer‟s protocol. The PCR Array Data 
Analysis Portal automatically performed the calculations and interpretation of the control 
wells including thresh-hold cycle data from the real-time instrument. The RT² Profiler PCR 
Array Data Analysis Template v3.3 software was used. Calculations were based on the ΔΔCt 
fold-change. Genes of interest were validated by RT-qPCR. 
Genes incorporated on the array were: 
Cell Adhesion Molecules: 
Transmembrane Molecules: CD44, CDH1, HAS1, ICAM1, ITGA1, ITGA2, ITGA3, ITGA4, 
ITGA5, ITGA6, ITGA7, ITGA8, ITGAL, ITGAM, ITGAV, ITGB1, ITGB2, ITGB3, ITGB4, 
ITGB5, MMP14, MMP15, MMP16, NCAM1, PECAM1, SELE, SELL, SELP, SGCE, SPG7, 
VCAM1. 
Cell-Cell Adhesion: CD44, CDH1, COL11A1, COL14A1, COL6A2, CTNND1, ICAM1, 
ITGA8, VCAM1. 
Cell-Matrix Adhesion: ADAMTS13, CD44, ITGA1, ITGA2, ITGA3, ITGA4, ITGA5, 
ITGA6, ITGA7, ITGA8, ITGAL, ITGAM, ITGAV, ITGB1, ITGB2, ITGB3, ITGB4, ITGB5, 
SGCE, SPP1, THBS3. 
Other Adhesion Molecules: CNTN1, COL12A1, COL15A1, COL16A1, COL5A1, COL6A1, 
COL7A1, COL8A1, VCAN, CTGF, CTNNA1, CTNNB1, CTNND2, FN1, KAL1, LAMA1, 
LAMA2, LAMA3, LAMB1, LAMB3, LAMC1, THBS1, THBS2, CLEC3B, TNC, VTN. 
Extracellular Matrix Proteins: 
Basement Membrane Constituents: COL4A2, COL7A1, LAMA1, LAMA2, LAMA3, 
LAMB1, LAMB3, LAMC1, SPARC. 
Collagens & ECM Structural Constituents: COL11A1, COL12A1, COL14A1, COL15A1, 
COL16A1, COL1A1, COL4A2, COL5A1, COL6A1, COL6A2, COL7A1, COL8A1, FN1, 
KAL1. 
ECM Proteases: ADAMTS1, ADAMTS13, ADAMTS8, MMP1, MMP10, MMP11, MMP12, 
MMP13, MMP14, MMP15, MMP16, MMP2, MMP3, MMP7, MMP8, MMP9, SPG7, 
TIMP1. 
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ECM Protease Inhibitors: COL7A1, KAL1, THBS1, TIMP1, TIMP2, TIMP3. 
Other ECM Molecules: VCAN, ECM1, HAS1, SPP1, TGFBI, THBS2, THBS3, CLEC3B, 
TNC, VTN 
2.15. Panorama
®
 Antibody Microarray - XPRESS Profiler725 Kit 
The Panorama
®
 Antibody Microarray - XPRESS Profiler725 Kit, a proteomics tool 
that measures the relative level of protein expression (protein microarrays) in cell or tissue 
extracts was used for comparing protein expression profile between two samples (reference 
samples vs. test). The Panorama Antibody Microarray-XPRESS Profiler725 Kit contains 725 
different antibodies, each spotted in duplicate on nitrocellulose-coated glass slides. These 
antibodies represent families of proteins known to be involved in a variety of different 
biological pathways. Each sample was labeled with a different Cy Dyes (Cy3 or Cy5) and the 
two paired samples were applied simultaneously at equal protein concentrations on the array. 
Fluorescent signal intensity for each sample was then recorded individually at the wavelength 
corresponding to the dye label of the sample and compared. Cy3 and Cy5 Monofunctional 
Reactive dyes were from (GE Healthcare). Two independent experiments were performed. 
One including MDA-MB-231 cells treated with NCT siRNA and control GFP siRNA, and 
the other using HCC1806-NCTsh and HSS1806-Luc1 cells. Control samples were labelled 
with the Cy3 and treated samples with the Cy5 dye, and the 2 samples were applied 
simultaneously on the array. Treated and control cells were washed twice with cold 0.01 M 
PBS, pH 7.4. 3 and 1 ml of Buffer A was added directly onto each plate and incubated for 5 
min on ice. The plates were scraped using a rubber policeman and samples were collected 
into a microcentrifuge tube. Samples were centrifuged for 10 sec at 10,000 g. Supernatants 
were transferred to a new microcentrifuge tube and protein concentration was determined by 
the Bradford protein assay. Samples were diluted to 1 mg/ml in Buffer A and 1 ml of extract 
(1 mg/ml) was used for labeling with Cy3 or Cy5. Vials were mixed thoroughly and the 
reaction was incubated for 30 min at RT, mixing the solution every 10 min. Free Cy3/Cy5 
from the labeled sample was removed using SigmaSpin columns. 150 µl of the labeled 
protein sample solution was applied directly onto the center of the SigmaSpin column and 
centrifuged for 4 min at 750 g. Before hybridisation, the dye-to-protein molar ratio was 
determined followes by the calculations supplied with the antibody microarray kit. Only 
samples with a dye-to-protein molar ratio >2 were applied to the antibody microarray as 
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recommended. Each of the Cy3 and Cy5 labeled samples (150 mg), at equal protein 
concentrations (30 mg/ml), were mixed with 5 ml of Array Incubation Buffer and slides were 
incubated for 30 min at RT on a rocking shaker at a moderate shaking frequency of ~30 rpm. 
Slides were then washed, dried and scanned at 532 nm and 635 nm excitation wave lengths, 
respectively (Molecular Devices Axon 4000B). The software used for data analysis was 
GenePix 6. Each array contained spots with a monoclonal antibodies specific for Cy3/Cy5, 
which served as positive control. Normalisation was done using the housekeeping protein β-
actin. F635/F532 ratio was calculated according to the manufacturer‟s protocol, and values of 
interest were those with a Cy5/Cy3 ratio higher or lower than 2. 
2.16. Mammosphere culture 
HCC1806-Luc1 and HCC1806-NCTsh cells were plated as single cells in ultralow 
attachment plates (Corning) at a density of 5 x 10
3
 viable cells/well in a 6-well plate. Cells 
were grown in a DMEM:F12 (1:1) culture medium supplemented with 0.4% bovine serum 
albumine (BSA), 5 μg/ml insulin, 10 ng/ml basic FGF and 20 ng/ml EGF. Mammospheres 
were grown for 10-14 days and phase contrast images were obtained using the ImageXpress 
Micro microscope (Molecular Devices, UK). Cells were collected by gentle centrifugation 
(800 rpm) and processed for mRNA extraction (359). 
2.17. CD44/CD24 Cell Sorting 
HCC1806-Luc1 and HCC1806-NCTsh cells were grown to 70-80% confluence, 
washed once with PBS and harvested using 0.02% EDTA. Detached cells were washed and 
resuspended in PBS containing 1% FCS and 1% penicillin/streptomycin (10
6 
cells/100 μl). 
Combinations of fluorochrome-conjugated monoclonal antibodies against human CD44-
FITC and CD24-PE or their respective isotype controls were added to the cell suspension at 
concentrations recommended by the manufacturer and incubated at 4 °C in the dark for 40 
min. The labeled cells were washed and fixed in PBS containing 1% paraformaldehyde, and 
then analysed on a FACSAria (BD Biosciences). 
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2.17.1. Overlay three-dimensional culture on Matrigel 
Matrigel is considered as the basement membrane and is generated from EHS 
sarcoma cells. Matrigel contains not only basement membrane components (collagens, 
laminin, and proteoglycans), but also matrix degrading enzymes, their inhibitors and growth 
factors. Invasion of tumour cells into Matrigel has been used to characterise involvement of 
extracellular matrix receptors and matrix degrading enzymes which play roles in tumour 
progression (Figure 20). 
Matrigel was thawed on ice overnight at 4 ºC. Matrigel (40 µl/well) was added into 
each of the wells of the eight-well glass slide chambers, and spread evenly in the well to form 
a 1 mm thick bed using the tip of a P-200 pipette tip while monitoring for air bubbles or 
overspread so no to form a high meniscus on the border. Matrigel was left to solidify at 37 ºC 
for 45 min. Then, cells (5 x 10
3
/well) were plated in medium containing 2% Matrigel and 
allowed to grow in a 5% CO2 humidified incubator at 37 ºC. The day that the assay was set 
up corresponds to Day 0; addition of treatment was every 2 days. The cells formed clusters 
by Day 10. 
 
 
 
Figure 20.Overlay method of 3D Matrigel cell culture 
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2.17.2. Immunofluorescent staining of the 3D cultures 
Media was aspirated from the chambers and cells were rinsed twice with ice-cold 
PBS. Cultures were fixed using 4% paraformaldehyde at RT for 20 min. Fixation was 
stopped by aspirating 4% paraformaldehyde, and cells were then washed three times with 
PBS. Blocking was done using 10% human-AB serum (Sigma-Aldrich), followed by 1 h 
incubation with the primary antibody. Cells were then washed three times with PBS and 
secondary antibody was added for 1 h. Staining was done at RT. Secondary antibody was 
removed and cells were washed three times with PBS. DAPI was dissolved in water to 
produce 20 mg/ml stock solution which was then added to the chamber wells at 1:5000 
dilution for 5 min; washed three times with PBS and the chamber slide was mounted using 
VECTASHIELD Mounting Medium without DAPI (H-1000) (Vector Laboratories). 
2.17.3. Recovery of the cells from the Matrigel matrix  
In order to recover cells cultured in 3D Matrigel, the culture media was removed and 
the cells in each chamber were washed 3 times with cold PBS. Dispase (Invitrogen) was used 
to disintegrate the cells from the Matrigel. Dispase was dissolved in PBS at the final 
concentration of 2 U/ml, and pre-warmed to 37 ºC. Dispase solution was added to the wells 
and incubated at 37 ºC for 30 min. Dispase solution containing the cells was pipetted out 
from the wells and the solution was centrifuged to obtain a cell pellet. Dispase solution 
supernatant was discarded. Cells were used to isolate mRNA and protein.  
2.18. Purification of malignant epithelial cells from primary breast 
tumours 
Fresh breast cancer tissue was obtained from the Department of Pathology, Charing 
Cross Hospital, London, UK. Required ethic approval was in place (RREC3386). The tissue 
was minced to small pieces and digested by incubation with Collagenase A (1 mg of 
Collagenase A in 1 ml of DMEM containing 5% FBS), at 37°C for 2-5 h on a shaking 
platform, to obtain a single-cell suspension. The digestion reaction was stopped by the 
addition of 10 ml of cold DMEM-5% FBS, and the preparation was then subjected to serial 
filtration steps using 50 μm-, 38 μm- and 28 μm- pore nylon meshes sequentially.  
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The filtered preparation was centrifuged at 1,200 g for 5 min at 4 °C, and the cell 
pallet was washed twice with PBS containing 2% FBS. Epithelial cells were immunoaffinity 
purified using super-paramagnetic, polystyrene beads (Dynal Ltd, New Ferry, Wirral, UK) 
coated with an epithelial membrane antigen (EMA) antibody (marker of epithelial cells), on a 
rotating platform for 1 h at 4 °C. After the incubation, epithelial cells bound to the magnetic 
beads were separated by placing the cell preparation on a magnetic holder for 5 min. Cells 
pallets were obtained and processed for mRNA or protein extraction.  
2.19. Clinical specimens and tissue microarrays 
Archival formalin-fixed, paraffin-embedded (FFPE) blocks of normal breast tissue 
from reduction mammoplasty, fibroadenoma and paired primary breast tumour and metastatic 
lymph node samples were obtained from the Pathology Department, Charing Cross Hospital, 
London. No patient identifiers were used. For the purpose of analysing Nicastrin expression 
in other normal tissue, the TMA (BN-481) was obtained from US Biomax. Images were 
taken on the Chromavision Automated Cellular Imaging System II.  
Primary operable breast cancer cases from the previously validated Nottingham 
Tenovus Primary Breast Carcinoma Series were employed with the ethics approval 
(REC202313). A 13-slide series breast cancer TMA (n = 1050 cases) comprising 4 m thick 
formalin fixed paraffin embedded tissue cores was immunostained for nicastrin expression. 
The cohort comprised women aged up to 70 years, who presented between 1986 and 1999. 
This well-characterised resource contains information on patients‟ clinical and pathological 
data including histological tumour type, primary tumour size, lymph node status, histological 
grade and data on other breast cancer relevant biomarkers. These include ERα, PR, HER2, 
cytokeratins (CKs: 5/6, 7/8, 18), Ki67 and E-cadherin. Patients within the good prognosis 
group (Nottingham Prognostic Index (NPI) ≤ 3.4) did not receive adjuvant therapy. Hormonal 
therapy was prescribed to patients with ERα positive tumours and NPI scores > 3.4 (moderate 
and poor prognostic groups). Pre-menopausal patients within the moderate and poor 
prognosis groups were candidates for chemotherapy. Conversely, postmenopausal patients 
with moderate or poor NPI and ERα positive were offered hormonal therapy, while ERα 
negative patients received chemotherapy. Data collected are presented here in line with the 
REMARK criteria (360). Clinical data were maintained on a prospective basis with a median 
follow-up of 124 months (range 1 to 233).  
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Anti-nicastrin Ab (N-1660, Sigma) was optimised to a working concentration of 2 
μg/ml on full-faced excisional breast cancer tissue sections, and further used for all the tissue 
samples. The anti-nicastrin pAb was incubated for 3 h at room temperature without antigen 
retrieval. Secondary labelling using indirect streptavidin-avidin-biotin was performed 
followed by detection with diaminobenzidine chromogen. Negative controls were performed 
by omission of the primary antibody. Immunostained sections were counterstained with 
hematoxilin. Nicastrin immunoreactivity was detected in the cytoplasm and cell membrane 
and was scored based on staining intensity ranging from 0 to +3; 0 = null, +1 = low, +2 = 
intermediate and +3 = high level of staining intensity. All cases were scored without prior 
knowledge of the clinic-pathological or outcome data.  Images from the breast cancer TMAs 
were analysed using the high resolution digital imaging (NanoZomer, Hamamatsu Photonics, 
Welwyn Garden City, UK) at 20x magnification with a web-based interface (Distiller, 
SlidePath Ltd., Dublin, Ireland). Standard cut-offs were used for established prognostic 
factors: ERα, PR and cytokeratins 5/6, 7/8 and 18, positive if ≥ 10%; E-cadherin positive if 
H-score ≥45. Cut-off values for different biomarkers included in the study were chosen 
before statistical analysis. 
 
2.19.1. Statistical analysis of patient samples 
Statistical analysis for TMAs was performed using SPSS 16.0 statistical software 
(SPSS Inc., Chicago, IL, USA). Analysis of categorical variables was performed with the 
appropriate statistical test. Survival curves were analysed using the Kaplan-Meier method 
with significance determined by the Log rank test; multivariate analysis was performed by 
Cox hazards regression analyses. Overall survival (OS) was defined as the time from the date 
of the primary surgical treatment to the time of death from breast cancer, death being scored 
as an event,
 
and patients who died as a result of other causes or were still
 
alive were excluded 
at the time of last follow-up.  
2.19.2. Statistical analysis of other experiments 
 
 Standard deviation (SD), mean and standard error of the mean (SEM) of independent 
experiments were calculated for proliferation assays, cell migration and invasion assayas as 
well as RT-qPCR analysis. The applied statistical method, as well as number of independent 
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experiments is outlined in the figure legends. Statistical analysis was performed using a two-
tailed Student‟s t-test to determine the statistical significance of the differences observed. A 
p-value below 0.05 was considered significant. 
2.20. Polyclonal Antibody Production (Biogenes, GE) 
 
RNA from a breast cancer cell line (MDA-MB-231) was reverse transcribed using 
randon hexamers (Dr Dongmin Shao, Imperial College, London).  
            5‟-GGATCCGAAGCCTATAAATACAACTGGGA-3‟ and  
5‟- GCGGCCGCTCACTGAACTGTGTCGCTGAAGTTG-3,  
The above primers were used to amplify a DNA fragment corresponding to the 
nicastrin 261-512 a.a. domain using the LongRange PCR kit (Qiagen), ligated to pET-duet 
(Novagen), which introduces a His-tag in the recombinant protein, and transformed into 
Rosetta E. coli cells. His-tagged protein was isolated using denaturing conditions (soluble 
protein conditions: 100 mM Na phosphate, 10 mM Tris, 8 M urea pH 8.0 with protease 
inhibitors; inclusion body conditions: extraction with 20 mM Tris; pH 8.0; 150 mM NaCl; 
1% NP40; 1 mg/ml lysozyme; 0.01% v/v protease inhibitors), purified on a nickel column 
and eluted (20 mM Tris; 300 mM imidazole; 300 mM NaCl, pH 8.0). Protein was dialysed in 
PBS and the precipitate collected and resuspended in PBS (1 mg/ml). Protein (4 ml) was 
dialysed against 500 ml of PBS overnight. Precipitate was collected and washed 3 times with 
3 ml of PBS. Protein in PBS was then measured by UV. The net weight protein in the pellet 
(8.1 mg) was resuspended in 8 ml PBS. Purity of the recombinant NCT protein (261-502 a.a.) 
that was used as an immunogen was 90-95% and concentration 0.5-1 mg/ml.  
 The immunisation protocol was: 
Day 1:    1st immunisation/ collection of pre-immune serum   
Day 7:    2nd immunisation  
Day 14:  3rd immunisation  
Day 28:  bleeding/ boost  
Day 35:  final bleeding (20 ml/animal)  
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Animals were intramuscularly immunised using BioGenes' proprietary adjuvant. The 
adjuvant was mixed 2:1 with the provided antigen. Monospecific antibody purification was 
carried out from the bleeding preparations. Nicastrin protein used for immunisation was also 
used to prepare the antigen column (CNBr-Sepharose), for affinity purification of the 
bleedings. The purified antibodies were dialysed against PBS, sterile-filtered and provided 
without preservatives.  
2.21. Monoclonal antibody production and purification (Genovac, 
GE) 
 
A DNA fragment corresponding to nicastrin amino acids 34-669 a.a. was generated as 
in Section 2.20. using the following primers (Dr Dongmin Shao, Imperial College London):  
5‟-GCTAGCATGGCTACGGCAGGGGGTGGC-3‟ and  
5‟-GCGGCCGCTCAGTATGACACAGCTCCTGGC-3‟.  
Amplified DNA was cloned into pIRES-neo2 (Clontech) and sent to Genovac. Antibodies 
were raised by genetic immunisation of WISTAR rats using a cDNA, encoding for the 
extracellular domain of nicastrin (34-669 a.a). This cDNA was cloned into proprietary 
GENOVAC expression vectors specially developed to maximise an immune response in 
mammals and to allow screening of the resulting immune sera. The immunisation constructs 
were introduced into the animals using a Genegun. Following several DNA boosts test sera 
were taken from the animal and tested for the presence of antibodies in a transient 
transfection assay in flow cytometry against the corresponding GENOVAC screening vector. 
Once an immune response had been identified, lymphocytes were removed for further 
processing (fusion with mouse myeloma cell line, screening, subcloning by limited dilution). 
Monoclonal antibodies were purified by Protein G affinity chromatography from cell culture 
supernatant after cultivation in serum free medium (ISF-1 from Biochrom). 
2.21.1. Monoclonal antibody sequencing  
Hybridoma cells from the 1E2, 2H6, 10C5 and 10C11 clones were cultured and 1 x 
10
7 
cells/clone were harvested. Cells were lysed for mRNA extraction which was conducted 
using the Qiacube, Qiagen, UK. RNA (1 μg) was reverse transcribed using the First Strand 
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cDNA Synthesis Kit (Roche), to yield 20 μl of the final volume. 5 μl of cDNA/clone was 
used in the PCR reactions. Kappa light chain DNA was isolated by the polymerase chain 
reaction (PCR) using primers that hybridise to the 5‟ end of the kappa chain constant domain 
and the framework 1 region of the r chain variable domain. The 3' heavy chain variable 
region DNA was isolated using primers that hybridize to the framework 1 region of the heavy 
chain variable domain and to the amino-terminal portion of the y chain constant 1 domain 
(361).  
 
 
 
 
 
 
 
 
Each primer (10 pmol) and 2.5 μg of cDNA were used in a 100 μl reaction mix 
containing 250 M of each dNTP, 10 mM Trisaminomethane/ HCl, pH 8.3, 2.5 mM MgCl2, 50 
mM KCI, 0.01% gelatine and 1.25 U taq DNA polymerase. 35 cycles of 1 min at 94 °C, 2 
min at 52 °C and 2 min at 72 °C were carried on the Veriti Thermal Cycler, Applied 
Biosystem. The PCR reaction (10 μl) was run on a 1.2% agarose gel. Band at 350 kb 
indicated the amplified variable region. The TA cloning kit (Invitrogen) was then used to 
perform the ligation. Ligation was performed in a 10 μl volume containing 1 μl fresh PCR 
reaction, T4 DNA ligase. The reaction was performed over-night at 14 °C. LB-agar plates 
with 100 μg/ml Ampicilin were allowed to set and dry at 37 °C. X-gal (5-bromo-4-chloro-3-
indolyl-b-D-galactopyranoside) was dissolved in dimethlylformamide (DMF) to a final 
concentration of 40 mg/ml. X-gal (40 µl/plate) was spread on LB/Amp plates and allowed to 
dry for 30 min at 37 °C the following day and prior to seeding the competent cells. 
Transformation of TA competent cells, INVαF´, with the ligated DNA was performed as 
follows. INVαF´ cells were thawed on ice and 2 μl of the ligated reaction was added and 
allowed to incubate for 30 min on ice. The cells were heat shocked by transferring the tubes 
into a preheated thermo-mixer (42 °C) for 45 sec. The tubes were then immediately placed 
back into ice. S.O.C medium (250 μl) was added to each tube and then transferred to a 
shaking incubator, set at 37 °C, for 1 hour in order to allow the bacterial cell growth. Finally, 
5'-GGTGATATCGTGAT( A/G)AC(C/A)CA( G/A)GATGAACTCTC 
5'-GGTGATATC(A/T)TG(A/C)TGACCCAA(A/T)CTCCACTCTC 
5'-GGTGATATCGT(G/T)CTCAC(C/T)CA(A/G)TCTCCAGCAAT 
5'-GGGAAGATGGATCCAGTTGGTGCAGCATCAGC 
5'-C'I'C'I'AGATTAATGATGATGGTGATGGGATCCACq~I'GGTGCAGCAACAGC 
5'-GAGGTGAAGCTGCAGGAGTCAG GACCTAGCCTGGTG 
5'-AGGT(C/GXA/C)AACTGCAG(C/G)AGTC(A/T)GG 
5'-AGGT(C/GXA/C)AGCTGCAG(C/G)AGTC(A/T)GG 
5'-AGGT(C/G)CAGCTGCAG(C/G)AGTC(A/T)GG 
5'-CCAGGGGCCAGTGGATAGACAAG C'I'I'G G GTGTCG'VITI" 
 
Bi6 
Bi7 
Bi8 
Bi5 
Bi5b 
Bi3 
Bi3b 
Bi3c 
Bi3d 
Bi4 
Priming region                      Name                                    Sequence 
Κ chain variable domain 
a.a. 1-10 
 
Κ chain constant domains 
a.a. 116-109 
Heavy chain variable domain 
a.a. 1-8 
 
3‟chain constant domain 
a.a. 127-15 
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200 µl of each reaction was plated onto agar plates (1.5% Bacto-Agar in LB medium) 
containing 100 µg/ml Ampicillin and X-gal. The plates were incubated at 37 °C overnight. 
LB medium: 1% Bacto tryptone, 0.5% Bacto yeast extract, 20 mM NaCl. The next day, six 
white colonies were picked per each condition and grown overnight in LB media 
supplemented by 100 μg/ml Ampicilin at 37°C. Mini-preps (Qiagen) were performed and 
cDNA quantified. Presence of an appropriate insert was assessed by digesting the DNA with  
EcoRI enzyme for 2 h at 37 °C.  
2.21.2. Restriction endonuclease analysis of DNA 
The recombinant plasmids were cut with the use of specific endonucleases. The 
reaction was performed in 20 µl containing 500 ng plasmid DNA, 1 x buffer (specific for 
each endonuclease), 100 µg/ml BSA and 5 units of restriction enzyme. The reaction was 
incubated at 37 °C for 3 h. 
EcoRI buffer: 100 mM Tris-HCl pH 7.4, 10 mM MgCl2, 50 mM NaCl, 0.025% Triton-X 100 
2.21.3. Principle of blue/white selection of positive recombinant colonies 
 
The pCR21 plasmid that contains bacterial lacZ gene can produce β-galactosidase (β-
gal) if its open reading frame isn't interrupted by insert DNA. β-galactosidase can turn X-gal 
into a blue colour product. When a foreign DNA is inserted into the multiple cloning site 
within the lacZ gene, the open reading frame of lacZ is changed and will not produce β-
galactosidase, therefore the recombinant colony of interest will be in white colour. 
2.21.4. Agarose gel electrophoresis 
The DNA products from the PCR reactions and from restriction-enzyme digestions 
were separated on a 1.5% agarose gel (1.5 g agarose in 100 ml of 1x TE buffer). Ethidium 
bromide 1 µl was added to the solution. Samples were loaded with 10% of DNA loading 
buffer. Along with the samples a DNA marker (1 Kb ladder) was also loaded in order to 
estimate the size of the DNA products. The electrophoresis was carried out at 80 V for 45 
min. The current was derived from a controlled power supply (Biorad, Model 200/2). 
Detection of DNA was performed under UV light (254 nm) and pictures of the gels were 
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taken using a fluorescent gel imager). The PCR products were sequenced by GATC-Biotech 
AG, Konstanz, Germany. 
TAE buffer: 1 mM EDTA, 40 mM Tris-acetate pH 8.0 
DNA loading buffer: 50 % glycerin, 0.05% bromophenol blue 
Sequences of M13 forward and M13 reverse primers: 
M13 Forward primer sequence: 5‟ GTAAAACGACGGCCAG 3‟ 
M13 Reverse primer sequence: 5‟ CAGGAAACAGCTATGAC 3‟ 
2.21.5. Fab fragment preparation 
Fab fragments were purified from whole IgG2b molecules (1E2, 2H6, 10C5 and 
10C11), using papain digestion (Fab preparation kit, Pierce) according to manufacturer‟s 
protocol. This kit uses papain, a nonspecific thiol-endopeptidase, immobilised on an agarose 
resin. Whole IgG2b (1 μg/clone) was incubated with the immobilised papain resin for 4 h at 
37 °C on a tabletop shaker, producing Fab and Fc antibody fragments. Fab fragments were 
bound to protein A column and purified using PBS. Concentration of purified Fab fragments 
was determined using nanodrop spectrophotometer at 280 nm wavelength (mass extinction 
coefficient value of 1.4). For typical antibody solutions: Absorbance (A)          = 1.4. 
(www.piercenet.com/files/TR0006-Extinction-coefficients).  
2.21.6. Protein Gel Interpretation and Coomassie staining 
The separation of Fab from the Fc fragment was analysed by reducing SDS-PAGE. 
After electrophoresis, gels were stained for 10 min in Coomassie-blue staining solution, and 
then destained for 20 min in Coomassie destaining solution. 
Coomassie-blue staining solution: 1.2 g Coomassie Brilliant blue, 450 ml methanol, 90 ml 
acetic acid, 450 ml H2O 
Coomassie destaining solution: 10% isopropanol, 10% methanol, 80% H2O 
Whole, undigested IgG2b molecules were used as negative controls for respective clones. 
Boiling the IgG2b digest before gel loading resulted in a reduced sample. Present Fab 
fragments migrated near 25 kDa, and Fc fragments migrated at ~30 kDa.  
1 mg/ml 
 280 nm 
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The presence of Fc at ~30 kDa confirmed digestion of IgG2b. Also, an additional band, 
which is likely the undigested IgG2b heavy chain, appeared at ~50 kDa. 
2.21.7. Titration FACS and antibody Kd determination 
Cell-based FACS titration was performed using MDA-MB-231 cells. Non-
permeablised cells were incubated with each IgG (1E2, 2H6, 10C5 and 10C11) as the 
primary antibody in two fold serial dilution (1 mM to 0.01 nM), followed by the secondary 
FITC-conjugated antibody. This allowed MAb binding the endogenous, native, cell surface 
nicastrin antigen and determination of a cell-based Kd. As well as being physiologically 
relevant, this helped to show whether the binding of the MAbs is monovalent or bivalent. 
Cells were analysed on the FACSCalibur, BD Bioscience. The mean fluorescent intensity 
was obtained by analysis the Results using WinMDI 2.8 program (Verity Software House, 
Inc., Topsham, ME, USA). 
2.21.8.Kd determinantion of full IgG and Fab fragments by ELISA 
The binding of Fab fragments from all four clones as well as whole IgG2b molecules 
was measured directly by ELISA. Recombinant human nicastrin-Fc antigen was coated on 
96-well microtiter plates (5 μg/ml). The purified antibodies (IgG2b and Fab) were used as the 
primary antibody with a two-fold serial titration (1 mM to 0.01 nM), followed by the 
secondary detecting antibodies and colorimetric POD substrate The dissociation constant (Kd) 
was determined by fitting the binding curve to a sigmoidal four parameter logistic curve and 
calculating the 50% binding concentration from the Xo value (SigmaPlot software). 
2.21.9. BIACore Surface plasmon resonance technology  
BIAcore 3000 was used to determine the affinity of MAbs and Fabs. BIACore was 
also used to epitope-map the antibodies by determining which ones compete for binding. The 
preferred, direct immobilisation of NCT onto the chip, led to a non-binding protein. 
Therefore, each MAb was immobilised using NHS-EDC coupling on the surface of a separate 
BIAcore CM5 chip, followed by the flow of the human NCT-Fc antigen (1 μM). This 
resulted in formation of antigen-antibody binding. Next, each IgG chip was subjected to the 
flow all four Fabs (10 μM) for the purpose of deciphering the degree of competitive binding 
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between the antibodies. The rational behind this method is that if two MAbs bind the same or 
overlapping epitopes, addition of a Fab will compete off the pre-existing complexes on the 
chip. This is seen as a dissociation curve. Any additional increase in the binding curve will 
indicated the antibodies bind distinct, non-overlapping epitopes. All experiments were carried 
out on flow cell-2 (Fc2) and flow cell-1 (Fc1, blank chip) values were substratcted (Fc2-1 net 
binding). 
2.21.9.1. Production of the nicastrin extracellular domain Fc fusion protein 
(Fusion Antibodies, UK) 
 
 HEK293 cells stably expressing human nicastrin extracellular domain Fc-fusion 
protein (hNECD-Fc) were generated by Dr Dongmin Shao (Imperial College) and supplied to 
Fusion Antibodies. Cells were adapted to serum free cultures in shaker flasks. A large scale 1 
litre volume culture was seeded and grown for 12 days. hNECD-Fc was then purified via 
Protein A affinity chromatography. Final quality control was performed using SDS-PAGE, 
BCA and endotoxin detection. Cells were thawed at 37 °C and transferred to 12 ml of 
complete DMEM supplemented with 10% IgG serum, 1% non essential amino acids, 2 mM 
L-glutamine and 150 mg/ml Zeocin (all Invitrogen). Cells were incubated in a 75 cm
2
 tissue 
culture flask at 37 °C until subconfluent before passage by trypsinisation. Following two 
passages in complete DMEM adaption of cells to growth in serum free medium (Ex Cell 293 
serum free medium (Sigma), supplemented 150 g/ml Zeocin (Invitrogen)) was commenced. 
Once cells were considered adapted to serum free culture cells were seeded in one litre of Ex 
Cell 293 medium at a concentration of 5 x 10
5
 cells/ml in disposable Erlenmeyer shake flasks 
(Corning Inc, MA, USA) shaking at 130 rpm, 37 °C, 8% CO2. A sandwich ELISA to detect 
the presence of human IgG Fc in the culture supernatants was performed. The Fc fusion 
protein was then purified from medium supernatant using an Amersham Biosciences AKTA 
Chromatography system (AKTA Prime). Purification method was affinity using a 1ml protein 
A column. The fractions were analysed by a Bradford. Only the positive samples were 
combined and dialysed against PBS. After overnight dialysis, the purity of the final product 
was checked by SDS-PAGE analysis. Final quantification was performed using BCA. 
Purified hNECD-Fc (1.45 ml) was produced. According to the BCA, it corresponded to a 
total of 1.546 mg of the Fc fusion protein. 
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Purity  Concentration  Volume  Quantity  Endotoxin Level  Final Buffer  
>90%  1.066 mg/ml  1.45 ml  1.546 mg  1.35E U/mg  PBS  
 
2.21.10. Small scale preparations of plasmid DNA (Miniprep) 
A single bacterial colony was picked up and inoculated in 5 ml of LB medium 
containing 50 µg/ml ampicillin in sterile 15 ml tube. Then the tubes were incubated at 37 °C 
while shaking (200 rpm) overnight. 2 ml of the overnight culture was transferred into a new 
tube and centrifuged at 5,000 rpm for 5 min. The pellet was then resuspended by vortexing in 
200 µl of resuspension solution. Subsequently, 200 µl of lysis solution (0.2 M NaOH, 1% 
SDS) was added. The solution was mixed by gently inverting the tube. Neutralisation 
solution (3M potassium acetate pH 5.5) (200 µl) was added and mixed again by inverting the 
tube several times, incubated at 4
 
°C for 10 min and then centrifuged at 14,000 rpm for 10 
min. The supernatant (cleared lysates containing plasmid DNA) was carefully transferred to a 
new tube and the DNA was precipitated by 700 µl of isopropanol. After centrifugation at 
14,000 rpm for 10 min, the supernatant was aspirated and the pellet was washed with 100 µl 
of 70% ethanol. After a final centrifugation at 14,000 rpm for 5 min, the pellet was dried and 
eluted into 30 µl of H2O. 
Resuspension solution: 50 mM Tris-HCl pH 8.0, 10 mM EDTA, 100 µg/ml RNase A 
2.22. Large scale preparations of plasmid DNA (Maxiprep) 
E. coli bearing the control pCMV6-XL4 and the full length human nicastrin cloned 
into the pCMV6-XL4 vector (Origene) were cultured in LB for 18 h at 37 ºC with shaking. 
The cultures were centrifuged at 6,000 rpm for 15 min at 4 °C in Sorvall
®
 GSA centrifuge. 
All traces of supernatant were removed by inverting the open centrifuge tube until all 
medium had been drained. Bacterial pellet was resuspended in 10 ml Buffer P1 and pipetted 
up and down until no cell clumps remained. 10 ml of buffer P2 was added, mixed thoroughly 
by inverting 4-6 times, and incubated at RT for 5 min. 10 ml of chilled buffer P3 was added, 
mixed by inverting 4-6 times, incubated on ice for 15 min, and centrifuged at 13,000 rpm for 
30 min at 4°C. Supernatant containing plasmid DNA was removed promptly.  QIAGEN-tip 
500 was equilibrated by applying 10 ml buffer QBT, and columns were allowed to empty by 
gravity flow. The supernatant was applied to the QIAGEN-tip and allowed to enter the resin 
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by gravity flow. QIAGEN-tip was washed with 2 x 30 ml of the buffer QC. DNA was eluted 
with buffer QF. DNA was then precipitated by adding of 10.5 ml (0.7 volumes) RT 
isopropanol to the eluted DNA, mixed and centrifuged at 11,000 rpm for 30 min at 4 °C. 
Supernatant was decanted, DNA pellet washed with 5 ml of RT 70% ethanol, and centrifuge 
at 10,000 rpm for 10 min. Supernatant was decanted without disturbing the pellet. The pellet 
was air-dried for 5-10 min, and DNA re-dissolved in a suitable volume of TE buffer (pH 8.0, 
or 10 mM Tris-Cl, pH 8.5). 
Resuspension buffer P1: 50 mM Tris-Cl, pH 8.0; 2–8°C, 10 mM EDTA; 100 μg/ml RNase 
Lysis buffer P2 : 200 mM NaOH, 1% SDS 
Neutralisation buffer P3 : 3.0 M potassium acetate 
QIAfilter washing buffer FWB2 : 1 M potassium acetate 
Equilibration buffer QBT :750 mM NaCl; 50 mM MOPS, pH 7.0; 15% isopropanol; 0.15% 
Triton X-100 
Wash Buffer QC : 1.0 M NaCl; 50 mM MOPS, pH 7.0; 15% isopropanol 
 
2.23. Generation of nicastrin stably overexpressing MCF10A cell line  
 
The cDNA encoding full length human nicastrin was subcloned into a retroviral expression 
vector pMXs-puro and the construct was kindly provided by Prof. Gopal Thinakaran, 
University of Chicago, USA (330). The pMXs-puro-nicastrin retroviral vector was used to 
infect MCF10A cells (Dr Ylenia Lombardo, Imperial College, London). Control cells were 
generated by retroviral transduction of the empty vector pMXs-puro (Cambridge Bioscience). 
Stable, polyclonal cell populations were established after puromycin selection (0.5 μg/ml) by 
Dr Ylenia Lombardo, Imperial College London. 
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CHAPTER 3 
 
Results 
 
 
Nicastrin expression in breast cancer 
cells and consequences of its genetic 
silencing 
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3.1. Introduction 
Tumour progression and metastatic spread involve upregulation of molecular 
components that constitute numerous proteolytic and cell migration pathways and help drive 
cell invasion into the surrounding tissue (362). Gamma-secretase (GS) is a unique multi-
protein complex with activity as a cell surface protease that directly cleaves a variety of 
transmembrane proteins to modify their function. The proteolytic targets of GS include a 
number of proteins involved in tumour cell proliferation, adhesion and invasion (363).  
Small molecule GS inhibitors are currently being used in the clinic, however ongoing 
patient trials in advanced and metastatic solid tumours have indicated multiple side effects 
(364), which suggests the need for more controlled and tissue specific regulation of GS-
associated biological activities. This could potentially be achieved by targeting nicastrin 
(NCT), which provides critical structural support for GS complex assembly and facilitates 
molecular recognition of multiple substrates for cleavage by the catalytic component of the 
complex, presenilin. 
A recent report that implicated NCT to function independently of the GS complex in 
the control of p53-mediated cell death (235), as well as observations that its expression was 
upregulated following treatment of colon cancer cell lines with chemotherapeutic agents, and 
that overexpression of NCT is sufficient to enhance GS activity (365), serve as an indication 
that NCT could be specifically targeted when it is upregulated during disease pathology. We 
have therefore focused our attention on elucidating the expression pattern and functional 
implications of NCT expression in breast cancer cells. RNA interference (siRNA) has 
become a powerful approach to characterise gene function. In this chapter we investigated the 
expression of NCT in breast cancer cells and used transient NCT gene silencing as a method 
to derive information about its functional role in breast cancer cells.  
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3.2. Results 
3.2.1. Nicastrin expression in breast cell lines and functional effects of 
nicastrin gene silencing in breast cancer cells 
Given that NCT expression had not yet been explored in breast cells, we initially 
performed western blotting analysis of NCT protein levels in the non-tumourigenic breast 
epithelial cell line, 184A1 (366), and breast cancer cell lines (MCF-7, MDA-MB-231, 
BT474, SKBR3) (Figure 21) (367). Nicastrin expression was weak in the non-tumourigenic 
breast cell line 184A1, while breast cancer cell lines expressed markedly upregulated NCT 
levels. Both the immature and the mature NCT were detected, as noted by the close doublet 
band migrating at ~140 kDa and ~125 kDa. This result promted us to to investigate 
differential expression of NCT between normal breast tissue and primary breast cancers 
(described and discussed in detail in Chapter 5), which confirmed that NCT was indeed 
absent from normal breast tissue while being present in abundance in malignant breast 
disease. Furthermore, high NCT levels were predictive of overall survival in ERα negative 
patients (Chapter 5, Figure 43). This suggested that NCT might play a role in more 
aggressive breast cancer cells. The triple negative (ERα-, PR-, HER2- negative), basal B 
type, MDA-MB-231 cells were therefore chosen for subsequent experiments in order to 
investigate the functional role of NCT in invasive breast cancer, and the luminal A, MCF-7 
cell line  (368) was used for comparison of NCT functional role in the non-invasive cell line 
counterpart. 
           
Figure 21.Nicastrin expression is upregulated in breast cancer cell lines compared to normal 
breast cells. a) Western blotting of nicastrin protein levels in a normal breast cell line 184A1 and four 
breast cancer cell lines (MCF-7, MDA-MB-231, BT-474 and SK-BR-3). Cell lines were cultured to 
70-80% confluence and whole cell protein lysates were prepared. 20 μg of protein was loaded per 
lane. Both mature and immature nicastrin forms are detected. β-actin was used as the loading control. 
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3.2.2. Titration and functional analysis of NCT silencing in MDA-MB-231 
cells 
 
In order to determine the appropriate concentration and combination of the four NCT 
siRNA oligos (Dharmacon), we have transfected MDA-MB-231 cells with each individual 
siRNA and a pool of all four oligos at 10 nmol and 40 nmol concentrations, and measured 
NCT mRNA levels after 48 h of treatment. In deconvoluted analysis, siRNA1 had no effect, 
while siRNA3 reduced NCT mRNA only by 10-20%. siRNA2 and 4 induced a potent 
inhibition of NCT gene transcription, peaking at 40 nmol concentration. In pooled analysis, 
the combination of siRNA2 and 4 was the most effective, inhibiting NCT mRNA levels by > 
95 % (Figure 22a). We have therefore used a combination of siRNA2 and 4 in all subsequent 
experiments, from here on referred to as „NCT siRNA‟. In order to further confirm the 
optimal dose, we next investigated whether NCT siRNA would affect proliferation of MDA-
MB-231 cells in a dose-dependent manner that would reflect the degree of gene inhibition 
observed in the previous experiment. We have transfected MDA-MB-231 cells with 
increasing concentrations of NCT siRNA, and measured cell proliferation after 96 h of 
treatment. The dose of 40 nmol was the most potent, inducing a marked reduction of cell 
proliferation (Figure 22b). Control siRNA against the green fluorescent protein (GFP) was 
used at an equivalent concentration as the negative control in all experiments, and did not 
induce significant cell toxicity. Therefore the dose of 40 nmol of NCT siRNA was taken 
forward to all subsequent experiments. Silencing efficiency was monitored and achieved (> 
90%) for both NCT mRNA (Figure 24a) and protein levels (Figure 25a) in all reported 
experiments. 
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Figure 22.Selection of the optimal NCT siRNA concentration. a) Titration of NCT siRNA. MDA-
MB-231 cells were transfected with 10 nmol and 40 nmol of Control siRNA (non targeting) and four 
NCT siRNA oligos. RT-qPCR for NCT was performed 48 h after transfection. GAPDH was used for 
normalisation. Error bars represent SEM of two separate experiments, each in triplicate; changes 
observed throughout these experiments were statistically significant * p < 0.01. b) Cell proliferation 
assay. MDA-MB-231 cells were transfected with increasing concentrations of Control siRNA and 
NCT siRNA and cell viability was measured at Day 4. Error bars represent SEM of two separate 
experiments, each done in quadruplicate, * p < 0.01.  
 
* 
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3.2.3. Nicastrin silencing inhibits proliferation of breast cancer cells by 
inducing a sub-G1 cell cycle arrest 
 In order to investigate the impact of NCT silencing on breast cancer cell proliferation 
we have transfected MDA-MB-231 and MCF-7 cells with NCT siRNA and monitored cell 
viability in two-day intervals using the SRB assay. Nicastrin depletion markedly inhibited 
proliferation of both MDA-MB-231 cell (82±6.2%) and MCF-7 cells (75±8.1%) (Figure 
23a). Furthermore, cell cycle analysis following NCT silencing in both cell lines confirmed 
that cells were accumulating in the sub-G1 phase of the cell cycle, i.e. undergoing apoptosis. 
More precisely, 37 % and 48% of cells were registered in the sub-G1 phase upon NCT siRNA 
vs. 2.4 % and 17 % in the Control siRNA treated MDA-MB-231 and MCF-7 cells, 
respectively (Figure 23b). Interestingly, treatment of these cells with a small molecule GSI 
(GSI1, Calbiochem), which inhibit the proteasome in addition to inhibiting the GS enzyme, 
also inhibited breast cancer cell proliferation although by inducing a G2/M arrest (369). This 
suggests that the inhibition of cell proliferation by interfering with the GS complex via NCT 
silencing may be more specific, and hence infers a different profile of the cell cycle arrest.    
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Figure 23.Nicastrin siRNA inhibits breast cancer cell proliferation. a) Cell proliferation 
assay. MDA-MB-231 and MCF-7 cells were treated with 40 nmol of the Control siRNA, NCT siRNA 
and the positive control Death siRNA. The day of transfection was annotated as Day 0. Proliferation 
(SRB) assay was performed every 2 days until Day 6, *p = 0.005. Error bars represent SEM of two 
separate experiments, each done in triplicate. b) Cell cycle analysis. MDA-MB-231 and MCF-7 cells 
were treated with 40 nmol of the Control siRNA and the NCT siRNA and cell cycle profile was 
analysed after 72 h.  
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3.2.4. Nicastrin silencing inhibits the gamma-secretase complex in breast 
cancer cells 
 
 We next investigated whether NCT genetic silencing disrupts the GS complex in 
breast cancer cells, by monitoring GS activity levels and Hes1 mRNA levels upon 
transfection of breast cancer cells with NCT siRNA. Nicastrin silencing was sufficient to 
significantly reduce GS complex enzymatic activity (p<0.001) (Figure 24b), equally so as the 
GSI1. Furthermore, NCT siRNA reduced the transcription of a direct target gene of the Notch 
signaling pathway, Hes1 (p<0.001) (Figure 24a).  
                        
Figure 24.Nicastrin silencing disrupts GS complex activity. a) RT-qPCRs were carried out to 
determine fold changes in expression of NCT and Hes1 in NCT siRNA treated samples compared to 
Control siRNA samples in MDA-MB-231 and MCF-7 cells. Data are the mean fold change in 
expression compared with Control siRNA samples. Error bars represent SEM of duplicate samples in 
three independent experiments, *p < 0.001. b) GS activity assay upon NCT silencing in MCF-7 and 
MDA-MB-231 cells. GS inhibitor (GSI1) (Calbiochem) at 1 μmol concentration was used as a 
positive control in this experiment, *p < 0.001. Degree of inhibition is comparable to that of a GSI in 
both cell lines. 
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In accordance with a previous report (370), NCT depletion appears to affect GS 
activity by inducing a concomitant loss of the PS1 protein in breast cancer cells as well 
(Figure 25a). Importantly, NCT silencing reduced protein levels of both the PS1 holoprotein 
and its N- and C- terminal fragments that are derived upon PEN2-mediated PS1 
endoproteolysis, which yields an active GS complex. Interestingly, mRNA levels of neither 
PS1 nor PEN2 were significant changed in response to NCT siRNA in MDA-MB-231 cells, 
while PS1 mRNA levels were only mildly reduced in MCF-7 cells (35±10.1%) (Figure 25b), 
suggesting a post-translational regulatory effect of NCT on PS. As previously demonstrated 
in mouse embryonic fibroblast cells and neuronal cell lines, where NCT knockdown results in 
the abolishment of PS1, NCT appears to be equally important for PS1 stability in breast 
cancer cells (315). Collectively, these data demonstrate that the loss of NCT is sufficient to 
destabilise the GS complex in breast cancer cells.  
 
 
Figure 25.Nicastrin silencing downregulates presenilin protein levels. a) Western blotting analysis 
using indicated antibodies after 72 h of treatment with Control siRNA and NCT siRNA. β-actin was 
used as loading control. The intensity of bands was quantified using Image J software. Numbers 
below the bands represent fold change compared to the non-treated samples, relative to the loading 
control. b) RT-qPCR of PS1 and PEN2 upon NCT silencing. GAPDH was used for normalization, *p 
= 0.04. Error bars represent SEM of two separate experiments, each in triplicate.  
 
 
 
 
 
     1       1.22   0.13        1       0.9    0.02   
     1      1.13    0.4          1       0.78   0.04 
     1      1.38    0.17         1    1.05    0.01            .     .17             1.05   .  
*   
137 
 
3.3. Nicastrin silencing affects breast cancer cell adhesion and 
invasion  
To investigate if NCT is able to functionally contribute to breast cancer cell 
adhesion/invasion, an siRNA targeting approach was used in MCF7 and MDA-MB-231 
breast cancer cell lines, which represent luminal and basal breast cancer phenotypes 
respectively (368). The GS substrate E-cadherin is required for the formation of stable cell-
cell adhesions in the normal breast epithelium. To investigate whether NCT affected the 
stability of breast cancer epithelium, the E-cadherin positive MCF-7 cell line was treated with 
NCT siRNA. NCT silencing in MCF-7 monolayers increased the total cellular levels of E-
cadherin mRNA and protein (Figure 26 a & b), and facilitated its enhanced localisation to the 
cell membrane (Figure 27). This suggests that NCT may play a role in the regulation of breast 
cancer cell-cell adherence junctions. A potential mechanism of adherence junction regulation 
by NCT might be via the release of the transcriptional repression upon E-cadherin (CDH-1) 
by Snail1 (SNAI1), since the levels of this pivotal transcriptional factor in the EMT program 
were significantly reduced following NCT silencing (p<0.001) (Figure 26b). 
 
Figure 26.Nicastrin silencing affects cell adhesion and invasion molecules in MDA-MB-231 and 
MCF-7 cells. a) Western blotting analysis using indicated antibodies in Control siRNA and NCT 
siRNA treated cells. β-actin used as loading control. The intensity of bands was quantified using 
Image J software. Numbers below the bands represent fold change compared to the non-treated 
samples, relative to the loading control. b) Nicastrin silencing regulates transcription levels of E-
cadherin, Snail and vimentin. Quantitative RT-PCRs were carried out to determine fold changes in 
expression of E-cadherin (CDH1), Snail (SNAI1) and vimentin (VIM) in NCT siRNA treated samples 
compared with control (Control siRNA) samples , *p < 0.001. GAPDH was used for normalisation. 
Error bars are SEM of the mean percent change in expression compared with control siRNA samples 
from duplicate samples in three independent experiments. 
 
 
   1      1.3   0.12     1     0.95   0.03 
 
 
 
    1      0.9     1.2         
 
     1      1.04   2.3     1     0.63   0.55 
 
                                   1    0.8   0.05 
138 
 
Additional evidence suggests that NCT-dependent regulation of E-cadherin may 
involve p120ctn, a molecule that is responsible for regulating E-cadherin turnover from the 
plasma membrane (371), thereby stabilising E-cadherin localisation to adherence junctions 
(372, 373). This regulatory mechanism may be modulated by the presence of a stable GS 
complex at the plasma membrane where PS1/GS can compete with p120ctn for binding to E-
cadherin (372). Following NCT silencing, we observed an increase in p120ctn protein 
expression (Figure 26a) and localisation to MCF-7 cell membrane (Figure 27), suggesting 
that there may be multiple levels at which NCT can regulate the stability of luminal epithelial 
cell-cell adhesions. Although expression levels of the β-catenin and phalloidin were not 
affected, their alignment at the cell membrane upon NCT silencing was observed, 
corroborating the possibility of the formation of functional cell-cell adhesions (Figure 27). 
                       
Figure 27.Nicastrin silencing affects E-cadherin and p120 in MCF7 breast cancer cells.          
Cells were transfected with Control siRNA and NCT siRNA and after 72 h fixed, permeabilised and 
stained with anti-E-caderin, anti-p120, anti-β-catenin MAbs. Polymerised actin was visualised with a 
tetramethylrhodamine isothiocyanate-phalloidin conjugate. The E-cadherin antibody was labeled with 
Zenon Alexa Flour 488 (Invitrogen), while the staining with the anti-p120, anti-β-catenin Mabs was 
followed by Alexa Flour 594 goat anti-mouse IgG (H+L) (Invitrogen). Nuclei were counterstained 
with DAPI (Vector Laboratories). Bar = 10 m. 
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3.3.2. Nicastrin silencing inhibits breast cancer cell motility and invasion  
Given a differential role of the membrane-associated p120ctn in cell-cell adhesions 
and the proinvasive role of the cytoplasmic p120ctn, we investigated the effect of NCT 
silencing on p120ctn in MDA-MB-231 cells. Although p120ctn protein expression following 
NCT siRNA was only mildly reduced (Figure 26a), p120ctn became associated with F-actin 
fibers at the sites of cell-cell contact in these cells (Figure 28). This signified that the loss of 
NCT could promote formation of cell-cell junctions in cells such as MDA-MB-231 that have 
previously undergone progressive transformation towards a scattered, single cell distribution. 
Furthermore, immunofluorescence staining has demonstrated that MDA-MB-231 cells 
intrinsically assume the elongated morphology (Figure 28, white stars), as well as a more 
rounded shape, consitent with the amoeboid cell motility (Figure 28, while circles).  
140 
 
        
Figure 28.Nicastrin silencing promotes formation of cell junctions in MDA-MB-231 cells. MB-
MDA-231 cells were transfected with Control and NCT siRNA and after 72 h cells were fixed, 
permeabilised and stained with anti-p120 MAb followed by Alexa Flour 488 goat anti-mouse IgG 
(H+L) (Invitrogen). Polymerised actin was visualised with a tetramethylrhodamine isothiocyanate-
phalloidin conjugate (red). Nuclei were counterstained with TO-PRO-3 (blue). Bar = 10 m. White 
arrow heads indicate cell-cell junctions. White star indicates mesenchymal shaped cells which move 
in an elongated fashion. White circle indicates round cells with membranous bleb-like protrusions, 
which are characteristics of the amoeboid-type motility. 
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Since this result suggested that NCT silencing may play a role in the loss of cellular 
features which are characteristic of a migratory behavior, we decided to investigate the effect 
of NCT siRNA on a well established promoter of cell migration and invasion, vimentin (374). 
Interestingly, NCT depletion was sufficient to reduce transcription and protein expression of 
the mesenchymal marker and promigratory cytoskeletal protein vimentin (Figure 26). Given 
the observed phenotypic and molecular changes in MDA-MB-231 cells upon NCT 
knockdown, all consistent with a decrease in the cellular invasive features, we next 
performed two-dimensional (2D) and three-dimensional (3D) analyses of cellular motility 
and invasiveness. This allowed us to monitor the functional consequences of NCT depletion 
on breast cancer cell motility and invasion. Motility can be studied using 2D experimental 
systems, which provide insights into cell movement patterns and can also give insight into the 
molecular machinery driving cell motility/migration (375). We have monitored the effects of 
NCT siRNA on motility of MDA-MB-231 cells, by treating the cells with Control or NCT 
siRNA for 72 h, after which the cells were imaged for 12 h in an environmental chamber (37 
°C, 5% CO2) by means of video time-lapse microscopy. This allowed us to obtain 
information regarding the motility of the cells in the 2D environment.  Although informative, 
the mechanical properties of 2D motility assays on rigid surfaces are not fully comparable to 
those found in a 3D, in vivo setting. Epithelial cells in vivo are supported by both the basal 
membrane and the extracellular matrix. These structures play a key role during the invasion 
process by providing both a mechanical barrier preventing the invasion of the deeper tissues, 
as well as a substratum allowing malignant cells to migrate. Tumour cells leaving the primary 
tumour must therefore acquire the ability to invade the surrounding matrix in order to 
disseminate. To investigate the cellular invasive capacity in a 3D system, we used the trans-
well invasion chamber method, where the cells are introduced into the upper chamber and 
allowed to invade through the Matrigel-coated porous filter, mimicking the basement 
membrane and the extracellular matrix, into the lower chamber containing the chemo-
attractant, where they are collected from and counted. Matrigel does not only contain the 
basement membrane components (collagens, laminin, and proteoglycans), but also matrix 
degrading enzymes, their inhibitors and growth factors. Invasion of tumour cells into 
Matrigel has been used to characterise involvement of extracellular matrix receptors and 
matrix degrading enzymes which play roles in tumour progression (376).  
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Time-lapse microscopy experiments indeed revealed a decreased migratory speed of 
MDA-MB-231 cells upon NCT siRNA (Figure 29a). This was consistent with a reduction of 
the cell invasive capacity by 32±9.2% MDA-MB-231 cells upon NCT siRNA treatment in 
the trans-well invasion assay (Figure 29b).  
                                       
Figure 29.Nicastrin silencing inhibits migration and invasion of MDA-MB-231 cells. a) Effect of 
NCT silencing on the migration of MDA-MB-231 cells. Bars represent mean of cell migratory speed 
nm/sec ± SD from three separate experiments.  b) Effect of nicastrin silencing on invasion of MDA-
MB-231 cells. Bars represent mean number of invaded cells ± SD from three separate experiments. 
Statistical difference from control levels, *p = 0.01. 
 
To validate the phenotypic and behavioural changes associated with NCT silencing in 
breast cancer cells, and also to address the issue that the inhibition of cell invasion in the 
trans-well assay might have been observed due to the acute cytotoxic effects of NCT siRNA 
treatment, we repeated the live imaging and motility analysis using the mouse embryonic 
fibroblast cells (MEFs), where NCT has been stably depleted (NCT 
-/-
) (Figure 30a) (370). 
Unlike NCT 
+/+
 MEFs, which displayed a typical fibroblastic spindle-like morphology with a 
scattered distribution, NCT 
-/-
 MEFs were rounded (377), and formed dense aggregates 
(Figure 30b), with a marked reduction in migratory speed (Figure 30c).  
 
a) 
b) 
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Figure 30.Stable NCT knockdown in mouse embryonic fibroblast cells induces profound 
morphological and functional changes. a) Western blotting for nicastrin in NCT 
+/+
 and NCT 
-/-
 
MEFs. b) Phase contrast microscopy image of NCT 
+/+
 and NCT 
-/-
 MEFs. c) Cell migration assay 
(µm/h ± SD) of NCT
+/+
 and NCT
-/-
 MEFs. Magnification x10. * p < 0.01. 
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The evidence that genetic ablation of NCT in stromal fibroblasts of true mesenchymal 
origin induces a marked phenotypic and behavioural conversion towards a less motile cell 
model, strengthened our emerging hypothesis that silencing NCT may be able to induce 
restoration of a less invasive phenotype, thereby reversing the EMT-like program that has 
been proposed to promote breast cancer progression.  
3.3.3. Nicastrin silencing inhibits cell proliferation machinery in MDA-
MB-231 cells 
In order to further examine the downstream signaling effectors that may be modulated 
by NCT inhibition in MDA-MB-231 cells, we assessed the protein levels of some of the 
mediators of cancer cell invasion and proliferation, which have also been implicated the 
Notch-dependent cellular processes. Nicastrin silencing in MDA-MB-231 cells induced an 
upregulation of the p21 cell cycle regulator and a concurrent inhibition of the nuclear 
proliferation marker Ki67 and of the anti-apoptotic protein Bcl-2. Furthermore, two 
established oncogenic pathways were inhibited in the NCT siRNA treated cells, namely the 
ERK1/2 and the Akt, as demonstrated by reduced protein levels of their respective 
phosphorylated/activated forms. Corroborating the impaired function of the Akt pathway, its 
direct effector, the translation initiation factor 4E (eIF4E) protein, was equally inhibited. 
Interestingly, protein levels of the CD147, a recently established accessory protein to the GS 
complex, were downregulated in NCT siRNA treated cells (Figure 31).  
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Figure 31.Nicastrin silencing affects cell proliferation markers as well as the ERK1/2 and the 
Akt pathway. Western blotting showing expression of marked proteins in MDA-MB-231 cells 
treated with Control siRNA and NCT siRNA for 72 h. β-actin was used as the loading control. The 
intensity of bands was quantified using Image J software. Numbers below the bands represent fold 
change compared to the Control siRNA treated samples, relative to the loading control. 
 
These data indicated that NCT could be mediating its anti-proliferative and anti-
invasive effects by cooperating with established cellular oncogenic pathways. The observed 
effects may be mediated through the NCT siRNA-induced reduction of GS activity, PS1 and 
activated Notch proteins.  The cross-talk of Notch and MAPK signaling pathways has already 
been described in a number of cell types, playing a vital role in determining the context- 
specific functional outputs in the cell. Transformation by Notch requires active signals from 
the MAPK/ERK and PI3K/Akt (378). Also, activated Notch4 mediates anchorage-
independent growth through the MAPK/ERK pathway (378), while primary tumours from 
Notch4 transgenic animals have been shown to express active forms of ERK. This co-
operation is also reflected in vivo, as a subset of Notch positive human breast tumours 
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express phopsho-ERK1/2 in the nuclei. Such cases exhibit high node positivity, suggesting 
that Notch-ERK co-operation may lead to poor prognosis (165). Furthermore, a synergism 
exists between Notch and Akt in malignant disease (379), and Notch inhibition via targeted 
siRNA or GS inhibitors leads to concomitant downregulation of the cellular Akt activity 
(146). The deficits in Akt and ERK activation are also observed in cells deficient in both PS1 
and PS2 (380). 
The proliferation inhibitory and apoptotic effects resulting from NCT siRNA may be 
due to the downregulation of Notch activity and mediated through the expression of cell cycle 
regulatory proteins Bcl-2 and p21, and the activity of Akt signaling. It has been previously 
reported that the GS activity-regulated apoptosis is mediated via the Bcl-2-dependent cell 
death machinery (369, 381, 382), while the inhibition of Notch and Akt have been known to 
inhibit nuclear expression levels of the proliferation marker Ki67 (383). The eukaryotic 
initiation factor 4E (eIF4E) is a translational regulator that acts downstream of Akt and 
mTOR, and recapitulates the action of Akt in tumourigenesis (384). It is a major effector of 
the mTOR axis in Notch-mediated cell survival (385). Knockdown of eIF4E has been 
implicated in inhibition of proliferation via decreased expression of Bcl-2 in breast cancer 
xenografts (386). 
We have analysed the effect of NCT knockdown on CD147 protein because it has 
recently been identified as one of the accessory proteins able to regulate GS activity (234). 
CD174 also plays a critical role in the invasive and metastatic activity of cancer cells by 
stimulating the tumour-surrounding fibroblasts to express matrix metalloproteinases (MMP2 
and MMP9), as well as the VEGF, which promote tumour neoangiogenesis in malignant 
melanoma, prostate and bladder cancer. CD147 expression also is linked to development of 
multidrug resistance in breast cancer (387) (388). We have observed that NCT silencing 
downregulates CD147, suggesting this may be an accessory mechanism of NCT-mediated 
effects on cell invasion. 
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3.3.4. Overexpression of nicastrin is sufficient to increase GS activity in 
MCF-7 cells 
Having observed that transient NCT silencing in both MDA-MB-231 and MCF-7 
cells disrupts the GS complex and inhibits its activity, we wanted to investigate whether 
transient NCT overexpression would have the capacity to induce an opposite effect. For this 
experiment, we have transiently overexpressed NCT in non-invasive, MCF-7 cells, using a 
full-length NCT construct cloned into a pCMV6-XL4 expression vector. Nicastrin mRNA 
levels were significantly increased (Figure 32a), which translated to an upregulation of the 
NCT protein. This increase of NCT was sufficient to induce a concurrent upregulation of 
PS1, as well as an enhancement of the active, cleaved forms of GS substrates (Notch1, 
Notch4 and E-cadherin) (Figure 32b). This result indicated that NCT overexpression could 
indeed promote GS activity in breast cancer cells. The fact that we have observed an increase 
in E-cadherin-ICD, which is a nuclear chaperone of the p120ctn required for the activation of 
the proinvasive MMP7 gene and the disassembly of adherence junctions (269, 373), indicated 
that NCT overexpression may be acting in direct contrast to the NCT siRNA-induced effects 
in MCF-7 cells, where membrane E-cadherin levels were increased, suggesting a re-
enforcement of cell-cell junctions.  
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Figure 32.Nicastrin overexpression in MCF-7 cells. MCF-7 (2 x 10
5
) cells were plated in a 6 cm 
Petri dish and transfected with 1.5 ng of full-length NCT cDNA (SC100655, Origene) and the 
pCMV6-XL4 empty vector control, using Lipofectamine 2000 (Invitrogen). Cells were incubated for 
48 h and then lysed for mRNA and protein extraction. a) RT-qPCR of NCT showing a marked 
increase of NCT mRNA levels. GAPDH was used for normalizing. GAPDH was used for 
normalisation. Error bars represent SD of two separate experiments, each in triplicate; changes 
observed throughout these experiments were statistically significant * p = 0.0006.  b) Western 
blotting of marked proteins showing the effects of transient NCT overexpression in MCF-7 
cellsonPS1, Notch1, Notch4 and E-cadherin proteins. β- actin was used as the loading control. The 
intensity of bands was quantified using Image J software. Numbers below the bands represent fold 
change compared to the control vector transfected samples, relative to the loading control. 
                
In order to further validate these findings in a system where NCT overexpression 
would be able to yield more robust effects, we used non-transformed, non-invasive 
immortalised MCF10A breast cells that do not express abundance of NCT, and generated an 
MCF10A cell line stably overexpressing NCT. Nicastrin overexpression was achieved by 
infecting the cells using a retroviral vector pMXs-puro, containing full length human NCT 
(NCT-pMXs-puro), kindly provided to us by Prof. Gopal Thinakaran, University of Chicago, 
USA (330). As previously reported, overexpression of NCT resulted in a predominant 
accumulation of its immature form at ~125 kDa (326, 365, 389). Nicastrin overexpression in 
MCF10A cells induced more rapidly proliferating acini-like structures in 3D Matrigel (Figure 
33a). At the same time, protein levels of PS1, Aph-1 and PEN2, as well as of the cleaved 
Notch1 were induced, indicating that NCT-induced synthesis and activity of the GS complex 
Furthermore, Numb, the negative regulator of Notch, was downregulated (Figure 33b). 
* 
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   1         2.4     
   1         1.35     
   1           2     
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Dowstream of active the Notch1, we also show that the transcription of the Notch target gene, 
Hes1 was stimulated (Figure 33c). Importantly, we observed a marked elevation of vimentin, 
both at the protein and mRNA levels (Figure 33b, d). At the same time, proinvasive genes 
SIP1, Twist and Snail, were induced in the context of NCT overexpression (Figure 33e). 
Interestingly, NCT affected matrix-metalloproteinases, as observed by the induction of 
MMP7 transcription, which may be a consequence of an increase in E-cadherin cleavage 
(269), which is currently under investigation. The induction of EMT promoters inferred a 
functional consequence, since the invasive capacity of MCF10A NCT-expressing cells was 
enhanced, compared to control cells (Figure 33f). Collectively, these data confirm that 
overexpression of NCT is able to promote breast cell invasiveness.  
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Figure 33.Nicastrin overexpression in MCF10A non-transformed breast cells induces cell 
growth and invasion. a) Phase contrast microscopy image of acini-like structures formed by 
culturing MCF10A Control pMXs-puro and NCT expressing NCT-pMXs-puro cells in the 3D 
Matrigel overlay assay. The pictures were taken at day 12. Original magnification  x20. b) Western 
blotting analysis of MCF10A Control pMXs-puro and NCT expressing NCT-pMXs-puro whole cell 
lysates with indicated antibodies. β-actin was used as a loading control. The intensity of bands was 
quantified using Image J software. Numbers below the bands represent fold change compared to 
MCF10A Control pMXs-puro cells, relative to the loading control. RT-qPCR depicting fold change of 
quantitative mRNA levels of:  c) HES1, *p =0.02; d) Vimentin, *p = 2.56E-06; e) SIP1, *p = 0.003; 
TWIST, *p = 2.26E-05; SNAIL1, *p = 0.0002; MMP7, *p = 0.004; MMP9, *p = 0.19.  GAPDH was 
used for normalising. Error bars represent SEM of the fold change from two separate experiments, 
each in triplicate. f) Trans-well invasion assay. Bars represent fold change of the invasive capacity ± 
SD from two separate experiments, each in triplicate. Statistical difference from control cells, *p = 
0.01.  
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3.4. Discussion 
Most studies to date have focused on the expression and function of GS substrates, 
such as the Notch proteins, E-cadherin, CD44 and HER4, and have reported altered 
expression and function of these proteins in normal and diseased human tissues. Limited 
attention has been given to investigating the expression of individual GS components in 
breast cancer cells, with a general notion that the function of all four GS members is united 
within this enzyme complex. We have demonstrated a marked upregulation of NCT in human 
breast cancer cell lines compared to normal breast cells. Our efforts to characterise the 
functional implications of NCT expression in breast cancer cells by employing the siRNA 
targeting approach have indicated that NCT is important in maintaining breast cancer cell 
invasive and proliferative capacity. 
Both of these aspects of the NCT function may be related to its role within the GS 
complex, and may be mediated through NCT siRNA-induced impairment of GS activity, 
causing inhibition of the GS substrate cleavage and activation, particularly that of Notch. 
Indeed, we have shown that mRNA levels of Hes1, an immediate target of the Notch pathway 
is inhibited by NCT silencing. Nicastrin inhibition was able to inhibit proliferation of both the 
basal-like (MDA-MB-231) and the luminal (MCF-7) breast cancer cell lines. However, in 
patient samples, high NCT expression predicted for worse overall survival only in the ERα 
negative patients. This fact indicates that NCT may be a particularly significant molecule in 
aggressive breast cancer, and proposes that a correlation exists between NCT overexpression 
and breast cancer aggressiveness. 
We next demonstrated that targeting NCT in breast cancer epithelial monolayers and 
metastatic breast cancer cells in vitro, was sufficient to promote cell-membrane localisation 
of the principle cell-cell adhesion proteins and reduce cellular invasive capacity. The 
mechanism underlying these newly identified properties of NCT appears to involve the 
regulation of E-cadherin and p120ctn localisation to the cell membrane and downregulation 
of vimentin as part of an EMT-like program in breast cancer cells. The upregulation of E-
cadherin protein and mRNA levels, as well as the enhanced cell membrane localisation upon 
NCT silencing could involve several mechanisms. The first mechanism could relate to the 
fact that the absence of NCT inflicts impaired GS activity, hence may reduce GS cleavage of 
E-cadherin, which consequently may reduce E-cadherin turnover from the cell membrane.  
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A secondary mechanism of regulation could occur via the activation of the 
transcriptional targets. Mechanistically, this could in part represent a Notch-mediated event. 
This is corroborated by reduced transcription of the Notch target Hes1 in MCF7 cells upon 
NCT silencing. Notch-mediated effects on Snail were previously shown in an ovarian cancer 
model (169). Nicastrin-dependent E-cadherin regulation could also involve p120ctn, which 
stabilises E-cadherin localisation to adherence junctions by regulating its turnover or 
competing with PS for direct binding to E-cadherin (372, 373). Nicastrin overexpression in 
MCF10A cells induced a more rapid proliferation of acini-like structures grown in Matrigel. 
This is an effect already observed upon Notch1-ICD overexpression in MCF10A cells (390), 
and may very well be a Notch-mediated consequence in our experiment as well. Treatment of 
MCF10A NCT-expressing cells with a gamma-secretase inhibitor would help discern the 
extent to which the proliferation induction is dependent on GS/Notch activation or NCT-
dependent cellular signaling. Should a GSI revert the growth rate to basal levels, it will 
indicate that NCT overexpression exerts its pro-proliferative function mainly via GS/Notch 
activity. Regulation of vimentin by NCT silencing appears to occur at the transcriptional 
level, as suggested by a marked decrease in vimentin mRNA levels upon NCT siRNA and 
increase upon NCT overexpression. Inhibition of vimentin, a bona fide EMT denominator, 
has previously been shown to reduce cellular invasive capacity in the reversal of an EMT 
program (374). Notch receptor-mediated regulation of vimentin has thus far been examined 
in human salivary gland (HSG) epithelial cells in the context of salivary acinar growth and 
differentiation (391), and in rat alveolar epithelial cells in the context of examining Notch 
signaling in the process of pulmonary fibrosis (392). It has been demonstrated that only 
simultaneous inhibition of all four Notch receptors in capable of inducing a reduction of 
vimentin protein (391). We have demonstrated a profound inhibition of vimentin protein 
upon NCT silencing in MDA-MB-231 cells. In alveolar epithelial cells, ectopic expression of 
active Notch induced an EMT phenotype accompanied by E-cadherin inhibition, induction of 
the smooth muscle actin and migratory behavior of cells (392). Although the authors state 
that vimentin mRNA levels were equally elevated, this increase was 1.3-fold from baseline 
levels, while we have observed a ~20-fold increase in vimentin transcription upon NCT 
overexpression in MCF10A cells.  
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Given the degree of vimentin inhibition and induction upon NCT silencing and 
overexpression, respectively, our data suggest that while to some extent vimentin may be 
regulated by Notch signaling in breast cancer cells, there may also be an additional layer of 
Notch-independent/NCT-dependent regulation of vimentin. Metastatic invasion in breast 
cancer is a critical event leading to patient mortality, and the identification of molecular 
contributors specific to metastasis is essential for the development of effective targeted 
therapies. Our data suggest that NCT upregulation may have an important mechanistic role 
underlying the increased risk of dissemination of breast cancer cells. 
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Results 
 
 
Effects of stable nicastrin depletion 
in the invasive breast cancer cells 
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4.1. Introduction 
Molecular profiling of the HCC1806 breast cancer cell line has revealed that they 
represent an in vitro model of basal-like breast cancers, as they are triple negative and EGFR 
positive cells, derived from the squamous cell primary breast tumour (367). EGFR is 
commonly expressed in basal-like breast cancers, as are the Notch receptors that have been 
recognised for their hyper-activation in this breast cancer subtype (158). 
The group of Prof. M. Loren et al. has generated a stable HCC1806 cell line lacking 
NCT expression (164). Short hairpins targeting human NCT with the sequences: 5′-
CCCATCTTTCTTCTTGAAGAT-3′ and 5′-GCTCTACTGAATACTCTACAT-3‟, were 
cloned into the lentiviral vector pLKO-puro. Control cells were generated by lentiviral 
transduction of a short hairpin targeting the luciferase gene, which contains coding sequences 
not present in the human genome. Stable, polyclonal knockdown cell populations were 
established after infection and drug selection. Cells harbouring the NCT short hairpins 
showed a significant decrease of NCT protein levels (164). GS inhibition in HCC1806 cells 
significantly disabled the Notch signaling pathway, which in conjunction with EGFR 
inhibition using gefitinib, resulted in a potent inhibition of cell viability, exceeding the anti-
proliferative effects of gefitinib and the GS inhibitor DAPT as single treatments (164). 
Mechanistically, this loss of cell viability was due to Notch1-mediated effects on the Akt 
pathway, whose activation is an established mechanism of resistance to treatment with EGFR 
inhibitors (393). To rule out the possibility that off-target (toxic) effects of the GSI (DAPT) 
have contributed to the observed additive cytotoxicity upon gefitinib and DAPT combined 
treatment, this group has generated a stable HCC1806 cell line lacking GS activity by 
knocking down NCT, and has replicated the data obtained with the use of the DAPT (164).  
The HCC1806 control and NCT knockout cells represented an advantageous tool to 
use in our experiments as well, and were obtained as a kind gift from Prof. M. Loren, 
University of Washington, USA. It is important to emphasise that the HCC1806 cells are, like 
the MDA-MB-231 cells used to transiently silence NCT, a triple-negative, basal-like, breast 
cancer cell line, the fact that enabled us to compare and contrast the results obtained from 
these two cell line models.  
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Furthermore, given the nature/durability of the stable NCT depletion, these cells 
allowed us to investigate the impact of NCT inhibition on cellular invasion in the trans-well 
assays, while avoiding the possible hindrance of acute cytotoxic effects and lack of durability 
of the transient siRNA.  
4.2. Results 
4.2.1. Stable nicastrin depletion impairs proliferation and invasion of 
breast cancer cells 
In order to investigate the impact of the stable NCT depletion in HCC1806 breast 
cancer cells on cell behaviour and morphology, we have performed phase contrast 
microscopy of the HCC1806-Luc1 and HCC1806-NCTsh cells cultured in a 2D assay, 
allowing us to monitor cell shape and distribution, as well as in the 3D Matrigel-overlay 
assay, enabling us to examine the acini-forming capacity of HCC1806-NCTsh vs. control 
cells.  
Absence of NCT had a profound effect on cell morphology, since the spindle shape 
and scattered distribution of HCC1806-Luc1 cells were notably changed to a rounded 
phenotype and compact cell clusters in the HCC1806-NCTsh cells (Figure 34a). The more 
physiologically relevant 3D Matrigel-overlay model, which allows integration of the crucial 
extracellular matrix signaling components, showed that control HCC1806 cells formed grape-
like complex acini structures, which are characterised by the absence of functional cell-cell 
adhesions and increased migratory behaviour (67). Conversely, NCT depleted cells yielded 
significantly smaller acini and their shape was more rounded (Figure 34a), suggesting that the 
cells lacking NCT expression may have undergone a reversal of the EMT. Since the size of 
the cellular acini was greatly affected in a 3D assay, we speculated that the rate of 
proliferation might be reduced in HCC1806-NCTsh cells. Therefore, we conducted a 2D 
proliferation assay with HCC1806-Luc1 and HCC1806-NCTsh cells in 96-well plates and 
detected that the rate of proliferation in NCT depleted cells was indeed reduced by 47±4.1% 
(p < 0.01) over the period of 6 days (Figure 34b).  
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Furthermore, the invasive capacity of the HCC1806-NCTsh cells was reduced by 
51.4±1.7% compared to control cells (Figure 34c), which compared to the reduction of 
invasion in MDA-MB-231 cells upon transient NCT silencing, indicates that stable NCT 
depletion is more potent in interfering with the aggressive behaviour of breast cancer cells. 
This was further confirmed by a marked downregulation of vimentin protein levels in 
HCC1806-NCTsh cells (Figure 34d). 
In order to explore the downstream signaling pathways responsible for inferring the 
observed functional effects in HCC1806-NCTsh cells, we prepared whole cell lysates of 
HCC1806-Luc1 and HCC1806-NCTsh cells and firstly examined the effect of NCT depletion 
on other GS components. Protein levels of PS1, Aph-1 and PEN2 were reduced, suggesting 
that the GS complex has been impeded, which was in line with reduced levels of the cleaved 
Notch1 (Figure 34d). As previously reported by Dong et al., we have also observed that the 
Akt pathway was inhibited in NCT depleted cells, as measured by the levels of 
phosphorylated Ser473 residue. Furthermore, the EGFR protein was markedly 
downregulated, which could help explain the additive effect that gefitinib and NCT inhibition 
had on cell proliferation (164). Slower proliferation rate of HCC1806-NCTsh cells we have 
observed (Figure 34d) is in line with the lower levels of the proliferative marker, Ki67, as 
well as with the noted increase in p21 (Figure 34d), the expression of which mediates the cell 
cycle G1 phase arrest in response to a variety of stimuli (394).  
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Figure 34.Stable NCT depletion impedes proliferation and invasion of HCC1806 cells.        
 a) Phase contrast microscopy image of HCC1806-Luc1 and HCC1806-NCTsh cells cultured in 2D 
(upper panels) and in the 3D Matrigel-overlay chambers (lower panels); Magnification x10.              
b) HCC1806-Luc and HCC1806-NCTsh cells were plated (3 x 10
3
/well) in 96-well plates and 
allowed to adhere over-night, when one plate was fixed and annotated as Day 0. Cells were grown and 
SRB assay was performed every 2 days until Day 6. Error bars represent SEM of two independent 
experiments, each in quadruplicate, *p = 0.017. c) Trans-well invasion assay.  Bars represent mean 
number of invaded cells ± SEM from three separate experiments, each in triplicate. Statistical 
difference from control levels, *p = 0.001. d) Western blotting analysis of HCC1806-Luc1 and 
HCC1806-NCTsh whole cell lysates with indicated antibodies. β-actin was used as a loading control. 
The intensity of bands was quantified using the Image J software. Numbers below the bands represent 
fold change compared to HCC1806-Luc1 cells, relative to the loading control. 
 
4.2.3. Nicastrin depletion affects the breast cancer stem-cell like population  
The role of Notch signaling has recently been implicated in the maintenance of the 
stem cell pool, both in the normal mammary epithelium, and in the cancer stem cells (395). 
Notch4 has been described as the key downstream effector of the Notch signaling axis, and 
also the main receptor of this family whose expression levels are elevated in breast cancer 
stem cells (BCSCs) (176). We sought to investigate whether NCT expression was altered in 
BCSCs compared to non-CSC population, as well as to explore the effect of NCT depletion 
on the Notch pathway in the BCSCs population.  
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Cancer stem cells are characterised by the multi-potency to give rise to various 
cellular lineages within the primary tumour, as well as to survive and form mammospheres, 
which are structures enriched in cells with functional characteristics of stem/progenitor cells, 
in anchorage independent conditions (396). We tested the mammosphere forming capacity of 
HCC1806-Luc and HCC1806-NCTsh cells by culturing them on a non-adherent surface in 
the presence of growth factors. We demonstrated that the mammospheres were more 
abundant in NCT expressing cells (Figure 35a & b), suggesting that NCT depletion may play 
a role in inhibiting the pool of stem/progenitor cells in the HCC1806 breast cancer cell line. 
Therefore, we next wanted to examine in more detail the impact of NCT inhibition in breast 
cancer stem cells. In order to isolate the appropriate cell population, we employed a stem-cell 
enrichment protocol which relies on immunosorting and the use of antibodies against cell-
surface proteins. Based on the phenotypic signature of BCSCs proposed by the work of Al 
Hajj et al. (87), we used CD44 and CD24 as the relevant cell surface markers. Both the 
HCC1806-Luc and HCC1806-NCTsh cells were sorted according to the expression of cell 
surface CD44 and CD24, and the percent of the BCSCs baring the CD44
+/
CD24
-
 signature 
were compared. A reduction of the BCSC pool in the HCC1806-NCTsh cells (4.2±1.5% in 
NCT depleted cells vs. 10.1±2.3% in the control cell line) was observed (Figure 35c & d). 
This further strengthened our hypothesis that NCT may be important for the maintenance and 
function of BCSCs.  
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Figure 35.Stable NCT depletion reduces stem-cell-like properties of HCC1806 cells. a) Phase 
contrast microscopy of HCC1806-Luc1 and HCC1806-NCTsh cells grown in low attachment 6-well 
plates and cultivated in serum-free mammary epithelial growth medium, supplemented with 20 ng/ml 
EGF, 20 ng/mL FGF and 4 μg/mL heparin. Images were taken 10 days after cell plating. HCC1806-
Luc1 cells form mammospheres (> 60 μm in size), while HCC1806-NCTsh cells predominantly form 
doublets, triplets and small-cell aggregates. Magnification x20. b) Bar graph represents the sphere 
forming efficiency mammosphere forming efficacy of HCC1806-Luc1 and HCC1806-NCTsh. Sphere 
forming efficacy was calculated as the number of spheres formed in 10 days divided by the original 
number of single cells seeded and expressed as a percentage. Bars represent mean percent of 
mammospheres ± SD from two separate experiments. Statistical difference from HCC1806-Luc1 
cells, *p < 0.01. c) HCC1806-Luc1 and HCC1806-NCTsh cells were dual-labeled with fluorochrome-
conjugated monoclonal antibodies against human CD44 (CD44-FITC) and CD24 (CD24-PE), and 
subjected to cell sorting on the FACSAria, BD. The bars represent percent of isolated stem-cell-like 
cells (CD44
+
/CD24
-
) ± SD from three separate experiments. Statistical difference from HCC1806-
Luc1, *p < 0.01. d) Western blotting showing protein levels of NCT in the HCC1806-Luc1 and 
HCC1806-NCTsh non-stem cell (non-SC) and the stem-cell (SC) populations derived from the cell 
sorting. β-actin was used as the loading control. The intensity of bands was quantified using Image J 
software. Numbers below the bands represent fold change compared to the HCC1806-Luc1cells, 
relative to the loading control. 
 
 
 
 
 
* 
* 
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4.2.4. Nicastrin depletion inhibits Notch4 protein levels in breast cancer 
stem cells 
To investigate the impact of NCT depletion on the Notch pathway, we performed RT-
qPCR analysis of Notch1, Notch4, Hes1 and Numb. Firstly, we confirmed that the NCT gene 
was silenced in both the BCSC and the non-SC fractions of the analysed cell lines (Figure 
36a). Notch1 transcription displayed a trend of elevation, although not statistically significant, 
between non-SC and BCSC pools, in both the control and NCT depleted cells. This trend was 
mirrored by the Hes1 mRNA levels (Figure 36b & c). Interestingly, transcription of the 
negative regulator of the Notch pathway, Numb, was increased in the BCSC fraction of 
HCC1806-Luc1 cells compared to the non-SC population, even though Notch mRNA levels 
were still upregulated (Figure 36c & e). This may represent a negative feed-back mechanism 
as a tendency to counteract the activation of Notch in the BCSCs. Increased levels of Numb 
were maintained at this higher level in both the BCSC and the non-SC of the HCC186-
NCTsh cells (Figure 36d).  
As previously reported (176), we also found that the Notch4 was most markedly 
upregulated in the BCSC population of both HCC1806-Luc1 (6.5-fold) and HCC186-NCTsh 
cells (8-fold) compared to their respective non-SC counterparts (Figure 36e). Upon analysis 
of the cleaved Notch4 protein levels, we have observed that Notch4-ICD was indeed 
markedly upregulated in BCSCs in the HCC1806-Luc1 cells, mimicking the increase in 
mRNA levels (Figure 36f). Strikingly, even though Notch4 transcription still remained high 
in the NCT depleted BCSCs, the increase of the activated Notch4 protein was partially 
prevented by NCT depletion in the BCSCs as well as in non-SCs (Figure 36f). 
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Figure 36.Stable NCT depletion affects the Notch pathway in non-SC and in the SC populations 
of HCC1806-Luc1 and HCC1806-NCTsh cells. RT-qPCR depicting fold change of quantitative 
mRNA levels of:  a) Nicastrin, *p = 0.0002 and **p = 0.004; b) Numb, *p = 0.02 and **p = 0.02; d) 
Notch4, *p = 0.009 and **p = 0.001. GAPDH was used for normalising. Error bars represent SEM of 
the fold change from two separate experiments, each in triplicate. f) Western blotting of the Notch4-
ICD. β-actin was used as the loading control. The intensity of bands was quantified using Image J 
software. Numbers below the bands represent fold change compared to the HCC1806-Luc1cells, 
relative to the loading control. 
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4.2.5. Nicastrin depletion inhibits proinvasive genes in breast cancer stem 
cells-like cells derived from HCC1806 cell line 
Genes commonly associated with basal breast cancer cell lines which are upregulated 
in EMT include SIP1, Vimentin, Twist, Snail, FOXC2, N-cadherin and Fibronectin etc. (54). 
Breast cancer stem cells display higher expression levels of the proinvasive genes. 
Furthermore, the „invasiveness gene signature‟ of the breast cancer cells expressing the 
CD44
+
/CD24
-
 phenotype was found to be predictive of patient outcome (397). Emphasising 
the relationship between the EMT and BCSCs, recent evidence proposed that passage of 
mammary epithelial cells through an EMT program has the capability to generate cells with 
stem cell properties (90). 
Considering the inhibitory effect of NCT depletion on cell invasion, as well as on 
vimentin protein levels, and the fact that EMT is a concept that is increasingly gaining 
recognition within cancer stem cells, we next checked whether NCT inhibition modulated 
transcription of the proinvasive genes in non-SCs and BCSCs in the HCC1806-Luc1 and 
HCC1806-NCTsh cell lines. We subjected HCC1806-Luc1 and HCC1806-NCTsh cells to 
immunosorting and generated non-SC and BCSC populations for each of the two cell lines. 
The mRNA was then isolated from the cells and NCT mRNA levels were proven to be 
downregulated in respective HCC1806-NCTsh populations (Figure 36a). 
As previously observed upon transient NCT knockdown in MDA-MB-231 cells, 
vimentin mRNA levels were 10-fold downregulated between the non-SC populations of the 
HCC1806-Luc1 and HCC1806-NCTsh cells. As expected, vimentin was markedly 
overexpressed (8.5-fold) in the BCSC pool of the NCT expressing cell line, compared to the 
non-SC counterpart (Figure 37a). NCT depletion, however, was able to prevent a similar 
increase of vimentin mRNA levels in the BCSCs of the NCT depleted cell line, maintaining 
the levels comparable to those in the HCC1806-NCTsh non-SCs. The same trend was 
observed for the SIP1 (Figure 37b) and Snail1 (Figure 37c), while NCT inhibition had 
negligible effects on Fibronectin and N-cadherin (Figure 37e & f). Twist1 transcription was 
elevated in the HCC1806-Luc1 BCSCs compared to the non-SC counterpart, however, NCT 
inhibition did not confer a reduction of Twist1 mRNA levels (Figure 37d). 
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Figure 37.Stable NCT depletion inhibits the expression proinvasive genes in non-SC and in the 
BCSC populations of HCC1806-Luc1 and HCC1806-NCTsh cells. RT-qPCR depicting fold 
change mRNA levels of a) Vimentin, *p < 0.001 and **p = 1.84E-05. b) SIP1, *p = 0.0005 and **p = 
2.11E-05. c) Snail1 *p <0.01 and **p = 0.001. d) Twist, *p = 0.003. GAPDH was used for 
normalising. Error bars represent SEM of two individual experiments, each in duplicate. 
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4.2.6. The Human Extracellular Matrix and Adhesion Molecules PCR 
Array 
Having demonstrated that stable nicastrin depletion inhibits proinvasive genes, we have 
next used HCC1806Luc-1 and HCC1806-NCTsh cells to perform a gene array that profiles 
the expression of 84 genes important for cell-cell adhesion and cell-matrix interactions. This 
array contained genes encoding for basement membrane constituents, collagens, and other 
genes defining extracellular matrix structure: integrins, selectins, cell-cell adhesion molecule 
family members (full gene list is included in Chapter 2). 
Nine genes were upregulated in the HCC1806-NCTsh compared to HCC1806-Luc1 
cells: COL14A1, COL15A1, COL5A1, VCAN, ITGA4, ITGA7, ITGAL, LAMA1, VTN. 
According to the analysis software, seven of these were ruled out due to a high threshold of 
detection (> 30 cycles), or variations between replicate wells. The two upregulated genes that 
passed the internal quality control were COL14A1 and ITGA4, while the two downregulated 
genes were ITGB2 and SELL (Table 6).  
 
The PCR Array PAHS-013 (Qiagen) consisted of a set of optimised real-time PCR primers on a 96-
well plate. The array included built-in positive control elements for: i) proper data normalisation, ii) 
detection of genomic DNA contaminations; iii) quality of the mRNA samples. HCC1806-Luc1 and 
HCC1806-NCTsh cells were cultured and 1 x 10
6 
cells were lysed using the RNAlater (Qiagen), and 
mRNA was prepared. HCC1806-Luc1 and HCC1806-NCTsh cDNA was made using the RT² First 
Strand Kit (Qiagen, UK). RT² qPCR SYBR Green/ROX Master Mix was used in the reactions 
according to the manufacturer‟s protocol. The PCR Array Data Analysis Portal automatically 
performed the calculations and interpretation of the control wells, including thresh-hold cycle data 
from the real-time instrument. The RT² Profiler PCR Array Data Analysis Template v3.3 software 
was used. Calculations were based on the ΔΔCt fold-change. 
 
 
Genes Overexpressed in  HCC1806-NCTsh  vs. HCC1806-Luc1   
Position on array 
plate 
Gene 
Symbol 
Fold Regulation Comments RT2 Catalog 
A09 COL14A1 4.2203 OKAY PPH02129B 
C08 ITGA4 7.2858 OKAY PPH00659E 
 
Genes Under-Expressed in  HCC1806-NCTsh  vs. HCC1806-Luc1 
Position on array 
plate 
Gene 
Symbol 
Fold Regulation Comments RT2 Catalog 
D05 ITGB2 -5.967 OKAY PPH00679E 
F08 SELL -20.5478 OKAY PPH00677E 
Table 6.PAHS-013 cell-adhesion and cell-matrix gene array 
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We have then validated COL14A1, ITGA4 and ITGB2 genes in an independent 
experiment (Figure 38). The SELL gene validation is pending. Collagen XIVA1 (COL14A1), 
upregulated 4-fold in NCT depleted cells, is a large extracellular matrix glycoprotein that 
associates with mature collagen fibrils. Frequent absence of COL14A1 is recorded in the 
vicinity of invading tumours, such as the Kaposi sarcoma and oral squamous cell carcinoma. 
This gene is often methylated and silenced in renal cancer (398). Integrin alpha 4 (ITGA4), 
upregulated 4-fold in HCC1806-NCTsh cells compared to control, is a cell surface integrin 
whose downregulation has been associated with tumour invasiveness (399), while expression 
of integrin beta 2 (ITGB2), which was inhibited > 4-fold by the stable NCT knockdown, 
facilitates tumour cell migration. The SELL gene encodes the cell surface adhesion molecule 
L-selectin that belongs to a family of homing receptors. It is required for binding and 
subsequent rolling of leucocytes on endothelial cells, facilitating their migration into 
lymphoid organs and inflammation sites (400). It has been shown that experimental 
metastasis were significantly reduced in the absence of L-selectin (401).  
 
           
Figure 38.Validation of the PAHS-013 gene array. RT-qPCR confirming NCT knockdown in 
HCC1806-NCTsh cells as well as demonstrating the same trend and level of regulation of the cellular 
matrix and adhesion genes yielded as hits in the PAHS-013 gene array. NCT, *p = 0.0005; COL14A1, 
*p = 0.0004; ITGA4, *p = 0.0004; ITGB2, *p = 2.57E-05. GAPDH was used for normalising. Error 
bars represent SEM from two independent experiments, each in triplicate. 
 
* 
* * 
* 
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4.3. Identification of proteins affected by nicastrin silencing in MDA-
MB-231 and HCC1806 cells using XP725 Profiler Antibody Array (Sigma) 
Having demonstrated that both the transient and the stable nicastrin gene silencing 
result in inhibition of cell invasion and proliferation, we chose to perform an antibody array 
analysis in order to try and identify protein networks which are responsible for these effects 
upon nicastrin depletion in invasive breast cancer cells. 
Protein arrays, for which antibodies are printed onto array surfaces, are designed to 
capture and measure the relative abundance of their cognate antigens in the applied samples 
(402). Protein profiles obtained by the antibody arrays, represent comprehensive means of 
analysing the signaling cellular proteome content and deriving information about the 
governing signaling cellular networks. A combination of complex changes involving multiple 
proteins is required for malignant transformation of normal cells.  For this reason, profiling of 
the cancer-associated alterations requires simultaneous measurement of many proteins in a 
single sample (403). Investigation of the proteomic changes is also important since there is 
not always a direct correlation between the mRNA levels and protein expression. 
Furthermore, post-translational modifications, which cannot be detected at the mRNA level, 
may play an important role in the level of expression of the oncogenic proteins. Multiple 
studies so far have utilised antibody arrays to investigate protein expression profiles in breast 
cancer cells, conditioned media, or tumour infiltrating interstitial fluid, and have derived 
significant conclusions regarding: 
 differential protein expression in malignant and adjacent normal breast tissue, such as a 
decrease in the protein 14-3-3e, and an increase in casein kinase Ie, annexin XI, CDC25C, 
eIF4E and MAP kinase 7 (404); 
 association of IL-8 with the ERα negative status, vimentin expression and breast cancer 
invasiveness (405); 
 identification of E-cadherin as an MDM2 interacting proteins targeted for proteasomal 
degradation in MDA-MB-453 breast cancer cell extracts, as a part of the MDM2-mediated 
promotion of cell adhesion disassembly (406); 
 identification of the IL-8 and the growth related oncogen as a part of the HER2-induced 
cytokine signature in breast cancer (407); 
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 identification of the cytokine expression signature in the interstitial fluid that perfuses the 
tumour microenvironment: i) interleukins (IL-8, IL-10, IL-12, IL-13, IL-16); ii) growth 
factors (TGF-β1/2/3, TNF-α/β, VEGF, PDGF); iii) oncostatin M, monocyte chemo-
attractant proteins 1-3, neurotrophins etc. (408); 
 the proteins involved in the development of doxorubicin resistance in the MDA-MB-231 
cell line model. A decrease in the expression of mitogen-activated protein kinase, cyclin 
D2, cytokeratin 18, cyclin B1, and heterogeneous nuclear ribonucleoprotein m3-m4 were 
associated with doxorubicin resistance (409).  
 
Given that both the MDA-MB-231 and HCC1806 cells used in the antibody array 
represent the basal-like breast cancer subtype, we were able to compare the array outputs. 
This also allowed us to monitor the level of consistency of the NCT depletion-induced effects 
in two distinct triple negative breast cancer cell lines. 
4.3.1. XP725 Profiler Array reveals NCT regulated signaling networks in 
MDA-MB-231 and HCC1806 breast cancer cells 
MDA-MB-231 cells were treated with the Control and NCT siRNA for 72 h and the 
degree of NCT protein inhibition was confirmed by western blotting. HCC1806-Luc1 and 
HCC1806-NCTsh cells were cultured to 70-80% confluence and processed for protein 
extraction. Protein lysates from both cell lines (control and NCT depleted), were labeled with 
the Cy3 and Cy5 fluorochroms, respectively, and hybridised to the array platform (XP725 
Profiler Array, Sigma). This array consisted of 725 monoclonal antibodies spotted in 
duplicate on the nitrocellulose membrane. The level of NCT knockdown in MDA-MB-231 
cells treated with NCT siRNA and in HCC1806-NCTsh cells was confirmed by western 
blotting prior to proceeding with the hybridisation of the samples onto the antibody array 
slide (Figure 39). 
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Figure 39.Confirmation of nicastrin protein downregulation in the samples hybridised on the 
XP725 antibody array. MDA-MB-231 cells were treated with Control siRNA and NCT siRNA for 
72 h. HCC1806 cells were cultured to 70-80% confluence and harvested for protein lysis extraction. 
Western blotting was used to examine the level of nicastrin knockdown in both cell lines. β-actin was 
used as a loading control. The intensity of the bands was quantified using the Image J software. 
Numbers below the bands represent fold change compared to the control siRNA/shRNA samples, 
relative to the loading control. 
 
The signal obtained from each spot of the scanned array slide was dependent on the 
abundance of the corresponding antigen in the applied sample, as well as on the 
quality/preservation of the individual spots. Nicastrin depletion affected expression of 
multiple proteins which participate in known cellular signaling pathways that regulate cancer 
cell proliferation, invasion and apoptosis. Most of the changes induced by transient NCT 
silencing in MDA-MB-231 cells were mirrored in the HCC1806-NCTsh, stable depleted cell 
line, to the same extent or to a higher degree (Table 7-10 and Annex 1) 
 
 
 
 
 
 
 
 
 
  1               0.28                        1            0.19 
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4.3.1.4. Proinvasive proteins regulated by nicastrin silencing 
 
Protein lysates of MDA-MB-231 cells treated with the Control and NCT siRNA for 72h, as well as 
lysates from HCC1806-Luc1 and HCC1806-NCTsh cells were prepared and extracts with protein 
concentrations ≥ 1.0 mg/ml were used for fluorescent labeling with Cy3 and Cy5 fluorochroms. Only 
samples with a dye-to-protein molar ratio >2 were applied to the antibody microarray. The hybridised 
antibody microarray slides were scanned using a GenePix Personal 4100A Microarray Scanner (Axon 
Instruments, Union City, CA) with 532 and 635 nm lasers. Primary analysis was done with the 
GenePix Pro (version 4.1) software package (Axon Instruments). Images of the scanned antibody 
microarrays were gridded and linked to a protein print list. Absent spots were flagged automatically 
by GenePix Pro; however, all spots were manually reviewed. The log ratios of Cy5 to Cy3 were 
determined for each spot to estimate the relative concentration of each protein. Values were 
normalised according to the manufacturer‟s protocol to the values of a chosen normalising protein, in 
this case β-actin.  Only samples showing > 2-fold upregulation or downregulation in expression were 
deemed significant. This cut-off was selected as it has been used previously in antibody microarray 
experiments (410). Empty cells in the table reflect the undetected sample in a particular cell line. This 
may be due to loss of antibody activity by denaturation during printing or array storage or low levels 
of the respective antigen in the sample.  The tables (Table 7-10) list the proteins that are up- or down- 
regulated by at least 2-fold in at least one of the cell lines used. Full antibody list:  
www.sigmaaldrich.com/etc/medialib/docs/Sigma-Aldrich/General_Information/xp725_ab_list.pdf 
 
 
 
Table 7. Sigma       Fold Change p-value 
Protein Antibody ID MDA231    
NCTsi          
HCC1806-
NCTsh 
MDA-MB-231                           
 
HCC1806-NCTsh 
 
β-actin A1978     1.02        1.05   
Myosin Ib Nuclear M3567 -2.7 -2.94 3.93E-05 0.0006 
Myosin IIA M8064 -2.42 -2.22 5.16E-05 0.001 
Myosin Light Chain Kinase M7905 -2.04 -2.56 8.78E-05 0.0009 
Myosin Va M4812 -2.94 -3.22 1.70E-07 5.56E-06 
Myosin VI M0691 -2.94 -3.125 9.61E-08 8.88E-06 
Zip Kinase Z0134 -4 -6.67 1.91E-05 0.0003 
Rsk1 R5145 -1.85 -2.22           0.0008 0.0005 
RhoE R6153 1.2 5.6 0.029 0.048 
Smad4 S3934 -1.85 -2.38 0.0001 0.001 
Transforming Growth 
Factor-b pan 
T9429 5.5  0.005  
Zyxin Z0377 2.5 4.5 5.21E-06 0.0009 
FAK pTyr577 F8926 -3.44 -8.33 2.55E-05 0.0002 
Sp1 S9809 -3 -3.33 3.08E-05 0.0005 
Fas ligand F2051 -2.56 -3.44 1.40E-07 5.68E-06 
cRaf pSer621 R1151 -4 7.14 1.94E-05 0.0002 
Fibronectin  F3648 -2.38 -3.57 0.008 0.003 
171 
 
Myosins are a large family of structurally diverse actin-dependent molecules involved 
in cell migration through acto-myosin dynamics. Acto-myosin cytoskeleton has a 
fundamental role in the activation of migration and disassembly of cell-cell adhesions. 
Myosin IIa colocalises with metastasin-1 at the leading edge of cancer cells. Depletion of 
myosin IIA using siRNA impairs cancer cell migration (411). Upregulation of myosin Va by 
Snail is involved in cancer cell metastasis (412). Myosin VI is overexpressed in aggressive 
prostate and ovarian cancers.  RNA-mediated myosin VI knockdown results in impaired in 
vitro migration (413). Myosin light chain kinase promotes transcellular intravasation of breast 
cancer cells through the underlying endothelial cells, facilitating invasion (414). Myosin light 
chain kinase is also responsible for high proliferative ability of breast cancer cells via the p38 
pathway (415). All of the above myosin molecules were downregulated by NCT inhibition, 
suggesting that NCT could be regulating breast cancer cell motility/invasiveness through the 
network of myosin proteins.  
The ZIP kinase, inhibited by NCT depletion, has an important function in cell motility 
and migration. It is necessary for the phosphorylation and the activity of myosin II, which is 
essential for maintaining acto-myosin contractility during cell motility. Attenuation of the 
ZIP kinase using siRNA in fibroblast cells results in the failure of stable myosin filament 
formation in stress fiber structure thus changing cytoskeletal structure and cell morphology, 
which inferrs decreased motility (416).  
Small GTPase Rho signaling pathways underpin the motility of breast cancer cells 
during the invasive growth and metastasis (417). The RSK1 protein, which was 
downregulated by NCT depletion, drives p27 phosphorylation which promotes RhoA activity 
and increases cell motility (418). RhoE, upregulated by stable NCT knockdown, is an 
antagonist of the RhoA, and leads to the formation of highly sealed tight junctions in 
mammary epithelial tumour cells (419), and was upregulated by NCT inhibition.  Smad4 is a 
signal transducer for TGF-β signaling. Smad4 inhibition, here observed upon NCT 
knockdown, inhibits TGF-β-induced EMT, and in MDA-MB-231 breast cancer xenograft 
models, Smad4 siRNA strongly inhibits the frequency of bone metastasis (420).  
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Focal adhesions are actin-rich structures that enable cells to adhere to the extracellular 
matrix. Zyxin is a zinc-binding phospho-protein that concentrates at focal adhesions and 
along the actin cytoskeleton. It is important in the execution of the EMT program as it 
redistributes to points of cadherin-based adhesion at the end of individual actin cables in cells 
that have been induced to undergo EMT. So far it has been demonstrated that cells expressing 
zyxin fail to initiate EMT, and show significantly delayed scattering time (248 min) 
compared to zyxin knockdown cells (162 min) (421). It is intriguing that we observed an 
increase in zyxin protein levels in MDA-MB-231 (2.5-fold) and HCC1806 cells (4.5-fold) 
upon NCT knockdown, as zyxin-mediated effects appear to be a part of the mechanism of 
NCT depletion-mediated inhibition on EMT.  
Cancer cell surface associated fibronectin induces secretion of MMPs by the 
extracellular matrix, a step which facilitates cancer cell invasion into the surrounding stroma 
(422). Nicastrin depletion reduces cancer cell-associated fibronectin levels, thereby proposing 
an additional mechanism for NCT siRNA induced reduction of breast cancer cell invasion. 
Focal adhesion kinase (FAK) is an intracellular protein-tyrosine kinase that regulates 
formation and disassembly of cell-cell focal contacts, required for efficient cell movement. It 
acts as an integrator of cell motility-associated signaling events. FAK phosphorylation on 
tyrosine 577 is consistent with activation of Src signaling and is commonly linked to changes 
in cell motility. FAK-mediated cell invasion is associated with the accumulation of activated 
FAK (phosphorylated at Tyr-397, 576, and 577) in both growing and retracting lamellipodia 
and pseudopodia (423). Efficient inhibition of activated FAK is achieved by NCT depletion 
(3.4-fold in MDA-MB-231 and 8.3-fold in HCC1806 cells) in invasive breast cancer cells. 
The transcriptional factor Sp1 plays an important role in invasion and metastasis of 
tumours. In breast cancer tissue in vivo, as well as in invasive MDA-MB-231 cells, Sp1 
overexpression stimulates the proinvasive urokinase-type plasminogen activator and its 
receptor (424). An antibody array analysis also revealed that CDK4 was one of the 
interacting partners of Sp1, capable of inducing Sp1 mRNA levels (425). Concurrent 
decrease in CDK4 we have observed in the antibody microarray, may suggest a plausible 
mechanism of the Sp1 protein reduction upon NCT silencing. Furthermore, Sp1 positively 
regulates CD147 mRNA levels in lung cancer cells (426), a protein which is a reported 
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regulator of GS activity and one we have found downregulated in MDA-MB-231 breast 
cancer cell line by NCT siRNA. Therefore, reduction of Sp1 may be a causative factor in the 
CD147 reduction in MDA-MB-231 cells.  
The Fas-ligand secreted by tumour cells binds to the Fas-receptors on T-cells which 
infiltrate the tumour stroma causing apoptosis of these immune effector cells as a means of 
cancer immune evasion (427). Fas-ligand expression in the primary tumour is considerably 
less frequent among breast cancer patients with bone metastases, compared to women 
without skeletal spread. Many treatments, like tamoxifen, lower the amount of the Fas-ligand, 
creating an immune permissive environment and facilitating killing of cancer cells by 
activated lymohocytes (428). NCT depletion could therefore be facilitating the cytotoxic 
effects of immune effector cells in a similar manner, as it also lowers Fas ligand protein 
levels. 
4.3.1.1. Cell-cycle and cell apoptosis regulating proteins affected by nicastrin silencing 
 
 
 
Table 8. Sigma      Fold Change p-value 
Protein Antibody ID MDA231    
NCTsi  
     HCC1806-
NCTsh                   
MDA-MB-231 HCC1806-NCTsh 
β-actin A1978 1.02 1.05   
Bcl2 B3170    -1.47 -2.02 0.0005 0.01 
BclxL B9304    -2.70 -2.94 2.01E-07 1.03E-05 
BID B4305    -3.22 -2.85 4.23E-05 8.60E-05 
BUB1   B0561     1.27 2.9 0.003 0.002 
cMyc C3956    -2.32 -2.63 9.77E-05 0.0009 
Cdk1 C4973 1.6 4.00 0.006 0.01 
Cdk4 C8218 -1.53 -2.22 0.0003 0.001 
DRAK1 D1314 -5 -9 1.52E-05 0.0002 
E2F1 E8901 -2.43 -2.85 3.35E-05 0.0006 
E2F2 E8776 -2.43 -2.77 5.45E-05 0.0008 
E2F4 E8526 -2.63 -3 4.14E-05 0.0007 
GADD153 G6916 -3 -3.125 2.98E-05 0.0006 
PUMA bbc3 P4618 -3 -3.22 5.73E-07 1.12E-05 
MTBP M3566 -4.5 -4.76 1.68E-05 0.0003 
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In both cell lines, the MDA-MB-231 and HCC1806, NCT inhibition affected the 
cellular apoptotic machinery, as demonstrated by a downregulation of the anti-apoptotic 
proteins Bcl-2 and Bcl-xl. These effects were more pronounced in the HCC1806 cells upon 
stable NCT inhibition. Bcl-2 is known to block programmed cell death in combination with 
its anti-apoptotic family member Bcl-xl, and pro-apoptotic Bad, Bax, and Bid proteins (429). 
We observed a downregulation of the pro-apoptotic protein Bid. The p53 upregulated 
modulator of apoptosis (PUMA) also known as Bcl-2-binding component 3 (bbc3), is a pro-
apoptotic protein, member of the Bcl-2 protein family (430). The array detected a 
downregulation of PUMA bbc3 upon NCT silencing in both cell lines, which together with 
Bid downregulation, could potentially be acting as a negative feed-back mechanism in 
response to the pro-apoptotic stimuli inferred by NCT inhibition.  
The MDM2 binding protein (MTBP) promotes MDM2-mediated ubiquitination and 
degradation of p53. Its effects have been studied in MCF-7 cells where transfection of the 
human MTBP results in the proteasomal degradation and inhibition of the p53 tumour 
suppressor (431). We demonstrates that NCT silencing induced inhibition of MTBP by > 4-
fold, indicating that NCT could be promoting the p53-mediated tumour-suppressor functions 
in breast cancer cells via the MTBP-mediated regulation of p53 degradation. 
Cyclin-dependent kinases (CDKs) are a family of protein kinases first discovered for 
their role in regulating the cell cycle. CDK4 is a genetically validated therapeutic target in 
cancer, and much efforts have been invested in developing selective CDK4 inhibitors as anti-
cancer agents (432). Furthermore, a combination of a CDK4 inhibitor and a GSI (MRK-003) 
has significantly additive anti-tumourigenic effects in a T-ALL model, as the addition of a 
CDK4 inhibitor reduces MRK-003 GI50 values by 6-8-fold (209). CDK1 activity in cancer 
cells reflects the activation state of the spindle assembly checkpoints and is required for 
execution of the chemotherapy-induced cancer cell death (433). Nicastrin inhibition induced 
a downregulation of the CDK4 by 2.2-fold and an upregulation of CDK1 by 4-fold in 
HCC1806-NCTsh cells, while the same trend was noted in MDA-MB-231 cells only to a 
lesser degree, indicating that CDKs may be important downstream effectors in of the NCT-
mediated effects on cell survival. 
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Disturbed mitotic checkpoints are a common trait of many human cancers and can 
lead to chromosomal instability and aneuploidy, a feature present in over 90% of all solid 
tumours (434). One of the regulators of mitotic checkpoints is the Bub1 serine/threonine 
kinase, essential for preventing cell cycle progression into anaphase in the presence of spindle 
damage. Reduced expression of Bub1 has been identified in several human tumours such as 
colon, esophageal, gastric and breast cancer (435). Indications for possible Bub1 involvement 
in tumourigenesis also stem from animal experiments, where mice with reduced Bub1 
expression show an increase in tumour susceptibility (436). Bub1 was upregulated 2.9-fold in 
response to stable NCT inhibition.  
The E2F transcriptional factor proteins regulate the activity of promoters containing 
the E2F binding sites. E2F factors target the genes that regulate cell cycle progression. 
Mitogenic stimulation leads to activation of the E2F-dependent transcription and the S-phase 
entry (437). Low E2F1 transcript levels are a strong determinant of favorable breast cancer 
outcome (438), and expression of E2F4 in invasive breast carcinomas is associated with poor 
prognosis (439). Nicastrin inhibition led to a downregulation of E2F1, E2F2 and E2F4 by > 
2-fold in both analysed cell lines. C-myc is a cellular proto-oncogene and known 
transcriptional target of Notch1 (123). It interacts with E2F transcription factors and CDKs in 
the regulation of cell cycle progression and programmed cell death (440). C-myc 
downregulation in cells leads inhibition of cell proliferation characterized by S phase delay. 
The observed downregulation of c-myc levels upon NCT silencing may be a Notch-mediated 
effect, as well as an effect mediated effect through E2F/CDK regulators. 
The growth arrest and DNA damage inducible gene 153 (GADD153) is a 
transcription factor which belongs to the CCAAT/enhancer binding protein family (C/EBP 
family). The protein levels of C/EBP family members are significantly higher (15-times) in 
triple negative breast cancer tissue (441), while GADD153 mRNA levels are also increased 
in breast cancer tissue compared to normal breast (442). GADD153 overexpression alone is 
not sufficient to induce tumourigenesis but it does induce cancer cell hyperplasia, rendering 
the cells vulnerable to further oncogenic hits (441). GADD153 protein levels were reduced > 
3-fold by the NCT knockdown.  
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The death-associated protein kinase (DRAK1), downregulated by NCT silencing in 
MDA-MB-231 and HCC1806 cells, is a serine/threonine kinase which is a positive mediator 
of programmed cell death through its catalytic activity (443).  In an in vivo experimental lung 
cancer model, the overexpression of DAP kinase sensitises cancer cells to apoptotic stimuli 
and inhibits metastatic progression, providing a mechanism that links apoptosis to metastasis 
(444). The mechanism of DRAK1 downregulation upon NTC silencing in breast cancer cells 
remains unknown, however, we anticipate that this may be a cellular mechanism of resistance 
to anti-proliferative and anti-invasive effects of NCT inhibition.  
4.3.1.2. Histon deacetylases affected by nicastrin silencing 
 
Classical histone deacetylases (HDACs) are a class of enzymes that remove acetyl 
groups from an ε-N-acetyl lysine amino acid on a histone, and are a promising novel class of 
anti-cancer drug targets. First HDAC inhibitors have been evaluated in clinical trials and 
showed activity against several cancer types. HDAC1 knockdown causes cell cycle arrest, 
growth inhibition and apoptosis. HDAC3 inhibition induces expression of differentiation 
genes and disrupts the cell cycle. HDAC4 is upregulated in breast cancer compared with 
renal, bladder, colorectal cancer, and its knockdown inhibits expression and functional 
activity of HIF-1α. HDAC10 knockdown down-regulates VEGFR (445). Nicastrin inhibition 
causes a reduction of HDAC3/4/10 protein levels by ≥ 2.5-fold, suggesting that its effects on 
gene transcription may be executed via this group of transcriptional regulators. 
 
 
Table 9. Sigma      Fold Change  p-value 
Protein Antibody ID MDA231    
NCTsi  
HCC1806-   
NCTsh               
MDA-MB-231 HCC1806-NCTsh 
β-actin A1978     1.02 1.05                             
HDAC3 H6537 -2.7 -3 0.0006 0.007 
HDAC4 H9411 -2.12 -2.56 1.03E-06 5.41E-05 
HDAC10 H3413 -2.56 -2.5 4.28E-05 0.0009 
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4.3.1.5. Oncogenic pathways affected by nicastrin silencing 
 
Protein kinase C (PKC) family consists of at least 12 serine-threonine kinases with an 
established oncogenic potential. Most common iso-enzymes displaying altered expression 
during cancer progression are PKC-a, -b and -d (446). The fact that PKC inhibition prevents 
Notch1 upregulation (447), and that NCT downregulation in MDA-MB-231 and HCC1806 
cells acts as a negative regulator of PKC isoforms expression, proposes a complex bi-
directional cross-talk between the GS and the PKC. 
The c-Jun activation domain-binding protein-1 (JAB-1) is is a direct target of the 
EGFR signaling in ERα negative breast cancer cells. MDA-MB-231 and HCC1806 cells are 
representative of the triple negative breast cancer where the EGFR pathway is active (448). 
We have previously shown that NCT depletion in HCC1806 cells reduces protein levels of 
EGFR, and JAB1 downregulation may be a confirmation that the downstream effects of the 
EGFR pathway are equally inactivated upon NCT silencing.  
 
The MAP kinase cascade is a critical signal transduction pathway in transmitting 
extracellular signals to the nucleus. The fact that we have observed downregulation of active 
MAPK on the antibody array (MEK and ERK1/2), corroborated our previous observation that 
Table 10. Sigma     Fold Change p-value 
Protein Antibody ID MDA231    
NCTsi  
HCC1806-
NCTsh                
MDA-MB-231 HCC1806-NCTsh 
β-actin A1978 1.02            1.05                 
MAP Kinase Erk1/Erk2 M5670 -1.85 -2.38 0.0001 0.001 
MAP Kinase Kinase MEK  M5795 -2 -2.08 9.98E-05 0.001 
JAB1 J3020 -2.94 -3.125 0.0002 0.001 
Protein Kinase Ca P4334 -2.04 -2.22 8.85E-05 0.001 
Protein Kinase Cb2 P3203 -3.125 -3.22 2.97E-05 0.0005 
Protein Kinase Cd P8333 -2.27 -2.7 6.38E-05 0.0007 
Protein Kinase C P0713 -2.04 -2.63 7.09E-07 1.32E-05 
cRaf pSer621 R1151 -4 7.14 1.94E-05 0.0002 
S6 Kinase S4047 -1.96 -2.63 9.76E-05 0.0008 
mTOR T2949 -2.49 -2.94 4.57E-05 0.0006 
Nicastrin N1660 -1.67 -1.42 0.0002 0.01 
Presenilin 1 P7854 -1.49 -1.44 0.0002 0.0005 
Notch1 N6786 -1.47 1.1 0.0006 0.97 
p21WAF1Cip1 P1484 -2.56 -2.7 4.10E-05 0.0007 
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NCT inhibition interferes with the ERK1/2 activation. We have previously noted as well that 
NCT silencing inhibits the Akt phosphorylation at Ser473 residue. The array revealed that an 
important down-stream effector of both the Akt and the MAPK pathways, the S6 kinase 
(449), was downregulated by NCT depletion.  
The Raf proteins provide a link between Ras/MAPK signaling and
 
ERK activation. 
Direct binding of Raf to active Ras (Ras-GTP) results in c-Raf recruitment
 
to the plasma 
membrane. Phosphorylation of c-Raf at residue Ser621 occurs at the plasma membrane and 
appears to be essential
 
for c-Raf activation (450, 451). The array has indicated that transient 
NCT silencing in MDA-MB-231 cells inhibited c-Raf, which is consistent with the inhibition 
of the MAPK/ERK cascade, while in stably depleted cells its phoshorylation is increased, 
potentially acting to compensate the inhibition of the MAPK pathway inferred by chronic 
NCT depletion.  
Mammalian target of rapamycin (mTOR) pathway was downregulated > 2.4 fold in 
both cell lines upon NCT ablation. mTOR is a direct target of the activated Akt pathway, 
which is attenuated upon NCT silencing. Attenuation of Notch signaling in breast cancer cells 
has been shown to inhibit the PI3K/Akt-mTOR axis (383). Furthermore, MCF-7 cells 
exhibiting aberrant Notch activity display resistance to chemotherapy due to mTOR pathway 
hyperactivation, which can be reversed by an mTOR inhibitor (385). Therefore, the effects 
we have observed on the Akt/mTOR are a likely Notch-mediated effect.   
Interestingly, the degree of NCT inhibition we have detected by western blotting was 
higher than the one reflected on the array. Also, our data have shown that Notch1-ICD was 
significantly reduced in both cell lines upon NCT silencing, which was bearly observed in the 
MDA-MB-231 cells and absent in the HCC1806 set (Table 10). This may reflect the different 
antibodies used. We have performed western blotting using an antibody specifically raised 
against the cleaved Notch1 at Val1744 residue, while the Sigma N6786 antibody recognises 
both the full-length and the cleaved Notch1, the difference in the gel mobility of which (300 
kDa and 110 kDa, respectively) cannot be reflected on the array spot. Furthermore, we have 
shown that NCT silencing in MDA-MB-231 and HCC1806 cells induces p21 upregulation. 
The array produced an opposite result. All these differences and inconsistencies observed 
may also reflect technical issues (hybridisation efficacy, scanning, spot preservation) with the 
particular areas on the platform.  
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Furthermore, greater reliability of the array data may be obtained if the array is 
repeated with inclusion of the „dye-swapping‟ step, which entails alternative labeling of the 
samples with Cy3 and Cy5. Each protein sample is labeled with each dye and respective pairs 
are hybridised onto two separate array slides per cell line. Both slides for each cell line are 
scanned and the ratio of the two dye signals is calculated and compared for each antibody-
antigen pair (404).  
4.4. Discussion 
In this chapter we have analysed the effects of stable NCT depletion in the triple 
negative, basal-like, HCC1806 breast cancer cell line. As in the context of transient NCT 
silencing using siRNA in MDA-MB-231 cells, stable NCT knockdown in HCC1806 cells 
resulted in the disruption of the GS enzyme complex and activity. Namely, protein levels of 
PS1, Aph-1 and PEN2 were reduced, with concurrent decrease in the cleaved Notch1 protein. 
This result confirms the relevance of NCT in maintaining the stability and functionality of the 
GS in breast cancer cells. Furthermore, the Akt pathway downstream of NCT/Notch was 
attenuated. As in MDA-MB-231 cells, NCT silencing resulted in a marked reduction of 
vimentin protein levels and cell invasion capacity. In terms of the functional effects, and 
extending the characterisation of the HCC1806-NCTsh cells, originally generated by the 
group of Prof. M Loren (USA), we have shown that NCT stable depletion induced a slower 
turnover rate of HCC1806 cells. We have shown that the proliferation marker Ki67 was 
markedly downregulated in HCC1806-NCTsh cels compared to the NCT expressing 
counterpart, which is line with the observed slower proliferation of HCC1806-NCTsh cells. 
Although a comparable percentage of cells was identified in the S-phase, in both the 
HCC1806-Luc1 and HCC1806-NCTsh cells in the work of Dong et al.(164), the reduced rate 
of cell division may be caused by slower S-phase progression in HCC1806-NCTsh cells. In 
order to address this issue in the future experiments, the rate of cell proliferation, calculated 
from the bi-variate BrdU/DNA flow cytometric data will be evaluated, in order to estimate 
the S-phase duration (377).  
 
Given the importance that has been attributed to the Notch signaling in maintaining 
and perpetuating the population cancer stem cells (110, 176), and in view of the fact that 
NCT depletion markedly inhibited active Notch1 in HCC1806 cells, we decided to extend our 
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research efforts into investigating whether NCT depletion affected breast cancer stem cells. 
In order to achieve this, we performed cell sorting using the CD44 and CD24 as markers of 
the cancer stem cell phenotype, in both the HCC1806-Luc1 and HCC1806-NCTsh cells. This 
experiment was previously not performed in MDA-MB-231 cells, as the context of transient 
NCT silencing by means of siRNA represented a disadvantageous setting where the full 
extent of prolonged, stable NCT depletion would not be appreciated. Cell population baring 
the CD44
+
/CD24
-
 phenotype from either cell line was considered to be enriched for breast 
cancer stem cells. The mammosphere forming experiment evaluated the capability of stem 
cells from HCC1806-Luc1 and HCC1806-NCTsh cells to form proliferative sphere structures 
in anchorage independent growth conditions, a characteristic inherent for cells with stem cell-
like properties. Indeed, NCT inhibition reduced the mammosphere formation efficacy, 
indicating that NCT may be relevant for breast cancer stem cell propagation. This effect may 
be mediated through NCT regulation of Notch, as we have further shown that NCT depletion 
inhibits protein levels of active Notch4, which is primarily responsible for Notch-induced 
propagation of breast cancer stem cells in vitro and in vivo (176). In further support of the 
fact that inhibition of NCT may act to suppress breast cancer stem cells, and considering that 
cancer cells acquire „stemness‟ features through EMT transformation (90), we observed a 
marked downregulation of the bone fide EMT promoter genes (Vimentin, SIP1, SNAIL) in 
HCC1806-NCTsh stem cells compared to the NCT expressing counterpart.  
 
Finally, in this chapter, we presented data from the protein array we performed to 
investigate the global effects of NCT silencing on the proteome of MDA-MB-231 and 
HCC1806 cells. In our hands, the protein array has proven to be a research tool which does 
not yield highly consistent results when compared to western blotting. However, some of the 
data obtained from this protein array are intriguing, and if validated by western blotting will 
represent important information about NCT downstream pathways, which may be involved in 
regulating cell invasion and proliferation. As a priority, we will focus on validating the 
observed changes in the protein levels of the myosin family members (myosin Ib, II, Va, VI, 
and myosin light chain), which are required for the acto-myosin contractility and cancer cell 
motility/invasion (452). Validation of the data would enable us to gain further insight into the 
mechanism(s) by which NCT could be regulating cell motility and invasion. 
 
. 
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CHAPTER 5 
 
Results 
 
 
Comparison of nicastrin silencing 
and Notch receptor silencing effects 
on gene expression in MDA-MB-231 
cells 
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5.1. Nicastrin regulates a Notch independent gene set in MDA-MB-
231 cells 
 In order to determine to which extent the effects of NCT silencing are mediated 
through the GS/Notch-dependent signaling, we developed a collaboration with Prof. L. Miele 
(University of Mississippi Cancer Institute, USA), and conducted a gene array screen 
comparing the effect of NCT depletion in MDA-MB-231 cells with the changes inferred by 
the treatment of MDA-MB-231 cells with the siRNA of individual Notch receptors.  
In our laboratory, we have treated MDA-MB-231 cells with NCT siRNA and NCT 
knockdown was validated by RT-qPCR. In order to compare and contrast the global gene 
changes induced by NCT downregulation vs. those induced by gene silencing of Notch 
receptors, the group of Prof. L. Miele have treated the same cell line with individual siRNAs 
for Notch1, Notch2 and Notch4. The mRNA from all samples, run in biological duplicates, 
was reverse transcribed and hybridised to an Affymetrix 2.0 platform. The array was 
performed by the Northwestern University Genomics Core Facility in Chicago, USA. 
Data analysis has thus far been been completed for 387 genes from the Affymetrix 
gene array, and encompasses genes that are predominantly regulated by either NCT siRNA or 
Notch2 siRNA. Genes up- or downregulated by ≥ 2-fold were considered significantly 
affected by either type of treatment. Results have shown that: i) 56.9% (n = 220) genes were 
not affected by Notch1/2/4 siRNA or NCT siRNA; ii) 16.5% (n = 64) genes were regulated 
only by NCT siRNA (Table 11), while 16.5% (n = 64) genes were regulated by Notch2 
siRNA only; iii) 10.1% (n = 39) were shared between Notch2 siRNA and NCT siRNA 
(Figure 40, Annex 2). This 387 of analysed genes did not contain genes affected by Notch1/4 
siRNA or genes shared between all Notch receptors and NCT. The analysis of those genes is 
pending and will undoubtedly reveal more intriguing results. While keeping in mind that the 
Affymetrix gene array analysis is still incomplete, the results analyses to date suggest that 
NCT regulates a subset of genes that are not modulated by Notch, and/or that there are 
context-dependent GS enzyme activities, which are defined by distinct affinities to different 
Notch receptors. 
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Figure 40.Pie chart depicting the percentages of genes regulated by NCT siRNA and Notch 
siRNA in MDA-MB-231 cells. Data analysis has been completed for the 387 genes from the 
Affymetrix gene array. Regulation by ± 2-fold was considered significant. 56.9% (n = 220) genes 
were not affected by Notch1/2/4 siRNA or NCT siRNA. 16.5% (n = 64) genes were regulated by 
Notch2 siRNA only, while 16.5% (n = 64) genes were regulated only by NCT siRNA. 10.1% (n = 39) 
were regulated by both Notch2 siRNA and NCT siRNA.  
 
Table 11.Genes exclusively regulated by NCT siRNA    
                      Fold Change  
Gene Symbol Gene Discription Notch1 
siRNA 
Notch2 
siRNA 
Notch4 
siRNA 
NCT 
siRNA 
p-value 
NCTsiRNA vs. 
ControlsiRNA 
MT2A metallothionein 2A -1.97 -3.02 -1.04 2.94 0.00029 
IL10RB interleukin 10 receptor, beta -1.46 -1.61 -1.13 -2.37 3.84E-05 
PHLDA1 pleckstrin homology-like domain -1.42 -2.50 1.11 2.86 2.54E-07 
ASNS asparagine synthetase 1.41 2.46 -1.04 6.20 7.86E-07 
CST4 cystatin S -1.35 -1.59 -1.42 8.13 1.82E-09 
E2F2 E2F transcription factor 2 -1.34 1.50 -1.32 -2.06 9.61E-06 
MGLL monoglyceride lipase 1.34 1.61 1.09 4.28 3.92E-08 
MT1X metallothionein 1X -1.33 -5.76 1.25 2.42 0.00016 
BUB1 budding uninhibited by benzimidazoles 1  -1.28 1.78 1.06 -2.16 0.00067 
KHDRBS3 KH domain RNA binding signal 
transduction associated 3 
-1.22 1.55 -1.13 10.15 5.76E-09 
EIF4E2 eukaryotic translation initiation factor 4E  1.21 -1.70 -1.03 -2.01 1.74E-06 
SPANXA1 sperm protein associated X-linked A1  1.17 -1.55 1.16 12.54 9.71E-12 
TUBB2A tubulin, beta 2A -1.16 -1.94 -1.03 -2.00 0.00509 
AKR1B1 aldo-keto reductase family 1, member B1  -1.15 1.81 -1.07 -3.19 3.74E-05 
ID2 inhibitor of DNA binding 2, dominant 
negative helix-loop-helix protein 
1.09 -1.66 1.54 -2.68 0.00068 
GNG11 guanine nucleotide binding gamma 11 1.08 -1.66 -1.27 -3.98 1.65E-08 
UBE2T ubiquitin-conjugating enzyme E2T  -1.05 -1.75 -1.18 -3.19 2.69E-07 
ARHGDIB Rho GDP dissociation inhibitor (GDI) beta 1.05 1.96 1.26 2.39 2.43E-06 
SPANXB2 SPANX family, member B2 -1.02 -1.32 -1.04 8.03 2.86E-10 
Array experiment.MDA-MB-231 cells were treated with Control and NCT siRNA for 72h. mRNA 
was sent to Prof Lucio Miele, USA, where their own MDA-MB-231 cells were treated with the Notch 
siRNAs. Values represent fold change between NCT siRNA and Control siRNA; and Notch siRNAs 
vs. respective controls. The four types of treatment were therefore not normalised to the same control 
siRNA, and direct comparisons between the two types of treatment have to be validated, due to the 
fact that although the same cell line was used, the MDA-MB-231 cells did not originate from the 
same laboratory. 
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5.1.1. Common genes affected by NCT siRNA and a gamma-secretase 
inhibitor  
In addition to comparing the effects induced by NCT siRNA with the individual 
Notch receptor silencing, we also obtained information about the common genes regulated by 
NCT siRNA and a clinically tested GSI (Merck). The array performed by the group of Prof. 
L. Miele identified an 18-gene signature characteristic for the GSI-MRK0752 treatment in 
MDA-MB-231 cells. The GSI used was not an aldehyde peptide and it had no proteasome 
inhibitory activity. Of these 18 genes, 13 were also affected by NCT siRNA in the same 
direction (Table 12). The remaining 5 genes were only affected by the GSI, and hence 
represent information proprietary to our collaborators. At present, we do not possess 
information about the genes differentially regulated between the NCT silencing and GSI 
treatment. Therefore, the data obtained thus far comparing NCT siRNA and GSI effects in 
MDA-MB-231 cells is limited, and precludes arriving to a conclusion that NCT siRNA 
regulates a distinct set of genes compared to the GSI. Interestingly, both treatments induced a 
potent downregulation of the ABCA1 gene, which encodes a multi-drug resistant protein, i.e. 
a membrane pump which mediates efflux of anti-cancer drugs. This suggests that targeting 
the GS enzyme via a GSI or NCT inhibition may facilitate overcoming resistance to certain 
types of cancer therapeutics. The effect of silencing NCT was even more profound than that 
of the GSI on some of the genes in the signature, e.g. on an FGF antagonist SPRY1 
(upregulated 4.75-fold upon NCT siRNA vs. 1.73-fold upon GSI treatment) and ANXA8L2 
(downregulated 3.19-fold vs. 1.54-fold).  
 
 
 
 
 
185 
 
Table 12.Genes regulated by GSI and NCT siRNA 
Gene 
Symbol 
Gene Description  NCT  
siRNA 
                  GSI 
 
             p-value  
ABCA1 ATP-binding cassette, sub-family A member 1 -3.3 -7.06 9.24E-08 
SC4MOL sterol-C4-methyl oxidase-like 2.14 2.79 3.73E-06 
IL6 interleukin 6 (interferon, beta 2) -1.87 -2.13 1.28E-05 
SQLE squalene epoxidase 1.79 2.26 3.41E-05 
EPAS1 endothelial PAS domain protein 1 1.34 -2.07 1.01E-05 
TNFSF10 tumour necrosis factor (ligand) superfamily 10  -3.00 -2.02 6.33E-06 
MCM4 minichromosome maintenance complex 4 -1.43 -1.87 1.70E-05 
HNRNPAB heterogeneous nuclear ribonucleoprotein A/B -1.55 -1.8 3.68E-05 
SPRY1 sprouty homolog 1, antagonist of FGF signaling  4.75 1.73 1.80E-05 
ELOVL6 ELOVL family member 6 -1.53 1.61 1.40E-05 
DCTPP1 dCTP pyrophosphatase 1 -1.93 -1.56 2.24E-05 
ANXA8L2 annexin A8-like 2 -3.19 -1.54 1.78E-05 
C5orf41 chromosome 5 open reading frame 41 2.34 1.51 2.86E-05 
 
The ABCA1 multidrug resistance gene encodes the ATP hydrolysing cellular 
transporter, which is able to export a wide variety of natural and synthetic compounds from 
the cells (453). Drug resistance is a major obstacle in achieving the response to chemotherapy 
and ABCA1 is often overexpressed in many human malignancies, including breast cancer, 
representing a causal factor of resistance to apoptosis-inducing agents (454, 455). ABCA1 
was downregulated by the NCT siRNA and GSI by 3.3- and 7-fold, respectively. 
TNFSF10 (TRAIL) is a p53-transcriptional target gene, which activates Caspase 8 via 
the death receptor DR5. It could be a mediator of apoptosis induced by GSI and/or NCT 
knockdown (456). The protein encoded by the gene is the tumour necrosis factor-related 
apoptosis-inducing ligand (457). Impairment of the TRAIL-mediated apoptotic pathway 
contributes to oncogenesis by promoting survival of cells that could accumulate severe 
chromosomal alterations (458). TNFSF10 was downregulated by the NCT siRNA and GSI by 
3- and 2-fold, respectively. 
Microarray studies have linked annexin A8 (ANXA8L2) mRNA expression to a „basal 
cell-like‟ subset of breast cancers. High expression of this gene in invasive breast carcinomas 
was shown to have has a significant adverse effect on disease-free and overall survival (459). 
ANXA8L2 was downregulated by the NCT siRNA and GSI by 3.19- and 1.54-fold, 
respectively. 
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Sprouty (SPRY) is a negative regulator of the fibroblast growth factor (FGF) pathway 
signaling. Sprouty binds to, and displaces Shp2 from FRS2 and Grb2, preventing subsequent 
activation of Ras and Raf pathways, resulting in the net inhibition of the MAPK/ERK2 
activation (460). A majority of breast cancers (~80 %) show a downregulation of SPRY1 and 
SPRY2 mRNA levels (461). SPRY1 was upregulated by the NCT siRNA and GSI by 4.75- 
and 1.73-fold, respectively. 
5.3.2 Validation of gene array data 
In order to validate our gene array data, we repeated the NCT siRNA treatment of 
MDA-MB-231 cells and performed RT-q-PCR analysis for the chosen genes. We also 
performed RT-q-PCR analysis in the stably depleted HCC1806-NCTsh cell line, in order to 
investigate if the effects of NCT silencing are reproducible in another cell line which 
represents the basal B like breast cancer. Furthermore, we anticipated that some of the genes 
may be more profoundly affected in the conditions of the stable, rather than the transient 
NCT depletion (Figure 41). 
Even though the degree of NCT silencing was comparable to that of the samples used 
for the Affymetrix array, from the genes we have attempted to validate thus far, we were not 
able to reproduce the effects on SPRY1 and CTGF genes upon NCT inhibition in MDA-MB-
231 cells (Figure 41a). However the effect was observed in the HCC1806-NCTsh cell line, 
where NCT depletion induced an 8.5-fold increase in SPRY1 and a 13.5-fold increase in 
CTGF gene levels compared to HCC1806-Luc1 (Figure 41b). Effects on CST4, TNFSF10 
and SPANXB2 were validated in the MDA-MB-231 cells. CST4 was also not regulated by 
NCT depletion in HCC1806-NCTsh cells. Failure to reproduce some of the array data may be 
due to the difference between the probes used in the gene array vs. primers used for the RT-
qPCR experiment. Also there are reported splice variants of the SPRY1 gene (462) and single 
nucleotide polymorphisms of the CTGF (www.ensembl.org), which if present in any of our 
cell lines, coupled with the differences in primers we used and probes used on the gene array, 
may have been the cause of failure to detect the same degree of regulation as achieved by the 
array probes. Design of alternate primer sets for the genes in question will be conducted in 
order to address this hypothesis.  
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Figure 41.RT-qPCR validation of the Affymetrix gene array in MDA-MB-231 and HCC1806 
cells. Fold change of relative mRNA levels of NCT, SPRY1, CTGF, CST4, TNFSF10 and 
SPANXB2 is shown. a) MDA-MB-231 cells were transfected with the Control and NCT siRNA at 40 
nmol concentration and after 72 h cells were harvested for mRNA extraction. Bars represent mean 
value of the mRNA fold-change ± SEM from three separate experiments, each in triplicate. GAPDH 
was used for normalising. NCT, *p = 0.0002; SPRY1, *p = 0.35; CTGF, *p = 9.88E-05; CST4, *p = 
0.001; TNFSF10, *p = 0.036 and SPANXB2, *p = 0.015; b) HCC1806-Luc1 and HCC1806-NCTsh 
cells were cultured to 70-80 % confluence and harvested for mRNA extraction. Bars represent mean 
value of the mRNA fold-change ± SEM from three separate experiments, each in triplicate. GAPDH 
was used for normalising. NCT, *p = 0.003; SPRY1, *p = 0.001; CTGF, *p = 0.005; CST4, *p = 0.02; 
TNFSF10, *p = 0.02 and SPANXB2, *p = 0.001. 
 
 
* 
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5.4. Discussion 
We have employed gene array analysis as a tool to investigate global transcriptome 
changes in MDA-MB-231 cells upon transient NCT silencing. Furthermore, we sought to 
compare the effects of the nicastrin knockdown to that induced by a gamma-secretase 
inhibitor and silencing of individual Notch receptors. Although the array analyses are not 
fully complete, the data obtained thus far indicate that NCT may regulate a subset of genes 
which are not affected by Notch receptors.  
SPANXA1 and SPANXB2 are cancer/testis-associated genes, which are located in a 
cluster on chromosome X. They are not only expressed in the germ cells, but also in a 
number of tumours (463). Overexpression of Fra-2 (a Fos-related AP1 transcription factor 
that is implicated in progression of cancer) in MCF-7 cells, promotes cancer cell invasion, an 
effect accompanied by a substantial, 4.75-fold reduction of the SPANX genes (464). NCT 
siRNA induces an increased in SPANXA1 and SPANXB2 by 12.5- and 8-fold, respectively. 
Guanine nucleotide binding protein gamma 11 gene (GNG11) expression has been 
identified as one of the markers of the EMT and a gene whose expression correlates with the 
basal B subtype of breast cancer (54). NCT siRNA inhibited GNG11 by 3.9-fold. 
Non-muscle myosin II-B (MYH10) plays a major role in cell motility by regulating 
the retraction phase of the migratory cycle. Downregulation of MYH10 in human 
malignancies counteracts invasion of cancer cells (465). NCT siRNA downregulated the 
expression of the MYH10 gene by 2.4-fold. 
Connective tissue growth factor (CTGF) expression is associated with tumour 
development and progression. There is growing body of evidence that CTGF may regulate 
cancer cell migration, invasion, angiogenesis, and anoikis. Furthermore, CTGF expression is 
positively correlated with the basal B subtype of breast cancer and is considered an EMT 
promoting gene (54), as well as a factor facilitating bone metastasis in breast cancer (466). 
NCT siRNA upregulated CTGF expression by 3.5-fold (Annex 2), potentially reflecting a 
compensatory cellular mechanism against the anti-invasive effects induced by the NCT 
silencing. 
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The Rho GDP dissociation inhibitor beta (D4-GDI/ARHGDIB) is a member of a 
major class of RhoGTPase regulators, RhoGDIs. RhoGDIs have a cell context dependent role 
in either inhibiting Rho activities by retaining Rho effectors in their inactive form (467), or 
promoting their function by facilitating cellular transport to the plasma membrane (468). D4-
GDI has 78% homology to other Rho-GDIs. It binds and inhibits Rac2 in cells via its N-
terminal domain. It has been identified as a metastasis suppressor gene in bladder cancer. 
With regards to the expression and role of D4-GDI in breast cancer, the data is conflicting 
(468). In breast cancer, its expression is higher in invasive MDA-MB-231 than in the non-
invasive MCF-7 cells, however its knockdown has no effect on cellular invasive capacity. It 
is therefore proposed that its role in inhibiting or promoting Rho activity may be dependent 
on the stage of cancer progression, as well as cancer type. NCT siRNA increased ARHGDIB 
expression by 2.4-fold. The actual implications of the elevated D4-GDI levels on Rho activity 
in breast cancer cells, in the context of NCT silencing, needs to be addressed by investigating 
the level of Rac activity, as well as monitoring the cellular localisation of the Rho effector 
proteins. 
The aldo-keto reductase1 B1 (AKR1B1) is overexpressed in human malignancies such 
as liver, breast, and lung cancer. It plays a role in the development and progression of cancer 
through carbonyl detoxification, retinoic acid homeostatic regulation, and lipid metabolic 
control. Therefore, AKR1B1 inhibitors have been highlighted as a novel class of antitumour 
agents (469). NCT inhibition reduced AKR1B1 levels by 3.2-fold. 
 
Breast cancer patients with tumours that are negative for PHLDA1 protein expression 
have a shorter disease-free survival (p < 0.001) and overall survival (p < 0.001) than patients 
with tumours that are positive for PHLDA1 protein (470). NCT siRNA induced upregulation 
of PHLDA1 by 2.86-fold.  
Cystatin S (CST4) belongs to the family of tumour suppressors which undergo 
methylation-dependent, epigenetic silencing in human malignancies (471).  NCT siRNA 
increased expression of the CST4 by 8.1-fold.  
Ubiquitin-conjugating enzyme E2T (UBE2T) has a critical role in the development 
and progression of breast cancer, as it plays a role in controlling the function of various 
cellular proteins, including critical regulators of signal transduction, cell proliferation, and 
apoptosis. It also represents a potential therapeutic target.  
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Its function relates to the breast cancer susceptibility gene, BRCA1, which is lost in some 
breast cancers due to genetic mutation, epigenetic silencing, or haploinsufficiency. UBE2T 
siRNA upregulates BRCA1 protein levels in breast cells, as a part of its anti-tumour effect 
(472). NCT siRNA reduced UBE2T expression by 3.2-fold. 
A screen which utilised the National Cancer Institute bank of 60 cancer cell lines 
(NCI-60) has demonstrated that the expression of the ASNS gene correlates with the 
sensitivity of cancer cells to treatment with L-asparaginase (bacterial enzyme used to treat 
acute lymphoblastic leukemia). Absence of this gene selectively starves cells that cannot 
synthesize sufficient asparagine for their own needs (473). NCT siRNA caused upregulation 
of the ASNS gene by 6.2-fold.  
Taken together, the gene array demonstrated that nicastrin silencing may regulate 
genes which function as a part of the cellular pathways which mediate cancer cell migration 
and invasion. Many of these genes have already been documented as drivers of the EMT 
(54), and denominators of common breast cancer metastasis signatures: i) TNFSF10 and 
ARHGDIB in the MDA-MB-231 lung cancer model and human tumours; ii) SPANX and 
CTGF in the MDA-MB-231 lung and bone metastasis model; iii) ANXA in the MDA-MB-
435 cell line  breast cancer model (474). Interestingly, NCT depletion induced a potent 
upregulation of tumour suppressor genes, like CST4 and SPRY1. Some of the effects we have 
observed may be induced as a result of the cellular negative feed-back mechanism. For 
example, the fact that the proinvasive CTGF gene was significantly increased may possibly 
be a response to invasion inhibitory effects induced by NCT siRNA treatment. Genes 
regulated by NCT do not belong to one cellular pathway, rather many of them interact and 
cross-talk. Therefore, the level of the functional output of NCT-mediated transcriptome 
modulation is a reflection of the cumulative effects on its targets. Given the diverse 
expression of NCT targets, the functional consequences of its inhibition may also be cell-
context dependent. Importantly, our data have revealed that while many NCT downstream 
effects are mediated through the GS complex and Notch signaling, NCT possesses a 
proprietary set of target genes which are not affected by Notch receptors.   
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CHAPTER 6 
 
Results 
 
 
Clinical implications of nicastrin 
expression in human breast cancer 
tissue 
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6.1. Introduction 
Tumour pathology provides useful insights into breast cancer biology and into the 
relevance of potential new biomarkers. Biomarkers are determinants of the tumour molecular 
profile, its aggressiveness and the likelihood of response to certain therapies. They can be 
measured from the tumour tissue or other biological samples (i.e. patient serum) and can be 
determined by DNA, mRNA or protein expression analyses. Immunohistochemistry (IHC) 
remains the method of choice for determining the expression levels of protein biomarkers in 
cancer tissue (475). Biomarkers can be stratified into:  
 Diagnostic (screening) biomarkers:  
They are used to detect and identify a given type of cancer. These markers are expected to 
have high specificity and sensitivity (e.g. CA-125 for ovarian cancer, CA15-3 for breast 
cancer, CA19-9 for colon cancer etc.)  
 Prognostic biomarkers: 
They are determined once the diagnosis has been confirmed for the purpose of predicting 
the probable course of the disease in terms of recurrence, i.e. disease aggressiveness 
(tumour grade, ERα, HER2 status etc.).  
 Predictive biomarkers: 
They serve to predict the response to a drug before the treatment is initiated. These 
markers classify patients as likely responders or non-responders to a particular type of 
treatment. 
 
A valid biomarker needs to be specific and sensitive. Specificity refers to the 
proportion of control individuals who test negative for the biomarker. Sensitivity is the 
proportion of individuals with confirmed disease who test positive for the biomarker.    
 Despite continuous effort, only a few tissue biomarkers of breast cancer have entered 
routine use (ERα, PR, HER2), and in some laboratories E-cadherin, EGFR and p53 (476). 
Furthermore, ERα and HER2 are not just biomarkers but also therapeutic targets in breast 
cancer. However, diseases like the triple negative breast cancer, which lack expression of the 
common biomarkers, are the primary focus of laborious efforts to discover new determinants 
of tumour aggressiveness and prognosis, and thereby new therapeutic target.  
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    6.2. Immunohistochemistry of nicastrin expression in breast tissue 
Led by our data showing marked NCT upregulation in breast cancer cell lines 
compared to a non-transformed mammary epithelium cell line, we hypothesised that NCT 
would be upregulated in human breast cancer tissue compared to normal breast tissue as well. 
To explore this, we obtained normal breast tissue from reduction mammoplasties, as well as 
samples of benign breast disease (fibroadenoma), and a tissue microarray (TMA) containing 
1050 breast cancer cases with known clinico-pathological outcomes. This allowed us to 
assess the suitability of NCT as a therapeutic target in breast cancer as well. 
Nicastrin antibody (N-1660), raised against the C-terminus of the protein (691-709 
a.a.) (220), was used to optimise the IHC staining on full-faced sections of the normal breast 
and breast cancer tissue. Specificity of the IHC staining was verified using pre-incubation 
with the NCT blocking peptide. Representative images of the NCT staining pattern and 
intensity are shown in Figure 42. Scoring was done on the basis of staining intensity as being 
negative = 0, weakly positive = 1+, moderate = 2+, and strong = 3+. We then dichotomised 
the groups into NCT low expressors containing cases with scores 0 and 1+, and NCT high 
expressors, encompassing 2+ and 3+ scores (Figure 42). 
Normal breast tissues from reduction mammoplasties (n = 40) were examined and 
NCT was absent (IHC score 0) in 30/40 cases, and expressed at very low levels (IHC score 
1+) in the remaining 10 cases. Benign breast disease (fibroadenoma) tissue (n = 10) equally 
displayed absence of NCT in the luminal cell compartment, while the basal cells showed an 
upregulation of NCT staining intensity (Figure 42). 
Nicastrin immunostaining in breast cancer TMAs showed predominant cytoplasmic 
localisation with variable cell membrane staining. Informative data were obtained in 1050 
tissue cores, of which 52.5% showed low (0 and 1+ intensity score) and 47.5% showed high 
(2+ and 3+ score) expression (Table 13). We further obtained paired primary tumour and 
lymph node samples (n = 15) and observed that NCT expression was retained in the lymph 
node metastasis at the same level as annotated to the primary tumour.    
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Figure 42.Nicastrin expression is upregulated in breast cancer compared to normal breast 
tissue. Representative images of normal breast tissue (n = 40), fibroadenoma (n = 10), showing 
absence of nicastrin expression and expression in myopepithelial cells respectively. Nicastrin 
expression in breast cancer tissue (n = 1050). Representative images of nicastrin null, 1+, 2+ and 3+ 
staining in breast tumours. Nicastrin expression is preserved in lymph node metastasis (n = 15). Pre-
incubation with competing peptide confirms the specificity of the N-1660 antibody.  
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Table 13.Expression of nicastrin in breast cancer tissue 
Nicastrin intensity score Number of cases Percent (%) 
0 54 5.2 
1 497 47.3 
2 349 33.2 
3 150 14.3 
Total 1050 100 
 
Given the comprehensive characterisation of the breast cancer tissue cohort we used, 
we were able to correlate NCT expression with other known clinical and pathological 
parameters (Table 14). High NCT expression positively correlated with the ERα and PR 
hormonal receptors (p < 0.001). There was a direct correlation with cytokeratin 18 
(p < 0.001) and E-cadherin (p< 0.01), and inverse with basal cytokeratines 5/6 (p = 0.01). 
Nicastrin expression correlated with patient age (p = 0.031), where patients > 50 years were 
more likely to have tumours expressing high NCT levels. Surprisingly, nicastrin expression 
inversely correlated with tumour grade (p < 0.001). More nicastrin abundance was recorded 
in both grade 1 and particularly grade 2 tumours. With respect to tumour type, NCT appeared 
to be significantly upregulated in tubular carcinomas (n = 208/1050), with 61% (n = 127/208) 
showing high expression, versus 39% (n = 81/208) with low levels (p = 0.002). In patients 
with invasive ductal carcinoma (624/1050), 54.3% (n = 339/624) had high and 45.7% 
(n = 285/624) low NCT levels. No correlation was observed with tumour size (Table 14). 
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        Table 14.Patients’ characteristics and tumour biomarkers showing nicastrin expression 
 
Variable/biomarker           Nicastrin expression       p-value  
       Low (%) High (%) 
Patients age (years) 
 ≤50 231 (41.8) 173 (35.3) 0.031 
 >50 321 (58.2) 325 (64.7) 
Grade 
 1 70 (12.8) 96 (19.4) <0.001 
 2 166 (30.3) 187 (37.7) 
 3 312 (56.9) 213 (42.9) 
Stage 
 1 337 (51.8) 313 (48.2) 0.827 
 2 164 (52.9) 146 (47.1) 
 3 48 (55.2) 39 (44.8) 
Tumour type 
 Tubular 81 (39) 127 (61) 0.002 
 Invasive ductal 285 (45.7) 339 (54.3) 
Estrogen receptor 
 Negative 170 (61.8) 105 (38.2) <0.001 
 Positive 355 (49.2) 367 (50.8) 
Progesterone receptor 
Negative 251 (59.6) 170 (40.4) <0.001 
 Positive 270 (47.7) 296 (52.3) 
HER2 receptor 
 0/1+/ 503 (53.4) 439 (46.6) 0.076 
 2+/3+ 33 (42.3) 45 (57.7) 
Cytokeratin 18 
 Negative 67 (13.3) 437 (86.7) <0.001 
 Positive 30 (6.4) 439 (93.6) 
Cytokeratin 5/6 
 Negative 432 (50.7) 420 (49.3) 0.01 
 Positive 96 (61.9) 51 (38.1) 
E-cadherin          
Negative 219 (60.2) 145 (39.8)           < 0.01  
Positive 309 (48.1) 333 (51.9)  
 
 
 
 
197 
 
Kaplan-Meier survival analysis was then performed to evaluate a potential impact of 
NCT expression on disease-free and overall survival (breast cancer specific survival). High 
NCT expression was not predictive of disease-free survival, nor of breast cancer specific 
survival (overall survival) in the whole dataset (p = 0.664). Equally, we saw no impact of 
high nicastrin levels on overall survival in the ERα positive subset of patients (p = 0.183). In 
further pre-defined subset analysis, high NCT levels had borderline predictive value for 
overall survival at 5 years (p = 0.05) in the ERα negative patients (n = 275/1050) (Figure 43). 
Nicastrin expression did not retain significance in a multivariate analysis model combined 
with tumour grade, stage, and size. Nicastrin expression did not predict outcome to systemic 
adjuvant treatments (endocrine or chemotherapy). 
 
Figure 43.Kaplan-Meier model comparing breast cancer specific survival in breast cancer patients 
according to nicastrin protein expression. a) Entire analysed cohort (p = 0.664). b) ERα positive 
patients (p = 0.183). c) ERα negative patients (p = 0.05) 
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Furthermore, we analysed sections of primary breast cancer tissue (n = 40), which 
contained the in situ and the invasive component represented on one full faced tissue 
preparation. Immunostaining for NCT has revealed that in 8/40 cases (20%), NCT was absent 
from the non-invasive, in situ tumour, while it was upregulated in the invasive breast cancer 
tissue counterpart (Figure 44). 
                                                      
Figure 44.Differential expression of NCT in in situ and invasive breast cancer. Representative 
image of a full faced breast cancer tissue section showing NCT expression the in situ (white arrow) 
and invasive breast cancer (black arrow head). Magnification  x100. 
 
We have also obtained fresh primary breast cancer tissue and axillary lymph nodes 
containing breast cancer metastases, which were processed using the magnetic beads coated 
with an epithelial marker in order to purify and enrich the preparation for epithelial tumour 
cells. Obtained purified cells were often insufficient to yield the sample suitable for protein 
extraction. However, we managed to probe two tumours and two metastatic lymph node 
samples for NCT protein expression. MDA-MB-231 cell whole cell lysates were used as a 
positive control. The tumour (TU2) and the lymph node (LN2) lanes annotate a paired sample 
from the primary tumour and the corresponding lymph node metastasis, respectively (Figure 
45). Here, albeit at low levels, we were able to show that NCT expression is preserved in the 
lymph node metastasis to the same level as in the primary tumour. Interestingly, the 
visualised NCT band in the primary tissue corresponded to the mature NCT, as the immature 
NCT band was absent, unlike in MDA-MB-231 cells where both NCT forms were detected. 
This is similar to the previously reported data where only the mature NCT band was detected 
from whole cell lysates of mouse cortical neurons (248). 
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Figure 45.Western blotting demonstrating NCT protein expression in primary tissue. MDA-
MB-231 whole cell lysates were used as positive control. Primary breast cancer tissue (TU) and 
metastatic lymph nodes (LN) were processed according to the Dynal beads separation protocol and 
preparations enriched for epithelial tumour cells were obtained. 30 μg of protein was loaded in each 
lane. β-actin served as the loading control.                                  
6.3. Nicastrin expression in the normal tissue of other organs  
Expression of NCT was next investigated in the normal tissue from other organs. 
Nicastrin was expressed in the normal skin (IHC score = 2+; n = 12), normal liver (1+/2+; n 
= 7), renal tubules (1+/2+; n = 7), heart muscle ( 2+, n = 2), vaginal portion of the cervix ( 2+, 
n = 2),  but absent or expressed at low levels in the normal prostate (0/1+; n = 12), colon ( 
0/1+, n = 7), lung (0, n = 7), testis (0/1+, n = 5), endometrium (1+, n = 5), cerebrum (1+, n = 
7), thyroid (0, n = 5), and renal glomeruli (0, n = 7) (Figure 46).  
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Figure 46.IHC staining showing NCT expression in normal tissues. a) kidney; b) colon; c) 
thyroid; d) heart; e) endometrium; f) testis; g) lung; h) skin; i) prostate; j) liver; k) stomach; l) 
cerebral white matter; m) vaginal cervix. Magnification is x 100. For vaginal cervix, skin and liver 
Magnification is x 40. 
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6.4. Discussion  
Even though it has been demonstrated that overexpression of active Notch is a 
characteristic of a subset of breast cancers, where it confers worse survival (158, 477), 
activity of the GS enzyme or expression of its components (NCT, PS, PEN2, Aph-1) in breast 
cancer tissue has not yet been examined. In this chapter we have demonstrated that NCT 
protein is not expressed in epithelial cells of the normal breast tissue, while it is markedly 
upregulated in breast cancer tissue. Furthermore, analysis of benign breast lesions, 
fibroadenomas, showed increased NCT expression in the basal cell compartment, while the 
luminal cells maintained NCT negativity. Several studies have considered fibroadenomas as a 
risk factor for developing breast cancer (478). In fibroadenomas, genes related to collagen 
synthesis, fibrosis and growth factors are overexpressed compared to the normal mammary 
gland. This stroma is deemed capable to provide a permissible milieu for the malignant 
transformation of adjacent epithelium (479). Upregulation of NCT in the basal cells of 
fibroadenomas may be a response to pro-oncogenic signals derived from fibroadenoma-
related stroma, and an example of the importance of the extracellular matrix-breast tissue 
cross-talk in malignant cell transformation. 
Of the 1050 analysed breast cancer cases, 47.5% exhibited high NCT expression. 
Nicastrin expression correlated significantly with that of the ERα, PR and the luminal marker 
CK18, linking its expression with the luminal breast cancers. Its high expression was 
associated with ductal carcinomas, which is in line with the positive association of NCT and 
E-cadherin levels, as E-cadherin is used as one of the markers distinguishing ductal from 
lobular breast cancers (480). In our in vitro experiments, we have observed NCT expression 
in ERα negative cell lines (MDA-MB-231, HCC1806 and SKBR3), as well as ERα positive 
cell lines (MCF-7 and BT474). Nicastrin silencing reduced proliferation of MCF-7 cells, and 
BT474 cells expressed mature NCT which migrated at a higher molecular weight. These data, 
together with the fact that we saw a trend towards a direct correlation between HER2 and 
high NCT expression (p = 0.076), proposes that NCT might be important in luminal A (MCF-
7) and luminal B (BT-474) breast cancers as well. The fact that survival analysis failed to 
identify an impact of high NCT levels in the ERα positive cohort suggests that the hormonal 
treatment these patient have received (tamoxifen), may have alleviated the „oncogenic‟ 
impact of high NCT expression.  
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A similar observation has recently been reported by Giamas et al., where even though 
high expression of a tyrosine kinase LMTK3 correlated inversely with ERα levels in the same 
cohort used for NCT expression analysis, LMTK3 abundance predicted for worse outcome of 
ERα positive patients treated with tamoxifen (481). Regarding potential estrogenic regulation 
of NCT, with the help of Dr Jason Carol (Cambridge, UK), we have observed that there are 
potential estrogen response elements 20-30 kb upstream of the NCT promoter in two ERα 
positive cell lines (Figure 47). If ERα is regulating NCT, these may be the cis-regulatory 
elements. These are non-coding DNA sequence in or near a gene required for proper spatio-
temporal expression of that gene, often containing binding sites for transcription factors. The 
NURSA gene expression tool, which gives a p-value to any estrogen regulated gene changes, 
based on multiple combined studies (http://www.nursa.org/gems), suggested that in MCF-7 
cells, NCT is downregulated by estrogen. Therefore, it is worth exploring in more detail a 
possible cross-talk between NCT and ERα in breast cancer cells. 
 
Figure 47.Estrogen response elements near the promoter of NCT gene. Bio-informatics 
analyses in the NCT promoter revealed a potential ERE motif located ~20-30 kb upstream of the 
transcriptional start site of the gene. The coloured boxes represent ERα binding sites in the three cell 
lines. 
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Of the 1050 patients, 23.8% (n = 250) were ERα negative. ERα negative breast 
cancers are by nature more aggressive (482). Being deprived of anti-hormonal therapy as a 
treatment option, these patients receive only chemotherapy after surgical excision of the 
primary tumour, and anti-HER2 therapy is provided if HER2 is overexpressed and/or 
amplified. High NCT levels in the ERα negative subgroup were predictive of worse breast 
cancer specific survival at 5 years, suggesting that NCT contributes to the disease 
aggressiveness of this particular breast cancer subtype. This is in line with our in vitro data 
using MDA-MB-231 cells and HCC1806 cells, representative of the ERα negative breast 
cancer model (367), as well as the MCF10A cells overexpressing NCT, where NCT appears 
to help maintain the EMT state. Furthermore, since Notch1 overexpression has been linked to 
the basal breast cancers, which are ERα negative (158), and we have observed an impact of 
NCT abundance in this same subset of patients, it may be worth assessing the Notch1-ICD 
expression in our patient cohort and investigating whether it positively correlates to that of 
NCT. Furthermore, we will investigate whether PS1 expression follows the trend of NCT in 
this patient group, as this will allow us to gain insight if the adverse impact on overall 
survival we have observed is conferred due to NCT high levels, or to the overall high 
expression levels of the GS in the breast cancer tissue. Previous reports have investigated 
NCT expression in non-human tissues by western blotting and PCR. The most elaborate 
study of NCT expression in mouse tissues identified significant levels in the skeletal muscle, 
heart and lung, as well as a prominence of lower molecular weight NCT glycoforms in the 
brain and liver (220). Our analysis of NCT expression in a panel of normal human tissues 
indicated a moderate expression in the renal tubules, liver and heart, with a higher expression 
in the skin. Lung and colon tissues did not demonstrate immunorectivity for NCT. Since the 
antibody used to detect NCT in mouse tissues was the same one we used, N-1660 directed 
against the C-terminus of NCT, it appears that NCT exhibits species-dependent tissue 
expression. Evaluating tissue distribution of a potential therapeutic target is of vital 
importance as it helps predict possible sites/organs of side-effects. Our data suggest that 
targeting NCT might induce certain consequences in the skin. Previous reports have noted 
that inhibition of GS in a NCT knockdown mouse model gives rise to proliferative skin 
lesions and skin tumours (370). Therefore, should an anti-NCT therapy be utilised in the 
treatment of breast cancer, a therapeutic window may need to be identified which would 
allow for achievement of clinical benefit, while avoiding treatment related toxicities.  
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Results 
 
 
Development and characterisation of 
anti-nicastrin monoclonal antibodies 
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7.1. Introduction 
An optimal target for monoclonal antibody (MAb) therapy in cancer is a molecule 
expressed on the cell surface of the tumour cells, whose expression and function contribute to 
the development and/or progression of the disease, and the inhibition of which selectively 
targets the cancer cells while inducing minimal side-effects. 
Monoclonal antibodies serve two important functions: i) they bind to the target 
protein (antigen) and modulate its expression and/or function; ii) they bind immune effector 
cells or elements of the complement system, inducing cytotoxic or immunological effects 
(32). Apart from their specific mode of action, another advantage of MAbs as biological 
therapy module over small molecules is that they persist in the circulation with long half-lives 
and enable lower frequency of administration (483). The most commonly targeted tumour-
associated antigens are the growth factor receptors, frequently overexpressed in human 
malignancies (19). Anti-HER2 MAb (trastuzumab) is the best example of this type of 
biological treatment. It is approved for the treatment of both primary and metastatic breast 
cancers that display overexpression of the HER2 protein, and/or amplification of the HER2 
gene (484). Many new MAbs are in clinical trials and in preclinical investigations. Recently, 
a MAb against N-cadherin extracellular domain has been proposed for the treatment of 
prostate cancer (483). 
We hypothesised that NCT would be a candidate target for the development of 
antagonistic MAbs based on the following facts:  
i) NCT is a transmembrane protein with a large extracellular domain which harbours 
important functional domains 
ii) NCT is overexpressed in breast cancer tissue compared to the normal breast  
iii) NCT expression confers worse overall survival in ERα negative breast cancer patients 
iv) NCT silencing inhibits invasion and proliferation of breast cancer cells. 
In this chapter we describe the characterisation and functional effects of anti-NCT 
antibodies.  
 
206 
 
7.2. The advantages and disadvantages of polyclonal and monoclonal 
antibodies 
Antibodies are produced by lymphocytes upon exposure to a specific antigen. 
Numerous epitopes are recognised by a large number of lymphocytes which proliferate and 
differentiate into plasma cells, and the consequent antibody response is polyclonal. 
Polyclonal Abs (PcAbs) are hetrogeneous and can be generated much more rapidly and cost-
effectively. However, the quantity of PcAbs that can be obtained is dependent on the size of 
the animal used as a host and its lifespan (485). 
In contrast, monoclonal antibodies (MAbs) are produced by a single B lymphocyte 
clone. Their purity levels are higher, they are homogeneous and consistent. Fusion of the 
myeloma cells and spleen cells upon immunisation of the host, yields hybridoma cell lines, 
each capable of producing a single MAb clone as an indefinite source. The hybridoma 
supernatants are then screened and selected against the antigen, and subsequently expanded. 
Generation of hybridomas, production and purification of MAbs is more costly and time-
consuming. However, the mono-specificity renders MAbs superior to the PcAbs as they are 
able to serve as therapeutics, as well as valuable tools for mapping functional epitopes on the 
antigen, and for potential structural analysis (485). 
7.3. Anti-NCT polyclonal antibody (PcAb) 
For the purpose of conducting proof of principle experiments, we generated anti-NCT 
PcAbs and firstly investigated whether they recognised endogenous NCT in breast cancer 
cells. For this purpose, we performed FACS analysis on non-permeabilised MCF-7 and 
MDA-MB-231 cells and confirmed that the anti-NCT PcAb 4631 successfully bound to the 
cell surface NCT ectodomain (Figure 48a) in both cell lines. We next performed western 
blotting using whole cell lysates of MCF-7 and MDA-MB-231 cells and observed that the 
PcAbs were able to detect the mature, immature and the non-glycosylated forms of NCT 
(Figure 48b). PcAb 4631 was used in the following experiments. Since we based our decision 
to primarily focus on NCT function in ERα negative cells based on the fact that NCT 
abundance in the ERα negative patient population conferred worse survival, we performed 
the  functional experiments with anti-NCT antibodies using MDA-MB-231 cells.  
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We treated MDA-MB-231 with increasing concentrations of the PcAb and 
demonstrated that it induced a dose-dependent anti-proliferative effect. An inhibition of 
25.9±1.3% was induced by the 25 μg/ml dose, while 50 μg/ml and 100 μg/ml inhibited breast 
cancer cell proliferation by 35.2±1.8% and 50±2.9%, respectively (Figure 48c). Furthermore, 
cell cycle analysis indicated that the mechanism by which the anti-NCT PcAb achieved the 
anti-proliferative effect was via induction of the cellular sub-G1 arrest, mimicking the effect 
of NCT genetic silencing (Figure 48d). In addition, blocking NCT using the PcAb reduced 
Bcl-2 levels, which is in line with the sub-G1 cellular accumulation, disrupted the GS 
complex activity, as demonstrated by the marked reduction in Notch1-ICD levels, and 
reduced protein levels of the Akt (Figure 49).  
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Figure 48.Anti-nicastrin PcAb inhibit proliferation of MDA-MB-231 cells. a) Anti-NCT PcAb 
recognises endogenous cell surface NCT on breast cancer cells. Non-permiabilised MCF-7 and 
MDA-MB231 cells were incubated with 100 μg/ml of the anti-NCT PcAb (4631) followed by the 
secondary anti-rabbit-FITC conjugated secondary antibody. FACS analysis were  performed on the 
FACSCalibur, BD. b) Western blotting showing that the anti-NCT PcAbs (4631 and 4632) at the dose 
of 1 μg/ml recognise endogenous NCT in MCF-7 and MDA-MB-231 cell lysates. c) MDA-MB-231 
cells were plated (3 x 10
3
/well) in 96-well plates and treated with increasing doses (25-50-100 μg/ml) 
of the anti-NCT PcAb. Rabbit IgG isotype control was used as a negative control at the equivalent of 
the highest anti-NCT PcAb concentration (100 μg/ml). GSI1 at 1μM was used as a positive control. 
Anti-NCT PcAb inhibits proliferation of MDA-MB-231 cells in a dose-dependent manner: 25 μg/ml 
(25.9±1.3%), 50 μg/ml (35.2±1.8%), 100 μg/ml (50±2.9%). Error bars represent SEM from two 
independent experiments, each in quadruplicate; *p = 0.03; **p = 0.02. d) MDA-MB-231 cells were 
plated in 6-well plates (2 x 10
5
/well) and treated with the anti-NCT PcAb (100 μg/ml) and Rabbit IgG 
as an isotype control for 24 h. Cells were then processed for cell cycle analysis using the CycleTEST 
Plus DNA Reagent Kit.  
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Figure 49.Treatment of MDA-MB-231 cells with the anti-NCT PcAb reduces NCT protein levels 
and inhibits Notch1. Western blotting showing the effects of the anti-NCT PcAb (100 μg/ml) on 
NCT, Bcl-2 and Akt and Notch1-ICD. β-actin was used as the loading control. The intensity of bands 
was quantified using Image J software. Numbers below the bands represent fold change compared to 
MDA-MB-231 Control antibody treated cells, relative to the loading control. 
 
7.3.2. Anti-NCT PcAb inhibits breast cancer cell invasion 
We next measured the invasive capacity of MDA-MB-231 cells treated with 
increasing concentrations of the anti-NCT PcAb (10-100 μg/ml). Compared to the rabbit IgG 
isotype control, the anti-NCT PcAb was a potent inhibitor of cell invasion in a dose 
dependent manner. Namely, the dose of 25 μg/ml induced a 36±3.8% reduction, while 50 
μg/ml and 100 μg/ml inhibited cell invasion by 54±2.9% and 57.2±2.3%, respectively (Figure 
50a). When the anti-NCT PcAb was preincubated with the NCT recombinant protein, used as 
the immunising antigen, the inhibitory effect on cell invasion was rescued, signifying the 
reliance of the anti-invasiveness effect of the PcAb on targeting NCT (Figure 50b). 
1       0.42 
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Figure 50.Effects of the anti-NCT PcAb on breast cancer cell invasion in vitro. a) Effects of anti-
NCT PcAb on the invasion of MDA-MB231 cells, in a dose dependent manner. Doses of 25–
100 μg/ml produce a significant inhibition (25 μg/ml = 36±3.8%, *p = 0.009; 50 μg/ml = 54±2.9%, 
$
p < 0.001; 100 μg/ml = 57.2±2.3%, #p < 0.001). Error bars represent SEM from three independent 
experiments, each in triplicate. b) Pre-incubation of the anti-NCT Pc-Ab at the dose of 100 μg/ml with 
20 μg/ml of the NCT recombinant protein used as an antigen to produce the PcAb, rescued the PcAb- 
induced inhibition of cell invasion. Error bars represent SEM from three independent experiments, 
each in triplicate. * p = 0.0003; **p = 0.004. 
Taken together, we have shown that inhibition of NCT using the targeted Ab 
approach, which can potentially be exploited for development of an anti-NCT Ab therapeutic, 
is able to induce the anti-proliferative and anti-invasive effects similar to the levels generated 
by purely experimental NCT genetic silencing.  
7.4. Production and selection of anti-NCT monoclonal antibodies 
Anti-NCT monoclonal antibodies (MAbs) were raised by genetic immunisation of rats 
using a cDNA, encoding for the extracellular domain of NCT (34-669 a.a.). This cDNA was 
cloned into proprietary expression vector (Genovac), specially developed to maximise an 
immune response in mammals and to allow screening of the resulting immune sera. The 
immunisation constructs were introduced into the animals‟ skin using a Genegun. Once an 
immune response had been identified, lymphocytes were removed for fusion with mouse 
myeloma cells and hybridoma supernatant screening. We opted for genetic immunisation, as 
this novel technique simplifies and shortens the MAb production procedure, by eliminating 
the step of producing and purifying the protein immunogen.  
* 
** 
* 
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The second advantage of genetic vaccination is that it more closely resembles 
activation of an immune response upon an infection with a pathogen, which increases the 
magnitude of antibody production (486).  
In order to decide which hybridomas to take forward and based on the efficacy of the 
previous experiments with anti-NCT PcAbs, we decided to introduce a dual discrimination 
approach, where we would select those clones that recognised endogenous NCT and inhibited 
invasion of MDA-MB-231 cells. We have therefore screened the 21 MAb clones by FACS 
and the transwell invasion assay. From the 21 clones originally selected as being positive by 
FACS analysis against the cell line transfected with the NCT cDNA (Genovac) (Figure 51), 
we found that ten clones (1E2, 1H4, 2H6, 6H5, 6H11, 9G7, 9F1, 10C5, 10C11, 10E9) 
recognised endogenous NCT on non-permeabilised MDA-MB-231 cells (Figure 52). This 
could be explained by the fact that we have used the cells in a non-permeabilised condition in 
order to monitor the binding capacity to the cell surface antigen, mimicking the desired in 
vivo conditions. Furthermore, the concentration of the NCT antigen on the cell surface of 
MDA-MB-231 cells may have been a limiting factor, compared to the concentration of NCT 
in the transfected, Genovac propriety cell line, which was an artificial system generated to 
overexpress NCT.  
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Figure 51.FACS analysis of hybridoma supernatants (Genovac). Antibodies were raised by 
genetic immunisation of WISTAR rats using the cDNA, encoding for the ECD of nicastrin (34-669 
a.a). This cDNA was cloned into a proprietary GENOVAC expression vector developed to maximise 
an immune response in mammals and to allow screening of the resulting immune sera. The 
immunisation constructs were introduced into the animals using a Genegun. Following DNA boosts, 
test sera were taken from the animals and tested for the presence of antibodies in a transient 
transfection assay in flow cytometry against the corresponding GENOVAC screening vector. Labels 
bellow the histograms annotate the MAb clone reference number. 
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Figure 52.FACS analysis assessing the binding efficacy of the 21 anti-nicastrin MAb clones. 
MDA-MB-231 cells were grown to 70-80% confluence. Cells were incubated with the supernatants 
obtained from the first round of hybridoma cloning (Figure 48) and with the rat IgG2b as the isotype 
control antibody at an arbitrary concentration of 50 μg/ml. The concentration of the MAbs in the 
preparations was at this phase unknown. Secondary anti-Rat-FITC conjugated antibody was used. 
FACS analysis was performed using the FACSCalibur, BD. The labels in the top left-hand corner of 
the histograms annotate the MAb clone reference number. Blue: Rat IgG2b isotype control; Green: 
MAb supernatants. 
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We further analysed the potency of the cultivated clones to inhibit invasion of MDA-
MB-231 cells. The clones that failed to recognise endogenous NCT in the FACS experiments 
also failed to produce a marked anti-invasive effect. From the ten clones which were positive 
by FACS, seven produced a reduction in the cell invasion: 1H4 (44±12.4%), 2H6 (60±5.6%), 
6H5 (39±2.6%), 6H11 (40±6.4%), 9G7 (42±11.2%), 10C5 (65±10.2%) and 10C11 
(50±10.3%), while three clones (1E2, 9F1 and 10E9) had no effect (Figure 53).  
 
 
 
 
 
 
 
 
 
Figure 53.Anti-nicastrin monoclonal antibodies affect MDA-MB-231cell invasion. MDA-MB-231 
cells were treated with indicated anti-NCT MAbs and subjected to the transwell invasion assay for 72 
h. Bars represent mean number of invaded cells ± SEM from three separate experiments, each in 
triplicate. Statistical difference from IgG2b isotype control antibody. 1H4, *p = 0.01; 2H6, *p = 
0.0005; 6H5, *p = 0.01; 6H11, *p = 0.01; 9G7, *p = 0.01; 10C5, *p = 0.02; 10C11, *p = 0.004. Anti-
nicastrin PcAb (100 μg/μl) was used as a positive control,*p < 0.001. 
 
We have therefore decided to take the clones 1E2, 2H6, 10C5 and 10C11 into the 
second round of subcloning to generate pure hybridomas. The 1E2 clone was chosen in order 
to represent a „negative control‟ anti-NCT MAb, based on the criteria that it recognised the 
antigen but failed to induce a functional consequence.  
 
 
* 
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7.5. Characterisation of the anti-NCT MAbs clones (1E2, 2H6, 10C5 
and 10C11) 
We further tested the chosen anti-NCT MAb clones upon the second round of 
subcloning. In order to evaluate whether the supernatants contained any Ab molecules, we 
subjected them to denaturation and ran the samples on a 10% SDS-PAGE, followed by the 
transfer into a PVDF membrane and Ponceau staining. We were able to observe two distinct 
bands in all four samples, at ~50 kDa and ~25 kDa, corresponding to the heavy- and the 
light- Ab chains. We could not estimate the MAb concentration, but the abundance of the 
bands appeared comparable. The dominating band at ~50 kDa reflected the presence of the 
serum albumin from the hybridoma culture media, and possibly obscured the 50 kDa heavy 
chain Ab band (Figure 54).  
 
                         
 
Figure 54.MAb clone supernatants (1E2, 2H6, 10C5 and 10C11) from the second round of sub-
cloning were denatured and run on a 10% SDS-PAGE under reducing conditions. Upon transfer to a 
PVDF membrane, Ponceau staining revealed the presence of the heavy- and the light- MAb chains in 
each samples, at ~50 kDa and ~25 kDa, respectively. Protein observed in abundance at ~ 50kDa 
corresponds to the serum albumin, originating from the hybridoma culture media (ISF-1). 
  
 We than repeated the cell invasion assay using the 1E2, 2H6, 10C5 and 10C11 
supernatants from the second round of subcloning. Furthermore, we have expanded the scope 
of the experiments by treating the MDA-MB-231 cells with the MAbs clones and 
investigating their capacity to inhibit cell proliferation as well. As previously observed, the 
2H6, 10C5 and 10C11 clones consistently produced an anti-invasive effect, while the 1E2 
had no impact on cell invasion (Figure 55a). This functionality of the MAbs was mirrored in 
a proliferation assay.  
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The growth rate of the MDA-MB-231 cells treated with the 1E2 clone was unchanged 
compared to control, while the clones 2H6 and 10C5 induced a 23.7±5.5% and 25.8±5.5% 
inhibition of cell proliferation, respectively, and the 10C11 clone impeded cell growth by 
40±3.3% over the period of 3 days (Figure 55b).  
 
Figure 55.Cell proliferation and invasion assays using anti-NCT MAb clones. a) MDA-MB-231 
cells were grown to 70-80% confluence. Cells were detached using EDTA, washed once with PBS 
and pre-incubated with anti-NCT MAbs supernatants derived from the second round of sub-cloning. 
Rat IgG2b isotype control was used in as a negative control. After incubation, cells (5 x 10
4
/well) 
were plated in the upper wells of the transwell invasion plate. The lower chamber contained the 
chemo-attractant. Cells were incubated for 72 h at 37 °C, and number of invaded cells from the lower 
chamber was counted using the Casy counter. Bars represent mean number of invaded cells ± SEM 
from three separate experiments. Statistical difference from IgG2b isotype control antibody: 2H6 
(47.7±7.7, *p = 0.014); 10C5 (60±10.1%, 
# 
p = 0.01); 10C11 (50±5.3%, 
$ 
p =0.004). b) MDA-MB-
231 cells processed the same as above and pre-incubated with anti-NCT MAbs supernatants derived 
from the second round of sub-cloning at RT for 30 min. Rat IgG2b isotype control was used as 
negative control Ab. Cells were plated (3 x 10
3
/well) in 96-well plates and this time point 
corresponded to Day 0. MAb treatment was supplemented every day, and the SRB assay was 
performed until Day 6. Absorbance was measured at 492 nm. Error bars correspond to SEM from two 
independent experiments, each in quadruplicate. The p-values are in relation to IgG2b isotype control: 
2H6 (23.7±5.5%, *p = 0.04); 10C5 (25.8±5.5%, *p = 0.04); 10C11 (40±3.4%, 
# 
p = 0.02).  
 
7.6. Characterisation of the purified anti-NCT MAbs 
Having reproduced the effectiveness of the chosen MAb clones from the second 
round of sublcloning, the production of 1E2, 2H6, 10C5 and 10C11 MAbs was scaled up 
using serum-free hybridoma culture conditions, and MAbs were affinity purified using a 
protein A column (Genovac). We confirmed that the purified, endotoxin free MAbs of a 
known concentration, bound endogenous NCT on MDA-MB-231 cells (Figure 56e), and 
furthermore explored whether they recognised distinct NCT glycofoms by western blotting.  
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Interestingly, we observed that the clones 1E2 and 10C11 were able to pick-up the 
deglycosylated NCT as well as its immature and mature forms in all four breast cancer cell 
lines used (MCF-7, MDA-MB-231, BT474, HCC1806), while the 2H6 clone recognised the 
immature and the deglycosylated forms. However, only the 10C5 clone distinguished the 
deglycosylated form of NCT in all samples (Figure 56 a-d). This result is highly intriguing 
since it implies that in breast cancer cells some amount of partially glycosylated NCT reaches 
the cell surface, since the 10C5 clone recognised NCT on the cell surface of MDA-MB-231 
cells. We have also observed a higher mobility of the mature NCT in BT474 cells (Figure 
56a), as detected by MAbs 1E2, suggesting that the mature NCT in this particular cell line 
might be undergoing additional post-translational modifications, like phosphorylation. 
Intriguingly, this was the only HER2 positive cell line in the panel, suggesting that the cross-
talk between NCT and HER2 may be worth exploring. We have also confirmed that the 
purified MAbs were able to recognise the cell surface NCT on MDA-MB-231 cells (Figure 
56e & f). 
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Figure 56.Western blotting using MAb IgGs. Whole cell lysates from MCF-7, MDA-MB-231, BT-
474 and HCC1806 cells were prepared and run on a 10% SDS-PAGE under reducing conditions, and 
probed with a) 1E2; b) 2H6; c) 10C5 and; d) 10C11 at 4 μg/ml concentration. The signal was detected 
using the secondary anti-Rat HPR antibody. Arrows indicate expected molecular weight for the 
deglycosylated, immature and mature NCT. e) Non-permeabilised MDA-MB-231 cells were 
incubated with the Rat IgG2b isotype control (blue) and purified anti-NCT MAbs at 100 μg/ml 
concentration (green line). Anti-Rat-FITC conjugate was used as a secondary antibody. Histograms 
indicate a shift upon binding of the anti-NCT MAbs to NCT on MDA-MB-231 cells. Labels in the 
upper left hand corner of the histograms annotate the MAb. f) Overlay of the individual histograms. 
Color bars in the upper right hand corner of the histogram correspond to the lines and are 
accompanied by respective MAb labels.  
 
We next investigated the anti-invasive and anti-proliferative effect of the purified 
clones in MDA-MB-231 cells. Clones 2H6, 10C5 and 10C11 were potent inhibitors of cell 
invasion with the dose of 50 μg/ml and 200 μg/ml inducing a similar degree of inhibition of 
invasion: 2H6 (66±10%), 10C5 (48±9.2%) and 10C11 (51.2±3.4%) (Figure 57a). The 1E2 
MAb had no effect on either cell invasion or proliferation. The dose of 200 μg/ml was used in 
the proliferation assay and induced a 28.2±5.2% inhibition of cell growth with the 2H6 and 
25.3±8.2% with the 10C5 clone, while a 57.2±5.3% impediment of cell growth was observed 
with the 10C11 MAb (Figure 57b). 
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Figure 57.Cell proliferation and invasion assays using purified anti-NCT MAbs. a) MDA-MB-
231 cells were grown to 70-80% confluence and detached using EDTA. Cells were washed once with 
PBS and pre-incubated with purified MAbs (1E2, 2H6, 10C5 and 10C11) at RT for 30 min. Rat 
IgG2b isotype control was used as a negative control Ab. Cells (5 x 10
4
/well) were plated in the upper 
wells of the transwell invasion plate. The lower chamber contained the chemo-attractant. Cells were 
incubated for 72 h at 37 °C, and number of invaded cells from the lower chamber was counted using 
the Casy counter. Bars represent mean number of invaded cells ± SEM from three separate 
experiments. Statistical difference from the respective concentration of the IgG2b isotype control 
(2H6 50 μg/ml, p = 0.005; 2H6 200 μg/ml, p = 4.95E-05; 10C5 50 μg/ml, p = 0.0001; 10C5 200 
μg/ml, p = 0.0002; 10C11 50 μg/ml, p = 0.0007; 10C11 200 μg/ml, p = 0.0002). b) MDA-MB-231 
cells were processed in the same way as stated above and pre-incubated with purified MAbs (1E2, 
2H6, 10C5 and 10C11), at RT for 30 min. Rat IgG2b isotype control was used as negative control Ab. 
Cells were plated (3 x 10
3
/well) in 96-well plates and this time point corresponded to Day 0. MAb 
treatment was supplemented and the SRB assay was performed every 2 days until Day 6. 
Measurements were performed at 492 nm. Error bars represent SEM from two independent 
experiments, each one in quadruplicate, *p < 0.05, 
#
p < 0.02.  
 
 
Since our data have shown that NCT silencing reduces vimentin protein levels and 
affects cell invasion, we next investigated whether anti-NCT MAbs were inducing similar 
downstream effects. Western blotting of MDA-MB-231 cells treated for 72 h with the MAbs 
at the concentration of 200 μg/ml showed a reduction of vimentin protein levels. The 2H6 
MAb was most potent in inhibiting this proinvasive protein, consistent with its potency to 
inhibit breast cancer cell invasion (Figure 58). 
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Figure 58.Treatment of MDA-MB-231 cells with anti-NCT MAbs reduced vimentin protein 
levels. MDA-MB-231 cells were treated with anti-NCT MAbs 1E2, 2H6, 10C5 and 10C11 (200 
μg/ml) for 72 h. Cells were then lysed and protein extracts were examined for vimentin protein 
expression by Western blotting. β-actin was used as the loading control. The intensity of bands was 
quantified using Image J software. Numbers below the bands represent fold change compared to the 
IgG2b control antibody treated samples, relative to the loading control. 
 
 
We next cultured MDA-MB-231 cells in 3D Matrigel chambers and supplemented the 
culture media containing 2% Matrigel with 200 μg/ml of each MAb. The treatment was 
replenished every 2 days and at day 6, we performed phase contrast imaging of the formed 
acini-like structures. As previously observed in HCC1806-NCTsh cells grown in 3D 
Matrigel, the MDA-MB-231 cells treated with anti-NCT MAbs 2H6, 10C5 and 10C11 
underwent growth arrest and produced more regular and rounded acini-like structures, 
compared to the appearance of the control treated cells (66). This effect was consistent with 
the 2D proliferation assay, but strikingly the 1E2 MAb also induced a modest anti-
proliferative effect in 3D conditions (Figure 59). Having observed a change in the 3D acini 
morphology induced by anti-NCT MAbs, we next sought to investigate the effects on cellular 
polarity. During tumour progression, tissue polarity is lost as a function of deregulated 
oncogenic signaling. The PI3K/Akt pathway is one of the main regulators of cellular polarity 
during malignant transformation, and chemical inhibition of this pathway results in re-
establishment of the apico-lateral tight junctions and the reorganisation of the actin 
cytoskeleton (70). Using the basal extracellular matrix receptor, α6-integrin, aberrantly 
localised to the cytoplasm in the control cells, we demonstrated that treatment with anti-NCT 
MAbs restored basal tissue polarity in MDA-MB-231 cells, as judged by the membrane 
relocalisation of α6-integrin (Figure 60). Since the Akt pathway was inhibited by the 
treatment of MDA-MB-231 cells with the anti-NCT PcAb, we speculate that the effect of the 
MAb treatment on cell polarity may be, at least in part, induced by impaired Akt downstream 
of NCT. 
1             1.05         0.65          0.75           0.8 
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Figure 59.Treatment of MDA-MB-231 cells with anti-NCT MAbs inhibits growth of acini-like 
structures. MDA-MB-231 cells (1 x 10
3
/chamber) were plated in the 3D Matrigel overlay 
experiment. Cells were cultured in the media containing 2% Matrigel, supplemented with the isotype 
control Rat IgG2b antibody and the 1E2, 2H6, 10C5 and 10C11 MAbs at 200 μg/ml. Treatment was 
added upon plating and every 48 h until Day 6. Cells were then imaged using the phase contrast 
microscopy. Magnification x10. 
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Figure 60.Treatment of MDA-MB-231 cells with the anti-NCT MAbs induces repolarisation of 
the α6-integrin. MDA-MB-231 cells (1 x 103/chamber) were plated in the 3D Matrigel overlay 
experiment. Cells were cultured in the media containing 2% Matrigel, supplemented with the isotype 
control Rat IgG2b antibody and the 1E2, 2H6, 10C5 and 10C11 MAbs at 200 μg/ml. Treatment was 
added upon plating and every 48 h until Day 6. Cells were then fixed, permeabilised and stained with 
anti-α6-intergin (red), anti-GM130 (green) antibodies. Alexa Flour 488 goat anti-rabbit, and Alexa 
Fluor 555 goat anti-mouse (Invitrogen) were used as secondary antibodies. DAPI (blue) was used to 
counterstain the nuclei. Magnification x40. 
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7.7. Determination of the binding properties of anti-NCT MAbs 
Tumour-targeting specificity of MAbs requires the target antigen to be primarily 
expressed on the tumour cells, while the efficacy requires sufficient binding affinity and 
sustainable tumour retention. The concept that MAbs must have high affinity in order to be 
therapeutically potent is being somewhat challenged (487). The „binding-site barrier‟ model 
predicts that as the strength of the antigen-antibody bond increases, the amount of MAb 
diffusing into a solid tumour decreases (30). Antigen expression and internalisation can also 
have profound effects on MAb penetration into tumours (28), and intrinsic affinity of MAb 
IgG molecules is an important determinant of their accumulation and penetration into solid 
tissue. It has been observed, however, that the higher-affinity antibodies also exhibit a 
higher degree of internalisation and catabolism by peri-vascular cells in both in vitro and in 
vivo studies (487). Therefore, a balance between antibody affinity and antigen density is 
required for optimal therapeutic effects.  
Enzymatically generated Fab fragments, lacking the Fc region responsible for most 
effector MAb functions, fail to produce meaningful therapeutic responses. Their in vivo blood 
clearance and catabolism are far more rapid than for whole IgG molecules, while 
accumulation in the tumour is diminished (488) (489). They are, therefore, as stand-alone 
molecules, less suitable as cancer therapeutics, but nevertheless, useful tools for in vitro 
investigation of MAb binding properties.  
We have, therefore, generated and purified antibody Fab fragments from all four 
whole IgG molecules (1E2, 2H6, 10C5 and 10C11), using a papain digestion method 
(Chapter 2). Successful digestion of whole IgGs is shown (Figure 61).  
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Figure 61.Coomassie gel. Fab fragments were made from 1E2, 2H6, 10C5 and 10C11whole IgG 
molecules using a papain-mediated digestion and purification on the protein A column (Pierce). 
Whole IgG and Fabs from all four MAbs were denatured, and samples were run on a 10% SDS-
PAGE under reducing conditions. The gel was stained using Coomassie blue. Whole IgG lanes: (1-3-
5-7) show the presence of the whole heavy chain (Hc) and the light chains (Lc). Digested IgG: lanes 
(2-4-6-8) show the presence of *Fab fragments at ~25kDa, as well as ** VH-CH1 fragments and the 
*** Fc fragments. 
 
This allowed a detailed characterisation of the MAb binding affinity and specificity, 
without the complication of bivalent avidity effects of whole IgGs. Fab fragments from all 
four clones as well as whole IgGs were subjected to the binding activity analysis by means of 
ELISA (Figure 62, Table 15). 
7.7.1. Dissociation constant (Kd) determination of full IgGs and Fab 
fragments by ELISA 
The binding of Fab fragments from all four clones as well as whole IgGs was 
measured directly by ELISA. The antigen used was the mammalian NCT ECD-Fc fusion 
protein (Fusion Antibodies). The Kd was determined to be 0.61 nM (high affinity) for the 
10C11 clone, and 3.7 nM (moderate affinity) for the 1E2 clone using whole MAbs.  Clones 
2H6 and 10C5 had 21.6 nM and non-detectable Kd values, respectively (Figure 62a, Table 
15a). The binding affinity reduced upon Fab fragmentation and measured 624 nM for the 1E2 
clone and 222 nM for 10C11, while values were not detectable for the 2H6 and 10C5 Fab 
fragments (Figure 62, Table 15b). This suggests a significant enhancement of binding affinity 
due to bivalent cross-linking.  
225 
 
IgG2b Kd (nM) SD 
1E2 3.7 0.83 
2H6 21.6 0.6 
10C5 ND - 
10C11 0.61 0.15 
 
7.7.2. Titration FACS and cell based Kd calculation 
Cell-based quantitative FACS was performed using MDA-MB-231 cells. This 
allowed MAb binding to the endogenous, native, cell-surface antigen and determination of a 
cell-based Kd. It was established to be 69 nM for the 1E2 clone, 57 nM for the 2H6, 536 nM 
for the 10C5 clone and 72 nM for the 10C11 clone (Figure 62c). As well as being 
physiologically relevant, the Kd values obtained indicated that the binding of the MAbs in 
vivo was predominantly monovalent. 
 
 
 
 
 
 
 
 
Fab Kd (nM)  SD  
1E2  624  92  
2H6  ND  -  
10C5  ND  -  
10C11  222  9.1  
Table 15.Kd values of anti-NCT MAb whole IgG2b- and Fab- molecules  
b)  a)  
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Figure 62.Determination of MAb Kd values in a non-cell bases ELISA assay and the cell-based 
FACS experiment. a) The binding of Fab fragments from all four clones and, b) whole IgGs was 
measured by ELISA. Recombinant human NCT-Fc antigen was coated on 96-well microtiter plates (5 
μg/ml). Purified IgGs and Fabs were used with a two-fold serial titration (1 mM to 0.01 nM), 
followed by secondary detecting antibodies and colorimetric substrate (POD, Roche). Reaction was 
quenched by adding 1N H2SO4, and the signal was measured at 492 nm. c) Cell-based FACS titration 
was performed by incubating non-permeablised MDA-MB-231cells with each IgG as a primary 
antibody in two fold serial dilution (1 mM to 0.01 nM), followed by the secondary anti-Rat FITC-
conjugated antibody. Non-cell based, and cell-based dissociation constant (Kd) were determined by 
fitting the binding curves to sigmoidal 1:1 binding curves and extrapolating the 50% binding 
concentration (SigmaPlot v10.0). 
 
 
 
 
a) b) 
c) 
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7.7.3. BIACore Surface Plasmon Resonance Analysis 
BIACore is designed for the routine analysis of biomolecular interactions. Surface 
plasmon resonance (SPR) detects reflective index changes close to the surface of the 
BIACore chip. Since all biomolecules have refractive properties, no labeling is required. SPR 
detects binding events as changes in mass at the chip surface. This method, therefore, enables 
real time kinetics measurement and qualitative rankings of MAbs. The association rate (Ka) 
reflects the rate of complex formation and MAb recognition capacity towards the cognate 
antigen, while the dissociation rate (Kd) reflects the stability, i.e. fraction of the complex that 
decoys per second (490). The principle of the assay is shown in Figure 63.         
         
 
             Figure 63.The principle of epitope mapping by the surface Plasmon resonance 
(BIACore).  
 
BIACore 3000 was used to epitope map the anti-NCT MAbs by determining which ones 
compete for binding to the NCT antigen. An indicated MAb was immobilised onto the 
surface of the BIACore chip which was then exposed to the flow of the human NCT-Fc 
protein (Figure 63). The sensogram registered a consequent increase in the chip weight 
corresponding to the association part of the curve. Next, a chosen Fab fragment was injected 
and flown over the chip surface. If the binding sites of the Fab were occupied by the 
immobilised IgG, then a dissociation (descending) curve was observed, indicating that the 
IgG and the Fab bound overlapping or same epitopes. If additional binding was observed 
(ascending curve), it indicated that the IgG and the Fab bound distinct epitopes. Indeed, we 
observed that 10C11 and 1E2 clones are binding overlapping epitopes (Annex 3a-c-d; 
displaced binding), while 10C11 and 2H6 clones are directed against spatially distinct regions 
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on the NCT protein (Annex 3b; additive binding). Other permutations of the immobilised 
MAb IgGs and Fab fragments in the competition binding BIACore assay are under way. 
Additionally, given that the 10C11 clone has thus far proven to possess the best binding 
affinity, we have also performed BIACore analysis of the 10C11 MAb binding kinetics. A 
range of NCT-Ig antigen concentrations were flowed over the surface of the immobilised 
10C11 MAb to give a series of associations and dissociations from which the association rate 
constant (Kon) of 4 x 10
3 
M
-1
 s
-1 
and the dissociation rate constant was (Koff) of 6 x 10
-4
 s
-1 
were determined. Consequently a Kd of 149 nm was calculated, which was comparable to the 
ELISA Kd analysis (Annex 3e). 
7.7.4. Isolation of IgG antibody Fv-DNA sequences from hybridoma cell 
lines  
Knowledge of the MAb sequence is important for the purpose of engineering higher 
affinity derivatives and humanised antibodies. The 1E2, 2H6, 10C5 and 10C11 hybridoma 
clones were grown in culture and cells from each clone were harvested for mRNA isolation. 
RT-PCR was carried out on all clones using primers designed to amplify the variable heavy- 
and light-domain sub-genes (361). Restriction sites introduced by the primers can enable the 
Fv-DNA to be inserted at the 3'-terminus of DNA coding for a bacterial leader sequence in 
many commercial expression vectors. After cloning the VH and VL genes into the pCR
®
2.1 
vector, the restriction fragments were analysed by gel electrophoresis, and subsequently sent 
for sequencing using M13 primers (sequences provided in Chapter 2). This will allow for 
definite identification of the critical, antigen binding domains of the antibody variable 
domains and complementarity determination regions (CDR) (Figure 64).         
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Figure 64.Agarose gel electrophoresis of amplified MAb DNA (1E2, 2H6, 10C5 and 10C11). 
Results for the heavy chain (VH) and the light chain (VL) amplification are shown. Expected PCR 
transcripts are visualized at ~ 350 kb. The temperature of hybridisation during the PCR was 52 °C. 
Amplification was successful for of 1E2 and 10C11 (VH & VL), 2H6 VL and 10C5 VL, while no 
product was detected for 2H6 VH and 10C5 VH. This indicates the need to further optimise the PCR 
conditions. 
 
7.6. Discussion 
An anti-NCT PcAb was developed against the DAP domain of the NCT protein (261-
502 a.a.), which harbours the functionally relevant DYIGS region and the E333 site, involved 
in GS substrate recognition, and NCT maturation (302). NCT-Pc Ab recognised endogenous, 
cell-surface NCT on breast cancer cells and inhibited cell proliferation, as well as cell 
invasion, both in a dose-dependent manner. Moreover, treatment of MDA-MB-231 cells with 
the PcAb reduced NCT protein levels and inhibited GS activity, as demonstrated by the lack 
of Notch1-ICD generation. We have also shown that the Akt pathway downstream of NCT 
was attenuated. These data served as a strong proof of principle that NCT could be targeted in 
breast cancer cells by means of a blocking antibody.  
We therefore developed anti-NCT MAbs by genetic immunisation of rats using the 
cDNA encoding for NCT ectodomain. From 21 positively screened hybridomas using a 
Genovac propriety cell line where NCT had been artificially overexpressed, we identified ten 
clones which recognised endogenous, cell-surface NCT on breast cells. Consequently, seven 
of those were also able to inhibit breast cancer cell invasion, as screened by using the 
transwell cell invasion assay. Clone 1E2, which bound NCT on MDA-MB-231 cells, but 
failed to infer a functional inhibitory effect on cell invasion was subcloned and expanded to 
kb 
230 
 
be used as a „negative MAb control‟. Positive clones taken forward were 2H6, 10C5 and 
10C11.  
The transwell cell invasion assay, has been widely implemented for screening 
inhibitors of cellular migration and invasion, and provides affordable and reproducible 
results. Matrigel is used as the standard matrix to coat the polycarbonate filter inserts. The 
standard pore size of 8 μm ensures that the cells do not passively fall into the bottom well but 
rather pass through by actively „squeezing‟ through the pores (491, 492). Furthermore, this 
3D model of cell invasion has advantages over 2D cultures in mimicking more physiological 
conditions with respect to dimensionality, architecture and cell polarity in vivo (493). 
The doses of MAb used for the treatment of MDA-MB-231 cells were 50 μg/ml and 
200 μg/ml for the invasion assay, and 200 μg/ml in all other assays. This high dose was 
chosen due to the fact that we were anticipating low antigen density of the cell surface, due to 
the reported GS spatial paradox and segregation into plasma membrane lipid rafts (242, 247). 
The same rational led us to hypothesise that the proximity of the neighbouring NCT 
molecules on the cell membrane would not be sufficient to allow for the bivalent binding of 
the MAbs, therefore we aimed to maximise the magnitude of MAb-antigen interaction by 
delivering increased amounts of the MAb.  
In the functional assays, purified clones 2H6 and 10C5 produced a comparable anti-
proliferative effect in MDA-MB-231 cells, while 10C11 was more potent. All three clones 
inhibited cell invasion to a similar degree at both 50 μg/ml and 200 μg/ml dose. This suggests 
firstly, that the degree of functional inhibition of cell invasion saturates at or below the dose 
of 50 μg/ml, and secondly, given the degree of inhibition at an equivalent dose, that the anti-
invasive effect of the anti-NCT MAbs could be predominant over their anti-proliferative 
effect. The anti-invasive effects may be mediated by the observed reduction of vimentin 
protein levels and the induction of cancer cell repolarisation. Further characterisation of the 
MAbs using a non-cell based ELISA assay and the cell-based FACS analysis, confirmed that 
the preferred mode of physiological IgG binding is monovalent (Figure 65), and that the 
10C5 clone is not the best candidate MAb due to the high Kd value. This information is 
valuable for the design of functional in vitro experiments as well as in vivo studies to 
determine MAb dose selection.  
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Figure 65.The concept of monovalent and bivalent MAb-antigen binding. Monovalent binding 
engages one arm of the MAb heavy- and light-chain variable regions for interaction with the antigen. 
Bivalent binding engages variable domains on both MAb arms. Antigen density of the cell membrane 
can be a limiting factor preventing bivalent binding. 
Interestingly, what emanated from the competition based BIACore analyses was that 
the 1E2 and 10C11 clones bind overlapping epitopes on the NCT antigen. Coupled with the 
fact that the 1E2 MAb did not infer significant inhibitory effects, this suggests that the non-
overlapping region between the two MAbs may be functionally important. Importantly, 2H6 
and 10C11 MAbs recognised distinct regions on NCT. Having in mind that the 10C11 clone 
was a more potent inhibitor of cell proliferation than the 2H6 MAb, while both had 
comparable impact on invasion, it is plausible that the 10C11 binding epitope on NCT is 
particularly relevant for mediating cell survival, while the region corresponding to the 2H6 
binding site primarily mediates cell invasion. 
The developed MAbs further differed in their ability to recognise NCT glycoforms. 
The 1E2 and 10C11 MAbs recognised all three NCT forms (deglycosylated, immature and 
mature) (220), while the 2H6 was superior in recognising the immature and the 
deglycosylated NCT. Remarkably, the 10C5 antibody only recognised the deglycosylated 
NCT. It has been demonstrated in vitro that only the fully post-translationally modified NCT 
reaches the cell surface (292). The fact that the 10C5 MAb was able to recognise NCT on the 
cell surface of MDA-MB-231 cells, as well as to induce functional effects in conditions 
where MDA-MB-231 cells were not permeabilised, leaves us with a hypothesis that a certain 
amount of not fully glycosylated NCT might reach the plasma membrane in breast cancer 
cells.  
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CHAPTER 8 
 
 
General Discussion 
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8.1. Nicastrin silencing in breast cancer cells disrupts the gamma-
secretase complex and affects cell adhesion and invasion regulators 
The marked upregulation of NCT protein expression in human breast cancer cell lines 
compared to normal breast cells prompted our efforts to employ the NCT siRNA targeting 
approach and elucidate whether NCT is functionally important in breast cancer cells. 
Nicastrin has thus far primarily been characterised and investigated as a member of the GS 
enzyme quartet, partnering with PS, PEN2 and Aph-1 to form a functionally active 
proteolytic complex (494). Given the diversity and the sheer number of GS substrates (190), 
the activity of which is inhibited by impaired GS function upon NCT silencing, both the anti-
proliferative and the anti-invasive aspects of NCT inhibition could be interpreted as being 
indirectly caused by deregulated GS substrate function. This is an entirely plausible 
argument, since we have been able to demonstrate that, as in other cellular systems (164), 
NCT silencing in breast cancer cells inhibits Notch signaling, but also affects mediators of 
cell apoptosis, adhesion and invasion, which are cellular processes affected by other GS 
substrates as well: CD44, HER4, E-cadherin, EpCAM etc. 
Our main observation upon NCT silencing in MCF-7 and MDA-MB-231 cells was 
the effect on cell adhesion and invasion proteins. The mechanism underlying the effects on 
cell-cell adhesions by NCT silencing appears to involve the regulation of E-cadherin and 
p120ctn localisation to the cell membrane. Since NCT inhibition also reduces cellular levels 
of PS1, which binds E-cadherin on the same motif involved in E-cadherin binding to p120ctn, 
we hypothesise that absence of PS1 allows for enhanced E-cadherin-p120ctn interaction, 
which facilitates cell adhesion (372). As for the effects on cell invasion, the most pronounced 
modulation was observed in the case of vimentin protein and mRNA levels, both of which 
were markedly decreased upon NCT silencing, and significantly increased upon its 
overexpression. This may be mediated via the coordinately modulated mRNA levels of the 
promoter of vimentin transcription, SIP1. As a major promoter of breast cancer cell invasion, 
vimentin maintains mesenchymal cell shape and behavior. Its overexpression in MCF-7 cells 
and MCF10A cells is sufficient to induce phenotypic changes characterised by elongation and 
reduction in cell height, which enable the invading cells to be more resilient and survive the 
shear mechanical stress associated with detachment from the primary tumour and invading 
through the tissue  to form metastatic deposits (495). 
234 
 
The anti-invasive effects of NCT silencing observed in MDA-MB-231 and HCC1806 
basal-like breast cancer cell lines reflect the changes in cell shape and distribution. 
Immunofluorescence imaging and phase contrast microscopy have demonstrated that NCT-
depleted MDA-MB-231 and HCC1806 cells lose their scattered distribution and assume a 
more cobble-stone like shape, with formation of cell-cell junctions.  
Cancer cell invasion can be mediated by two main forms of cell movement, the 
elongated and the amoeboid. These two forms can be interchangeable and depend on the cell 
intrinsic properties, position of cancer cells within the tumour, as well as on the signals from 
the tumour surroundings. Elongated, mesenchymal movement is driven by Rac-dependent 
signaling, integrin molecules, matrix-metalloproteases and proteolytic disintegration of the 
extracellular matrix (ECM). The acto-myosin contractility in amoeboid motility represents 
the force behind the formation of bleb-like protrusions on the cell membrane, enabling the 
cells to push and squeeze through the ECM without much need for ECM proteolysis (496). 
Inhibition of one of these forms of movement has been known to induce a switch to the 
alternate mechanism. Ideally, one would aim to inhibit both the amoeboid and the 
mesenchymal motility in order to abrogate formation of metastasis successfully (452). 
Recently, a model of MDA-MB-231 cell migration has shown that these cells predominantly 
engage in amoeboid cell movement during invasion through the 3D matrix, with myosin IIa 
accumulating at the rear of the cell. The RhoA-ROCK1 signaling axis promotes acto-myosin 
contractility during amoeboid movement (497), while RhoE inhibits motility by acting as a 
negative regulator of ROCK1-mediated signaling (498). Our protein array data have shown 
that NCT silencing could be upregulating RhoE levels and inhibiting myosin IIa, which 
suggests that the mechanism of anti-invasive effects of NCT depletion could be mediated 
through attenuation of amoeboid cell movement.  
In addition, the immunofluorescence imaging of MDA-MB-231 cells indicated that 
some cells adopt the elongated phenotype on a 2D substratum, when the locomotive force is 
predominantly generated by Rac1, in support of mesenchymal movement (452). This data, 
coupled with our RT-qPCR analysis upon NCT silencing and overexpression, which 
demonstrated that NCT modulates expression of integrins and MMP7 metalloprotease, both 
of which mediate Rac-induced motility, may serve as an indication that mesenchymal cell 
movement might be affected by NCT silencing as well. Interestingly, a Rac1 activating protin 
DOCK3 (499, 500), which is a member of the DOCK180 family of guanine nucleotide 
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exchange factors that facilitates GTP loading of Rac1 at the plasma membrane, has been 
identified as a binding partner of PS1 in neuronal cells (501). It was shown that 
overexpression of PS1 in Alzheimer‟s disease induces relocalisation of DOCK3 from the 
cytoplasm to the cell membrane (501). If PS1 and DOCK3 were interacting and colocalising 
at the plasma membrane in breast cancer cells as well, it could implicate PS1 and by 
inference GS, as potential regulators of Rac1, and thereby mesenchymal cell movement. If 
the PS1-DOCK3 interaction at the cell membrane observed in neurons, translates to the breast 
cancer cell model, then a hypothesis could be postulated that NCT depletion-induced 
reduction of PS1 acts as a mechanism to downregulate DOCK3, thereby attenuating Rac1 
mediated cell invasion.  
8.2. Stable nicastrin depletion in triple-negative breast cancer cells 
HCC1806 reduces the proportion of the stem-cell-like population and 
inhibits their invasive traits 
The importance of targeting breast cancer stem cells in order to achieve more durable 
effects of anti-cancer therapy, and ultimately prolong patient survival, has been established. 
Multiple neo-adjuvant clinical trials in breast cancer patients have shown that neither 
chemotherapy nor hormonal therapy are entirely successful in eradicating tumour initiating 
cells, but rather they increase the cancer stem cell pool in the residual tumour tissue (502). In 
2003, the work of Al Hajj et al. described CD44 and CD24 as relevant markers of this cell 
population within a tumour, and since then the CD44
+
/CD24
low/- 
phenotype has been widely 
used to isolate and characterise breast cancer stem cells in vitro and in vivo (87). Breast 
cancer stem cells express invasive features characterised by high vimentin and Slug levels 
and absence of E-cadherin (503).  
It has been demonstrated that Notch signaling also contributes to the maintenance and 
expansion of the breast cancer stem cell pool (110). Targeting Notch by direct siRNA and 
using GSIs potently reduced mammosphere formation (176, 504). Mammosphere formation 
in MCF-7, MDA-MB-231, BT-474, and SKBR3 cells was abolished by using a non-aldehyde 
containing GSI, MRK003, resulting in cell death after 7-10 days in all cell lines. Equally, 
Notch1 siRNA prevented mammosphere formation (504). Differential activity of Notch1 and 
Notch4 receptors has been observed in mammospheres from the sorted MCF-7 and MDA-
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MB-231 cells. Notch4 signaling was found to have a greater effect on breast cancer stem cell 
activity than Notch1 (176), and Notch inhibition by a GSI (MK-0752) reduced breast cancer 
stem cell number and activity (176). Our data using CD44/CD24 immunosorting in 
HCC1806-Luc1 and HCC1806-NCTsh cell lines, recapitulated the finding of the differential 
activity between Notch1 and Notch4 in breast cancer stem-cells, and further implicated NCT 
as a regulator of this cell population. The stem-cell pool was reduced in NCT depleted cells, 
and even though Notch4 mRNA levels remained high, NCT ablation reduced protein levels 
of the active Notch4. Our observations further expand by demonstrating that NCT acts as a 
potent inhibitor of cell invasion inducers in breast cancer stem cells including, vimentin, SIP1 
and Snail. It would be of interst to examine the effect of Notch4 siRNA on these markers of 
cell invasion in the context of breast cancer stem cells, and gain insight whether NCT 
silencing is acting to regulate them via Notch, or possibly in a Notch-independent manner. 
Recently, the issue of cancer stem cell plasticity has been addressed in the context of 
the breast cancer stem cell phenotype. It has been demonstrated that like the CD44
+
/CD24
- 
population, which propagates in vitro and in vivo, giving rise to a proportion of 
CD44
+
/CD24
+ 
cells, the CD44
+
/CD24
+ 
cells, initially deemed non-tumourigenic, are also able 
to interconvert and produce CD44
+
/CD24
- 
cells in vitro and in xenograft models of breast 
cancer (503, 505). The stem cell-like potential and interconversion appears to be mediated 
through the Activin/Nodal signaling pathway. Hence the authors propose that successful 
breast cancer stem cell targeting should aim to disable the Activin/Nodal signaling which 
would then impair this interconversion, thus preventing the CD44
+
/CD24
+
 to give rise to 
more invasive CD44
+
/CD24
- 
cells (503). Interestingly, Nodal is a direct target of the Notch 
pathway (506), and its expression in breast cancer tissue correlates with disease progression 
(507). Furthermore, Notch4 silencing potently downregulates Nodal in malignant melanoma 
(508). Therefore, we will explore the impact of NCT depletion on the levels of Nodal in 
breast cancer stem cells.  
In summary, considering the fact that NCT inhibition was able to reduce proliferation 
and invasion of differentiated breast cancer cells, and to impede proinvasive proteins in breast 
cancer stem cells defined by the CD44/CD24 phenotype, we speculate that the anti-NCT 
therapy in breast cancer may not only target the bulk of the primary tumour, but might also be 
potent in reducing the number and the invasive potential of breast cancer stem cells, deemed 
responsible for cancer relapse.  
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8.3. Nicastrin inhibition regulates a subset of Notch-independent 
genes in MDA-MB-231 cells 
Since the discovery of the roles for intracellular domains of GS substrates in gene 
transcription (Notch-ICD, APP-ICD etc.), the notion of GS as a major player in 
pathologically altered gene transcription has been extensively studied. Comparison of 
differentially regulated genes in Chinese hamster ovary (CHO) cells, in conditions where GS 
has been overexpressed vs. inhibited has revealed several affected functional gene clusters 
underlying GS-mediated cellular biology (222). We have similarly investigated genes that are 
transcriptionally susceptible to NCT activity in breast cancer MDA-MB-231 cells, by 
comparing global transcriptional changes between conditions of NCT silencing and silencing 
of the individual Notch receptors. 
Interestingly, some genes that appeared significantly affected in our experiment were 
also identified by the work of Magold et al. who investigated genes modulated between 
conditions of GS overexpression vs. GS inhibition in CHO cells. One of the genes with 3-fold 
increased transcription under enhanced GS activity compared to inhibited GS activity was 
Bub1. In line with that, Bub1 was downregulated in our experiments by NCT silencing. 
Furthermore, vimentin  and SPARC (secreted protein acidic and rich in cysteine), both genes 
involved in promoting EMT (53), were downregulated upon GS overexpression in CHO 
cells. In contrast to this, GS inhibition was ~previously shown to downregulate vimentin via 
Notch inhibition in salivary epithelial cells (391), and we have consistently found vimentin to 
be potently inhibited by NCT depletion in both MDA-MB-231 and HCC1806 cells. CD44 
and E-cadherin genes were downregulated by 3-fold, while Notch3 and Hes1 were increased 
under enhanced GS activity by 5-fold and 7-fold, respectively in CHO cells overexpressing 
GS (222). Of the genes involved in cellular migration, MYH10 transcript levels were 3-fold 
decreased, and we have found the same qualitative change of the MYH10 upon NCT 
silencing, which reduced GS activity. The fact that MYH10, vimentin and E-cadherin were 
regulated by NCT silencing in the same direction as they were by GS overexpression in CHO 
cells, which have been extensively used for the characterisation of the GS complex (326), 
proposes that GS/NCT activity may be highly cell context dependent, and at the same time 
emphasises the importance of NCT siRNA-induced anti-invasive effects in breast cancer 
cells. It is important though to emphasise that the comparisons in CHO cells were made 
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between two extreme conditions of GS overexpression vs. inhibition, while we have 
compared NCT siRNA effects with control, „base-line‟ levels, which could account for the 
differences.  
Furthermore, a recent microarray experiment has identified genes regulated by 
overexpression of active Notch1 in non-transformed breast cells MCF10A, and highlighted 
the importance of the Notch signal strength in induction of either malignant cell 
transformation (intermediate levels of Notch) or entosis (high levels of Notch) (390). The 
intergrin gene signature was prominently modulated by Notch1 induction, in line with the 
observed loss of cell-cell adhesions. Similarly, we have demonstrated that NCT stable 
knockdown increases integrin A4 and decreases integrin B2 mRNA, which therefore may be 
a Notch1-mediated effect in HCC1806-NCTsh cells.  
Interestingly, genes that we found regulated only by NCT silencing and not Notch1 
siRNA in MDA-MB-231 cells, were found regulated in the inverse fashion in MCF10A cells 
by Notch1 overexpression. These are PHLDA1 and ASNS which were downregulated by 2-
fold upon transfection of MCF10A with Notch1-ICD, and upregulated 2.86-fold and 6.2-fold, 
respectively by NCT depletion. Also, the E2F2 gene was inhibited by NCT silencing while its 
upregulation was noted upon Notch1 activity induction in non-malignant breast cells. These 
data suggest that the dependence of certain genes on NCT or Notch1 signaling may be 
dependent on the actual degree of Notch activation/inhibition, particularly since the 
importance of the Notch activity levels to induce differential cellular effects has been 
demonstrated. Furthermore, comparison of gene signatures in normal and breast cancer tissue 
revealed a malignancy-risk gene signature of 109 upregulated and 31 downregulated genes 
(509). Among the upregulated genes, some were those that we found affected by NCT 
silencing. For example, Bub1 and UBE2T were found 2.7- and 4.9-fold upregulated in breast 
cancer compared to normal breast tissue (509), while we found that they were downregulated 
by NCT siRNA by 2.2- and 3.2-fold, respectively. This suggests that NCT silencing may 
indeed be relevant for reversing some of the molecular changes acquired by malignant 
transformation of breast cells. Once we obtain complete Affymetrix gene array analysis, more 
of such genes may become apparent. It is also important to bear in mind that NCT silencing 
may be modulating the observed Notch-independent gene set in MDA-MB-231 cells via 
regulation of other GS substartes. This could be addressed by performing siRNA for selected 
GS substrates, such as HER4, CD44, EpCAM, N-cadherin etc., and investigating the effect 
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on the genes we have here attributed to being susceptible to NCT depletion. As 
transcriptional activity of genes translates into molecular functions, mapping the interactions 
of proteins encoded by the genes we validate, and proteins revealed in the antibody array we 
have performed, could more precisely highlight the cellular pathways mediated by NCT in 
breast cancer cells.  
8.4. Nicastrin is overexpressed in breast cancer tissue compared to 
normal breast  
Expression of GS components (NCT, PS, Aph-1 and PEN2) has thus far not been 
examined in breast cancer tissue. An indication that overall GS activity may be elevated in 
breast cancers, stems from the fact that activated Notch1 is overexpressed in a subset of 
breast cancer patients, where it predicts for worse overall survival (477). We have analysed 
NCT expression in human breast tissue using an antibody raised against the C-terminal 
portion of NCT that has previously been used for analysis of NCT expression in mouse tissue 
by IHC (220). We confirmed the antibody specificity in breast cancer tissue by pre-
incubation with the competing peptide, which abrogated the immunoreactivity altogether.  
We have observed that NCT is not present in the normal breast, while its levels 
appeared increased in the basal cell compartment of fibroadenomas and were increased in 
epithelial cells of breast cancer tissue. The intensity of NCT staining was dichotomised to 
NCT low and NCT high expressors. In the 1050 breast cancer tissue specimens examined, 
high NCT expression, detected in 47.5% of the examined cases, was predictive of worse 
overall survival in the ERα negative patient subset. 
This result directed our focus towards investigating the role of NCT in aggressive 
breast cancer, since the ERα negative tumours are clinically, as well as in vitro, more 
invasive than their ERα positive counterpart. Corroborating the importance of high NCT 
expression in invasive breast cancer, we demonstrated an elevation of NCT expression in the 
invasive component, compared to the associated in situ carcinoma on the full-faced sections 
of tumours, and have also showed that NCT abundance is retained in the breast cancer lymph 
node metastasis. Taking this into consideration, and having shown that targeting NCT using 
siRNA and specific monoclonal antibodies was able to inhibit the invasive cellular features at 
the molecular, phenotypic and functional level in vitro, we formed a hypothesis that targeting 
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NCT to inhibit aggressive breast cancer may be a therapeutic approach worth investigating 
further.  
Our IHC data equally highlighted the need to characterise the mechanism(s) 
responsible for inducing high NCT expression in breast cancer. The fact that NCT levels 
appeared elevated in the basal cell compartment of fibroadenomas proposes that the stromal-
derived factors may regulate NCT expression in breast epithelium in a paracrine manner. The 
importance of fibroblasts surrounding the breast epithelial tissue has recently been reiterated 
by the work which demonstrated that the stromal fibroblast compartment of breast tumours 
potently regulates stem-cell related genes in breast cancer cells (510). Namely, cocluture of 
breast cancer derived fibroblasts with MCF-7 cells in mammosphere-growth permissive 
conditions potently promoted expression of cancer stem-cell related genes, including Notch1, 
compared to the coculture models with normal breast tissue fibroblsts (510). Regulation of 
NCT gene expression has so far been examined in a panel of neuronal cell lines, where none 
of the cytokines or growth/differentiation factors used to treat the cells (TNF-α, IL-1β, brain-
derived neurotropic factor, PMA) had any effect on NCT transcription. Therefore, 
comparable coculture experiments, as well as treating breast epithelial cells which do not 
express high NCT levels (MCF10A) with a repertoir of factors (TGF-β, HGF, FGF, EGF 
TNF-α, VEGF, etc.) derived from breast cancer associated stroma (511), is warranted, in 
order to evaluate their potential to upregulate NCT mRNA and/or protein levels.  
Furthermore, our IHC analysis highlighted a direct correlation between high NCT 
expression and ERα positivity in breast cancer tissue. We suspect that the lack of predictive 
capacity of high NCT expression for survival of ERα positive breast cancers comes from the 
fact that benefit from hormonal therapy given to these patients could have abrogated adverse 
impact of high NCT levels. Our in vitro data where NCT siRNA was able to inhibit the 
proliferation of ERα positive, MCF-7 breast cancer cells, as well as preliminary analysis 
(www.nursa.org), which indicated that estrogen may be able to regulated NCT gene 
expression in breast cancer cells, highlight that investigating the molecular and functional 
implications of NCT expression in hormono-sensitive breast cancer may be important.  
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8.5. Anti-nicastrin monoclonal antibodies as potential means of 
targeting nicastrin in invasive breast cancer cells 
Our in vitro and in vivo data have revealed that NCT may be an important signaling 
molecule in breast cancer cells. Coupled with the fact that NCT architecture reveals a 
prominent extracellular domain which harbours important functional domains, we have 
hypothesised that an antagonistic monoclonal antibody would be a valid therapeutic to inhibit 
NCT function(s) in breast cancer cells. 
Selected anti-NCT MAbs proved to be potent inhibitors of breast cancer cell invasion 
and inducers of breast cancer cell repolarisation. All functionally effective MAbs (2H6, 10C5 
and 10C11) recognised NCT on the surface of breast cancer cells but had a differential 
potential to recognise NCT glycosylated forms in whole cell lysates. Particularly, the 10C5 
MAb detected only the deglycosylated NCT form by western blotting, prompting us to 
hypothesise that there could be a certain amount of partially glycosylated NCT which 
functions at the plasma membrane. It is also possible that the mature NCT conformation, 
which is consistent with increased glycosylation, represents steric hindrance for reactivity of 
this MAb with the peptide backbone. 
The differential reactivity of anti-NCT antibodies raised against distinct peptide 
epitopes has been recognised in membrane lysate preparations from adult and embryonic 
mouse brain-derived neural stem cells. NCT ectodomain antibody (331–346 a.a.) showed 
reactivity with immature and deglycosylated NCT, while a C-terminal antibody (691–709 
a.a.) detected mature NCT of ~145 kDa, in addition to lower molecular weight forms. 
Antibody generated to the hydrophobic region adjacent to the signal peptide on the NCT N-
terminal region (32-44 a.a.) detected NCT as two major bands, a stronger band at ~125 kDa, 
and a weaker band at ~145 kDa in the embryonic brain tissue, demonstrating thereby less 
reactivity for the more mature NCT forms (220).  
The differential ability of MAbs raised against distinct regions of an antigen may be 
explained by the unique sensitivity of each MAb to detect post-translational modifications 
(PTMs) of a protein they were raised against. This suggests that caution must be taken when 
choosing a MAb to detect highly modified proteins, such as NCT. An example of this are 
MAbs raised against recombinant osteopontin using phage display (512).  
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Osteopontin is a secreted phosphoglycoprotein found in a variety of tissues and body 
fluids, and a CD44 ligand. Degree of osteopontin phosphorylation plays a role in determining 
its physiological function, similar to the impact that the level of NCT glycosylation has on its 
ability to form a functional GS complex and localise to the cell membrane. All tested MAbs 
raised against osteopontin recognised the protein derived from conditioned medium of Ras-
transformed fibroblasts, while only one MAb (AK2A1) reacted with the protein secreted by 
the non-transfromed cells, which contains 17 additional phosphate modifications. However, 
even the AK2A1 MAb failed to recognise urin-derived osteopontin, which is additionally 
glycosylated, and may therefore contain unique modifications which are able to specifically 
inhibit AK2A1 binding (512). Glycosylation motifs of NCT may therefore be inhibiting the 
binding of the 10C5 anti-NCT MAb, rendering it incapable to identify higher molecular 
weight NCT isoforms. Anti-NCT MAb binding sensitivity to PTMs may be the feature that is 
determining their ability to identify subtle differences in the protein structure, thereby 
highlighting their usefulness. 
Thus far, the glycosylation profile or the presence of other PTMs of NCT (e.g. 
phosphorylation) in breast cancer tissue has not been investigated. In our future experiments 
we can apply NCT deglycosylation treatments (EndoH and PNGase) to breast cancer cells, in 
order to remove the high mannose moieties and total N-linked sugars, respectively, and test 
the binding ability of the MAbs in a cell based ELISA assay, by western blotting, as well as 
perform immunofluoresence colocalisation studies incorporating markers of cellular 
compartments (calnexin for the ER; GM130 for the Golgi). This may yield important 
information about expression levels and cellular distribution pattern of NCT glycosylation 
forms in breast cancer cells. Immunohistochemistry staining of breast cancer tissue is a 
methodology that cannot permit us to subject the tissue sections to manipulations such as 
deglycosylation treatments. Hence, analysis of NCT glycoforms‟ expression levels would 
only be feasible with MAbs raised against specific NCT glycoforms, which is not the case 
with the MAbs that we currently have at our disposal. However, we can apply the anti-NCT 
MAbs to immunostain breast cancer tissues, using consecutive sections of the same breast 
cancer TMA (University of Nottingham, UK). That would enable us to directly compare and 
contrast the staining pattern/intensity.  
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It would be of particular interest to evaluate eventual differences in the staining 
obtained using the 1E2/10C11 MAbs which recognise mature NCT and the 10C5 MAb, 
which on a western blot picks up only the deglycosylated form. Correlation of the staining 
intensity with the known breast cancer prognostic and predictive parameters, as well as 
disease-free and overall survival, could potentially reveal a differential impact of the NCT 
levels picked up by distinct MAbs, on survival, or a differential relation to relevant breast 
cancer biomarkers (ERα, PR, HER2, tumour grade etc.). 
Considering the fact that the anti-NCT MAbs elicit anti-invasive and anti-proliferative 
effects in breast cancer cells, it would be important to determine the exact epitopes on the 
NCT-ECD to which these MAbs bind, as they apparently map important functional domains 
of the NCT protein. Phage libraries displaying millions of peptides are extremely useful tools 
for mapping sequential (continuous) and conformational (discontinuous) epitopes of 
antibodies (513, 514). Another strategy is chemical cross linking followed by mass 
spectrometry (MS) (515). Cross-linking reagents generate patterns (covalent bonds between 
reactive amino acid side chains that are located in close proximity of each other), that are 
easily observed by MS, which is helpful in distinguishing cross-linker-modified peptides 
from unmodified peptides after proteolytic digestion.  
The cross-linked complex is subjected to tryptic digest, and since proteolysis does not 
lead to dissociation of immune complexes, an epitope can be identified by MS, as the method 
of choice for a rapid, specific and sensitive detection of protein/protein interactions stabilised 
by cross-linking (515, 516). 
In order to progress the best candidate anti-NCT MAb into well designed in vivo 
experiments and further design a clinically applicable therapeutic, features including antibody 
affinity, stability, effector functions, half-life, tissue penetration and distribution should be 
optimised (517). Furthermore, characteristics of NCT as an antigen in breast cancer tissue are 
equally important, as the balance between the antigen density, internalisation and antibody 
dissociation, affects therapeutic effects (488). 
The high cell-based Kd values of the anti-NCT MAbs in MDA-MB-231 cells (> 50 
nM) indicate that the mode of binding to cell surface NCT is primarily monovalent, most 
likely due to low antigen density. As such, they cannot at present be considered as desirable 
therapeutic tools. For example, the Kd value of the humanised anti-HER2 MAb (trastuzumab) 
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in SKBR3 cells, is 5 nM (518). We will examine the relative cell-surface abundance of NCT 
in other breast cancer cell line models (MCF-7, BT-474, SKBR3, HCC-1806) by performing 
the FACS titration assay. Since antigen density is an important parameter that needs to be 
considered for in vivo binding studies, this information will guide MAb dose selection for 
xenograft model experiments, as it will indicate whether the MAbs engage in monovalent or 
bivalent binding across the panel the breast cancer cell lines. Generally, if the target protein 
density is low so that only one arm of the IgG molecule can bind, the antibody-antigen 
interaction cannot be retained if antibody affinity is low. With high-affinity antibodies the 
strength of the interaction between a single binding site and the antigen is sufficient to retain 
antibody with only monovalent binding, and the antibody is bound effectively, irrespective of 
the antigen density (488).  
Thus far, turnover of NCT has been examined in the MEF cells using metabolic 
labeling (cell surface biotinylation) followed by the pulse-chase experiment. It has been 
established that the turnover of both mature and immature NCT is slow (> 24 h) in wild type 
and PS-deficient MEFs, emphasising that stability of NCT is not dependent on PS (248). We 
will perform this experiment in breast cancer cells in order to compare NCT membrane 
cycling dynamics with the off-rate of the MAbs, because if the antigen internalisation rate on 
the cell surface is faster than the off-rate of the MAb, then the MAb is internalised in the 
complex with the antigen and degraded (24).  
If the antibody affinity is very high it can represents a limiting factor for homogenous 
tissue distribution, inducing MAb accumulation at the tumour periphery in line with the „site-
barrier‟ model (30). This has been well demonstrated by investigating tissue permeability of 
anti-HER2 MAbs designed to recognise the same HER2 antigen epitope but with variable 
affinities (Kd values ranging from 270 to 0.56 nM) (487). Lowest affinity MAb (Kd = 270 
nM) had the best tumour penetration profile. Moderate affinity (Kd = 23 nM) was associated 
with the highest tumour accumulation, whereas high affinity (Kd = 0.56 nM) was found to 
produce the lowest tumour accumulation and confinement to the perivascular space and 
tumour rim (487). However, HER2 is the only target that has been studied in this way, so this 
may not be applicable to all (especially non-internalising) antigens. Therefore, tissue 
permeability of anti-NCT MAbs will be evaluated as a part of the in vivo xenograft model 
biodistribution studies, using immunohistochemistry penetration methodology, which enables 
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measurement of MAb distribution in relation to the tumour associated blood vessels 
visualised by co-staining with anti-CD31 antibody (487). 
Another important determinant of therapeutic MAbs is their mode of action. The 
therapeutic efficacy of anti-NCT MAbs will be dependent on their antigen binding ability as 
well as their ability to trigger effector activity in the form of ADCC and/or CDC, which is an 
aspect of their mode of action which will be assessed.  
Increasing the affinity of an antibody would allow lower doses to elicit a more 
profound biological activity which in turn would increase the therapeutic window and lower 
dose related toxicity. The approaches to improve antibody affinity can be divided into two 
categories. One is to create libraries of mutated CDRs or the entire variable domains by 
random CDR mutagenesis, chain shuffling, or DNA shuffling, and select for higher affinity 
variants. The other approach is to make small libraries by hot spot mutagenesis, mimicking 
the in vivo affinity maturation. Hot-spots are the amino acids that make a major contribution 
to the antibody-antigen interaction, and they are usually located in the central part of the 
epitope-paratope (antibody region recognising the antigen epitope) interaction site (517). 
Using  an  effective  method  of  selection,  it  is possible  to  obtain  recombinant  antibodies  
with  dissociation constant values reaching 10
–10
 M and below (21).  
Before engaging in the process of increasing antibody affinity, one should equally 
consider the clinical relevance of the process, especially if the relative density of an antigen 
on the target and non-target tissues is different. In such a case, it could be possible to select 
antibodies of specific affinity and valence to differentiate the target tissue. For example, if an 
epitope is present at a higher density on the tumour cells than in benign tissues, a lower 
affinity antibody would be a desirable therapeutic because bivalent binding could be used to 
discriminate between the two tissues (21). Therefore, biodistribution analysis and 
investigation of NCT antigen density on other tissues would be of great importance. Thus far, 
there are two main sites of concern regarding treatment related toxicities linked to NCT 
inhibition, the skin and the hematopoetic system, both observed in mouse models upon 
generation of NCT knockout strains. Namely, proliferative skin lesions and 
myeloproliferative disorder resembling chronic myeloid leukemia (splenic enlargement, 
leukocytosis and monocytosis in peripheral blood, myeloid infiltrates in the bone marrow and 
liver) occurred in NCT
-/- 
mice (154, 370).  
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We have detected NCT expression in normal skin, suggesting that the skin-related 
toxicity could be common in humans. Expression of NCT in human lymphocytes needs to be 
addressed. Nicastrin silencing in the context of the work performed by the groups of Liu et al. 
and Klinakis et al. acted as a means of Notch inhibition, which served to implicate Notch as 
both an oncogene and tumour suppressor in different hematological malignancies. 
Nevertheless, their work emphasises the importance of optimising the therapeutic window 
when considering NCT inhibition with MAbs as a therapeutic strategy, so to avoid treatment 
related toxicities and induction of other malignancies while treating breast cancer. 
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8. Final comment 
In the course of this thesis we have analysed the biological and clinical implications 
of nicastrin expression in breast cancer cells and tissue. Taken together, the results presented 
here have identified nicastrin as a potential novel therapeutic target in breast cancer. Nicastrin 
fulfills certain criteria in order to be considered as a target for monoclonal antibody therapy:  
i)  It is differentially expressed between normal breast and breast cancer tissue; ii) High 
nicastrin expression confers worse overall survival in ERα negative breast cancer patients, 
indicating its relevance in aggressive breast tumours; iii) Nicastrin inhibition attenuates breast 
cancer cell invasion and proliferation; iv) Nicastrin possesses an extracellular domain which 
harbours important functional sites and could be targetable by an antagonistic antibody.  
Based on the work encompassed in this thesis, we suggest that nicastrin function in 
breast cancer cells is important to maintain the stability and function of the gamma-secretase 
complex. We also propose that nicastrin is an important mediator of breast cancer cell spread, 
as its expression correlated with aggressive disease and its inhibition attenuated breast cancer 
cell invasion. Anti-invasive and anti-proliferative effects inferred by nicastrin silencing and 
anti-nicastrin monoclonal antibodies in breast cancer cells are, in large part certainly a 
consequence of the GS/Notch inhibition. Whether nicastrin possesses relevant GS/Notch-
independent functions in breast cancer cells, as proposed by the gene array that compared 
nicastrin silencing effects to those inferred by inhibiting Notch receptors, remains to be 
investigated. In addition, our further experiments will involve: i) characterisation of the 
nicastrin downstream signaling effects which mediate breast cancer cell invasion; ii) 
characterisation of the nicastrin antigen as a potential target for a monoclonal antibody (cell 
surface expression and turnover dynamics); iii) characterisation of the developed monoclonal 
antibodies in terms of epitope mapping, mode of binding, biodistribution and improving their 
binding affinity; iv) application of the anti-nicastrin monoclonal antibodies in in vivo breast 
cancer xenograft models.  
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ANNEX 1 
 
 
 
 
 
 
 
 
 
 
 
249 
 
XP725 Profiler Array Sigma              Fold Change 
Protein Antibody ID MDA231    
NCTsi  
                       HCC1806 
                         NCTsh                                            
 
β-actin A1978     0.98                             0.9 
AP2a A0844    -2.00 -2.00 
AP Edonuclease A2105     1.53 2.91 
ATF1 A7833    -2.32 -2.43 
ATF2 A4086    -2.27 -2.27 
ATF2 pThr69 71 A4095    -2.43 -2.56 
BACH1 B1310     2.6 5.21 
cJun pSer63 J2128  -8.3 
caspase 6 C7599    -2.77 -3.12 
caspase 7 C7724 -2.63 -3 
a-catenin C2081 -1.81 -2.43 
bCatenin pSer33 C2363 -2.22 -2.17 
Cathepsin D C0715 2 3.9 
Clathrin Heavy Chain C1960 1.1 2.2 
Connexin 32 C3470 -2.5 -2.77 
DcR2 D3188 -2.56 -3.00 
DcR3 D1814 1.8 2.6 
DEDAF D3316 -2.17 -1.96 
Desmosomal protein D1286 1.2 2.5 
Episialin E0143 1.25 2.1 
FKHRL1 FOXO3a F2178 -2.32 -2.77 
FRS2 F9052 -2.22 -2.5 
G9a Methyltransferase G6919 1 2 
GATA1 G0290 -2.63 -2.63 
Glutamate receptor NMDAR  G9038 -2.7 -2.43 
HAT1 H7161 -2.63 -2.32 
methyl Histone H3 MeLys9 H7162 -2.85 -2.85 
Histone H3 pSer28 H9908 -2.94 -3 
hSNF5 INI1 H9912 -2.7 -3 
IKKa I6139 -2.04 -2.04 
ILP2 I4782 -2.63 -2.63 
L1CAM L4543 1.1 2.78 
Laminin L9393 -3.22 -3.125 
Leptin L3410 -2.7 -2.7 
MBD4 M9817 -2.43 -2.32 
LRRK2 (PARK8) L3044 3.02 5.25 
Nerve growth factor 
receptor  p75 
N3908 -3.125 -3.44 
Neurofibromin N3662 -1.92 -2.43 
Nitric Oxide Synthase 
Endothelial  
N9532 -2.08 -2.43 
Nitrotyrosin N0409 -2.38 -2.22 
PARP P7605 -2.5 -2.5 
PCAF P7493 -2.32 -2.17 
Phospholipase C g1 P8104 -2.63 -2.43 
PINCH1 P9371 1.23 3.36 
PRMT4 P4995 -2.7 -2.7 
Rab9 R5404 1 3.5 
Reelin R4904 -2.43 -2.5 
RICK R9650 -2.63 -2.77 
RIP Receptor Interacting 
Protein 
R8274 -2.38 -2.77 
Serine Threonine Protein 
Phosphatase 1g1 
P7609 2.8  
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Protein lysates of MDA-MB-231 cells treated with the Control and NCT siRNA for 72 h, as 
well as lysates from HCC1806-Luc1 and HCC1806-NCTsh cells were prepared and extracts 
with protein concentrations ≥ 1.0 mg/ml were used for fluorescent labeling with Cy3 and Cy5 
fluorochroms. Only samples with a dye-to-protein molar ratio > 2 were applied to the 
antibody microarray. The hybridised antibody microarray slides were scanned using a 
GenePix Personal 4100A Microarray Scanner (Axon Instruments, Union City, CA) with 532 
and 635 nm lasers. Primary analysis was done with the GenePix Pro (version 4.1) software 
package (Axon Instruments). Images of the scanned antibody microarrays were gridded and 
linked to a protein print list. Absent spots were flagged automatically by GenePix Pro; 
however, all spots were manually reviewed. The log ratios of Cy5 to Cy3 were determined 
for each spot to estimate the relative concentration of each protein. Values were normalised 
according to the manufacturer‟s protocol to the values of a chosen normalising protein, in this 
case β-actin.  Only samples showing > 2-fold upregulation or downregulation in expression 
are deemed significant. This cut-off was selected because it is has been used previously in 
antibody microarray experiments (410). Empty cells in the table reflect the undetected sample 
in a particular cell line. This may be due to loss of antibody activity by denaturation during 
printing or array storage or low levels of the respective antigen in the sample. The table lists 
the proteins that are up- or down- regulated by at least 2-fold in at least one of the cell lines 
used. Full antibody list:  
www.sigmaaldrich.com/etc/medialib/docs/Sigma-Aldrich/General_Information/xp725_ab_list.pdf 
 
 
 
 
 
 
 
 
Serine Threonine Protein 
Phosphatase 2 A Bg 
P5359 4.4  
Sir2 S5313 -2.7 -3.22 
Spred2 S7320 1.8 4.6 
SUMO1 S5446 -3.33 -3.57 
TOM22 T6319 -2.63 -2.77 
Pinin P0084 -2.43 -4.16 
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A. Genes regulated by NCT siRNA in MDA-MB-231 cells 
                      Fold Change  
Gene Symbol Gene Discription Notch1 
siRNA 
Notch2 
siRNA 
Notch4 
siRNA 
NCT 
siRNA 
p-value 
NCTsiRNA vs. 
ControlsiRNA 
HSPE1 heat shock 10kDa protein 1  1.62 -1.72 1.31 -2.58 0.04156 
DYNLT3 dynein, light chain, Tctex-type 3 1.62 1.84 1.11 2.06 0.00038 
MYOF Myoferlin -1.44 1.58 1.07 2.25 7.96E-05 
NFE2L3 nuclear factor (erythroid-derived 2)like 3 -1.55 1.70 -1.28 -2.17 0.00102 
BRP44 brain protein 44 -1.45 -1.51 -1.26 -2.05 7.87E-06 
CLTB clathrin, light chain (Lcb) 1.44 1.53 -1.04 2.36 4.90E-06 
WFS1 Wolfram syndrome 1 –wolframin -1.36 1.87 1.10 4.93 6.52E-08 
PLOD2 procollagen-lysine, 2-oxoglutarate 5-
dioxygenase 2 
-1.35 1.61 1.36 2.12 4.08E-06 
LOC1001319 hypothetical LOC100131909 1.35 1.71 1.09 2.26 8.73E-06 
ABCB9 ATP-binding cassette B, member 9 -1.34 1.33 1.00 2.00 6.17E-07 
SEPW1 selenoprotein W, 1 -1.33 -1.67 -1.07 -2.12 4.92E-08 
BCAR3 breast cancer anti-estrogen resistance 3 -1.32 1.96 1.29 2.18 0.00012 
LRRC61 leucine rich repeat containing 61 -1.31 -1.76 -1.38 -2.93 3.78E-07 
RIPK2 receptor-interacting ser/thr kinase 2 1.31 1.63 1.31 2.08 0.00019 
C13orf15 chromosome 13 open reading frame 15 -1.31 1.88 1.01 3.99 1.43E-07 
MANF mesencephalic astrocyte neurotrophic 
factor 
-1.30 -1.50 -1.28 3.34 1.58E-06 
GPT2 glutamic pyruvate transaminase 2 1.30 1.66 1.01 3.06 1.18E-05 
LOC1001342 similar to mitogen-activated kinase  1.30 1.91 1.48 2.12 1.81E-06 
PAWR PRKC, apoptosis, WT1, regulator -1.26 1.58 1.36 2.35 6.57E-07 
PSMB2 proteasome subunit, beta type, 2 -1.26 -1.77 -1.30 -2.27 4.01E-05 
ADCY3 adenylate cyclase 3 1.23 1.59 1.48 -2.02 9.52E-06 
IL1RAPL1 interleukin 1 receptor accessory protein1 -1.23 1.82 1.17 2.47 8.63E-06 
PVRL3 poliovirus receptor-related 3 1.20 1.24 1.11 2.22 3.08E-05 
ITPRIP inositol 1,4,5-triphosphate receptor  -1.19 1.65 1.12 2.01 1.45E-05 
CCPG1 cell cycle progression 1 1.17 1.62 1.42 2.14 1.83E-06 
PXDN peroxidasin homolog (Drosophila) 1.15 1.60 -1.18 2.32 0.00030 
ZNF598 zinc finger protein 598 1.14 1.79 1.23 2.30 1.46E-07 
SHMT2 serine hydroxymethyltransferase 2  -1.13 1.51 -1.06 2.60 2.11E-06 
DYNLT1 dynein, light chain, Tctex-type 1 1.12 -1.86 -1.04 -2.24 5.11E-05 
POMP proteasome maturation protein -1.12 -1.78 -1.18 -2.06 3.42E-05 
LY6E lymphocyte antigen 6 complex, locus E 1.11 -1.84 -1.20 -2.63 9.49E-07 
SLC24A6 solute carrier family 24, member 6 1.10 1.51 -1.25 2.93 4.88E-07 
MRPL22 mitochondrial ribosomal protein L22 1.09 -1.49 -1.33 -2.34 6.50E-06 
NME1 non-metastatic cells 1, protein (NM23A)  1.08 -1.80 -1.30 -2.20 2.94E-07 
IGSF3 immunoglobulin superfamily, member 3 1.08 1.77 -1.45 -2.29 1.66E-06 
LDLR low density lipoprotein receptor 1.08 1.85 1.37 3.06 3.90E-07 
NUCB1 nucleobindin 1 1.07 1.73 1.27 2.60 0.00020 
GPR177 G protein-coupled receptor 177 1.07 1.44 -1.07 2.53 2.12E-07 
VGLL4 vestigial like 4 (Drosophila) 1.06 1.68 1.21 2.06 4.39E-07 
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PTS 6-pyruvoyltetrahydropterin synthase 1.05 -1.89 -1.43 -2.39 0.00370 
PRKRIR protein-kinase RNA dependent inhibitor 1.05 -2.94 1.29 2.34 6.15E-07 
LITAF lipopolysaccharide-induced TNF factor 1.04 -1.99 -1.13 -2.34 2.00E-05 
MAGOH mago-nashi homolog 1.04 -1.95 -1.19 -2.27 2.60E-06 
ZFAND5 zinc finger, AN1-type domain 5 1.02 1.89 1.25 2.26 1.03E-06 
EML3 echinoderm microtubule associated 
protein like 3 
-1.02 1.88 1.32 2.00 8.65E-05 
 
B . Genes regulated by NCT siRNA and Notch2 siRNA in MDA-MB-231 cells 
Gene 
Symbol 
Gene Description Notch1 
siRNA 
Notch2 
siRNA 
Notch4 
siRNA 
NCT 
siRNA 
p-value 
Notch2 
siRNA 
p-value 
NCT siRNA 
RFTN1 raftlin, lipid raft linker 1 -1.49 2.20 -1.04 2.23 0.003 0.0002 
KRT7 keratin 7 1.46 -2.46 -1.20 -2.62 0.000328 0.000211 
SLC3A2 solute carrier family 3 member 2 1.43 2.35 1.24 3.06 1.46E-06 1.97E-07 
TRPC4AP transient receptor cation channel 1.41 2.17 1.385 2.33 5.91E-06 3.11E-06 
LOC64531 coiled-coil-helix-coiled-coil-helix 
domain  
-1.41 -3.10 -1.46 -2.10 0.000108 0.001609 
S100A4 S100 calcium binding protein A4 -1.32 -3.04 -1.16 -2.06 5.13E-07 1.21E-05 
CD97 CD97 molecule 1.30 3.17 1.45 2.41 3.50E-08 2.69E-07 
CSK c-src tyrosine kinase 1.27 2.43 1.24 2.00 1.08E-06 6.02E-06 
CLCN7 chloride channel 7 1.26 2.37 1.26 2.54 1.11E-05 6.30E-06 
NINJ2 ninjurin 2 -1.25 -2.14 -1.06 -2.86 0.000417 4.71E-05 
TCTEX1D Tctex1 domain containing 2 -1.25 -2.50 -1.27 -2.65 3.97E-06 2.51E-06 
NDUFB3 NADH dehydrogenase 1 beta 3  1.25 -3.27 -1.07 -2.49 1.54E-06 1.03E-05 
ETS1 erythroblastosis virus E26 oncogene   1.24 2.37 1.46 3.57 1.88E-05 1.12E-06 
NEDD4L neural precursor cell expressed, 
developmentally downregulated 4 
-1.23 2.27 -1.10 2.73 2.23E-06 4.82E-07 
RPS24 ribosomal protein S24 -1.22 -4.06 -1.36 -2.87 1.11E-08 9.54E-08 
PCBD1 pterin-4 alpha-carbinolamine 
dehydratase/dimerization cofactor 
of hepatocyte nuclear factor 1 alpha 
-1.22 -2.06 -1.12 -2.35 4.72E-05 1.45E-05 
RPL26 ribosomal protein L26 -1.22 -3.10 -1.47 -3.98 3.10E-05 7.43E-06 
C7orf59 chromosome 7 open read frame 59 -1.21 -2.76 -1.45 -2.10 2.11E-07 2.21E-06 
NDUFB2 NADH dehydrogenase 1 beta 2 -1.20 -2.42 -1.06 -2.09 2.15E-06 7.88E-06 
GNG12 guanine nucleotide binding protein 
(G protein), gamma 12 
1.19 2.01 -1.00 2.00 4.52E-05 4.84E-05 
DERL1 Der1-like domain family, member 1 -1.19 3.06 1.11 2.14 6.97E-06 0.000103 
ATP6V0A ATPase, H+ transport-lysosomal V0 1.16 2.21 1.40 3.46 8.11E-08 2.76E-09 
LGMN Legumain -1.15 2.01 1.06 2.04 5.51E-06 4.88E-06 
VEGFC vascular endothelial growth factor C -1.14 2.11 1.43 4.40 6.69E-05 4.58E-07 
GMDS GDP-mannose 4,6-dehydratase 1.10 2.76 1.07 2.38 6.06E-07 1.96E-06 
ULK1 unc-51-like kinase 1 (C. elegans) 1.09 2.11 1.19 2.21 1.62E-06 1.07E-06 
C8orf59 chromosome 8 open reading frame  1.09 -3.47 1.04 -2.61 0.001667 0.006988 
ACTN1 actinin, alpha 1 1.08 4.01 1.22 2.18 3.43E-05 0.001515 
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TMEM66 transmembrane protein 66 1.07 2.03 1.29 2.36 3.98E-05 1.03E-05 
C14orf2 chromosome 14 open reading 
frame 2 
-1.07 -3.30 -1.23 -2.21 8.42E-07 1.64E-05 
FRMD6 FERM domain containing 6 1.07 2.33 -1.06 2.96 1.82E-05 3.01E-06 
DBI diazepam binding inhibitor  -1.04 -2.51 -1.18 -2.13 8.89E-08 3.83E-07 
TM4SF1 transmembrane 4 L six family 1 -1.04 2.01 1.32 2.16 1.19E-06 5.54E-07 
CCNI cyclin I 1.03 2.59 1.05 2.00 1.92E-05 0.00017 
CTGF connective tissue growth factor 1.02 3.87 1.38 3.51 2.23E-06 3.84E-06 
CCDC58 coiled-coil domain containing 58 1.02 -2.06 -1.39 -2.10 0.000334 0.000291 
LOC729973 hypothetical LOC729973 1.01 -3.66 -1.35 -2.28 2.09E-05 0.00043 
SLIT2 slit homolog 2 (Drosophila) 1.01 2.62 1.02 2.64 3.63E-07 3.38E-07 
CBX5 chromobox homolog 5  1.00 -2.30 -1.30 -3.06 2.41E-07 2.65E-08 
 
Array experiment.MDA-MB-231 cells were treated with Control and NCT siRNA for 72 h. mRNA 
was sent to Prof Lucio Miele, USA, where their own MDA-MB-231 cells were treated with the Merck 
GSI. Values represent fold change between NCT siRNA vs. Control siRNA; and Notch2 siRNA vs. 
Control  siRNA. The two types of treatment were therefore not normalised to the same control, and 
direct comparisons between the two types of treatment have to be validated, due to the fact that 
although the same cell line was used, the MDA-MB-231 cells did not originate from the same 
laboratory. 
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Sensogram of anti-NCT MAbs binding to the human NCT-Fc protein.            
a,b) 10C11 and c,d) 1E2 MAbs were immobilised using NHS-EDC coupling on the surface of a 
separate BIACore CM5 chip. This was followed by a 2 min flow of the human NCT-Fc antigen      
(15 μg/ml), which resulted in formation of antigen-antibody binding, represented by the initial 
ascending slope on the sensograms. Indication „tight binding‟ reflects the strength of the IgG-antigen 
interaction (flat line with slow decay). Next, each IgG chip was subjected to a 1 min flow of an 
indicated Fab   (25 μg/ml) for the purpose of deciphering the degree of competitive binding between 
the antibodies. Binding was measured at a flow rate of 10 μl/min for 5 min at RT. Dissociation was 
initiated upon replacement of the analyte solution with buffer. Response (flow cell, Fc2) is indicated 
as resonance units (RU) and is corrected for nonspecific binding to a blank chip (flow cell, Fc1). Net 
binding = Fc 2-1.  
 
 
 
258 
 
 
BIACore analysis of the 10C11 MAb binding kinetics. A range of NCT-Ig antigen concentrations 
were flowed over the surface of the immobilised 10C11 MAb to give a series of associations and 
dissociations from which the association rate constant (Kon) of 4 x 10
3 
M
-1
 s
-1 
and the the dissociation 
rate constant was (Koff) of 6 x 10
-4
 s
-1 
were determined. Consequently a Kd of 149 nm was calculated. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
e) 
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